Retroviral vector mediated gene trapping in mice by Wilkins, Julie A
Ca r d if f
U N I V E R S I T Y
P R I F Y S G O L
CAERPYd? knoll bbstcbiotochnology and  b iological aclonco* rM M fth  council
RETROVIRAL VECTOR MEDIATED GENE 
TRAPPING IN MICE
Thesis submitted for the Degree o f  Doctor o f  Philosophy by
Julie A. W ilkins
Cardiff University 
2003
UMI Number: U584637
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U584637
Published by ProQuest LLC 2013. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
DEDICATED TO DAD,
HE WOULD HAVE LIKED THIS
Acknowledgements
Firstly, thank you to my supervisor Prof. Martin Evans, for advice and all round 
wisdom supplied throughout this period of study. Financial assistance was provided 
by the Biotechnology and Biological Sciences Research Council (BBSRC) and also 
Knoll Pharmaceuticals, to whom I am extremely grateful.
Thanks to John Dixon, CRC, Cambridge for supplying us with the retroviral 
constructs being studied in this project.
Bundles of thanks must go to lab C.401, Susie, Nicky, Rach, Anna, Fiona, (Michelle) 
and Marleeny, there’s not many of us but as they say quality, not quantity. Thank you 
Susie for the cells and constant support; Nicky for the perfect coffees and many 
encouraging pep talks; Rach for being a fellow Herefordian and a terrific pal; Anna 
for being so generous with your magic in the lab and a great ally; Fiona and Mike for 
your constant guidance and a fabulous trip to Ireland, just what was needed and of 
course Marleeny - your collection of humorous anecdotes, THANK YOU ALL!
To my adopted adviser. Prof. Alan Clarke, thank you for supplying those all important 
boosts when required, greatly appreciated. James, your advice concerning my DNA 
concentrations will never be forgotten, thank you for saving my sanity!
Loads o f thanks to Andy, my computer whizz and Jab Jab, my escape to the outside 
world, loves you both!
A special thank you has to go to Val, Owen and Andy. I can honestly say, without 
your constant support, loyalty and friendship, this thesis would never have been 
written. Thank you all. so much!
And lastly, but by no means least, thanks to my family. My brothers who wont believe 
this until they see it and to Mum, who is an infinite source o f encouragement and 
inspiration, couldn't have done it without you, thanks Mum, love you!
DECLARATION
This work has not previously been accepted in substance for any degree and is not 
being concurrently submitted in candidature for any degree.
Signed...  (candidate)
Date.. .... S h  >... / ( / i  QL<CC. h . . . 'Q  Q O Jrh - 
STATEMENT 1
This thesis is the result o f my own investigations, except where otherwise stated.
Other sources are acknowledged by footnotes giving explicit references. A 
bibliography is appended.
Signed__ ..v.tL .  { &    (candidate)
Date.. ... S r t .  !.V .■ . .L i c U lZ .h . . .o k D O .l r k
STATEMENT 2
I hereby give consent for my thesis, if accepted, to be available for photocopying and 
for inter-library loan, and for the title and summary to be made available to outside 
organisations.
Signed ..............................(candidate)
Date U .  ... k k . t c . c . h .. S i  C C S h
ABBREVIATIONS AND CONVENTIONS
The following abbreviations are used throughout the text:
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P-gal Beta galactosidase
p-geo Beta galactosidase and neomycin phosphotransferase fusion
transcript
Blast Basic local Alignment search Tool
bp nucleotide base pairs
BSA Bovine Serum Albumin
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IRES Internal ribosome entry site
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LIF Leukaemia Inhibitory Factor
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M Molar concentration
MEM Modified Eagles Medium
min Minutes
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MoMLV Moloney Murine Leukaemia Virus
mRNA Messenger RNA
n Number of samples analysed
NCBI National Centre for Biotechnology Information
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neo Neomycin phosphotransferase
nt Nucleotide
OD Optical density
PBS Phosphate Buffered Saline
pc post coitum
PCR Polymerase chain reaction
pp post partum
RACE Rapid amplification of cDNA ends
R N A Ribonucleic acid
RT Room temperature
RT-PCR Reverse transcription -  polymerase chain reaction
SA Splice acceptor site
SD Splice donor site
sec Seconds
ss Single stranded
STO (SIM [Sandoz inbred Swiss mouse] thioguanine-resistant
ouabain-resistant) cells
T Thymine
TAE Tris Acetate -  EDTA buffer
TE Tris-EDTA buffer
Tm Melting temperature
Tris N-Tris[HydroxyMethyl]methylglycine; N-[2-Hydroxy-l, 1-
bis(hydroxymethyl)-ethyl]glycine 
tRNA Transfer RNA
U Uracil
UTR Untranslated region
UV Ultraviolet
w/v Weight by Volume
v/v Volume by Volume
The one and three letter abbreviations for nucleotides and amino acids are those 
recommended for use by the Biochemical Journal. Policy of the Journal and Instructions to 
Authors. (1983). Biochemical Journal., 209 ,1-27.
All laboratory materials employed are detailed according to their commercial name as given 
in the appropriate manufacturer's catalogue.
Summary
There is a great wealth of sequence information available nowadays, but this is 
accompanied by a serious lack of functional information. Functional genomics is an 
area that needs to be developed and one method being utilised is gene trapping.
In this project a gene trapping approach was employed to achieve insertional 
mutagenesis in vitro in embryonic stem (ES) cells. These early embryo derived cell 
lines can be manipulated in vitro and then returned to the embryo where they 
participate in the normal development of a chimeric mouse.
There are two types o f gene trapping retroviral vectors being investigated, one is a 
shuttle vector which contains plasmid backbone between the long terminal repeats 
(LTRs) allowing the rescue of any trapped gene. The other is a splice acceptor (SA) 
vector, which has a SA infront of a promoterless P-geo gene. The provirus integrates 
into the genome o f the ES cells and the trapped gene is tagged with the p-geo reporter 
gene. This enables trapped clones to be selected with G 418 and expression patterns to 
be visualised by staining for p-galactosidase activity. Generation of a fused RNA 
transcript between the trapped gene and vector sequences facilitates cloning of the 
trapped gene. Using the P-geo sequence of the integrated vector, 3' RACE PCR was 
used to amplify a segment of the trapped gene and subsequently obtain sequence data. 
Two retroviral vectors o f each type mentioned are examined in this project for their 
insertional mutagenesis ability in vitro in ES cells and subsequent analysis. Neither of 
the shuttle retroviral vectors gave any reproducible results. A comparison was made 
between the SA retroviral vectors, one containing an internal ribosome entry site 
(IRES), the other not. These vectors gave rise to resistant ES cell clones and 
subsequent 3' RACE PCR sequence data.
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CHAPTER 1
INTRODUCTION
t .  I k t p k T  I
1. INTRODUCTION
1.1. Functional Genomics
The recent sequencing of the human genome (Lander et al., 2001) stands as a 
landmark accomplishment that heralds enormous potential. Besides providing the 
blueprint for all human proteins, the sequence contains all the regulatory elements that 
govern the developmental interpretation of the genome.
This achievement, however, is not the end of the road but rather the first step toward 
the functional understanding of the genome. The determined linear nucleotide 
sequences remain only lists of A, C, G and T, unless they are given functional 
significance. The coding sequences of genes can be investigated by computational 
methods and comparisons can be made with homologous genes in different species to 
try and apply functional role. However, the exact function of protein products can 
rarely be determined without obtaining much additional information, for example, 
biochemical or cell biological methods. In reported cases, some homologous genes 
fulfil completely different functions in different species.
An impressive demonstration of this phenomenon has been given by the functional 
comparison of similar molecules in the two closely related nematodes Pristionchus 
pacificus and Caenorhabditis elegans, which revealed that homologous genes can be 
recruited to serve completely new functions in new regulatory linkages (Eizinger et 
al., 1999). While remaining in the original developmental program, genes were found 
to have changed their molecular specificity and at the same time, retained other 
functions. Genes have jumped in or moved out o f regulatory circuits and are suddenly 
expressed in a spatially and temporarily different manner, demonstrating that mere 
sequence or structural similarity does not necessarily allow conclusions on possible 
protein functions (Oliver, 1996).
However, it must be said that comparative analysis of genomic sequences is important 
as a tool to elucidate coding and regulatory regions in genomic DNA. Several 
comparative studies have been done on large sequence regions of human and various 
species (Hardison et al., 1997). It is evident from these studies that coding regions are 
generally well-conserved (Jareborg et al., 1999).
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With so much genomic information now available and especially since the advent of 
the mouse genome sequence (Waterston et al., 2002) it should be taken that 
orthologous gene information can be used as a guide to gene function in different 
species, but it remains clear that the actual function of each gene needs to be studied 
in the entire organism. Critical information for defining gene function is often 
provided by generating mutations and then determining the phenotypic consequence 
of the given mutation on the organism under study. However, it must be considered 
that in diploid organisms both copies of a recessive gene must be mutated for the 
organism to display a mutant phenotype. A genome that contains two copies of each 
gene, each copy located on a separate homologous chromosome, could be protected 
from inactivating mutations in essential genes (Mills and Bradley, 2001). 
Traditionally, the phenotype-driven approach (forward genetics) has been most 
fruitful in organisms with comparably small genomes (Floss and Wurst, 2002).
This project began with plans for a phenotype driven screen, but due to certain 
methodological constraints, it developed into a genotype driven screen, where 
sequence information was analysed prior to micro-injection of resistant ES cells into 
host blastocysts.
The number o f protein coding genes in an organism provides a useful first measure of 
its molecular complexity. Single celled prokaryotes and eukaryotes typically have a 
few thousand genes; for example, Escherichia coli (Blattner et al., 1997) has 4,300 
and Saccharomyces cerevisiae (Goffeau et al., 1996) has 6,000. Evolution of 
multicellularity appears to have been accompanied by a several-fold increase in gene 
number. However, many were surprised when published drafts of the human genome 
chopped tens of thousands o f genes off the long-held notion that making a human 
might require about 100,000 genes. The International Human Genome Sequencing 
Consortium found evidence for 29,691 human transcripts (Lander et al., 2001). The 
commercial genome project of Celera Genomics. Rockville, found 39,114 genes 
(Venter et al., 2001). These predictions are in line with a previous estimate (Ewing 
and Green, 2000) of 35,000 genes, gained by comparing a set of human expressed 
sequence tag (EST) contigs with human chromosome 22 and with a non-redundant set 
of mRNA sequences. This disparity indicates that the number of human expressed 
sequence (mRNA) forms was much higher than the number of genes, suggesting that
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evolution of the increased physiological complexity of vertebrates may, therefore, 
have depended more on the combinatorial diversification of regulatory networks or 
alternative splicing, than on substantial increase in gene number (Ewing and Green,
2000).
Following the completion of sequencing the human genome (Lander et al., 2001), the 
next step must be to assign function to identified genes. The final goal of genome 
research today may look futuristic, but the knowledge of the function of every single 
gene and the interactions between them will finally allow us to understand the 
development and functioning of an organism as a whole. This effort will enable 
understanding of the molecular mechanisms underlying normal development as well 
as to delineate pathways where subversion o f these processes culminates in human 
disease (Bronson and Smithies, 1994; Mills and Bradley, 2001).
1.2. Alternative splicing
Alternative splicing is an important cellular mechanism that leads to the temporal and 
tissue-specific expression of unique mRNAs. It was first predicted by Walter Gilbert 
(Gilbert, 1978) that different combinations of exons could be spliced together 
“alternative splicing” to produce different isoforms of a gene. This was subsequently 
verified by the discovery o f cDNA isoforms exhibiting the addition or exclusion of 
whole or partial exons (Adams et al., 1996; Breitbart and Nadal-Ginard, 1987), 
although identification o f such splice variants largely occurred on an ad hoc basis.
The development o f large EST sequence libraries over recent years, however, 
provides an opportunity to examine the incidence of alternative splicing globally by 
searching these libraries for exon skipping, exon truncation or inclusion of sequences 
currently described as intronic. As ESTs are derived from fully processed mRNA, that 
is, after 5' capping, splicing and polyadenylation, they provide a broad sample of 
mRNA diversity. In the last few years, bioinformatic studies have identified an order 
of magnitude more alternatively spliced genes than were found in the past 2 0  years 
and are beginning to provide a global view of alternative splicing in humans (Modrek 
and Lee, 2002).
4
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Studies have consistently reported a high rate o f alternative splicing in the human 
genome, with 35-59% of human genes showing evidence of at least one alternative 
splice form (Kan et al., 2001; Mironov et al., 1999). Moreover, given that the vast 
number o f ESTs have not been adequately assessed for alternative splice variants, it 
seems possible that more alternative splicing exists. These studies indicate that 
alternative splicing is far more abundant, ubiquitous and functionally important than 
previously thought and there are more types o f mRNA isoforms. For instance, 
bioinformatic studies have reported that about 25% of genes have alternative 
polyadenylation forms, which are mRNAs that have been cleaved and polyadenylated 
at different sites (Beaudoing et al., 2 0 0 0 ).
1-3. Experimental Animal Model
The history o f each o f the model organisms is slightly different. Beginning in the 
1940s, yeast had proven to be useful as a classical genetic model and in the 1980s it 
began to be used as a molecular genetic model (Schweizer et al., 1986). In the last 
decade, yeast has been used for its genomic advantage. The worm is the youngest 
model system, just turning 40. It is a very simple animal, having only 959 somatic 
cells. The complete cell lineage and wiring of the worm’s nervous system (302 cells) 
are known and it was the first multicellular organism to have its genome sequenced 
(Sulston et al., 1992). The fly has been a favoured system for genetic studies for more 
than 90 years and has proven to be an excellent model to identify genes involved in 
evolutionary' conserved development and cellular processes 
(http://flybase.bio.indiana.edu/). Finally, the mouse has been used as a model for 
genetic studies for as long as the fly. Fancy breeders of different coat colour variants 
were the first mouse geneticists, whose work was quickly recognised by different 
scientific fields in biology (http:www.informatics.jax.org/).
To understand fully the molecular nature underlying the biology of human genetic 
disease, which is a prerequisite before a therapeutic goal can be considered feasible, it 
is necessary to employ the use of experimental animals as model systems. This 
enables gene function to be studied in situ, where individual proteins play out their 
roles through protein interactions, signalling responses and metabolic outputs, in the 
context of multiple cell types and organs and different physiological and disease
5
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states. Observations recorded in the course o f in vitro experimentation with 
mammalian cell lines, although certainly highly informative as regards cellular 
biology, cannot be directly extrapolated as being o f relevance to the genetic disorder 
in vivo. The model species of choice in this field o f experimental science is the 
common house mouse, Mus musculus.
The mouse has been the experimental model generally chosen for defining gene 
function because o f it’s anatomical, physiological, reproductive and genomic 
similarity to humans. The biology of this species is o f far more physiological 
relevance to human biology than that of the other “classical” genetic model systems, 
such as those mentioned above. The mouse’s small size, fertility and short gestation 
period make their practical handling and storage convenient for often necessary large 
scale breeding programmes. Females breed well in the laboratory with an average of 
5-10 pups per litter and an immediate postpartum oestrus. It is also advantageous that 
the fathers do not harm their young and so breeding pairs can be maintained together 
after litters are bom. For developmental studies, the deposition of a vaginal plug 
allows an investigator to time all pregnancies without actually witnessing the act of 
copulation.
By the 1980s, the experimental embryology and molecular biology of the mouse had 
reached a point where their parallel development allowed a fruitful fusion. Sufficient 
understanding of gene structure and in vitro DNA sequence tailoring, combined with 
the efficient in vitro manipulation of the mouse embryo at pre-implantation stage, led 
to the first production o f transgenic mice expressing a viral (Brinster et al., 1981) and 
a human (Palmiter et al., 1982) gene. Introduction of exogenous, actively expressed 
transgenes into the mouse was the first and most extensively used genetic approach. It 
has provided invaluable information about the role of oncogenes and genes involved 
in development or cell function in normal and disease processes. Most of these 
transgenic studies were gain-of-function approaches. The advent of mouse embryonic 
stem (ES) cells (Evans and Kaufman, 1981; Martin, 1981) opened up the possibility 
of loss-of-function forward and reverse genetics.
The mouse has now become the premier mammalian model organism (Anderson and 
Ingham, 2003) for studying development and disease. The mouse genome sequence
6
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(Waterston et al., 2002) is now available and the mouse germline can be manipulated 
in almost every way imaginable, in both a random (Brown and Balling, 2001; Nolan 
et al., 2000; Stanford et al., 2001) and a direct fashion (Nagy et al., 2003; Yu and 
Bradley, 2001), to study the phenotypic consequences o f perturbations. As techniques 
for manipulating the genome have multiplied, so have the tools for the study of 
complex phenotypes (Mills and Bradley, 2001).
1.4. Embryonic Stem Cells
Embryonic stem (ES) cells are established in vitro from explanted blastocysts and 
retain their normal karyotype in culture (Evans and Kaufman, 1981; Martin, 1981). 
They are the in vitro counterparts of an in vivo population o f cells, known as the 
epiblast, which are specific to the early embryo (Burdon et al., 2002; Evans and 
Hunter, 2002).
These cells are pluripotent, which means that an individual cell can give rise to all cell 
types o f the foetus. ES cells retain the developmental identity and potential o f the 
epiblast even after prolonged culture (Burdon et al., 2002). This phenomenon has 
been shown conclusively, as when injected into host blastocysts, ES cells can colonise 
the embryo and generate chimeric animals that are mosaic in all their tissues. 
Mosaicism extends to the germ cell lineage and ES cells can contribute fully 
functional gametes (Bradley et al., 1984). Consequently ES cells are continually 
exploited as vehicles for introducing genetic modifications into the mouse germline 
(Akiyama et al., 2000; Bronson and Smithies, 1994; Gossler et al., 1989; Robertson et 
al., 1986).
The pluripotentiality o f ES cells and their capacity to respond to normal development 
signals, implies that they constitute a particularly appropriate system for the 
experimental investigation o f mammalian development. ES cells provide a resource 
that circumvents the inaccessibility of the early mammalian embryo to conventional 
biochemical approaches. (Nichols et al., 1990).
A fundamental problem of studying mammalian developmental genetics is that unlike 
other model organisms, such as flies and frogs, the murine embryo can not be readily
7
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observed as it develops. Detecting early phenotypic defects caused by mutations is 
therefore difficult. This is further complicated by “w utero” reabsorption o f nonviable 
offspring (Baker et al., 1997). With the breakthrough of the ES cell system, it 
suddenly became feasible to manipulate mouse embryonic cells ex vivo and generate 
animals carrying a single predetermined mutation. “Reverse genetic” methods, in 
which a gene is characterised before its mutant phenotype is known, have primarily 
been used to study the molecular basis o f murine development. The two principal 
reverse genetic approaches both modify the genome of ES cells, which are eventually 
introduced into blastocysts to secure germline transmission o f mutant alleles (Hill and 
Wurst, 1993; Joyner, 1991; Soriano, 1995).
One approach, targeted or site-directed mutagenesis (section 1.6.) was designed to 
disrupt the function o f specific murine genes, which have been identified by virtue o f  
their homology to genes o f other organisms. The principle drawback o f this approach 
is that the sequence o f the targeted gene must be known in order to carry out 
insertional or replacement mutagenesis (Bronson and Smithies, 1994; Soriano, 1995).
The other approach, gene trapping (section 1.7.) was pioneered in mammalian cells by 
combining both, insertional mutagenesis and the ES cell system (Gossler et al., 1989). 
Gene trapping was designed to identify novel, developmentally regulated genes in 
mouse embryos (Friedrich and Soriano, 1991; Skames et al., 1992; Wurst et al., 
1995).
Historically, ES cells have been isolated and maintained on feeder layers of  
mitotically inactivated embryonic fibroblasts (Robertson, 1987). The feeder cells are 
thought to have generalised effects, such as medium detoxification, in addition to 
more specific effects in promoting cell attachment and viability and preventing ES 
cell differentiation. However, the presence o f feeders is not always ideal when 
attempting genetic manipulation o f the ES cells (Hooper et al., 1987).
ES cells undergo symmetrical self-renewal, which means they produce two identical 
stem cell daughters when they divide. Self-renewal entails the suppression of 
differentiation during proliferation (Burdon et al., 2002). The differentiation o f ES 
cells in vitro can be inhibited by the presence o f leukaemia inhibitory factor (LIF) or
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related cytokines that can activate signal transduction from cell-surface receptors. The 
actions o f LIF are mediated via heterodimerisation of two members of the class I 
cytokine receptors, the low affinity LIF receptor (LIF-R) and gpl30 (Davis et al., 
1993; Gearing et al., 1991) LIF sustains self-renewal through activation of the 
transcription factor STAT3 (Niwa et al., 1998).
Currently there is considerable interest in the prospect o f exploiting this potential in 
analogous human pluripotent cells (Thomson et al., 1998) to generate specific, 
differentiated types o f cell for drug development, for therapies based on cell 
replacement and for delivering gene therapies (Xu et al., 2001).
1.5. Retroviral Insertional Mutagenesis
In 1976, the introduction o f exogenous retroviral DNA into the mouse germ line was 
first reported (Jaenisch, 1976) and ‘insertional mutagenesis” began to be hotly 
pursued in the mouse. As retroviral infection usually occurred after the one- or two­
cell stage o f embryonic development, multiplicity o f infection was extremely variable 
and could lead to the generation of chimeric animals. However, a mutation could be 
recovered by additional breeding if an insertion was transmitted through the germ line 
(Jenkins and Copeland, 1985; Spence et al., 1989). This insight that retroviral 
insertion could alter endogenous genes and their expression, leading to tumorigenesis 
and leukaemia (Jaenisch, 1976) in mutagenized mice, spurred the cloning of retroviral 
insertion sites to recover the affected, tumorigenic genes and validated the potential 
usefulness o f insertional mutagenesis.
1.5.1. Retroviral Life cycle 
Retroviruses are a family of RNA enveloped viruses with the ability to reverse 
transcribe their genome from RNA to DNA (Weiss, 1998). Virions measure about 
120nm in diameter and contain two identical copies of positive strand RNA genome 
complexed with nucleocapsid proteins. Reverse transcriptase, integrase and protease 
proteins are also contained in the nucleocapsid, the inner portion o f the virion. A 
protein shell, formed by capsid proteins, encloses the nucleocapsid and delimits the 
viral core. Matrix proteins form a layer outside the core and interact with an envelope 
consisting o f lipid bilayer, which surrounds the viral core particle. The envelope
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originates from the cellular membrane and incorporates viral envelope glycoproteins. 
The envelope glycoprotein, responsible for the virus interaction with the specific 
receptor, is the only viral protein on the surface o f the particle. It is formed by two 
subunits held together by di-sulphide bonds and noncovalent interactions. One 
transmembrane subunit anchors the protein into the envelope membrane and the 
surface subunit contains the receptor binding function (Palu et al., 2000).
The retroviral life cycle is divided into two distinct phases, an early phase involving 
entry, reverse transcription of the viral RNA into DNA and the insertion of the DNA 
into the host genome to establish the integrated provirus. Late phase involves the 
expression o f the viral RNAs and proteins, the assembly o f the virion particles and the 
release of these particles by budding through the plasma membrane (fig. 1.1.) (Goff,
2001).
The infection process begins with the interaction o f the viral particles with the cell 
surface. The binding of the viral glycoprotein to a specific receptor complex on the 
cell surface causes virus and cell membranes to fuse and the viral particle to be 
internalised. The cellular tropism depends on the native envelope glycoprotein, for 
example ecotropic MoMLV, being utilised in this study, has a strictly murine host 
range and native receptor is the cationic amino acid transporter CAT-1 for arginine, 
lysine and orthinine (Kim et al., 1991; Wang et al., 1991). After virus-cell membrane 
fusion, the virus core is released into the cytoplasm. The viral core is partially 
degraded to form a large nucleoprotein particle containing the viral genome (pre­
integration complex) and is transported into the nucleus. The process of entry differs 
between oncoretroviruses and lentiviruses (Lewis and Emerman, 1994). For HIV-1 it 
was established that efficient transport to the nucleus is active and uses the cellular 
nuclear import machinery (Bukrinsky et al., 1992). However, MoMLV cannot transit 
through the pores o f the nuclear membrane, it has to wait until the nuclear membrane 
dissolves during cell division. These retroviruses are mitosis-dependent which means 
the pre-integration complexes will not infect non-dividing cells (Roe et al., 1993).
As the vectors being studied in this project are based on MoMLV, it was essential that 
the ES cells being infected were actively proliferating during infection.
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Figure 1.1. Schematic representation of the retroviral life cycle (adapted from 
Retroviruses, edited by JM Coffin, SH Hughes and HE Varmus, Cold Spring Harbor 
Laboratory Press, 1997).
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Upon entry into the nucleus the proviral genome flanked by two identical long 
terminal repeats (LTRs) containing the c/s-acting regions, is randomly integrated into 
the host genome by the viral integrase. Synthesis o f viral RNA by the cellular RNA 
polymerase, can then be initiated from the LTR promoter. However, in the case of the 
vectors studied in this project the LTR promoter is deleted and synthesis is driven by 
a cytomegalovirus (CMV) promoter situated within the bacterial backbone of the 
vector (see Appendix I for vector diagram). A single RNA species is produced which 
can then be processed into genomic RNA or multiply spliced, giving rise to individual
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mRNA transcripts. Translation o f viral proteins can then begin and this is followed by 
the formation o f virion particles at the cell surface. The capsid and envelope are 
thought to assemble at the same time and once the viral genome is packaged into the 
nascent virion, along with the non-structural viral proteins, budding of the newly 
formed virion can occur (Palu et al., 2000).
1.5.2. Retro viral vectors
Retroviral vectors have become standard tools for gene transfer technology. 
Compared with other gene transfer systems, retroviral vectors have several 
advantages, including their ability to transduce a variety o f cell types, to integrate 
efficiently into the genomic DNA of the recipient cells and to express the transgene at 
high levels. When compared to plasmid vectors, retroviral vectors are advantageous 
primarily because they insert a single copy with the ends o f the vector intact (Neilan 
and Barsh, 1999). A retroviral vector contains the c/s-acting elements required for 
replication as a virus, but is missing some o f the viral genes, which are replaced by 
foreign coding sequences. In order for a retrovirus vector to replicate as a virus, it is 
necessary to provide in trans the missing viral genes, which is achieved by using 
packaging cells (section 1.5.5.).
Retroviral vectors can contain many foreign sequences to optimise efficiency of  
infection and ultimately trapping of endogenous genes. Section 1.7.2. gives a more 
detailed introduction to the varied development o f the retroviral vector.
1.5.3. Reverse Orientation Splice Acceptor (ROSA) (Friedrich and Soriano, 
1991)
Constructs lacking a promoter and including a reporter gene (p-geo) encoding a 
fusion protein with both P-galactosidase and neomycin phosphotransferase activity 
were designed, so that activation of the reporter gene depends on proviral insertion 
downstream of a flanking genomic promoter. To allow for expression o f the reporter 
gene when inserted into an intron, a splice acceptor sequence was included in the 
construct. In order to aid cloning and analysis, the SAp-geo construct was inserted 
into a self-inactivating retroviral vector pGen~. This vector lacks the viral enhancer 
sequences and contains a bacterial supF gene in the LTRs to facilitate cloning of the
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pro virus and flanking sequences (Soriano et al., 1991). The splice acceptor gene trap 
construct was inserted in reverse orientation relative to the viral transcription. This 
was necessary to avoid removing the viral'T packaging sequence by splicing from a 
viral upstream splice acceptor sequence. The resulting retroviral vector is termed 
ROSAP-geo (reverse orientation splice acceptor p-geo).
1.5.4. MoMLV Long Terminal Repeats (LTRs)
The long terminal repeat (LTR) is the control centre for gene expression of 
retroviruses. As may be expected because o f the integrated phase o f their life cycle, 
retroviruses have somewhat typical eukaryotic promoters with transcriptional 
enhancers and some also have regulatory elements responsive to either viral or 
specialised cellular trans-activating factors, for example hormonal. All of the requisite 
signals for gene expression are found in the LTRs: Enhancer, promoter, transcription 
initiation (capping), transcription terminator and polyadenylation signal (fig. 1.2.). 
Expression directed by the viral LTR signals is carried out entirely by host cell 
enzymes.
The enhancer and other transcription regulatory signals are contained in the U3 region 
of the 5' LTR and the TATA box is located roughly 25 bp from the beginning o f the R 
sequence (Speck and Baltimore, 1987).
TATA
CCAA PolyA
U3 U5
Figure 1.2. Schematic structure of the Moloney murine leukaemia virus long terminal 
repeat (LTR). U3, R and U5 are 449, 68 and 77 bp, respectively. Noted are the 
negative-acting upstream control region (UCR), the 75 bp direct repeats which have 
enhancer activity (enh), a GC rich region required for maximal enhancer activity, 
canonical promoter elements and the signal for polyadenylation (Poly A).
UCR enh enh GC
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Figure 1.3 Schematic Diagram of the Synthesis of Long Terminal Repeats 
A Schematic structure of viral RNA. r: terminal repeat. u5 and u3: regions next to r. 
uu and aa: nucleotides, pbs: primer-binding site, rna: remainder of viral genome 
containing coding sequences for viral proteins, pu: purine run next to u3.
B Schematic structure of provirus. CELL: cellular DNA containing a direct repeat 
(DR) of 4bp formed upon integration. R, U5, PBS, DNA, PU and U3: DNA copies of 
r, u5, pbs, ma, pu and u3, respectively. Boxes: LTRs.
C Synthesis of unintegrated linear viral DNA. The upper strand is 5' to 3'; the lower 
strand is 3' to 5'. A prime indicates the complementary nucleotides. Other 
abbreviations are as in (A).
The integrated provirus has two LTRs and the 5' LTR normally acts as an RNA 
polymerase II promoter, instructing the host polymerase when and where to initiate 
viral RNA synthesis. The transcript begins at the beginning of R, is capped and 
proceeds through U5 and the rest of the provirus, usually terminating by the addition
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of a polyA tract just after the R sequence in the 3' LTR. Transcription is not 
terminated in the 5' LTR, probably due to the failure of forming secondary structure 
in the RNA which uncouples RNA polymerase.
The LTR is formed during reverse transcription by copying the U5 and R regions 
from the 5' end o f viral RNA and transferring them to the 3' end o f viral RNA (fig.
1.3.C.i/ii.). They then act as primer for copying the U3 region at the 3' end of viral 
RNA, making one copy o f the LTR. This copy o f the LTR then acts as a template for 
synthesis o f another copy o f the LTR, which is transferred to the 5' end of the virus 
(Temin, 1981;Temin, 1982).
The proposed mechanism o f synthesis of the LTR in viral DNA from the viral RNA 
template requires two “jumps” of partial DNA copies (fig. I.3.C.) (Coffin, 1979; 
Gilboa et al.,* 1979). Synthesis o f viral (-) strand DNA starts near the 5' end o f viral 
RNA and is always initiated with a host tRNA primer (fig. 1.3.C.(i)). When the 
template is exhausted 100 to 180 bases from the initiation site, the first “jump” occurs. 
The viral ribonuclease H associated with the reverse transcriptase molecule digests r- 
u5-uu in viral RNA and the strong stop DNA (AA-U5'-R') with its attached tRNA 
primer “jumps” to the 3' end o f viral RNA, so that R' pairs with r (fig.l .3.C.(ii)). Once 
safely repositioned, the nascent (-) strand is extended, apparently continuously, over 
the major expanse o f the genome. Plus strand strong stop DNA, AA-U3-R-U5-TT- 
PBS (Varmus et al., 1978) is synthesised (fig. 1.3.C.(iv)). Ribonuclease H digests the 
tRNA primer from (-) strand viral DNA and also digests the rest o f viral RNA, 
including pbs. The (+) strand strong stop DNA “jumps” to the 5' end o f (-) strand viral 
DNA so that PBS pairs with PBS' (fig. 1.3.C.(v)). The 3' OH groups on both PBS and 
PBS' act as primers for completion of synthesis. Extension o f both strands produces a 
blunt-ended, linear duplex (fig. 1.3.C.(vi)), the major product o f retroviral DNA 
synthesis in the cytoplasm of infected cells (Varmus, 1982).
Retrovirus vectors have been used to infect a variety o f cell types in tissue culture as 
well as cells o f the developing mouse embryo. Such vectors have been used to 
transduce and express foreign genes in infected cells and have been used as cell
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lineage markers, as insertional mutagens and as a tag for specific chromosomal 
regions for many years now (Tsukiyama et al., 1989).
The MoMLV based retroviral constructs used in this project have enhancers and 
promoters deleted, relying on a cytomegalovirus (CMV) promoter (see Appendix I for 
vector diagrams) to drive replication in the packaging cells. The removal of these 
elements prevents any interference during the trapping process, for example, the viral 
promoter disturbing neighbouring genes and making interpretation of a mutant 
phenotype even more difficult.
1.5.5. Packaging Cells 
Virions are complete virus packages, which consist o f a protein coat surrounding the 
virus genome. This enables viral genomes to be carried from cell to cell, protecting 
them from inhospitable environments in which the virus cannot replicate (Bender et 
al., 1987). Packaging cell lines are designed to synthesise all retroviral proteins 
required for assembly o f infectious virion, but should not produce any replication 
competent virus. However, some packaging cells that are initially helper free can 
convert to helper virus positive during prolonged passage. This is possibly due to 
recombination between sequences used to make the packaging cells and endogenous 
retrovirus like elements found in most eukaryotic cells. Also, introduction of 
particular retroviral vectors into some packaging cells can result in helper virus 
production probably due to recombination between homologous regions of the vector 
and the defective virus used to make the packaging cells (Miller, 1990; Weiss and 
Tailor, 1995).
Several early packaging cell lines were made by using helper viruses from which the 
retroviral packaging signal had been deleted (Cone and Mulligan, 1984; Mann et al., 
1983; Miller et al., 1985). Although packaging cells of this type have been used with 
success in a number o f studies, most notably the v|/-2 cell line (Mann et al., 1983), 
these lines suffer ffom important deficiencies. Firstly, although deletion of the 
packaging signal reduces the amount of helper virus RNA that is packaged into virion, 
the block is far from complete. If the deleted helper genome is packaged, there are no 
further blocks to infection o f other cells, because the signals for reverse transcription
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and integration are in tact. Indeed, virus from this type of packaging cell is capable of 
rescuing retroviral vectors in the absence o f overt helper virus production (Cone and 
Mulligan, 1984; Miller and Buttimore, 1986), presumably due to the transfer of the 
deleted helper virus.
The retroviral vector used with a packaging line has a strong influence on the 
possibility o f helper virus production. Avoidance o f homologous overlap between 
vector and helper virus sequences in the packaging cells decreases the chance of 
helper virus production (Miller and Rosman, 1989; Miller et al., 1986). This can be 
accomplished by removing as much of the helper virus sequences from the vector as 
possible. In the case o f retroviral vectors based on murine leukaemia virus, overlap at 
the 5' end o f the vector with helper sequences is difficult to avoid because the 
packaging signal o f these viruses extends into the gag region o f the helper virus 
(Adam and Dusty Miller, 1988; Armentano et al., 1987; Bender et al., 1987).
Alternatively, the areas o f homologous overlap between vector and helper virus 
sequence in packaging cells can be avoided by using a vector derived from a helper 
virus that has little sequence similarity with the helper virus used to construct the 
packaging cells. For example, a vector based on spleen focus-forming virus (SFFV) 
has no tendency to produce helper virus when introduced into murine leukaemia virus 
based PA 12 packaging cells, even though there is extensive overlap between the gag 
regions o f the vector and helper DNA (Miller and Buttimore, 1986). In contrast, a 
vector based on the same murine leukaemia virus as the PA 12 cells and having similar 
overlap as the SFFV-based vector readily produced helper virus in the PA 12 cells 
(Miller and Buttimore, 1986). A possible difficulty with this strategy is potential 
incompatibility between a vector based on a different helper virus than the packaging 
cells, which might result in low titre.
In this project the BOSC (Pear et al., 1993) packaging cell line is being used to 
introduce in trans the necessary viral genes. To circumvent the problems o f stable 
producer cell lines, this packaging cell line is transiently transfected to produce high- 
titre, helper-free infectious retroviruses. The retroviral vectors contain the c/s-acting 
elements required for replication as a virus, but are missing some of the viral genes,
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which are replaced by foreign coding sequences. The BOSC cells contain the gag, pol 
and env retroviral genes and are therefore capable o f producing retrovirus from the 
experimental constructs on their own. However, there is probably only a single copy 
of each gene per BOSC cell and therefore greater titres can be achieved by co­
transfecting pHIT plasmids which provide further copies of the gag, pol and env 
genes (see Appendix I for plasmid information). The pHIT 60 plasmid contains the 
murine leukaemia virus gag/pol cassette under the control of the human 
cytomegalovirus immediate early promoter, whereas pHIT 123 contains the human 
cytomegalovirus promoter driving murine leukaemia virus ecotropic envelope.
1.6. Gene Targeting
With the advent o f “reverse genetic” methods to study the molecular basis o f murine 
development, it was no longer necessary to rely on random mutagenesis for the 
generation o f mutations. These are methods in which a gene is characterised before its 
mutant phenotype is known. In stark contrast to the hit and miss strategies is that of  
targeted mutagenesis by homologous recombination in ES cells. This approach 
modifies the genomes o f ES cells, which are eventually introduced into host 
blastocysts to secure germline transmission of mutant alleles. Targeted or site-directed 
mutagenesis was designed to disrupt the function o f specific murine genes which are 
known by virtue o f their homology to genes of other organisms (Capecchi, 1989).
The ability to manipulate the mouse genome using gene targeting has revolutionised 
the capacity to assess mammalian gene function and to generate models for human 
diseases. Gene targeting in the mouse is extremely useful for determining the function 
of individual genes, but only a few thousand genes have been subjected to this 
analysis. Although it is technically possible to generate individual mouse strains that 
are deficient for each of the estimated 30,000 to 40,000 genes within the mouse 
genome, this endeavour would require around 100 years to achieve at the current rate 
(Mills and Bradley, 2001).
There are other drawbacks to this approach, one being that the targeted gene must be 
known in order to carry out insertional or replacement mutagenesis. Another is the 
inability to reliably predict the exact biological process that will be affected.
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Sometimes, genetic redundancy causes diminished phenotypes, which can hinder the 
functional analysis o f the mutation. At other times, the targeted gene is required for 
early embryonic viability. The resulting failure o f a mutant embryo to survive 
prevents the function o f the gene in later developmental processes from being studied. 
In addition, the molecular lesion generated does not always have the predicted, and/or 
an easily interpretable effect. The advent of conditional recombinase systems, which 
allow gene expression to be controlled in a temporally and spatially manner, has 
helped to overcome this limitation (Dymecki, 1996; Lakso et al., 1992; Orban et al.,
1992).
Although being a very time consuming method o f mutagenesis, having to design and 
generate the targeting constructs, isolating clones, breeding and then analysing the 
phenotype (Bronson and Smithies, 1994; Mills and Bradley, 2001; Mitchell et al., 
2001; Soriano, 1995), gene targeting has led to unprecedented insights into gene 
function. However, the null mutations that are generally created by investigators using 
homologous recombination strategies often do not resemble the types o f molecular 
lesions found in disease. So, despite the success of gene targeting, the interest in 
random mutagenesis screens intensified.
1.7. Gene Trapping
Gene trapping was designed to identify novel, developmentally regulated genes in 
mouse embryos and potentially offers a powerful tool to generate numerous 
insertional mutations in mice and to perform phenotypic screens for developmental 
mutants (fig 1.4.). The trapping principle is a form of insertional mutagenesis 
specifically designed to disrupt gene function by producing intragenic integration 
events.
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Figure 1.4. Schematic outline of gene trapping strategy
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The basic strategy of gene trapping (Friedrich and Soriano, 1991; Gossler et al., 1989; 
Hicks et al., 1997; von Melchner et al., 1992; Wiles et al., 2000; Zambrowicz et al., 
1998) is to introduce into ES cells some marker transgenes that will only function if 
they have integrated into an active gene. Such an insertion usually results in the 
disruption of this gene. The disrupted gene is also tagged by the integration, so it can 
be readily identified by sequence and database analysis.
Gene trapping methodology is a powerful strategy for cloning and identifying 
functional genes, as it marks a gene with a tag and simultaneously generates a 
corresponding genetic variation for that particular locus. Therefore, gene trapping is 
an extremely useful tool for functional genomics, establishing correlation between the 
physical and genetic maps of the genome.
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1.7.1. Plasmid Rescue
Plasmid rescue (fig. 3.9.) is a style o f gene trapping that relies on a bacterial backbone 
being placed within the LTRs of the retroviral vector (Hicks et al., 1997; Niwa et al.,
1993). Analysis o f resistant ES cell clones trapped with a plasmid rescue construct 
rely on the ability to rescue the bacterial backbone with appended flanking sequence 
from it’s insertion location in the genomic DNA. This is achieved by digesting the 
genomic DNA with a selection of restriction enzymes (section 2.2.2.xii), ligating the 
ends to form a plasmid and then electroporate into bacteria. The bacterial backbone 
which is incorporated into the novel plasmid contains ampicillin resistance allowing 
selection. Resulting plasmid DNA can then be sequenced directly avoiding 
cumbersome molecular biology techniques such as RACE PCR.
A team in Japan devised an “exchangeable gene trapping system” which allowed 
replacement o f the (5-geo gene for another reporter gene, enhanced green fluorescent 
protein (EGFP), within the trapped clones (Araki et al., 1999). This system would 
enable random insertional mutagenesis in the first instance and then the introduction 
of another DNA fragment to be expressed under the control of the trapped gene, 
through Cre-mediated integration, allowing the induction of any type o f mutation at 
this locus.
1.7.2. Development o f gene trapping:
Each functional genomics approach has its strengths and weaknesses and only by 
taking advantage o f each one will the functions o f the mammalian genome be 
understood. Gene trapping takes the middle path between random and molecularly 
defined mutations. Gene trap vectors have evolved from enhancer-trap vectors, a 
molecular tool used to identify and characterise mammalian enhancer sequences from 
cell lines (Weber et al., 1984). This technique was quickly modified in both 
Drosophila and the mouse to generate vectors that adopt the transcriptional regulatory 
apparatus o f endogenous genes to report the endogenous expression of a gene that 
flanks the vector insertion site (Allen et al., 1988; Kothary et al., 1988; O'Kane and 
Gehring, 1987).
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O’Kane and co-workers developed an approach for the in situ detection of genomic 
elements that regulate transcription in Drosophila melanogaster (O’Kane and 
Gehring, 1987). The random generation of operon fusions in prokaryotes involves 
integrating a promoterless reporter gene, whose expression can easily be detected and 
assayed at many different positions in a target genome. This is possible due to the 
reporter gene coming under the control of a random selection of chromosomal 
promoters and inspired a similar approach in Drosophila. This approach would enable 
the isolation and characterisation of genes, simply by knowing or postulating their 
pattern o f expression. It was realised that in eukaryotes however, that for the efficient 
expression o f a reporter gene, not only would an active promoter be required, but the 
reporter gene would normally have to be the first gene in the fusion transcript. They 
decided to express the reporter gene, lacZ gene o f Escherichia coli, from a weak 
promoter and to integrate this promoter fusion by P-element transformation into the 
Drosophila genome. An increase in expression o f the reporter gene was expected to 
reflect the activity o f nearby enhancer like elements in the genome that can act at a 
distance on the weak promoter. Using P-element-based vectors, thousands of 
insertions have been generated to monitor chromosomal loci active during 
embryogenesis. The lacZ reporter provides a sensitive and easily assayable gene 
product to detect expression in whole embryos. Approximately 65% of the lines tested 
were found to express the lacZ reporter in a restricted pattern during embryogenesis. 
Furthermore, about 15% o f the P-element insertions caused recessive mutations that 
resulted in visible phenotypes (O’Kane and Gehring, 1987).
Gossler and co-workers devised a strategy for identifying regions o f the mouse 
genome that are transcriptionally active in a temporally and spatially restricted 
manner during development (Gossler et al., 1989). They based their experiments on 
previous work in which the integration of the lacZ gene linked to a weak promoter 
was shown to detect c/s-acting elements in the mouse genome that activated P- 
galactosidase expression in the developing spinal cord and caused a neurological 
mutation (Kothary et al., 1988). Also, similar developmental activation of lacZ 
constructs was reported in Drosophila (O'Kane and Gehring, 1987), as mentioned 
above and other transgenic mouse strains (Allen et al., 1988).
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Gossler and co-workers used two types o f construct, one being an enhancer trap 
construct, which relies on cis-acting regulatory elements close to the site of 
integration to activate a weak promoter and initiate expression of the lacZ gene 
(Gossler et al., 1989). It was expected that some integration events would cause a 
mutation in an endogenous gene. The ability to prescreen ES cells for desired 
insertion events, made possible the design of a second type of vector called the gene 
trap. The essential feature of the “gene trap” design is the placement of a splice 
acceptor in front o f a promoterless lacZ gene. Integrations o f the vector into the intron 
of a gene in the correct orientation were predicted to create lacZ fusion transcripts and 
if  the reading frame o f the endogenous genes and lacZ are the same, an active p- 
galactosidase fusion protein should be produced. Insertion o f the gene trap vector was 
expected to produce a mutation in the host genome in all cases. Vectors similar to the 
original bacterial vectors, termed promoter traps, have also been used (von Melchner 
et al., 1992). As they contain only the coding sequences o f the reporter gene, they are 
expected to require insertions into exons to activate reporter gene expression.
Expression patterns provided clues to the function o f developmentally regulated genes 
but final proof only came from analysing mutant phenotypes. In Drosophila, the 
majority o f enhancer trap insertions tested expressed p-galactosidase in a pattern 
similar to the adjacent endogenous gene (Bellen et al., 1989). The requirement for 
gene/promoter trap insertions to occur within transcription units, predicts an accurate 
portrayal o f endogenous gene expression.
In 1991 Glenn Friedrich and Phillippe Soriano (Friedrich and Soriano, 1991) first 
developed the ROSA strategy (introduced in section 1.5.3.). They developed a general 
strategy for selecting insertion mutations in mice. Constructs lacking a promoter and 
including a P-gal gene, or a reporter gene encoding a protein with both P-gal and 
neomycin phosphotransferase activity were designed so that activation of the reporter 
gene depended on its insertion within an active transcription unit. Insertion events 
created a mutation in the tagged gene and allowed its expression to be followed by p- 
gal activity. Results obtained from this promoter trap experiment suggested that a 
substantial proportion of mammalian genes identified by this approach are not 
essential for development.
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Skames and colleagues demonstrated the capacity o f a gene trap vector containing a 
splice acceptor site to generate lacZ fusion transcripts, accurately report endogenous 
gene expression and to mutate the endogenous gene at the site of integration. It was 
confirmed that gene trap vectors are able to create spliced fusion transcripts with 
endogenous genes and prevent the synthesis o f normal transcripts at the site of 
integration (Skames et al., 1992).
New trap vectors were developed to trap genes in murine ES cells (Niwa et al., 1993). 
The polyA addition signal of the neo gene was removed so that they needed to trap an 
endogenous polyA signal for expression o f the neo gene. It was found that the 
frequency o f gene-trap events of this type of vector was about five times higher than 
with the vector containing the polyA signal and only one copy o f the trap vector was 
integrated in most cases (Niwa et al., 1993). By employing a polyA trap, intragenic 
vector integration is selected for. A mRNA transcribed from a selectable marker gene 
lacking a polyA signal in a gene trap vector is stabilised only when the gene trap 
vector captures a cellular polyA signal. Since polyA trapping occurs independently of  
the expression o f the target genes, any gene could potentially be identified at almost 
equal probability regardless o f the relative abundance o f its transcripts in target cells 
(Ishida and Leder, 1999). Other gene-trap strategies enrich for intragenic integration 
events from the beginning, like the promoter/enhancer trap in which the expression of 
a promoterless selectable marker is dependent on the capture of an active 
transcriptional promoter/enhancer in the target cells. While this is a very reliable way 
to focus exclusively on functional genes, transcriptionally silent genes in the target 
cells are missed by this strategy.
The trap vector both serves as a sequence tag for the identification of the mutated 
locus and can provide a reporter-selection marker for monitoring endogenous gene 
activity. The presence o f splice donor (SD) or splice acceptor (SA) elements leads to 
the generation o f a fusion protein, even in the case of an intron integration.
A large number o f gene trap insertions can be isolated in mouse ES cells and are 
immediately accessible in molecular characterisation using high throughput methods 
to generate sequence tags for each mutated gene. New mutations can be generated in 
mice at a rate far exceeding that of conventional gene targeting and also recessive
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lethal phenotypes can be identified at all developmental stages and can be easily 
maintained. In addition, various criteria can be used to pre-select genes o f interest and 
their functional analysis can proceed rapidly based on a confluence of sequence, 
mapping, expression and phenotype information (Mitchell et al., 2001; Soriano,
1995).
The gene trap approach has had a number of successes in establishing mutant mice 
strains. One example is the “jum onjr mouse displaying abnormal groove formation 
on the neural plate and a defect in neural tube closure (Takeuchi et al., 1995). The 
gene trap construct contained a splicing acceptor sequence at the 5' terminus of the 
neomycin phosphotransferase gene, to enhance trapping efficiency. An internal 
ribosome entry site was inserted between neo and lacZ to enable the dicistronic 
expression o f two genes. The vector contained no promoter sequences so only trapped 
cells would be able to survive selection with G418. The sequence for nuclear 
transporting peptide derived from SV40 large T gene was placed at the 5' terminus of  
the lacZ sequence. This sequence is expected to concentrate lacZ products in the 
nucleus and facilitate detection of cells expressing trapped genes (Kimura et al.,
1994).
Another example used the ROSA Pgeo vector to disrupt the a-enolase gene by 
insertion of the splice trap vector into the first intron (Couldrey et al., 1998). This 
mutation resulted in an early recessive embryonic lethality. Mice heterozygous for 
this mutation showed no obvious phenotype.
New vectors are being designed to trap specific classes of protein. For example, 
Skames and colleagues used protein sorting and the fact that P-gal activity is 
abolished in the endoplasmic reticulum to design a vector that specifically traps genes 
that encode secreted and transmembrane proteins and are expressed in ES cells 
(Skames et al., 1995). By encompassing a variety of attributes in gene trapping 
constructs it will be possible to achieve saturation mutagenesis o f the genome.
In this gene trapping project a selection of retro vims based vectors are being used that 
contain a variety o f sequence information to aid integration and subsequent
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characterisation. Compared to plasmid vectors, retroviral vectors are advantageous, 
primarily because integration leads to a short direct duplication of host sequences at 
the site o f the single proviral insert with the ends o f the vector intact and does not 
result in other rearrangements in the host genome. Plasmid-based vectors are 
susceptible to nucleases during electroporation and recombination into the genome. 
Deletions from the ends of the vector reduce the efficiency o f cloning and make 
primer selection for subsequent analysis more difficult. Also, none o f the vectors 
utilised in this study contain a promoter driven resistance cassette. The promoter 
could disturb neighbouring genes, which would make interpretation o f the mutant 
phenotype even more difficult (Jaenisch, 1988).
1.7.3. Insertion location o f retroviral vectors 
Retroviral DNA integrates with high efficiency into the genome of the host cell, 
where it persists as a stable genetic element, the provirus. It must be considered, 
however, that target site preferences for retroviral integration may impair the ability to 
sample the genome effectively (Neilan and Barsh, 1999).
Chowdury and colleagues demonstrated in a large-scale gene trapping experiment 
using 5'RACE PCR, that gene trap vectors integrate stochastically into the genome 
(Chowdhury et al., 1997). Results showed that there was no preference for insertion 
site into individual mouse genes when using the SApGeo or the IRESpGeo vectors. 
Insertions were found either at the 5'-end, at the 3'-end or in the middle of a gene. It 
would be expected that most insertions at the 5'-end of a trapped gene would 
completely knockout the corresponding gene. In other cases, interesting phenotypes 
may be obtained representing partial inactivation o f the gene products or as a result of 
a dominant gain of function. A consideration with 3' insertions would be a resulting 
large fusion complex between the resistance marker and the trapped gene, leading to 
the inactivation o f the resistance marker due to inadequate protein folding.
Other evidence indicates that retroviral integration is not entirely random but occurs 
preferentially into regions close to deoxyribonuclease I-hypersensitive sites, which are 
characteristic for active genes. It is possible therefore that the chromatin conformation 
of a given gene can influence its chance of being mutated. An expressed gene with an
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opened chromatin conformation may represent a more likely target for integration and 
insertional mutagenesis than inactive heterochromatic genes (Craigie, 1992; 
Rohdewohld et al., 1987; Scherdin et al., 1990; Vijaya et al., 1986).
Areas o f high chromatin enzymatic accessibility, such as DNase I hypersensitive sites 
are often associated with enhancers or locus control regions. A preference for 5' 
integration events would generate preferable null mutations as opposed to 3' 
integrations which only partially disrupt the function o f the trapped gene (Floss and 
Wurst, 2002). Other useful features for 5' insertion o f the retroviral vector are, 
interpretation o f mutant phenotypes are less likely to be complicated by any 
dominated negative effects o f truncated protein products o f the affected locus and the 
potential for production of truncated proteins retaining sufficient normal activity to 
rescue the phenotype is reduced (Thomas et al., 2000).
Individual vector designs have their own inherent biases that will influence the range 
of target genes isolated. Gene trapping vectors are designed to detect insertions within 
transcribed regions o f the genome. A variety o f vectors have been developed that 
differ in their individual requirements for reporter gene activation. “Promoter trap” 
vectors simply consist o f a promoterless reporter gene that is activated after insertions 
into exons (Friedrich and Soriano, 1991). In contrast, “gene trap” vectors contain a 
splice acceptor sequence upstream of a reporter and are activated after insertion into 
introns (Komada et al., 2000; Skames et al., 1992; Takeuchi et al., 1995). Gene trap 
vectors are more efficient than promoter trap vectors, but will favour the detection of 
genes composed o f large intronic regions and are likely to miss genes possessing few 
or no introns.
Gene trap vectors are also constrained by the reading frame imposed by the splice 
acceptor sequence. Non-incorporation of an ATG site into the gene trap vector means 
that the activation o f the reporter gene depends on the production of an in-frame 
fusion to the N terminus of the target gene. However, to overcome this problem some 
gene trap vectors have an internal ribosome entry site (IRES) inserted 5' o f the 
reporter gene, to initiate translation independently o f the upstream open reading frame 
(Shirai et al., 1996; Takeuchi et al., 1995).
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1.7.4 Use o f polvbrene in gene trapping 
Retroviruses have short half-lives and therefore can only travel a limited distance by 
Brownian motion in infection medium before deactivating. With virus particles able 
to diffuse only a few microns before losing bioactivity, a large proportion of the 
initially active virus particles are inactive before they can interact with a target cell, 
fundamentally limiting achievable levels o f transduction efficiency (Chuck et al.,
1996). To circumvent these constraints, mechanical approaches, including 
centrifugation (Kotani et al., 1994) and flow-through transduction (Chuck and 
Palsson, 1996) have been developed to increase the likelihood and frequency of active 
virus-cell interactions by adding a convective component to the mass transport of 
virus. While these strategies do yield enhanced transduction efficiencies, their 
expense and difficult scale-up limit their usefulness for large-scale experiments. The 
classical approach to enhancing retrovirus transduction efficiency has been to add 
cationic polymers during the transduction process (Toyoshima and Vogt, 1969).
As previously stated retroviral virions are enveloped with a lipid coat from the 
producer cell line and therefore have a similar negative charge as the target cell. To 
overcome electrostatic repulsion between virion and cell, positively charged polymers 
such as polybrene are often used during transduction. Polybrene is a small, positively 
charged molecule that binds to cell surfaces and neutralises surface charge. This 
apparently allows the viral glycoproteins to bind more efficiently to their receptors as 
it reduces the repulsion between sialic acid containing molecules (Davis et al., 2002).
1.8. Rolling circle amplification (RCA)
It was felt necessary to introduce rolling circle amplification at this juncture, as the 
technique was employed during plasmid rescue (see section 3.11.2. for results). Due 
to the tiny amount o f plasmid DNA expected to be rescued it was felt necessary to try 
to amplify, prior to electroporation. To attempt this, the TempliPhi™ DNA 
amplification kit (Amersham Biosciences, UK Ltd., Bucks, UK) was obtained.
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Figure 1.5. Schematic representation of rolling circle amplification
/  \ +  dNTPs +
Phi29 DNA Polym erase
Template DNARandom Hexamer Prim ers
The TempliPhi method (fig. 1.5.) utilises bacteriophage <(>29 DNA polymerase 
enzyme to exponentially amplify single- or double-stranded circular DNA templates 
by rolling circle amplification (Blanco et al., 1989). Random hexamer primers anneal 
to the circular template DNA at multiple sites. Phi29 DNA polymerase (Blanco and 
Salas, 1984) extends each of these primers. When the DNA polymerase reaches a 
downstream extended primer, strand displacement synthesis occurs. The displaced 
strand is rendered single-stranded and available to be primed by more hexamer 
primer. The process continues, resulting in exponential, isothermal amplification.
The product of the TempliPhi reaction is high molecular weight, double stranded 
concatemers of the circular template.
1.9. AIMS
Gene trapping can be regarded as a more efficient method of insertional mutagenesis 
when compared to gene targeting, as having to design and generate targeting 
constructs, isolating clones and breeding is very time consuming. This study looks at
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four gene trapping retroviral constructs that have never been used in gene trapping 
experiments before.
They encompass two different types of trapping methodology. One strategy being 
plasmid rescue (fig. 3.9.), which relies on an ability to rescue the bacterial backbone 
of the retroviral construct and thereby retrieving any appended flanking sequence. The 
other trapping method is ROSA (section 1.5.3.) and due to the inclusion of a splice 
acceptor site, constructs are expected to be able to insert into introns as well as exons 
and achieve an active trapping event. The splice acceptor constructs are inserted into 
the retroviral vector in the reverse orientation relative to viral transcription, reverse 
orientation splice acceptor (ROSA), to avoid removing viral packaging sequence by 
splicing from a viral upstream splice acceptor sequence (Friedrich and Soriano, 1991).
Investigations will include the ability of these constructs to produce virion when 
packaged into an ecotropic packaging cell line, BOSC (Pear et al., 1993). Infection of 
murine pluripotent embryonic stem (ES) cells with the resulting virions. To assist in 
the gene trapping and subsequent characterisation these constructs contain a selection 
of sequence information. The splice acceptor constructs do not just contain a splice 
acceptor site they also contain a slice donor site, allowing 3' endogenous sequence to 
remain after splicing events and subsequently analysed. One splice acceptor construct 
contains a T7 promoter and an Isce-1 restriction site, the other splice acceptor 
construct contains an internal ribosome entry site and a lox P stuffer region, the theory 
behind these additions is explained when introducing the constructs (section 3.5.).
A comparison can be made between the number o f G418R ES cell lines resulting after 
infection from each construct. These ES cell lines will be manipulated in an 
appropriate manner, relating to which construct they originated from and sequence 
data obtained. Resulting sequence data can be compared with that held on sequence 
databases to ascertain the insertion location o f the retroviral construct. Successful 
trapping events can then be examined further, ES cell lines can be injected into host 
blastocysts to obtain germline transmission of the mutation.
It is hoped that a performance assessment will be achieved for each o f the new 
constructs being studied.
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MATERIALS AND METHODS
2. MATERIALS AND METHODS
For all procedures, solutions were made to the standard required for molecular 
biology using molecular biology grade and/or “tissue-culture-tested” reagents. All 
solutions were made using sterile double-distilled water and where appropriate 
autoclaved or filter sterilised.
2.1. TISSUE CULTURE
All tissue culture plates and plasticware was supplied by Nunc, Fisher Scientific 
Equipment UK Ltd., Loughborough, UK.
2.1.1. Medium Preparations:
2.1.1.1. Antibiotics:
Penicillin/streptomycin (5000 units/ml penicillin G sodium and 5000pg/ml 
streptomycin sulphate in 0.85% saline from Gibco BRL, Paisley, UK) used at IX 
concentration.
Broad spectrum antibiotic, Gentamicin (Gibco BRL, Paisley, UK) used at a 
concentration o f 50pg/ml.
2.1.1 .ii For Maintaining Pluripotent Embryonic Stem (ES) Cells:
500ml Modified Eagles Medium (MEM) Alpha medium without ribonucleosides and 
deoxyribonucleosides (Gibco BRL, Paisley, UK)
5ml (3 Mercaptoethanol lOmM (Gibco BRL, Paisley, UK)
5ml Glutamine 200mM (unstable amino acid) (Gibco BRL, Paisley, UK)
50ml Newborn Calf Serum (NCS) (PAA, Yeovil, UK)
50ml Foetal Calf Serum (FCS) (PAA, Yeovil, UK)
50units/ml medium - ESGRO® murine Leukaemia Inhibitory Factor (mLIF) 
(Chemicon Europe Ltd. Hampshire, UK)
2.1.1 .iii. For Maintaining STO (Fibroblast) Cells:
500ml MEM Alpha medium without ribonucleosides and deoxyribonucleosides 
(Gibco BRL, Paisley, UK)
50ml NCS (PAA, Yeovil, UK)
5ml Glutamine 200mM (Gibco BRL, Paisley, UK)
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2.1.1 .iv. For Maintaining BOSC Packaging Cells:
500ml MEM Alpha medium without ribonucleosides and deoxyribonucleosides 
(Gibco BRL, Paisley, UK)
50ml FCS (PAA, Yeovil, UK)
5ml Glutamine 200mM (Gibco BRL, Paisley, UK)
2.1.1 .v. Freezing Mix:
10% DMSO (Gibco BRL, Paisley, UK)
90% FCS (PAA, Yeovil, UK)
2.1.2. Preparation of feeder layers:
Using STO fibroblast cells (Robertson. 1987; Ware and Axelrad. 1972):
It is important that STO cells are passaged promptly when they reach confluency to 
prevent the accumulation of non-contact inhibited cells in the population.
Grew up a confluent 10cm plate of STO fibroblast cells.
Aspirated the medium and replaced with 6ml o f STO medium + 1 Opg/ml mitomycin 
C (Sigma-Aldrich, Poole, Dorset, UK).
Incubated at 37°C for 2-3 hours, avoiding longer exposure.
Removed mitomycin C medium and washed 3 times with PBS (phosphate buffered 
saline) (Gibco BRL, Paisley, UK).
Trypsinised the cells with 2ml of trypsin-EDTA (Gibco BRL, Paisley, UK) 
per plate for about 2min and then collected the cells in STO medium.
Pelleted the cells by centrifugation at 1500g for 5min and resuspended in STO 
medium, counted the suspension using a hemocytometer.
Prepared a dilution o f 106 feeder cells/ml o f medium.
Seeded a plate which had been coated in gelatin (0.1% gelatin in water) (Stem Cell 
Technologies Inc. Vancouver, Canada) 12x10 cells/cm .
The 106/ml feeder suspension can be stored at 4°C for up to 7 days and seeded as 
required.
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2.13. Passaging and Maintenance of ES cells:
Aspirated growth medium and washed the ES cells with PBS. Aspirated the PBS. 
Covered cells with cold trypsin /EDTA for a few seconds and then aspirated enough 
trypsin /EDTA just to leave a film covering the cells. Monitored the cells under a 
microscope to see when they had detached. Quickly added pre-warmed growth 
medium to inactivate the trypsin and resuspended the cells. Pipetted up and down a 
few times to generate a single cell suspension. Transferred the resuspended cells into 
a centrifuge tube and pellet at 1500g for 5min. Aspirated off the medium and 
resuspended the pellet in 10ml of pre-warmed growth medium. Counted the cells 
using a hemocytometer and calculated the number o f cells per ml. Aliquoted the 
appropriate number o f cells into pre-gelatinised plates for passage / experimentation. 
Checked the cells are attaching about 30-60 mins after replating.
It is important not to allow the cultures to become too crowded or too sparse during 
routine culture. Either situation sets up conditions in which selection for abnormal 
(fast growing, aneuploid) cells can occur. When in good health ES cells grow with a 
population doubling time of about 18-20 hours. For routine maintenance change the 
medium on day 2 and subculture on day 3.
2.5x104 ES cells/cm2 are replated so confluency achieved in 2-3 days.
2.1.4. Transfection of Packaging Cells:
2.1.4.i. Using Lipofectamine (Gibco BRL. Paisley .UK):
Day 1: Seeded a 100mm plate with 19xl05 BOSC cells.
Day 2: Prepared dilutions and solutions using Optimem (Gibco BRL,
Paisley, UK). Solution A: 640pl Optimem, 9.6pl DNA being transfected 
(0.5jig /pi). Solution B; 64pl Lipofectamine, 640pl Optimem. Added 
solutions A and B together. Allowed to stand at room temperature for 20 
minutes. Rinsed plate with 10ml Optimem. Added 5.12ml Optimem to 
transfection mix. Applied the 6.4ml transfection mix to the plate.
After 4 - 6  hours added 6.4ml of normal growth medium not containing antibacterial 
agents to the plate.
Day 3: Started retroviral supernatant production. 24 hours after the transfection mix 
was applied changed medium for 10ml o f normal growth medium.
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Day 4: Harvested 48 hour virion supernatant.
At 48 hours after transfection removed 5ml o f medium and centrifuged at 1500g for 5 
min. Sterilised the supernatant through a 0.45pm Nucleopore™ filter (Millipore UK 
Ltd., Herts, UK). Aliquoted into 1ml vials and froze at -70°C but PREFERABLY
used fresh by adding directly onto preseeded ES cells.
Day 5: Harvest 72 hour virion supernatant.
At 72 hours after transfection removed 5ml o f medium and treated the same as for the 
48 hour supernatant.
2.1.4.ii. Using Calcium Phosphate:
2X HEPES-buffered saline (HBS), (280mM NaCl, 1 OmM KC1, 1.5mM Na2HP04 
2H20 , 12mM dextrose, 50mM HEPES).
Adjusted the pH to 7.05 with 0.5 N NaOH and adjusted the volume to 100ml with 
distilled H20 . Sterilised the solution by passing it through a 0.22pm Nucleopore™ 
filter (Millipore UK Ltd., Herts, UK). Stored in 5ml aliquots at -20°C until required. 
2M CaCl2 Sterilised the solution by passing it through a 0.22pm Nucleopore™ filter 
(Millipore UK Ltd., Herts, UK). Stored in 1ml aliquots at -20°C until required.
0.1 X TE (pH 8.0), (ImM Tris' Cl (pH 8.0), 0.1 mM EDTA (pH 8.0)). Sterilised the 
solution by passing it through a 0.22pm Nucleopore™ filter (Millipore UK Ltd.,
Herts, UK) and stored at 4°C until required.
Prepared DNA (~20pg/106 cells) in 0.1 X TE (pH8.0) at a concentration of 40pg/ml.
Day 1: Seeded a 60mm plate with 1 x 106BOSC cells.
Day 2: Made up DNA mix, (5pg pHIT 60, 5pg pHIT 123, lOpg Construct).
For each 60mm plate to be transfected the calcium phosphate-DNA coprecipitate was 
prepared in a 2ml sterile eppendorf, (220pl DNA mix, 250pl 2XHBS). Gradually 
added 31 pi 2M CaCl2 with gentle agitation.
Incubated the mixture at room temperature for 20-30 mins. Removed the medium 
from the BOSC cells and replaced with fresh non-antibiotic BOSC medium 
(2.1.1.iv.). To 4.5ml o f medium added 0.5ml o f calcium phosphate - DNA suspension. 
Day 3: Approximately 20 hours later removed the transfection mix and replaced with 
normal BOSC growth medium.
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Day 4: Harvested virion supernatant.
At 48 hours after transfection remove the medium and centrifuge at 1500g for 5 
minutes. Sterilised the supernatant through a 0.45pm Nucleopore™ filter (Millipore 
UK Ltd., Herts, UK).
Aliquoted into 1ml vials and froze at -70°C but PREFERABLY used fresh by adding 
directly onto preseeded ES cells.
Day 5: Harvest virion supernatant.
At 72 hours after transfection removed the medium and treated the same as for the 48 
hour supernatant.
2.1.5. Retroviral Infection and G418 Selection of ES Cells:
Day 1: Seeded 60mm plates with 5xl05 ES cells/plate. It is important to also set up 
control plates o f the same ES cells, which will not undergo retroviral infection. This 
allows a more accurate judgement of completed selection.
Day 2: Began infection with the virion produced during retroviral packaging. Made 
up a master mix; Virion supernatant (volume retrieved during packaging), Polybrene 
lOpg/pl (40pl/p60 plate being infected), ESGRO® mLIF 106units (50units/ml), 
Growth Medium (make up final volume to 5ml/plate).
Aliquoted 5ml o f the master mix to each o f the test plates to be infected with the 
construct. On the control plates added exactly the same except for the virion 
supernatant, making up the final volume to 5ml/plate with normal ES growth medium 
(2.I.I.H.).
Day 3: 20 hours after the beginning of infection replaced the infecting medium with 
normal ES growth medium.
Day 4: Split the infected ES cells as necessary using normal ES growth medium and 
seeded onto STO feeders (2.1.2.).
Day 5: Began selection o f transfected colonies by introducing ES growth medium 
with G418 (Gibco BRL, Paisley, UK) included at a concentration previously 
established with the ES cells being used. The batch o f G418 utilised in this project is 
used at a concentration of 200pg/ml.
Day 6: Changed the G418 selection medium to clear away the initial abundance of  
cell debris due to the start o f selection.
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From this stage changed the G418 selection medium whenever deemed necessary. 
When all the colonies on the control plate had died it was reasonable to assume that 
all remaining colonies on the test plates contained a functional neomycin resistance 
gene. At this stage the remaining colonies were picked.
2.1.6. Replica plating of clones directly on picking:
Prepared a sterile round bottomed 96 multi well plate with aliquots of 3 5 pi 
trypsin/EDTA. Gelatin coated three flat bottomed, replica, 96 multi well plates. Added 
104 feeders/well with lOOpl of G418 selection medium.
Aspirated the medium from the plate containing the clones, washed with PBS and 
then covered the clones with a further 10ml of PBS.
Using a dissecting microscope with a 200pl pipette set at 5pl, sucked up the clones 
and ejected them one-by-one into the wells o f the round bottom multiwell dish, using 
a lid to prevent evaporation of the trypsin/EDTA.
Using an 8-way pipette resuspended the clones by pipetting up and down with 200pl 
of G418 selection medium. Transferred 70pl to each o f the three replicas, pre­
gelatinised multiwell plates.
Incubated in 37°C, 5% CO2 incubator.
Changed medium the next day and when a healthy culture was established (3-4 days), 
froze one or two o f the plates. Passaged the remaining plate or used it to prepare DNA 
or RNA samples for analysis.
2.1.7. Culturing of G418 resistant ES cell clones:
The clones needed to be grown up for further investigation. One vial of each clone 
was frozen away in liquid nitrogen with feeders and freezing mix in case of any 
mishap or future requirement.
When the clones had become confluent in the 96 well plate they were moved 
individually to 6 well plates with feeders, still using G418 selection medium. All of  
the clones grew at different rates so they needed to be examined individually on a 
daily basis.
37
Eventually when three confluent p60 plates o f each clone were established they were 
then harvested and prepped for DNA/RNA or stained for LacZ, depending on the type 
of clone. It must be remembered that when these ES cells are prepped they also 
contain a number o f feeder cells so there will be a certain amount of feeder genetic 
material in the resultant DNA/RNA preps. It was sometimes necessary to try and 
remove the ES cells from the feeder layer prior to preparation, as stated in the text. On 
these occasions the cells were passaged a number o f times until no feeder cells were 
visible.
2.1.8. Embryonic Stem (ES) Cell Metaphase Spreads:
Seeded cells in a 100mm dish overnight to be about 50-80% confluent the next day, 
- lx lO 6 ES cells.
Next day: Added Colcemid (Karyomax lOpg/ml, Gibco BRL, Paisley, UK ) to final 
concentration o f O.lpg/ml and incubated for 2-3 hours at 37°C. (Colcemid inhibits 
spindle formation and arrests dividing cells at mitotic metaphase). After incubation 
harvested cells as for normal passage, centrifuged at 1500g for 5 min. Aspirated 
medium. Resuspended in 5ml of PBS (37°C) gently, but thoroughly, so as to achieve 
a single cell suspension.
Centrifuged at 1500g for 5 min. Aspirated most o f the PBS (37°C), leaving about 
500pl and resuspend by gently flicking the tube. Added 10ml o f pre-warmed (37°C) 
0.075M KC1, (freshly made from 1M stock solution), and left at room temperature for 
15 minutes. (This time needs to be determined for different cell lines. The hypotonic 
KC1 swells the cells -  if  cells are excessively swollen chromosomes will scatter, if  
insufficiently swollen they will not separate.) For the black six cell line (SHB16.3) 
15min was found to be appropriate. Centrifuged at 1500g for 5min. Aspirated leaving 
about 500pl and resuspended by gently flicking the tube. With a PI000 Gilson 
pipette slowly added 2ml of fixative, dropwise. Incubated for 40min to allow fix to 
penetrate.
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—  Centrifuged at 1500g for 5 min. M----------------------
Aspirated leaving about 500pl of supernatant over pellet and resuspended by 
gently flicking.
-► Carefully added 10ml of fixative and inverted gently. --------------------------
Repeated the above steps twice. This removed cell debris and proteinaceous material. 
Removed all supernatant very carefully. Resuspended in less than 1ml of fixative 
(Methanol : Acetic Acid, 3 : 1 ) .  Dropped onto pre-cleaned microscope (soaked in 
50% EtOH : 50% Acetone), using a long-form glass Pasteur pipette. The nuclei burst 
and released the chromosomes. A height of about 20cm is optimal for good spreads 
with 1 drop/slide. The aim was to achieve discrete groups of well spread non- 
overlapping chromosomes. Allowed to air dry. The spreads could be examined under 
phase contrast but for a more distinguishable picture the spreads were stained with 
Geimsa / PBS 3% v/v for about 30min. Washed three times with PBS and examined 
under bright field.
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2.2. MOLECULAR BIOLOGY
2.2.1.MATERIALS
The sources o f specialised reagents are listed in Table 2.1. Reagents were of 
molecular biology grade, unless otherwise stated.
2.2.1.1. DNA Markers:
The DNA markers used were X DNA, X DNA digested with Hind III and lkb Plus 
DNA Ladder™. The fragment sizes of these markers (bp) are given in Table 2.2.
Table 2.2.1. Biological Reagents.
Reagent Supplier
TempliPhi™ 100 Amplification Kit, 
Sephaglas™ BandPrep Kit
Amersham Int. pic, Little Chalfont, 
Bucks., UK
Tris BDH Chemicals Ltd., Poole, UK
2mm and 1 mm Electrocuvettes Bio-Rad, Hertfordshire, UK.
Proteinase K Boehringer-Mannheim Ltd., Lewes, East 
Sussex
Clontech UK, Basingstoke, UK
Superffost Glass slides Coming Ltd., Bucks, UK
Dynal Oligo (dT) Magnetic Beads Dynal, Oslo, Norway
Chloroform, EDTA, Ethidium bromide, 
glycerol, hydrochloric acid, isopropanol, 
sodium chloride, sodium citrate, sodium 
hydroxide.
Fisher Scientific UK , Loughborough, 
UK.
Ladder, Oligonucleotide primers, DH5a 
Competent Cells, 50x TAE, 
SuperScrip™ II Reverse Transcriptase, 
RNase H, 3’ RACE System for Rapid 
Amplification of cDNA Ends, HEPES 
(N-[2-HydroxyEthyl]-Piperazine-N’-[2- 
EthaneSulphonic acid]), SOC Medium,
Gibco BRL, Paisley, UK.
Disposable Sterile Universal Tubes Greiner, Stonehouse, UK
Ethanol Hayman Ltd., Witham, Essex, UK.
0.22pM and 0.45 pM Nucleopore™ filters Millipore U.K. Ltd., Watford, 
Hertfordshire, U.K.
M13 sequencing primers, Custom 
Synthesised Primers
MWG Biotech UK., Milton Keynes, UK.
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Table 2.2.1 Biological Reagents. (Continued)
1 Restriction Enzymes New England Biolabs Inc. Hertfordshire, 
UK.
ABI Prism™ Dye Terminator Cycle 
Sequencing Reaction Ready Kit Version 
2.1
Perkin Elmer Applied Biosystems, 
Warrington, UK
Agarose, dNTPs, loading dye, MgCL 
(25mM), 10X Mg-free buffer, MMLV 
reverse transcriptase, Rnasin, 5X RT 
buffer, molecular mass markers (X and 
<p), Taq DNA Polymerase, Wizard plus 
SV Minipreps kit,
X-Gal, T4 DNA Ligase, 10X Ligation 
Buffer,
Promega Ltd., Southampton, UK.
RNeasy® Midi Kit, Plasmid Maxi Kit Qiagen Ltd., Crawley, Sussex, UK.
Ampicillin, BSA, chloroform, 
isoamylalcohol, formalin, formamide, 
HPLC water, LB agar, LB broth, Mineral 
oil, Sodium acetate, Phenol.
Sigma-Aldritch, Poole, UK.
Electro Ten-Blue™ Electroporation 
Competent Cells
Stratagene Cloning Systems, La Jolla, CA 
92037.
Better Buffer Web Scientific Ltd., Crewe, UK.
Table 2.2.2 DNA marker fragment sizes (bp) and their respective suppliers.
DNA marker Fragment sizes (bp) Supplier |
XDNA 48502 Promega Ltd., 
Southampton, 
UK.
A./HIND 111 23130, 9416, 6557, 4361, 2322, 2027, 564, 
125
Promega Ltd., 
Southampton, 
UK.
lkb Plus DNA 
Ladder™
12000, 11000, 10000, 9000, 8000, 7000, 
6000, 5000, 4000, 3000, 2000, 1650, 1000, 
850, 650,500, 400, 300, 200, 100
Gibco BRL, 
Paisley, UK.
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2.2.1.H. Medium:
LB-broth (mixture of casein enzymatic digest (10g/l), low-sodium yeast extract (5g/l), 
NaCl (5g/l), inert tableting aids (2g/l)) and LB-Agar (same as broth except for the 
addition o f bacteriological Agar (12g/l)) were prepared as described by the 
manufacturer, by the addition of the designated number of pellets to water. Following 
sterilisation, the medium was left to cool to below 50°C and where required, 
ampicillin was added at a concentration o f lOOpg/ml.
SOB medium (20M tryptone, 5M yeast extract, 0.5M NaCl, ImM MgCb, ImM 
MgS0 4 ) filter sterilised through 0.22pm Nucleopore™ filter (Millipore UK Ltd, 
Herts, UK).
Added to SOB medium to make SOC medium 20mM glucose solution, filter sterilised 
through 0.22pm Nucleopore™ filter (Millipore UK Ltd, Herts, UK).
2.2.1.iii. Antibiotics:
Stock solutions o f ampicillin (50mg/ml) and kanamycinin (lOmg/ml) in sterile dH20 
were passed through a 0.22pm Nucleopore™ filter (Millipore UK Ltd., Herts, UK) 
and stored at -20°C.
2.2.1.iv. Autoclaving Conditions:
Before any technique was performed using DNA or RNA, all equipment needed to be 
sterilised by autoclaving at 120°C at 15psi for 20 minutes.
2.2.1.v. Oligonucleotide Primers:
Lyophilised oligonucleotides were resuspended in sterile dH20 to a workable 
concentration as specified in the text and stored at -20°C.
Primers were designed using Apple Macintosh software called Amplify (Engels,
1993). Primers selected for optimal Tm (melting temperature) at the given primer 
length were assessed for possible sites of self-complementarity and complementarity 
to the second primer (especially 3' complementarity), mainly to reduce the risk of the 
formation o f primer-dimer products.
42
Table 2.2.3. Section 2.2. Routinely used primers, sequences and suppliers.
Primer DNA Sequence (5'->3') Supplier
M l3 forward GTTTTCCCAGTCACGAC
TT
MWG Biotech UK., Milton Keynes, 
UK.
M13 reverse CAGGAAACAGCTATAG
ACCATG
MWG Biotech UK., Milton Keynes, 
UK.
pAGAG5215 CG AG AT AC AG AGCT AG 
TT
MWG Biotech UK., Milton Keynes, 
UK.
pANE0659 CCGAGTACGTGCTCGCT
C
MWG Biotech UK., Milton Keynes, 
UK.
pAGAG4822 CAACGTCTCTTCTTGAC
ATCT
MWG Biotech UK., Milton Keynes, 
UK.
pANEOR887 C AACGCT AT GT CCT GAT 
AGCG
MWG Biotech UK., Milton Keynes, 
UK.
pANEO260 TGCAATCCGTCTTGTTC
A
MWG Biotech UK., Milton Keynes, 
UK.
Oligo-dT TTTTTTTTTTTTTTT Pharmacia Biotech Ltd., St. Albans, 
UK.
2.2.1.vi. Reagents and Buffers:
All routine laboratory solutions were prepared using db^O. Sterilisation was achieved 
by autoclaving at 120°C at 15psi for 20 minutes where required. Heat sensitive 
components were passed through 0.22pm Nucleopore™ filter (Millipore UK Ltd., 
Herts, UK) and added separately following autoclaving.
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Table 2.2.4. List o f routinely employed solutions, reagents and medium.
1 Procedure Solution Components I
Agarose Gel 
Electrophoresis
Electrophoresis loading 
dye
50% (v/v) Glycerol, 1% 
(w/v) Bromophenol blue, 
lx  TAE (sterilised)
mRNA Purification from 
Total RNA - Oligo (dT) 
Magnetic Beads
IX Binding buffer (Dynal) lOOmM Tris-HCl, pH 7.5 
500mM LiCl 
lOmM EDTA, pH 8.0 
1% LiDS 
5mM DTT
Washing Buffer B (Dynal) lOmM Tris-HCl, pH 7.5 
0.15M LiCl 
ImM EDTA
RNA preparation using 
Qiagen measy midi kit
Buffer RLN 50mM Tris.Cl, pH 8.0
140mM NaCl
1.5mM MgCl2
0.5% (v/v) Nonidet® P-40
(1.06g/ml)
Buffer RLT Protected recipe
Buffer RW1 Protected recipe
Buffer RPE Protected recipe
Polymerase Chain 
Reaction
lOx Taq Polymerase 
Buffer (Promega Ltd., 
Southampton, UK)
50 mM KC1, 10 mM Tris- 
HCl (pH 9.0 at 25°C), 0.1 
% Triton®x-100
Genomic DNA preparation Proteinase K lysis buffer lOmM Tris-Cl, pH 7.6 
lOmM EDTA 
0.6% SDS
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Table 2.2.4. (Continued) List of routinely employed solutions, reagents and medium.
I Mini Preparation of DNA 
using Promega Wizard SV 
Miniprep DNA 
Purification System
Cell Resuspension 
Solution
50mM Tris-HCl (pH 7.5) 
lOmM EDTA 
lOOpg/ml RNase A
Cell Lysis Solution 0.2M NaOH 
1% SDS
Neutralisation Solution 4.09M guanidine 
hydrochloride I 
0.759M potassium acetate 
2.12M glacial acetic acid 
Final pH is approximately 
4.2.
Column Wash Solution 60mM potassium acetate 
8.3mM Tris-HCl (pH 7.5) 
0.04mM EDTA (pH 8.0) 
60% ethanol
Gel Purification, 
Sephaglas™ BandPrep Kit 
(Amersham Int. pic, 
Bucks, UK)
Sephaglas BP 20% (w/v) Sephaglas BP 
suspended in distilled 
water containing 0.15% 
Kathon® CG/ICP Biocide.
Gel Solubiliser Buffered solution 
containing Nal.
Wash Buffer 20mM Tris-HCl (pH 8.0), 
ImM EDTA and O.lmM 
NaCl solution to which 
18ml o f absolute ethanol 
must be added before use.
Elution Buffer lOmM Tris-HCl (pH 8.0), 
ImM EDTA.
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Table 2.2.4. (Continued) List of routinely employed solutions, reagents and medium.
Maxi Preparation of DNA Buffer PI 50mM Tris.Cl, pH 8.0
Using Qiagen Maxi Kit lOmM EDTA, lOOpg/ml 
Rnase A
Buffer P2 200mM NaOH, 1% SDS
Buffer P3 3.0M potassium acetate, 
pH 5.5
Buffer QC 1.0M NaCl,
50mM MOPS, pH 7.0, 
15% Isopropanol
Buffer QBT 750mM NaCl, 50mM 
MOPS pH 7.0, 15% 
Isopropanol, 0.15% 
Triton® X-100
Buffer QF 1.25M NaCl 
50mM Tris.Cl, pH 8.5 
15% Isopropanol
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2.2.2. METHODS
2.2.2.i. Preparing Electrocompetent Bacterial Cells:
Streaked out and grew up the relevant bacteria overnight at 37°C on agar plates. 
Inoculated 10ml o f LB with a single colony and left overnight in shaker incubator at 
37°C and 225rpm. Inoculated 400ml of LB with 4ml of the overnight culture. Grew 
up in shaker incubator at 37°C and 225rpm for about 3 Va hours. Spun culture at 4°C 
for 10 mins, 7000g. Resuspended in 200ml ice cold ImM HEPES. Spun down at 4°C 
for 10 mins, 7000g.
Resuspended in 100ml ice cold ImM HEPES. Spun down at 4°C for 10 mins, 7000g. 
Resuspended in 20ml ice cold 10% Glycerol ImM HEPES. Spun down at 4°C for 10 
mins, 7000g. Resuspended in 5ml ice cold 10% Glycerol ImM HEPES. Aliquoted 
cell suspension in 50pl aliquots on ice and froze immediately at -70°C for storage 
until required.
2.2.2.ii. Electroporation of electrocompetent bacteria DH5 and HB101:
Thawed a 50pl vial o f electrocompetent bacteria on ice. Added 1 pi o f plasmid DNA 
(lOpg/pl) to be introduced into the bacteria and then transferred this mixture to a pre­
chilled 2mm cuvette and kept on ice. Set the Gene Pulser (Bio-Rad, Hertfordshire, 
UK) to 25pF and 2.5kV with the pulse controller set to 200Q. Dried the cuvette with 
tissue and placed into the electroporation chamber. Pulsed once. A pulse with a time 
constant o f 4.5 to 5 msec was obtained.
Added 300pi o f LB to the cuvette and then using a sterile pasteur pipette transferred 
lOOpl from the cuvette to each of three agar plates with the relevant antibiotic 
selection. Spread out using a sterile spreader, allowed to dry, inverted and incubated 
overnight at 37°C.
2.2.2.iii. Electroporation of ElectroTen Blue Electrocompetent Cells (Stratagene, 
La Jolla, CA.):
Thawed electrocompetent bacteria on ice. Added lpl o f plasmid DNA (10pg/pl)/40pl 
of bacteria. Transferred this mixture to a pre-chilled 1mm cuvette and kept on ice. Set
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the Bio-Rad Gene Pulser machine to capacitance 25pF, applied Volts 1700V and 
resistance 600Q. Dried the cuvette with tissue and placed into the electroporation 
chamber. Pulsed once and quickly removed the cuvette. A pulse with a time constant 
of 4.5 to 5msec was achieved. Immediately added 960pl of 37°C SOC medium to 
resuspend the cells. Transferred each cell suspension to a sterile 15ml polypropylene 
tube. Incubated the sample at 37°C for 90min while shaking at 225rpm. Using a 
sterile spreader, spread the transformation mixture onto LB-ampicillin agar plates, 
allowed to dry, inverted and incubated overnight at 37°C.
2.2.2.iv. Agarose Gel Electrophoresis:
DNA/RNA samples were resolved by gel electrophoresis. Agarose gels were prepared 
by melting the required amount of agarose to give a particular percentage strength gel, 
agarose : IX TAE buffer. When the gel mix was below 50°C ethidium bromide was 
added to a final concentration of 0.5pg/ml. (No ethidium bromide was added to the 
IX TAE running buffer as no suitable disposal available. This causes the dark and 
light variations o f the gel as the ethidium bromide travels in the opposite direction to 
the DNA). The appropriate amount of DNA/RNA was mixed with loading dye and 
loaded onto the gel. For DNA gels, the appropriate molecular weight marker was also 
loaded (Table 2.2).
Electrophoresis was performed at the required voltage over varying time periods in a 
Pharmacia GNA-100 tank in 1XTAE buffer. Nucleic acid bands were then visualised 
under ultraviolet light and a picture taken.
2.2.2.V. Gel purification and DNA precipitation:
Ran the preparative digest on the 1% agarose gel and then cut out the required DNA 
bands avoiding excessive exposure to ultraviolet light.
Using the Sephaglas™ BandPrep kit (Amersham Int. pic, Bucks, UK) eluted the DNA 
from the gel slice. Transferred the gel slice to a pre-weighed 1.5ml microcentrifuge 
tube. Determined the weight of the actual gel slice. It weighed <250mg so the 
following volumes were used, however if it weighs >250mg the reagent volumes are 
increased proportionately as advised by the manufacturer. 250pl o f gel solubiliser was
48
added, vortexed vigorously and incubated at 60°C for 5-10min or until the agarose 
slice was dissolved. Vortexed the container o f Sephaglas BP to form a uniform 
suspension, ensured no clumps of glass remained. Added 5 pi o f the suspension to the 
dissolved gel slice and vortexed gently. Incubated for 5min at room temperature, 
vortexing gently every minute to resuspend the Sephaglas. Pulsed for 30sec in a 
microcentrifuge and carefully removed the supernatant, taking care not to disturb the 
Sephaglas pellet. Repeated the pulse spin for 30sec in a microcentrifuge and carefully 
removed any residual liquid, taking care not to disturb the pellet. Added 80pl of Wash 
Buffer to the pellet and pipetted up and down several times to resuspend the pellet. 
Pulsed for 30sec in a microcentrifuge and carefully removed the supernatant, taking 
care not to disturb the pellet. Repeated this step twice for a total o f three washes. 
Tapped the tube to partially disperse the pellet. Allowed the pellet to air-dry for at 
least lOmin. Checked to be sure that the glass was completely dry. Added 20pl of 
Elution Buffer, vortexed gently to resuspend the pellet and incubated for 5min at 
room temperature with periodic agitation. Spun at high speed for lmin in a 
microcentrifuge. Carefully removed the supernatant and placed it in a clean 
microcentrifuge tube, taking care not to disturb the pellet. The eluted DNA was stored 
at -20°C until required.
2.2.2.vi. DNA Ligation:
Better to have a higher concentration of the insert than the digested plasmid so as to 
increase the probability o f them combining to form a recombinant plasmid.
Vector : Insert MOLAR ratio between 1:5 and 1:10.
Mixed ligation components together; Xpl Vector, Ypl Insert, 2pl Ligation Buffer, 
lfil Ligase, (20 -  (X+Y+3) pi) Sterile H2O.
Gently flicked the bottom of the tubes to mix the contents and then microfuged for 2- 
3 seconds so that all o f the contents were at the bottom of the tube. Incubated 
overnight at 16°C.
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2.2.2.vii. Single Analytical Digest:
For analytical analysis used 200-500ng o f plasmid DNA in a 20pl digest.
Mixed the following components; Xpl DNA, 2pi Digest Buffer, lpl Restriction 
Enzyme, (20 -  (X+3)pl) Sterile H2O. If BSA was required by the restriction enzyme 
being used, added to a final concentration o f lOOpg/ml. Gently flicked the bottom of 
the tube to mix the contents and then microfuged for 2-3 seconds so that all of the 
contents were at the bottom of the tube. Incubate at the optimum temperature for 
about 2-3 hours.
2.2.2.viii. Single Preparative Digest:
For preparative digests used 750-1500ng in a total volume o f 50pl.
Mixed the following components; Ypl DNA, 5pi Digest Buffer, 2pl Restriction 
Enzyme, (50 -  (Y+7)pl) Sterile H2O. If BSA was required by the restriction enzyme 
being used, added to a final concentration o f lOOpg/ml. Gently flicked the bottom of  
the tube to mix the contents and then microfuged for 2-3 seconds so that all o f the 
contents were at the bottom of the tube. Incubated at the optimum temperature for 
about 2-3 hours.
2.2.2.ix. Large Scale Preparation of Plasmid DNA:
DNA was isolated using Qiagen Maxi Prep Kit as described in the manufacturers 
protocol (Qiagen Ltd., Sussex, UK). Picked a single colony from a freshly streaked 
selective LB-Agar plate and inoculated a starter culture of 5ml LB medium containing 
the appropriate selective antibiotic. Incubated for about 8 hours at 37°C with shaking 
at 250rpm. Diluted the starter culture 1/500 into selective LB medium. Grew at 37°C 
for 12-16 hours with shaking at 250rpm. Harvested the bacterial cells by 
centrifugation at 6000g for 15min at 4°C. Resuspended the bacterial pellet in 10ml of  
Buffer PI (50mM Tris.Cl pH8.0, lOmM EDTA, lOOpg/ml RNAse A). Added 10ml of 
Buffer P2 (200mM NaOH, 1% SDS), mixed gently but thoroughly by inverting 4-6 
times and incubated at room temperature for 5min. Added 10ml of chilled Buffer P3 
(3.0M potassium acetate pH5.5), mixed immediately but gently by inverting 4-6 times 
and incubated on ice for 20min. Centrifuged at 20000g for 30min at 4°C. Removed
50
supernatant containing plasmid DNA promptly. Re-centrifuged the supernatant at 
20000g for 15min at 4°C. Removed supernatant containing plasmid DNA promptly. 
Equilibrated a QIAGEN-tip 500 by applied 10ml Buffer QBT (750mM NaCl, 50mM 
MOPS pH7.0, 15% Isopropanol, 0.15% Triton®X-100) and allowed the column to 
empty by gravity flow. Applied the supernatant containing the plasmid DNA to the 
QIAGEN-tip and allowed it to enter the resin by gravity flow. Washed the QIAGEN- 
tip with 2 x 30ml Buffer QC (1.0M NaCl, 50mM MOPS pH7.0, 15% Isopropanol). 
Eluted DNA with 15ml Buffer QF (1.25M NaCl, 50mM Tris.Cl pH8.5, 15% 
Isopropanol). Precipitated DNA by adding 10.5ml (0.7 volumes) room temperature 
isopropanol to the eluted DNA. Mixed and centrifuged immediately at 15000g for 
30min at 4°C. Carefully decanted supernatant. Washed DNA pellet with 5ml o f room 
temperature 70% ethanol and centrifuged at 15000g for lOmin. Carefully decanted 
supernatant without disturbing the pellet. Air-dried the pellet for 1 Omin and dissolved 
the DNA in a suitable volume of buffer TE, pH 8.0. Stored the purified plasmid at - 
20°C until required.
2.2.2.x. Preparation of Plasmid DNA:
Plasmid DNA was prepared using the Promega Wizard® PlusSV Minipreps Kit 
(Promega Ltd., Southampton, UK). Picked a single colony from a fresh selective LB- 
Agar plate and inoculated 10ml of LB medium containing the same antibiotic. 
Incubated overnight (12-16 hours) at 37°C with shaking at 225rpm. Harvested 1ml of 
bacterial culture by centrifugation for 5min at lOOOOg. Poured off supernatant and 
blotted the inverted tube on a paper towel to remove excess medium. Added 250pl o f  
Cell Resuspension Solution and completely resuspended the cell pellet by pipeting. 
Added 250pl o f Cell Lysis Solution (0.2M NaOH, 1% SDS) and mixed by inverting 
the tube 4 times. Incubated at room temperature until the cell suspension cleared, 
between l-5min, no longer. Added lOpl of Alkaline Protease Solution and mixed by 
inverting the tube 4 times. Incubated for 5min at room temperature. Added 350pl of 
Neutralisation Solution (4.09M guanidine hydrochloride, 0.759M potassium acetate, 
2.12M glacial acetic acid, pH4.2) and immediately mixed by inverting the tube 4 
times. Centrifuged the bacterial lysate at 14000g in a microcentrifuge for lOmin at 
room temperature. Transfered the cleared lysate to the prepared Spin Column by
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decanting. Avoided disturbing or transferring any o f the white precipitate with the 
supernatant. Centrifuged the supernatant at 14000g in a microcentrifuge for lmin at 
room temperature. Removed the Spin Column from the tube and discard the flow 
through from the Collection Tube. Reinserted the Spin Column into the Collection 
Tube.
Added 750pl o f Column Wash Solution to the Spin Column. Centrifuged at 14000g in 
a microcentrifuge for lmin at room temperature. Removed the Spin Column from the 
tube and discarded the flow through. Re-inserted the Spin Column into the Collection 
Tube. Repeated wash using 250pl o f Column Wash Solution (60mM potassium 
acetate, 8.3mM Tris-HCl (pH 7.5), 0.04mMEDTA (pH 8.0), 60% ethanol). 
Centrifuged at 14000g in a microcentrifuge for 2min at room temperature. Transfered 
the Spin Column to a new, sterile 1.5ml microcentrifuge tube being careful not to 
transfer any o f the Column Wash Solution with the Spin Column. Eluted the plasmid 
DNA by adding lOOpl o f Nuclease-Free Water to the Spin Column. Centrifuged at 
14000g for lmin at room temperature in a microcentrifuge. Stored the purified 
plasmid at -20°C.
2.2.2.xi. Genomic DNA preparation:
Washed a p i00 plate o f ES cells twice with PBS. Trypsinised the cells for about 2 
minutes and then inactivated with growth medium. Spun the suspension at lOOOOg for 
5 min. Resuspended the pellet in 1ml PBS, transferred to a microcentrifuge tube and 
spun at lOOOOg for lOmin. Aspirated the PBS leaving a little behind to resuspend the 
pellet by flicking the tube. Added 200pl of proteinase K lysis buffer and proteinase K 
to a final concentration o f 250pg/ml. Inverted the tube gently and incubate at 55°C for 
at least 3-4 hours, with regular inversion. Added 1ml 70% acetone / 5% DMF at - 
20°C with glass pipette. Inverted vigorously to get DNA out o f solution. Spun for 
lOmin at lOOOOg. Washed pellet twice with 70% EtOH. Dried pellet at room 
temperature . Dissolved precipitated DNA in 200pl TE pH8.0 by heating to 70°C. 
Measured concentration on spectrophotometer OD260/280-
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2.2.2.xii. Plasmid Rescue:
Set up preparative digests (2.3.8.) of genomic DNA (gDNA) harvested from shuttle 
vector gene trap clones (2.3.5.).
Table 2.2.5 -  Restriction enzymes fNew England BioLabs. Hertfordshire.
UK.) used to give particular flanking regions for each shuttle plasmid used.
PSHUT+124K (A) PSHUT+124K SD126 (1)
Enzymes to 
give both 
5’ and 3’ 
Flanking Regions
Enzymes to 
give 5’ 
Flanking 
Region Only
Enzymes to 
give 3* 
Flanking 
Region Only
Enzymes to 
give both 
5’ and 3’ 
Flanking Regions
Enzymes to 
give 5’ 
Flanking 
Region Only
Enzymes to 
give 3’ 
Flanking 
Region Only
Hind III BstE II Xba I Bsu36 I Nae I Bgl II
EcoR I Afl II Sail Aat II Nco I Hind III
Kpnl Bsu36 I S fil Kpnl Rsr II Xho I
Xba I
2.2.2.xii.a. Ligation of digested gDNA:
The gDNA has to be religated at low concentrations so as to increase the likelihood of 
circularisation of the various fragments, instead o f religation back into chromosome 
size pieces.
Mix the reaction components as follows; lpl digested gDNA, 5pi T4 DNA ligase, 
lOpl ligase buffer, 484pl sterile H2O. Incubated overnight at 4°C.
2.2.2.xii.b. Precipitation of ligated gDNA:
With such a dilute ligation mixture it was necessary to precipitate the DNA before 
transforming. DNA was precipitated overnight at -20°C, or 30 minutes at -80°C, by 
adding 2 volumes o f 100% ethanol and 0.1 volume of 3M sodium acetate (pH 4.8).
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The DNA was recovered by centrifugation at 13000g for 10 minutes. The supernatant 
was removed and the DNA pellet dried at room temperature. The DNA was 
resuspended in an appropriate volume of sterile water.
2.2.2.XU.C. Electroporation of Electro Ten-Blue Electrocompetent Bacteria 
(Stratagene) with Plasmid DNA:
These electrocompetent bacteria (Stratagene, La Jolla, CA.) have a very high 
efficiency of lxlO 10 cfu/pg of pUC18 DNA. This high efficiency is needed when 
working with plasmid rescue as the number o f re-ligated plasmids is likely to be low. 
To prepare the ligated DNA prior to transfection, Stratagene supply a vial of 
StrataClean resin to ensure the complete removal o f protein contaminants.
Vortexed the StrataClean resin to completely resuspend. Pipetted the 5pi o f slurry into 
the tube containing the ligation reaction. Vortexed mixture for 15 seconds. Pelleted 
the resin by centrifugation at 2000g for lmin. Carefully removed the supernatant 
containing the DNA to a fresh microcentrifuge tube. Used the entire lOpl supernatant 
sample to electroporate into the competent cells. Thawed the electrocompetent cells 
on ice. Aliquoted 40pl o f cells into chilled 1.5ml microcentrifuge tubes, pipeting very 
gently as electrocompetent cells are very fragile. Added experimental DNA to 
electrocompetent cells. For optimal efficiency, added lpl o f plasmid DNA (lOpg/pl) / 
40pl o f cells. Completed the procedure as specified in section 2.2.2.iii.
Picked resistant colonies containing rescued plasmid, grew up in LB and then mini 
prepped (Section 2.2.2.x.) prior to setting up sequencing PCR reaction (Section
2.2.2.xvi.)
2.2.2.xii.d. Rolling Circle Amplification:
Due to the limited amount o f circularised plasmid retrieved from the ligation reaction, 
amplification of that retrieved was attempted using TempliPhi™ DNA amplification 
kit (Amersham Biosciences, UK Ltd., Bucks, UK).
The reaction mixture consisted of lpl template DNA (precipitated ligation reaction
2.2.2.xii), 5pl Sample Buffer (random hexamers), 5pl Reaction Buffer (salts and 
deoxynucleotides), 0.2pl Enzyme mix (<|>29 DNA polymerasse in 50% glycerol).
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Incubated at 30°C for 8 hours. Inactivated polymerase by heating to 65°C for 10 
minutes. Proceeded with electroporation (2.2.2.xii.c.).
2.2.2.xiii. Preparation of Cytoplasmic RNA:
Cytoplasmic RNA was isolated using Qiagen RNeasy midi kit (Qiagen Ltd., Sussex, 
UK), instead o f total RNA to try and minimise DNA contamination.
(% oUsed 5 x 1 0  -  1 x 10 cells grown in a monolayer. Lysed cells directly on culture dish 
by adding 1ml o f cold (4°C) Buffer RLN [50mM Tris.Cl pH 8.0, 140mM NaCl, 
1.5mM MgCb, 0.5% (v/v) Nonidet® P-40 (1.06g/ml)]. Detached cells gently using a 
cell scraper and transferred to a centrifuge tube. Incubated on ice for 5min. 
Centrifuged lysate at 4°C for 5min at 500g. Transferred supernatant to an RNase-free 
15ml centrifuge tube and discarded the pellet. Added 4ml Buffer RLT. Mixed 
thoroughly by shaking. Added 2.8ml 100% ethanol and mix thoroughly by shaking. 
Applied the sample to RNeasy midi column placed in a 15ml centrifuge tube. 
Centrifuged at 3000g for 5min. Discarded the flow through. Added 15ml Buffer RW1 
to the RNeasy column. Centrifuged at 3000g for 5min. Discarded the flow through. 
Added 2.5ml Buffer RPE to the RNeasy column. Centrifuged at 3000g for 2min. 
Discarded the flow through. Added another 2.5ml Buffer RPE to the RNeasy column. 
Centrifuged at 3000g for 5min to dry the RNeasy silica-gel membrane. Eluted by 
transferring the RNeasy column to a new 15ml collection tube. Pipetted 200pl of  
RNase-free water directly onto the spin-column membrane. Let it stand for lmin and 
then centrifuged for 3min at 3000g. Stored RNA at -70°C until required.
2.2.2.xiv. Messenger RNA Extraction:
Used 75jig total RNA and adjusted the volume of total RNA sample to lOOpl using 
RNase free water. Heated the sample to 65°C for 2 min to disrupt secondary 
structures. Remove 200pl o f resuspended Dynabeads Oligo (dT)25 into a 1.5ml 
microcentrifuge tube and place the vial onto the magnetic stand (Promega Ltd., 
Southampton, UK). After 30 seconds pipetted off the supernatant and washed the 
Dynabeads Oligo (dT)25 once. Removed the tube from the magnet, resuspended the 
beads in lOOpl Binding Buffer (lOOmM Tris-HCl (pH7.5), 500mM LiCl, lOmM
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EDTA (pH8.0), 1% LiDS, 5mM DTT) and placed the tube back on the magnet. After 
30 seconds pipetted off the supernatant and removed the tube from the magnet. N.B. 
Do not leave the Dynabeads Oligo (dT)25 unsuspended for a long period as drying of 
the beads may reduce their efficiency.
Added lOOpl Binding Buffer to the Dynabeads Oligo (dT)25 and the added the total 
RNA to the Dynabeads Oligo (dT)25 in Binding Buffer.
Mixed thoroughly and annealed by rotating on a mixer for 3-5 min at room 
temperature. Placed the tube on the magnet for at least 30sec or until the solution is 
clear and removed the supernatant. Removed the tube and washed twice with 200pl 
Washing Buffer B (lOmM Tris-HCl (pH7.5), 0.15M LiCl, ImM EDTA) using the 
magnetic stand. Removed all the supernatant between each washing step. The 
complete removal o f supernatant is extremely important when working with small 
volumes.
Eluted in lOpl RNase free water by heating to 80-90°C for 2 min. Placed the tube 
immediately on the magnet and transferred the eluted mRNA to a new RNase free 
tube.
2.2.2.xv. PCR Amplification:
PCR was performed using a reaction mixture containing the target DNA, 5U Thermus 
aquatic us (Taq) polymerase, 0.4pM of specific primer, 0.2mM dNTPs, 2.5mM MgCL 
and IX Taq buffer. Preparative mixtures (lOOpl) were contained in 500pl thin walled 
PCR tubes and overlaid with mineral oil. Denaturing, annealing and chain extensions 
were performed on a Biometra thermocycler (Biometra, Thistle Scientific, Glasgow, 
UK) programmed according to required conditions. Following amplification, the 
aqueous layer was transferred to a fresh tube for analysis.
2.2.2.xvi. DNA Sequencing using A B I3100 System:
The DNA to be analysed (approximately lOOng PCR product) was combined with 
ABI BigDye™ V2.1 (lp l), Better Buffer (5pl) (Web Scientific Ltd., Crewe, UK) and 
1.6pM M l3 forward/reverse primer (1.5pl). A final volume of 15pi was achieved by 
the addition of sterile water. The reaction mix was placed in a Biometra thermocycler
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using the programme of 96°C for 3 minutes (initial denaturation), followed by 25 
repeated cycles of 96°C for 15 seconds (denaturation), 50°C for 10 seconds 
(annealing) and 60°C for 2 minutes (extension). Labelled sequencing products were 
precipitated by the addition of 2.5M EDTA (2pl) and 95% ethanol (60pl). The 
reaction mix was centrifuged at 2000g for 30 minutes (4°C), then the supernatant 
removed and the pellet washed with ice-cold 70% ethanol (250pl). The mix was spun 
for a further 15 minutes at 2000g (4°C), the supernatant removed and the pellet air- 
dried.
Prior to sequence analysis, the pellet was dissolved in 15pl sequencing grade 
formamide and denatured at 95°C for 2 minutes before placing on ice for 1 minute. 
Sequence analysis was performed by capillary electrophoresis by the sequencing 
technician, Mr. Ezra Linley.
2.2.2.xvii. Quantification of Nucleic Acid Concentration by Spectrophotometry:
Nucleic acids absorb at a wavelength of 260nm. Given that an absorbance o f 1 OD is 
equivalent to 50pg/ml o f double stranded DNA or 40pg/ml single stranded DNA and 
RNA, it was possible to quantify DNA and RNA concentrations. Furthermore, 
determining absorbencies at 230nm and 280nm provides a means of examining 
sample purity. Pure preparations of DNA and RNA will have A260/A280 ratio of 
approximately 1.8 and 2.0 respectively. Any protein or phenol contaminants will 
lower these values. Likewise a A260/A280 ratio of less than 2 is considered to be 
indicative of ethanol or salt contamination (Sambrook and Gething, 1989).
Optical density readings were performed on a Camspec M330 spectrophotometer 
(Camspec, Cambridge, UK).
2.2.2.xviii. PCR Screening of Bacterial Colonies:
PCR was used to amplify cDNA inserts from bacterial colonies harbouring plasmid 
DNA. A single recombinant colony was inoculated into 1ml of LB medium 
containing the appropriate antibiotic selection. The culture was incubated with 
constant agitation (37°C for 3 h at 300rpm). A 500pl aliquot was placed in a sterile 
microcentrifuge tube and the cells were pelleted by centrifugation (10 OOOg for lmin
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at RT). The medium was removed and the cells were resuspended in 50pl of sterile 
dE^O. The cells were lysed (95°C for 5 min) and centrifuged (10 OOOg for 1 min at 
RT) to pallet any debris. The supernatant (which contained the plasmid DNA 
template) was removed to a clean microcentrifuge tube and stored (-20°C) for future 
use.
Amplification reactions containing 2pl template, 0.2mM dNTP’s 0.4pM M l3 
forward/reverse primers, lx reaction buffer, 2.5mM MgCh and 5U of Taq DNA 
polymerase were aliquoted into sterile 0.5ml microcentrifuge tubes. The reactions 
were made up to a final volume of 20pl with sterile dH20. The tubes were briefly 
centrifuged (10 OOOg for 10 seconds at RT) and a drop o f mineral oil was laid on top 
to minimise evaporation. Amplifications were performed as detailed previously 
(Section 2.3.15.).
2.2.2.xix. Purification of PCR Products Using QIAquick PCR Purification Kit:
PCR products were purified using QIAquick PCR purification kit (Qiagen Ltd, 
Crawley, UK), as described in the manufacturers protocol.
Added 5x volume o f buffer PB to lx  PCR product and mixed thoroughly. The 
solution was transferred to a QIAquick spin column and spun at lOOOOg for 1 minute. 
To wash, added 750pl buffer PE and spun at lOOOOg for 1 minute, discarded the flow 
through and spun for a further minute to dry the QIAquick spin column membrane. 
Moved the column to a clean 1,5ml microcentrifuge tube and eluted the DNA in 50pl 
TE pH8 by adding it to the centre of the QIAquick spin column membrane and 
spinning for 1 minute at lOOOOg. Purified cDNA was stored at -20°C.
58
2 3 . CREATING TRANSGENICS
NB: Even though no transgenics were ever created in this project it was felt that it 
was appropriate to include this section o f procedures as a great deal of time and effort 
was dedicated to this endeavour.
All animals were maintained in accordance with Animal Scientific Procedures Act 
1986.
23.1. Collecting blastocysts:
On day 3.5 post coitum (pc) the pregnant female is killed by cervical dislocation. 
Abdominal skin is sterilised by swabbing with 70% ethanol.
Grasped the skin with blunt forceps and lifted, using a pair o f dressing scissors 
opened the abdominal cavity to display the contents. Displaced the guts to one side, 
located and removed the two uterine horns. Trimmed away the associated adipose 
tissue and mesenteries using a pair of fine scissors. Filled a 1ml disposable syringe 
with Optimem media, BSA (4mg/ml) and 2x penicillin-streptomycin, attached a 25- 
gauge hypodermic needle. Introduced the needle into one end o f the uterine horn and 
recovered the contents by flushing a stream of medium through the uterine lumen into 
a p35 tissue culture dish (Nunc, Fisher Scientific Equipment UK Ltd., Loughborough, 
UK). Discarded the one horn and repeated with the remaining horn. The resulting 
blastocysts were then transferred using a drawn out Pasteur pipette held in a mouth- 
controlled tube to small drops of pre-equilibrated media under inert liquid paraffin oil 
and returned to a 37°C, CO2 incubator until required.
23.2. Injecting selected ES cell clones into host blastocysts:
2.3.2.i. Preparation of pipettes:
Before injecting pipettes were pulled on an automatic electro-magnetic electrode 
puller (Model 773, micropipette puller, Campden Instruments, Sileby, UK). The glass 
capillary tubing used to construct the pipettes was thin walled (1.0mm external 
diameter, 0.8mm internal diameter) borosilicate glass without a fibre (Harvard 
Apparatus, Edenbridge, Kent). Once a number of pipettes have were pulled they were 
fashioned into either injection or holding pipettes.
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2.3.2.1.a. Injection pipettes; have an internal diameter only marginally larger than the 
stem cells they are designed to inject and a sharp point which allows the needle end to 
penetrate cleanly into the blastocoel cavity. This was achieved by snapping the glass 
capillary by hand under a stereo dissecting microscope, at a magnification of x40, 
using a sharp scalpel blade and a spongy transparent silicon rubber sheet. As thin 
walled borosilicate glass was used the pulled glass usually breaks with a sharp 
bevelled end when touched with the edge o f the scalpel blade. Using a De Fonbrune 
microforge (Beaudouin, Rue Ratud, Paris) a 30° bend was introduced and the 
orientation of the bend is important as it must be ensured that the bevel is facing the 
experimenter when in place in the injection chamber.
2.3.2.1.b. Holding pipettes; are blunt flame-polished pipettes through which suction is 
applied to immobilise the blastocyst. An appropriate diameter is about 80 -100pm. 
Secondary structure was necessary to enable the micro-instruments to be moved 
freely in the injection chamber (using the joystick manipulator arm) in the plane of 
focus without the necessity of re-adjusting their position. Using a De Fonbrune 
microforge (Beaudouin, Rue Ratud, Paris) 30° bends were introduced.
2.3.2.ii. Injecting:
Using a magnification o f x200 selected the cells for injection from the population 
seeded on the floor of the injection chamber. Collected the cells into the injection 
pipette by gentle suction. Selected about 12-15 cells and positioned them near the tip 
of the injection pipette.
Orientated the blastocyst so that the inner cell mass (ICM) was at the side being held 
by the pipette. Did not apply too much suction as this would cause the blastocyst to 
collapse. When the injection pipette was positioned correctly pushed the pipette into 
the blastocoel cavity. The speed of the movement was important and had 
consequences on the success of the injection. If entry was too slow and hesitant, the 
pressure in the blastocoel would be released and the embryo would collapse before 
the pipette had penetrated. If the entry movement was very fast and uncontrolled, the 
pipette would enter the blastocoel and it is easy to accidentally damage the end on the 
opposing holding pipette, or damage the ICM component of the embryo.
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When the pipette was clearly within the blastocoel the cells were expelled from the 
injection pipette by gently increasing the pressure.
When the cells had been expelled, slowly withdrew the pipette. Retained the 
blastocyst by suction on the holding pipette, changed to lower power objective and 
moved the embryo to a remote location in the injection chamber. Released the 
blastocyst by reducing the suction.
Repeated this procedure on successive blastocysts, placing successful embryos in one 
group and segregating failed embryos in another group.
Transferred the successfully injected embryos back to the culture drops and incubated 
at 37°C. Re-expansion of the blastocysts normally occurs within 1-3 hours.
2.3.3. Surgical transfer of embryos to pseudo-pregnant females:
Embryos were transferred to 2.5 day p.c. pseudo-pregnant foster mothers 1-6 hours 
after injection. If they are left too long after injection the re-expanding embryos 
begin to hatch from the zona pellucida which makes them more difficult to handle. A 
minimum of five blastocysts per uterine hom were transferred. If fewer were 
transferred, embryonic growth would be too rapid, resulting in a large foetus which 
could exceed the nutritive capacity of the placenta and result in pre-natal death. 
Weighed the mouse and anaesthetised by intra-peritoneal injection of Avertin 
anaesthetic (0.02ml/g body weight). Placed the mouse dorsal side uppermost and 
swabbed the back with a liberal quantity of 70% ethanol. Grasped the skin on the 
midline with blunt forceps at the midpoint of the back and raised the skin away from 
the body wall. Holding the dressing scissors vertically cut the skin with a single 
action and produced a lateral incision about 4-5mm long. Used the incision in the 
skin as a “window” by sliding it ventrally over the surface o f the underlying body 
wall. Both uterine horns could be accessed through this single incision. Moved the 
hole to a position about one third of the distance between the dorsal and ventral 
surfaces. It was possible to see through the body wall and distinguish the pink ovary 
and cream ovarian fat pad against the dark contents of the gut. When the general 
position had been located used fine forceps to grasp the slippery body wall. Made a 
small incision in the body wall using fine iris scissors. It was important to avoid 
cutting the blood vessels which run dorso-ventrally. Holding the cut edge of the body
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wall with fine forceps, inserted blunt forceps into the abdominal cavity and grasped 
the ovarian fat pad. It was important to handle the reproductive tract by the 
associated fat only. By gently pulling the fat through the opening it was followed by 
the ovary, oviducts and finally the upper part of the uterus. Under the microscope 
loaded the transfer pipette (drawn-out Pasteur pipette) with embryos. Included two 
marker air bubbles above and below the position o f the embryos in the capillary. 
Under the stereo dissecting microscope (xlO magnification) focused on the exposed 
uterine hom. Gently grasped the top of the uterus with blunt forceps and selected an 
area which is relatively devoid of blood vessels. Inserted a 25-gauge hypodermic 
needle through the uterine wall into the lumen. Whilst looking at the hole picked up 
the loaded transfer pipette and inserted the end about 3mm into the uterine lumen. 
Gently blew the embryos into the uterus using the air bubbles to monitor the transfer. 
After transfer, checked that the embryos have been transferred by expelling the 
remainder o f the fluid in the pipette back into the culture drop and examined under 
the microscope. Grasped the edge of the incision with fine forceps and gently pushed 
the uterus, fat pad and ovary back into the peritoneal cavity using the blunt forceps. 
Repeated the process on the other side. Closed the incision by clipping the skin with 
one or two Michel clips. When the foster mother(s) regained consciousness 
transferred them to clean cages in groups o f two to four. They should litter 17-18 
days later.
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2.4. PHENOTYPE SCREENING
Table 2.4.1. Section 2.4. routinely used primers, sequences and suppliers.
Primer DNA Sequence (5'->3') Supplier
M l3 forward GTTTTCCCAGTCACGAC
TT
MWG Biotech UK., Milton Keynes, 
UK.
M 13 reverse CAGGAAACAGCTATAG
ACCATG
MWG Biotech UK., Milton Keynes, 
UK.
Universal 
Adapter Primer 
(UAP)
CUA CUA CUA CUA 
GGC CAC GCG TCG ACT 
AGT AC
Invitrogen, Paisley, UK. |
Adapter Primer 
(AP)
GGC CAC GCG TCG ACT 
AGT ACT TTT TTT TTT
Invitrogen, Paisley, UK.
Nested 3'RACE 
UDG primer
CAU CAU CAU CAU TTC 
CTC GTG CTT TAC GGT 
ATC
MWG Biotech UK., Milton Keynes, 
UK.
Gene Specific 
Primer (Isce-1)
CAU CAU CAU CAU TAG 
GGA TAA CAG GGT TAA 
T
MWG Biotech UK., Milton Keynes, 
UK.
Neo Specific 
Primer (3'RACE 
UDG)
CAU CAU CAU CAU ATA 
TTG CTG AAG AGC TTG 
GCG GC
MWG Biotech UK., Milton Keynes, 
UK.
gDNANEO R GCA CGA GGA AGC 
GGT C
MWG Biotech UK., Milton Keynes, 
UK.
gDNANEO F TGC GCA GCT GTG CTC 
GACG
MWG Biotech UK., Milton Keynes, 
UK.
Template switch 
(TS)
AAG CAG TGG TAA CAA 
CGC AGA GTA CGC GGG
MWG Biotech UK., Milton Keynes, 
UK.
Oligo-dT TTTTTTTTTTTTTTT
1
Pharmacia Biotech Ltd., St. Albans, 
UK.
2.4.1. T7 Enrichment step for pCRR+SD126 T7 I-Sce-X Selected Clones:
2.4.1.1. First strand cDNA synthesis
Mixed in a PCR reaction tube 0.01 - 5pg tRNA in 9pl DEPC H2O with lpl (0.1 -  
0.5pg/pl) oligo dT primer and heated to 70°C for 3 mins.
Cooled to room temperature and added the following; 4pl 5X First strand buffer 
(supplied with Superscript II enzyme), lpl (0.1 -  0.5pg/pl), template switch (TS)
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primer, 2pl 0.1M DTT, lpl RNAsin (Promega Ltd. Southampton, UK), 2pl lOmM 
dNTP, 2pi Superscript II (200U/pl, Invitrogen, Paisley, UK). Heated to 42°C for 
90min in thermal cycler.
2.4.1.ii. Second strand cDNA synthesis
To the reaction tube added 106pl DEPC H2O, 15pi Advantage PCR buffer (supplied 
with Advantage cDNA polymerase), 3pi lOmM dNTP mix, lpl RNase H (2U/pl 
Invitrogen, Paisley, UK), 3pl Advantage cDNA Polymerase mix (Clontech, 
Basingstoke, UK).
Ran in thermal cycler (37°C for 5 min to digest mRNA, 94°C for 2 min to denature, 
65°C for 1 min for specific priming, 75°C for 30 min for extension). Stopped reaction 
with 7.5pl 1M NaOH solution containing 2mM EDTA, incubated at 65°C for lOmin 
to inactivate enzymes. The reaction was stored at -20°C.
2.4.1.iii. Double stranded cDNA cleanup 
Phenol-Chloroform-Isoamyl isolation and ethanol precipitation.
Added lpl Linear Acrylamide (O.lpg/pl), (Ambion, AMS Biotechnology(UK) Ltd., 
Abingdon, UK) and 150pl Phenol:Chloroform:Isoamyl alcohol (25:24:1) (Boehringer 
Mannheim), mixed well by pipetting.
Transferred the slurry solution to phase lock gel tube (Eppendorf) and spun at 14000g 
for 5mm at room temperature. Transferred the aqueous phase to an RNase/DNase 
free 1.7ml tube and added 70pl of 7.5M ammonium acetate and then 1ml 100% 
ethanol. Mixed well and centrifuged immediately at 14000g for 20 min at room 
temperature to prevent co-precipitation of oligos. A white pellet suggested successful 
precipitation. Washed the pellet with 800pl 100% ethanol and spun down at 14000g 
for 8 min. Repeated the washing step once. Air dried the pellet and resuspended the 
double stranded cDNA in 70pl DEPC H2O.
2.4.1 .iv Gel-filtration
Prepared micro bio-spin chromatography column (Bio-gel P-6 column in Tris, Bio- 
Rad). Inverted the column several times to resuspend the settled gel and remove any 
bubbles. Snapped off the tip and placed the column in a collection tube. Removed the 
cap and let the buffer drain out.
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Discarded the drained buffer and applied 700pl DEPC treated H2O to the column. 
Discarded the flow through and repeated the step 3 times.
Spun column at 700g for 2 mins at room temperature. When opening the column 
aspirated off any gel from the underside of the cap and washed with DEPC H2O to 
prevent contamination. The provided collection tubes were not RNase-free, so 
ensured RNase-free tubes were used instead to collect the sample. Loaded 70pl 
sample to the centre of the column and spun at 700g for 4 min. Dried collected sample 
and resuspended in 8pl DEPC H2O.
2.4.1.v. In Vitro T7 Enrichment Step
To the 8 pi double stranded cDNA sample added [2pl o f each 75mM NTP (A, G, C 
and UTP), 2pl reaction buffer, 2pi enzyme mix (RNase inhibitor and T7 phage RNA 
polymerase)]
Incubated the mix for 6 hours at 37°C
2.4.1.vi. Amplified RNA purification
Added lpl of TRIzol to the in vitro transcription tube and mixed well by pipetting up 
and down. Added 200pl chloroform/lml chloroform. Mixed by inverting the tubes for 
15 seconds and incubated at room temp for 2-3 min. Centrifuged at 12000g for 15 min 
at 4°C. Transferred the aqueous phase to a new RNase free tube and added 500pl of  
isopropanol/lml TRIzol. Incubated sample at room temp for 10 min and then 
centrifuged at 14000rpm for 15min. Washed pellet twice with lml 70% ethanol in 
DEPC treated water. Air dried pellet and quickly resuspended in 20pl DEPC-treated 
water. Checked RNA concentration and quality by measuring OD260 and OD260/280 
(Section 2.2.2.xvii.).
2.4.2. First Strand cDNA synthesis and 3' RACE of Splice Acceptor Series 
Selected Clones:
2.4.2.1. First strand cDNA Synthesis -
Used 1 to 5pg of total RNA OR 50ng of mRNA, made the sample volume up to 11 pi 
using RNase free water (Ambion, AMS Biotechnology (UK) Ltd., Abingdon, UK) in
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a 0.5ml microcentrifuge tube. Added lpl o f lOpM Adapter Primer (Invitrogen Ltd., 
Paisley, UK), mixed gently and collected the reaction by brief centrifugation. Heated 
at 70°C for lOmin and then chilled on ice for at least lmin. Collected the contents by 
brief centrifugation and added the following, (2pl 10X PCR buffer, 2pl 25mM MgCL, 
1 pi lOmM dNTP mix, 2pl 0.1M DTT). Mixed gently and collected the reaction by 
brief centrifugation.
Equilibrated the mixture to 42°C for 5min. Added lpl o f Superscript II RT and 
incubated the tube at 42°C for 50min. Terminated the reaction by incubating at 70°C 
for 15min. Chilled on ice. Collected the reaction by brief centrifugation. Added 1 pi of 
RNase H, mixed and incubated for 20min at 37°C. The cDNA can be stored at -20°C 
but it was found that better results were obtained if the cDNA was immediately 
transferred to the 3' RACE PCR reaction.
2.4.2.ii y  RACE PCR Reaction (Frohman et al.. 1988)-
Made up the following 3' RACE PCR mix per reaction; lOpM Neo Specific Primer 
lpl (3'RACE UDG), lOpM Universal Adapter Primer lpl (UAP), Taq DNA 
Polymerase (2 to 5 units/pl), 10X PCR buffer 5pl, 25mM MgCh 3pl, lOmM dNTP 
mix 1 pi, Sterile dH20 36.5pl.
Added 2pl of the cDNA synthesis reaction (2.4.2.i.) to the tube. Mixed gently and 
collected by brief centrifugation. Covered the reactions with a thin layer of mineral oil 
to minimise evaporation. The reactions were place in Biometra thermocycler using the 
programme of 95°C for 3 minutes (initial denaturation), followed by 30 repeated 
cycles of 95°C for 1 minute (denaturation), 66°C for 1 minute (annealing) and 72°C 
for 3 minutes (extension). There was a final 10 minutes at 72°C to complete 
extension.
Analysed the amplified sample using agarose gel electrophoresis with the appropriate 
molecular size standards and ethidium bromide staining (2.2.2.iv). If no definite 
product was visible, proceeded with Nested PCR amplification (2.4.2.iii.).
2.4.2.iii. Nested 3' RACE PCR Reaction:
The nested amplified reaction was conducted if there was no definite, discrete band 
when the original 3' RACE reaction was analysed on an agarose gel (2.2.2.iv.). If
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there was a smear of bands then using a capillary pipet removed a small (~ 5pi) 
agarose plug from the areas of the gel containing the bands. Prepared an amplification 
mix as in 2.4.2.ii, except used the Nested 3' RACE UDG primer in place of the 
original 3' RACE UDG primer. Performed the PCR reaction as in 2.4.2.ii. and 
analysed the amplified sample using agarose gel electrophoresis with the appropriate 
molecular size standards and ethidium bromide staining (2.2.2.iv).
2.4.3. Cloning 3'RACE Products Using Uracil DNA Glycosylase (UDG):
The relevant 3' RACE band products were cut out of the agarose gel and purified 
using Sephaglas Band Prep Kit (Amersham Int. pic, Bucks, UK) (2.2.2.V.)
To a 0.5ml microcentrifuge tube on ice, add the following components;
10-50ng isolated 3' RACE PCR products, 25 ng/pl pAMPl vector DNA (Invitrogen, 
Paisley, UK.), IX Annealing Buffer (20mM Tris-HCl (pH8.4), 50mM KC1, 1.5mM 
MgCh), lU/pl Uracil DNA Glycosylase (Invitrogen, Paisley, UK). Mixed and then 
incubate at 37°C for 30min. After incubation placed the reaction tube on ice. After 
annealing, a portion o f the reaction mix (1 - 5pi) was used for transformation into 
ElectroTen Blue Electrocompetent Cells (Stratagene) (2.2.2.xii.c).
2.4.4. Beta Galactosidase Staining of Eukaryotic Cells in vitro:
Washed confluent p60 plate 3 times with PBS being careful not to dislodge cells from 
the surface. Aspirated PBS, added 3ml of 0.2% Glutaraldehyde / PBS. Fixed the cells 
for 5 min at room temperature.
After 5 min aspirated the fix solution and washed the cells 3 times with PBS. 
Essential to remove all the glutaraldehyde as this could inhibit the staining reaction. 
Covered the cells with 4ml of freshly prepared X-Gal solution (1 mg/ml X-Gal 
(20mg/ml in dimethylformamide), 5mM Potassium ferricyanide (0.5M made in sterile 
dlUO), 5mM Potassium ferrocyanide (0.5M made in sterile dL^O), 2mM MgCb, 
made up volume using PBS). Left cells at 37°C overnight in a humidified incubator, 
the plate would dry out quickly if incubated in a normal oven.
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2.4.5. Sequence analysis:
Obtained DNA sequence data as specified in 2.2.2.xvi. and the nucleotide sequences 
were subject to comparison of all database entries:
2.4.5.i. BioEdit Sequence Alignment Editor
The computer programme BioEdit sequence alignment editor (version 4.8.10) was 
used to retrieve and open a DNA sequence. The sequence was then saved in FAST A 
format for further investigation.
2.4.5.ii. NCBI Database Entrez Nucleotide
Used VecScreen on this site to discover if sequence information retrieved from 3' 
RACE products was in fact vector sequence, before proceeding further.
2.4.5.iii. The CAP EST Assembler at IFOM
Used this site (http://bio.ifom-firc.it/ASSEMBLY/assemble.html) to create a 
consensus sequence of multiple sequence data obtained for a single clone.
2.4.5.iv. NCBI Database
Once a consensus sequence minus vector sequence was obtained the DNA sequences 
were compared to all database entries, searching for nucleotide similarities (BlastN 
searches), using the Blast search analysis programme.
2.4.6. High Throughput 3' RACE Screen for Gene Trapped Clones:
When 96 well plate of clones was generally confluent, aspirated medium and washed 
cells with PBS. Kept plate cool on ice, added 20pl/well lysis buffer (0.5% Nonidet 
P40, 20mM Vanadyl-Ribonucleoside Complexes, ImM DTT, lOmM Tris-Cl 
pH8.6, 1.5mM MgCl2, 0.14M NaCl).
Left for about 5min with constant agitation. Spun the plate at 500g for 5min @ 4°C. 
Transferred supernatant to a fresh 96 well PCR plate and added 20pl binding buffer 
(0.2M Tris-Cl pH 8.0, 25mM EDTA pH 8.0, 0.3M NaCl, 2% SDS, 5mM DTT, Filter 
sterilised 0.2um) (1:1, lysis buffer : binding buffer), mix.
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Added oligo dT25 beads -  (Removed 20pl/well of beads, ~ 2ml / 96well, resuspended 
in lOpl/well, lml binding buffer).
Aliquoted lOpl/well. Incubated at room temperature ~ lOmin with agitation. Moved 
to magnetic plate, removed supernatant (~50pl), resuspended beads in lOp.1 RNase 
free water. Heated at 85°C ~2min, then transferred directly to magnetic plate. 
Transferred supernatant to fresh PCR plate (~10pl). Set up RT Superscript II reaction. 
Aliquoted 9pl of RT Superscript II reaction mix (200pl lOx buffer, 200pl 25mM 
MgCl2, lOOpl lOmM dNTP, 200pl 0.1M DTT, lOOpl lOuM oligo dT, lOOpl 
Superscript II) per well then transferred the plate to PCR machine to run (50min @ 
42°C, 15min @ 70°C)
Removed plate from PCR machine and put on ice. Spun down briefly, added 1 pi 
RNaseH/well. Incubated 20min @ 37°C. Aliquoted out 2pl/well o f cDNA to a fresh 
96 well PCR plate. Added 48pl/well of 3’ RACE master mix (500pl lOx PCR Buffer, 
300pi 25mM MgCl2, lOOpl lOmM dNTP, lOOpl lOpM Adapter primer, lOOpl 
Neomycin primer lOpM, 50pl Taq Polymerase (Promega), 3650pl dH20).
Transferred plate to PCR machine and run on 3’ RACE programme; 3min @ 95°C 
(initial denaturation), then 35 cycles of lmin @ 95°C (denaturation), lmin @ 58°C 
(annealing), lmin @ 72°C (extension). A final lOmin @ 72°C to complete extension. 
Analysed the amplified sample using agarose gel electrophoresis with the appropriate 
molecular size standards and ethidium bromide staining (2.2.2.iv).
2.4.7. Genomic DNA PCR:
Set up PCR reaction as specified in Section 2.2.2.xv. using the primers gDNANEOF 
and gDNANEOR (MWG Biotech UK., Milton Keynes, UK.) (Table 2.4.1.). Ran the 
reaction on a programme of 3minutes at 95°C (initial denaturation), then 30 cycles of 
1 minute at 95°C (denaturation), 1.5 minutes at 65°C (annealing), 1.5 minutes at 72°C 
(extension). A final lOminutes at 72°C to complete extension. Analysed the amplified 
sample using agarose gel electrophoresis with the appropriate molecular size 
standards and ethidium bromide staining (2.2.2.iv).
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CHAPTER 3
RESULTS
3. RESULTS
Due to the way this project has progressed it was felt that it would be clearer to 
present the results as a single chapter, thereby allowing the flow of progression to be 
appreciated.
3.1. RETROVIRAL VECTORS
As mentioned in the introduction retroviral vectors have become a standard tool for 
gene transfer technology. Compared with other gene transfer systems, retroviral 
vectors have several advantages, including high efficiency o f gene transfer and 
insertion of transferred genes into host cell chromosomes. When compared to plasmid 
vectors, retroviral vectors are advantageous primarily because they insert a single 
copy with the ends of the vector intact. Plasmid-based vectors are susceptible to 
nucleases during electroporation and recombination into the genome. Deletions from 
the ends o f the vector would reduce the efficiency o f cloning and make primer 
selection more difficult.
Construction of retroviral vectors involves placement of gene(s) to be transferred 
between viral long terminal repeats (LTRs), which contain elements required to drive 
gene expression, reverse transcription and integration into the host chromosome 
(Armentano et al., 1987).
The vectors used in this project are based on the oncogenic Moloney murine 
leukaemia virus (MoMLV) and essentially all o f the viral protein encoding regions 
can be deleted with retention o f a transmissible vector. Oncogenic retroviruses require 
a dividing host cell to allow the pre-integration complexes to enter the nuclei. 
However, lentiviruses such as human immunodeficiency virus type 1 (HIV-1) are less 
restricted by cell proliferation. Unlike MoMLV, which have to wait until the nuclear 
membrane dissolves during cell division, HIV-1 can enter the nuclei of nondividing 
cells through the nuclear pore (Lewis and Emerman, 1994).
The ability o f retroviruses to stably integrate their own genome into the host genome 
of many cells has led to the production of vector systems capable of long-term gene 
transfer.(Bender et al., 1987) The biology o f retroviruses has made possible the 
development o f packaging cell lines which provide in trans all the viral proteins 
required for viral particle formation. The design of different types of packaging cells
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has evolved to reduce the possibility of helper virus production. (Miller and 
Buttimore, 1986)
3.2. PACKAGING CELLS
Retroviral vectors promote the efficient transfer o f genes into a variety of cell types 
from many animal species. An important contribution to their utility was the 
development of retrovirus packaging cells, which allow the production of retroviral 
vectors in the absence o f replication-competent virus (RCV). A critical element in 
producing the components to carry out retroviral-mediated gene transfer, is the cell 
that generates the retroviral particles carrying the gene to be transferred. These cells 
are called “packaging cells” because they “package” the retroviral vector into the 
delivery vehicle, carrying the exogenous gene(s) to be delivered to the cells (Miller, 
1990).
After the formation o f a retrovirus virion, no further viral protein synthesis is required 
for the events leading to retrovirus integration into the genome of an infected cell. All 
of the viral protein coding regions can be removed from a replication competent virus 
without markedly affecting the ability of viral RNA to be encapsidated, reverse 
transcribed and integrated. This is the principle behind the retroviral vector system 
(Mann et al., 1983).
The retroviral vector consists of DNA sequences intended for transfer flanked by the 
signals present at the ends o f the retroviral genome and the packaging cells are 
designed to produce all o f the retroviral proteins and promote “packaging” of 
retroviral vector RNA into virion. Retroviral vectors produced by using packaging 
cells are expected to infect cells but be unable to replicate further.
3.3. REVERSE ORIENTATION SPLICE ACCEPTOR (ROSA)
A couple o f the retrovirus vectors used in this project are based on the ROSAp-geo 
design (Friedrich and Soriano, 1991). This means that the splice acceptor (SA) p-geo 
cassette is inserted in reverse orientation relative to viral transcription. This is 
necessary to avoid removing the viral v|/ packaging sequence by splicing from an 
upstream splice acceptor sequence. The resulting retroviral vector is termed ROSAp-
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geo, which due to the reporter gene (3-geo, also exhibits kanamycin resistance along 
with neomycin resistance and (3-gal activity as well.
3.4. INTRODUCING THE PACKAGING CELL LINE USED IN THIS PROJECT 
A retroviral vector contains the cis-acting elements required for replication as a virus, 
but is missing some of the viral genes, which are replaced by foreign coding 
sequences. In order for a retrovirus vector to replicate as a virus, it is necessary to 
provide in trans the missing viral genes. BOSC cells are designed to provide all viral 
proteins but not to package or transmit the RNAs encoding these functions. Virion 
produced by packaging cells can infect but cannot replicate further.
The generation of high titre, helper free retroviruses by transient transfection was 
achieved by using the highly transfectable 293T cell line into which are stably 
introduced constructs that express retroviral packaging functions. The resulting 
ecotropic virus packaging cell line BOSC 23 produces infectious retrovirus at > 106 
infectious units /ml of supernatant within 72 hours after calcium phosphate mediated 
transfection (Pear et al., 1993).
The BOSC cells contain the gag, pol and env retroviral genes and are therefore 
capable o f producing retrovirus from the experimental constructs on their own. 
However, there is probably only a single copy of each gene per BOSC cell and 
therefore greater titres can be achieved by co-transfecting pHIT plasmids which 
provide further copies o f the gag, pol and env genes.
The retroviral vectors being used in this project were co-transfected with packaging 
vectors pHIT 60 and pHIT 123. These vectors encode MoMLV gag/gag-pol and the 
MoMLV env gene respectively (see Appendix I for plasmid diagrams). The pHIT 60 
plasmid contains the murine leukemia virus gag/pol cassette under the control of the 
human cytomegalovirus immediate early promoter, whereas pHIT 123 contains the 
human cytomegalovirus, that is to say driven murine leukemia virus ecotropic 
envelope.
Virion supernatant was harvested 48 hours and 72 hours post-transfection to ensure 
the expression of the various genes and therefore optimal retrieval of virus particles.
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3.5. INTRODUCING THE RETROVIRAL VECTORS USED IN THIS PROJECT 
At the outset, this project consisted of studying four retroviral vectors, two shuttle and 
two splice acceptor vectors.
3.5.1. Shuttle Series
This series of retroviral vector is rather special in that they contain a plasmid 
backbone within the LTRs of the construct. This enables plasmid rescue when the 
provirus is incorporated into genomic DNA (gDNA).
It is possible to retrieve shuttle vectors from genomic DNA (gDNA) with flanking 
regions o f the endogenous trapped gene attached. It is necessary to digest the gDNA 
at sites that are not present in the vector (section 2.2.2.xii). This means the fragment 
that contains the provirus and plasmid backbone will be flanked by 5’ and 3’ regions 
at the site of insertion. Alternatively, the gDNA can be cut with an enzyme that cuts 
within the vector as long as the site is beyond the origin and ampicillin, then any 
rescued plasmid will contain only the 5’ flank. This avoids the confusion of having 
the 5’ flank fused to the 3’ flank in the rescued plasmid, but has the drawback o f only 
providing information of one flanking region.
3.5.1.a. Proviral pSHUT+124K SD126-1 
This retroviral vector would be expected to insert near to an exon due to the lack of a 
splice acceptor site. Activation would require either in-frame exon integration or 
integration in 5' UTR of an actively expressed gene. With there being no poly A site 
after the neo cassette, a polyA signal from an endogenous gene would be required to 
generate stable neo mRNA and in turn, G418 resistant clones. Suggesting that only 
insertions in genes should generate G418 resistant clones and background intergenic 
insertions should be lost.
Due to these requirements for activation it is expected that this construct would 
appear inefficient with the number of G418 resistant colonies being low (Niwa et al., 
1993; Salminen et al., 1998; Yoshida et al., 1995; Zambrowicz et al., 1998).
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Figure 3.1. Schematic representation of the shuttle retroviral vectors used in this 
study (supplied by John Dixon, CRC Institute, Cambridge).
(A) Pro viral pSHUT+124K SD126-1 and (B) Proviral pSHUT+124K-A. 
Abbreviations: Neo, E. coli neomycin phosphotransferase gene; Splice Donor, mouse 
Pax-2 splice donor site; FI ori, filamentous phage origin of replication which 
produces ssDNA; p lactamase, E. coli TEM-7 beta lactamase gene; ColEl Ori, 
bacterial origin of replication; gag, Moloney murine leukemia virus gag gene; BGH 
pA, transcription termination and polyadenylation region from the bovine growth 
hormone gene; Koazak ATG, sequence is contiguous with ATG start codon, greatly 
increases the efficiency of translation by slowing down the rate of scanning by 
ribosome and improving chance of recognising start of translation at ATG start codon.
ColEl oriBGHpA FI ori P lactamase
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3.5.1 .b. Proviral dSHUT+124K-A 
As with the above retroviral vector (3.5.1.a.), this construct would also be expected to 
insert near to an exon and require either in-frame exon integration or integration in 5' 
UTR of an actively expressed gene to be activated. This construct contains a polyA 
site opposed to a splice donor site, so it is expected that more G418 resistant colonies 
will appear as there is not the constraint o f utilising an endogenous polyA.
3.5.2. Splice Acceptor Series
These vectors differ from the shuttle series in that they contain splice acceptor sites, 
meaning in contrast to the shuttle series, it is expected that they are unlikely to insert 
near to an exon. This can be a disadvantage, as the insertion occurs in an intron, 
alternative splicing can sometimes take place, leading to lower levels of wild-type 
transcripts and often resulting in hypomorphic alleles.
Another difference is that the splice acceptor series do not contain a plasmid 
backbone so plasmid rescue is not possible. The splice acceptor series contain a 
promoterless pgeo gene, which codes for a fusion transcript of p-galactosidase and 
neomycin phosphotransferase. As expression of this gene relies on the activity o f the 
trapped promoter, all G418 resistant clones represent gene trap events.
Drug selection identifies cells that have integrated the vector, in the correct 
orientation, into an intron o f an expressed gene such that the reporter can be spliced 
in-frame into the gene transcript. This transcript encodes a fusion protein possessing 
both neomycin phosphotransferase and P-galactosidase (/acZ/p-gal) activities. 
(Friedrich and Soriano, 1991) ES cell clones can be selected using G418 and the 
trapped gene can be studied by staining for p-galactosidase activity.
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Figure 3.2. Schematic representation of the splice acceptor retroviral vectors used in 
this study (supplied by John Dixon, CRC Institute, Cambridge.
(A) Proviral pCSI+SD126 -2 and (B) Proviral pCRR+SD126 T7 I-Sce-X. 
Abbreviations: Neo, E. coli neomycin phosphotransferase gene; Splice Acceptor, 
adenovirus major late transcript splice acceptor sequence; Splice Donor, mouse Pax-2 
splice donor site; IRES, encephalomyocarditis virus internal ribosome entry site; 
pgeo, a fusion gene between the p-galactosidase (p-gal) and neomycin 
phosphotransferase (neo) genes; Lox P, lox-cre site specific recombination system of 
bacteriophage PI; gag, Moloney Murine Leukemia Virus gag gene; T7, bacteriophage 
T7 promoter; I-Sce, intron encoded endonuclease from the mitochondria of 
Saccharomyces cerevisiae.
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3.5.2.a. Proviral dCSI+SD126 L4-2
This retroviral splice acceptor vector contains an internal ribosome entry site (IRES) 
which acts as a ribosome landing pad. IRES sequence allows ribosomes to bind in a 
cap-independent fashion and start translation at the next AUG codon downstream. 
Kim et al showed that lacZ was expressed throughout the entire chimeric embryp 
derived from ES cells transfected with phophoglucokinase-1 promoter-neor-IRES- 
lacZ vector. The result suggests that there is no tissue specifity for IRES function 
(Kim et al., 1992).
The efficiency o f gene trapping can be limited by the requirement to produce in frame 
fusion proteins, which retain reporter activity. By using IRES to allow independent 
translation o f the reporter from fusion transcripts this can be bypassed. It is predicted 
to significantly enhance the frequency o f productive integrations because any 
insertion into an active gene should give functional reporter expression (Mountford 
and Smith, 1995).
A lox P stuffer region o f about 330 base pairs is also present in this construct which 
when trapped lines are crossed through a ere expressing strain should be lost, aiding 
the identification o f heterozygous and homozygous progeny.
3.5.2.b. Proviral pCRR+SD126 T7 I-Sce-X
This retroviral splice acceptor vector also contains a T7 promoter just upstream of the 
splice donor site, which should allow an enrichment step (section 2.4.1.) to be carried 
out after cDNA synthesis. In theory the T7 RNA polymerase should copy more RNA 
from the promoter through the splice donor and trapped transcript to the poly A and 
appended anchor sequences. By performing 3' RACE on this enriched template it 
would be more likely that the correct region be amplified.
This construct also contains an I-Sce site included in the T7 oligo. It is expected that 
this will enable easy retargeting of the same locus. This could be useful to remove an 
exon and create a definite null or even replace lacZ with GFP.
The theory is that I-Sce is an extremely rare restriction enzyme that cuts an 18 base 
pair site, which is more than likely absent from the mouse genome, unless the trap 
vector has been integrated. To retarget this locus, a normal targeting or expression
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vector could be electroporated along with the I-Sce 1 enzyme. This enzyme causes a 
double strand break, which triggers repair enzymes and this localised recruitment of 
repair enzymes greatly increases homologous recombination at the trapped 
locus. This would allow recombinase-mediated, post-insertional modifications of the 
gene trap locus.
This “knock-in” strategy permits additional modifications to be made to a trapped 
locus, such as allowing the promoter elements o f the trapped gene to drive the 
expression of a knocked-in transgene for use in rescue or cell-labelling experiments. 
In addition, this approach can also be used to generate an allelic series by 
recombining in different mutant cDNAs of the trapped gene.
Another example (Westerman and Leboulch, 1996) is inserting simian virus 40 large 
T (SV40T) antigen into a locus to target the lineages that express the trapped gene for 
immortalization.
3.6. ANNOTATED SEQUENCE OF SHUTLLE AND SPLICE ACCEPTOR 
CONSTRUCT
It was felt it would be prudent to try and confirm sequence information for one of 
each type o f vector being studied.
Proviral pSHUT+124K (A) and proviral pCRR+SD126 T7 I-Sce (X) were selected.
Sequencing reactions were conducted commercially (Oswell Research Products Ltd, 
University of Southampton, UK) and contiguous sequence prepared using CAP EST 
Assembler at IFOM (section 2.4.5.iii.).
See the following, figure 3.3a annotated sequence of Proviral pSHUT+124K(A) and 
figure 3.3b annotated sequence of Proviral pCRR+SD126 T7 I-Sce(X)
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Figure 3.3.a. - Annotated sequence of proviral pSHUT+124K (A)
Ko/ak
B lactamase ColEl oriBGHpA FI on
NB. Arrows indicate the direction of transcription
5'MoMLV LTR l-248bp [Shinnick, 1981 #335]
5'AATGAAAGACCCCCGCTGACGGGTAGTCAATCACTCAGAGGAGACCCTCCCAAGGAAC  
AGCGAGACCACAAGTCGGATGCAACTGCAAGAGGGTTTATTGGATACACGGGTACCCGGG  
CGACTCAGTCAATCGGAGGACTGGCGCCCCGAGTGAGGGGTTGTGCTAGCTTGCCAAACC 
T AC AGGTGGGGTCTTTC ATTCCCCCCTTTTTCTGG AG ACT AA AT AAAATCTTTT ATTTTATC 
GATAAGC
Kozak ATG 249-257bp 
[Kozak, 1987 #230] Neomycin Phosphotransferase 258-1051 bp [Beck, 1982 #336]
CCACCATGGGAATTGAACAAGACGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGA
GGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCG
GCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCCTGAAT
GAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCA
GCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCG
GGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATG
CAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAGCGAAACA
TCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGATCTGGA
CGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGCATGCC
CGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGA
AAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAG
GACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGCTGACCGC
TTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCT
TGACGAGTTCTTCTGA
STOP
TCTAGAGAGCTCAGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTG
CCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAA
BGHpA 1162-1258bp
ATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGTGGGGTGG
GGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAG
STOP
CAGGCATGCTGGGGATGCGGTGGGCTCTATGGCTTCTGAGGCGGAAAGAACGTCGACGAA  
TTCGAGCTCGGCCGACTTGGCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTGGCC  
GTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAC 
AC ATCCCCCTTTCGCC AGCTGGCGT A AT AGCG A AG AGGCCCGC ACCG ATCGCCCTTCCC A 
ACAGTTGCGCAGCCTGAATGGCGAATG
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Phage FI Origin 1528-1985bp
GACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACC 
GCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCAC 
GTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGA 
GCTTT ACGGC ACCTCG ACCGC A A A A A ACTTG ATTTGGGTG ATGGTTC ACGT AGTGGGCCAT 
CGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACT 
CTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCTATTCTTTTGATTTATAAGGG 
ATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAATATTTAACGCGA 
ATTTT AAC A A A AT ATT A ACGTTT AC AATTT
CGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATATGGTGCA 
CTCTCAGT AC A ATCTGCTCTG ATGCCGC AT AGTT A AGCCAGCCCCG AC ACCCGCC AAC ACC 
CGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACC 
GTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGACGA 
A AGGGCCTCGTG AT ACGCCT ATTTTT AT AGGTT A ATGTC ATG AT A AT A ATGGTTTCTT AG A 
CGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAAT 
AC ATTC AA AT ATGT ATCCGCTC ATG AG AC A AT AACCCTGAT A A ATGCTTCA AT AAT ATTG A 
AAAAGGAAGAGT
Beta lactamase 2424-3285bp [Kalnins, 1983 #326]
ATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTT
TTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGA
GTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAA
GAACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTCATACACTATTATCCCGTAT
TGACGCCGGGCAAGAGCAACTCGGTCGCCGGGCGCGGTATTCTCAGAATGACTTGGTTGA
GTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAG
TGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGG
ACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGT
TGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGT
AGCAATGCCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGG
CAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCC
CTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTA
TCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGG
GGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGA
TTAAGCATTGGTAA STOP
Col. El Origin 3286-4227bp
CTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAA
AAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTT
TCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTT
TTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTT
GCCGG ATC A AG AGCT ACC AACTCTTTTTCCG AAGGT A ACTGGCTTC AGC AG AGCGC AG AT
ACCAAATACTGTCCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCA
CCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGT
CGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCT
GAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGAT
ACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGG
T ATCCGGTAAGCGGCAGGGTCGG AAC AGG AG AGCGC ACGAGGGAGCTTCCAGGGGG AAA
CGCCTGGT ATCTTT AT AGTCCTGTCGGGTTTCGCC ACCTCTG ACTTGAGCGTCG ATTTTTGT
GATGCTCGTCAGGGGGGCGGAGCCTATCGAAAAACGCCAGCAACGCGGCCTTTTTACGGT
TCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGG
AT A ACCGT ATT ACCGCCTTTG AGTG AGCTG AT ACCGCTCGCCGC AGCCG A ACG ACCGAGC
GCAGCGAGTCAGTGAGCGAGGAAGCGGAAGA
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GCGCCC A AT ACGC AAACCGCCTCTCCCCGCGCGTTGGCCG ATTC ATT A ATGC AGCTGGC AC 
GACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGCTC  
ACTC ATT AGGC ACCCC AGGCTTT AC ACTTT ATGCTTCCGGCTCGT ATGTTGTGTGG A ATTGT 
GAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTATTTAG  
GTGACACTATAGAATACTCAAGCTTATGCATGCGGCCGCATCTAGCGAATTCG
Truncated gag gene 4525-5404bp [Leis, 1988 #327] with Psi+ extended viral 
packaging signal 4984-5404bp [Alford, 1991 #334]
M-------
GCGCCTAGAGAAGGAGTGAGGGCTGGATAAAGGGAGGATCGAGGCGGGGTCGAACGAGG
AGGTTCAAGGGGGAGAGACGGGGCGGATGGAGGAAGAGGAGGCGGAGGCTTAGGGTGT
ACAAAGGGCTTGACCCAGGGAGGGGGGTCAAAAGCCAAGGCTTCCCAGGTCACGATGTA
GGGGACCTGGTCTGGGTGTCCATGCGGGCCAGGTGAAAAGACCTTGATCTTAACCTGGGT
GATGAGGTCTCGGTTAAAGGTGCCGTCTCGCGGCCATCCGACGTTAAAGGTTGGCCATTCT
GCAGAGCAGAAGGTAACCCAACGTCTCTTCTTGACATCTACCGACTGGTTGTGAGCGATC
CGCTCG AC ATCTTTCCAGTG ACCT AAGGTC A A ACTTA AGGG AGTGGT A AC AGTCTGGCCC
AT ATTCTCAG AC A A AT AC AG A A AC AC AGTC AG AC AG AG AC A AC AC AG AACG ATGCTGCA
GCAGACAAGACGCGCGGCGCGGCTTCGGTCCCAAACCGAAAGCAAAAATTCAGACGGAG
GCGGG AACTGTTTT AGGTTCTCGTCTCCT ACC AG A ACC AC AT ATCCCTCCTCTAAGGGGGG
TGCACCAAAGAGTCCAAAACGATCGGGATTTTTGGACTCAGGTCGGGCCACAAAAACGGC
CCCCGAAGTCCCTGGGACGTCTCCCAGGGTTGCGGCCGGGTGTTCCGAACTCGTCAGTTCC
ACC ACGGGTCCGCC AG AT AC AG AGCT AGTT AGCT AACT AGTACCG ACGC AGGCGC AT AAA
ATCAGTCATAGACACTAGACAATCGGACAGACACAGATAAGTTGCTGGCCAGCTTACCTC
CCGGTGGTGGGTCGGTGGTCCCTGGGCAGGGGTCTCCCG
MoMLV V5' LTR 5405 -  5662bp [Shinnick, 1981 #335]
<-----
ATCCCGGACGAGCCCCCAAATGAAAGACCCCCGCTGACGGGTAGTCAATCACTCAGAGGA 
GACCCTCCCAAGGAACAGCGAGACCACAAGTCGGATGCAACTGCAAGAGGGTTTATTGGA  
TACACGGGTACCCGGGCGACTCAGTCAATCGGAGGACTGGCGCCCCGAGTGAGGGGTTGT 
GCT AG AT AACTTCGT AT AGT AT AC ATTAT ACG A AGTT ATCT AGCTTGCC A A ACCT AC AGGT 
GGGGTCTTTCATT 3'
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Figure 3.3.b. -  Annotated sequence of Proviral pCRR+SD126T7 I-Sce (X)
Splice
acceptor
Splice
donor
Eco R1
NB. Arrows indicate the direction of transcription
MoMLV V3' LTR 1-341 bp [Shinnick, 1981 #335]
< ------
5'AATGAAAGACCCCCGCTGACGGGTAGTCAATCACTCAGAGGAGACCCTCCCAAGGAAC  
AGCG AG ACC AC AAGTCGG ATGC AACTGCAAG AGGGTTT ATTGG AT AC ACGGGT ACCCGGG 
CGACTCAGTCAATCGGAGGACTGGCGCCCCGAGTGAGGGGTTGTGCTAGCTTGCCAAACC 
T AC AGGTGGGGTCTTTC ATTCCCCCCTTTTTCTGG AG ACT A AAT A AAATCTTTT ATTTT ATC 
TATGGCTCGTACTCTATAGGCTTCAGCTGGTGATATTGTTGAGTCAAAACTAGAGCCTGGA  
CCACTGATATCCTGTCTTTAACAAATTGGACTAATCGAT
CTCGACCTCGAGACTAGTGGATCCCCCGGGCTGCAGATCTGTAGGGCGCAGTAGTCCAGG
GTTTTCCTTGATGATGTCATACTTATCCCTGTCCCTTTTTTTTCCAC
Splice Acceptor 
449-450bp
AGCTCGCGGTTGAGGACAAACTCTTCGCGGTCT
TTCCAGTGGGGATCGACGGTATCGATAAGCTTGATGATCTGTGAC
Beta Geo with ATG 527-4409bp [Soriano, 1991 #325]
ATGGCGGATCCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTA
ATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCG
ATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGCGCTTTGCCTGGTTTCCGGC
ACCAGAAGCGGTGCCGGAAAGCTGGCTGGAGTGCGATCTTCCTGAGGCCGATACTGTCGT
CGTCCCCTCAAACTGGCAGATGCACGGTTACGATGCGCCCATCTACACCAACGTAACCTAT
CCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTTGTTACTCGCTCA
CATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATTATTTTTGATGGCG
TT AACTCGGCGTTTC ATCTGTGGTGCAACGGGCGCTGGGTCGGTT ACGGCC AGG AC AGTC
GTTTGCCGTCTGAATTTGACCTGAGCGCATTTTTACGCGCCGGAGAAAACCGCCTCGCGGT
GATGGTGCTGCGTTGGAGTGACGGCAGTTATCTGGAAGATCAGGATATGTGGCGGATGAG
CGGCATTTTCCGTGACGTCTCGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCCAT
GTTGCCACTCGCTTTAATGATGATTTCAGCCGCGCTGTACTGGAGGCTGAAGTTCAGATGT
GCGGCGAGTTGCGTGACTACCTACGGGTAACAGTTTCTTTATGGCAGGGTGAAACGCAGG
TCGCCAGCGGCACCGCGCCTTTCGGCGGTGAAATTATCGATGAGCGTGGTGGTTATGCCG
ATCGCGTCACACTACGTCTGAACGTCGAAAACCCGAAACTGTGGAGCGCCGAAATCCCGA
ATCTCTATCGTGCGGTGGTTGAACTGCACACCGCCGACGGCACGCTGATTGAAGCAGAAG
CCTGCGATGTCGGTTTCCGCGAGGTGCGGATTGAAAATGGTCTGCTGCTGCTGAACGGCA
AGCCGTTGCTGATTCGAGGCGTTAACCGTCACGAGCATCATCCTCTGCATGGTCAGGTCAT
GGATGAGCAGACGATGGTGCAGGATATCCTGCTGATGAAGCAGAACAACTTTAACGCCGT
GCGCTGTTCGCATTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTG
TATGTGGTGGATGAAGCCAATATTGAAACCCACGGCATGGTGCCAATGAATCGTCTGACC
GATGATCCGCGCTGGCTACCGGCGATGAGCGAACGCGTAACGCGAATGGTGCAGCGCGAT
CGTAATCACCCGAGTGTGATCATCTGGTCGCTGGGGAATGAATCAGGCCACGGCGCTAAT
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CACGACGCGCTGTATCGCTGGATCAAATCTGTCGATCCTTCCCGCCCGGTGCAGTATGAAG
GCGGCGGAGCCGACACCACGGCCACCGATATTATTTGCCCGATGTACGCGCGCGTGGATG
AAGACCAGCCCTTCCCGGCTGTGCCGAAATGGTCCATCAAAAAATGGCTTTCGCTACCTG
GAGAGACGCGCCCGCTGATCCTTTGCGAATACGCCCACGCGATGGGTAACAGTCTTGGCG
GTTTCGCTAAATACTGGCAGGCGTTTCGTCAGTATCCCCGTTTACAGGGCGGCTTCGTCTG
GGACTGGGTGGATCAGTCGCTGATTAAATATGATGAAAACGGCAACCCGTGGTCGGCTTA
CGGCGGTGATTTTGGCG AT ACGCCG AACG ATCGCC AGTTCTGT ATG A ACGGTCTGGTCTTT
GCCGACCGCACGCCGCATCCAGCGCTGACGGAAGCAAAACACCAGCAGCAGTTTTTCCAG
TTCCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTTCCGTCATAGCGATA
ACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGC
CTCTGGATGTCGCTCCACAAGGTAAACAGTTGATTGAACTGCCTGAACTACCGCAGCCGG
AGAGCGCCGGGCAACTCTGGCTCACAGTACGCGTAGTGCAACCGAACGCGACCGCATGGT
CAGAAGCCGGGCACATCAGCGCCTGGCAGCAGTGGCGTCTGGCGGAAAACCTCAGTGTGA
CGCTCCCCGCCGCGTCCCACGCCATCCCGCATCTGACCACCAGCGAAATGGATTTTTGCAT
CGAGCTGGGTAATAAGCGTTGGCAATTTAACCGCCAGTCAGGCTTTCTTTCACAGATGTGG
ATTGGCGATAAAAAACAACTGCTGACGCCGCTGCGCGATCAGTTCACCCGTGCACCGCTG
GATAACGACATTGGCGTAAGTGAAGCGACCCGCATTGACCCTAACGCCTGGGTCGAACGC
TGGAAGGCGGCGGGCCATTACCAGGCCGAAGCAGCGTTGTTGCAGTGCACGGCAGATACA
CTTGCTG ATGCGGTGCTG ATT ACG ACCGCTCACGCGTGGCAGC ATC AGGGG A A A ACCTT A
TTTATCAGCCGGAAAACCTACCGGATTGATGGTAGTGGTCAAATGGCGATTACCGTTGAT
GTTGAAGTGGCGAGCGATACACCGCATCCGGCGCGGATTGGCCTGAACTGCCAGCTGGCG
C AGGT AGC AG AGCGGGT A A ACTGGCTCGG ATT AGGGCCGC A AG A A AACT ATCCCGACCG
CCTTACTGCCGCCTGTTTTGACCGCTGGGATCTGCCATTGTCAGACATGTATACCCCGTAC
GTCTTCCCGAGCGAAAACGGTCTGCGCTGCGGGACGCGCGAATTGAATTATGGCCCACAC
CAGTGGCGCGGCGACTTCCAGTTCAACATCAGCCGCTACAGTCAACAGCAACTGATGGAA
ACCAGCCATCGCCATCTGCTGCACGCGGAAGAAGGCACATGGCTGAATATCGACGGTTTC
CATATGGGGATTGGTGGCGACGACTCCTGGAGCCCGTCAGTATCGGCGGAATTCCAGCTG
AGCGCCGGTCGCTACCATTACCAGTTGGTCTGGTGTCAGGGGATCCCCCGGGCTGCAGCC
AATATGGGATCGGCCATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTG
GAGAGGCTATTCGGCTATGACTGGGCACAACAGACAATCGGCTGCTCTGATGCCGCCGTG
TTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCGACCTGTCCGGTGCCC
TGAATGAACTGCAGGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTT
GCGCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAG
TGCCGGGGCAGGATCTCCTGTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGC
TGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTCGACCACCAAGC
GAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGATCAGGATGA
TCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCG
CATGCCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCAT
GGTGGAAAATGGCCGCTTTTCTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCG
CTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAGCTTGGCGGCGAATGGGC
TGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGC AGCGC ATCGCCTTCTATC
GCCTTCTTGACGAGTTCTTCTGA
STOP
T AAT ACG ACTC ACT AT AGGGCG ATCG AG
T7 Promoter Site 
4410-4426bp
TTACGCTAGGGATAACAGGGTAATATAGTCTA
I-Sce 1 Restriction Site 
4438-4461 bp
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Splice Donor 
4476-4477bp
GAACTAGTGGATCCAGCTTATCGAGCTTGCCAACTACAGCAGGTAAGCATATTTATGAAA
AATGCTGATTGTGTTAGCTACTTGTGTCAGTGTTGTGATAGTCGAC
Truncated GAG gene 4576-5455bp[Leis, 1988 #327] with Psi+ extended viral 
packaging signal 5035-5455bp [Alford, 1991 #334]
M-----
GGCGCCTAGAGAAGGAGTGAGGGCTGGATAAAGGGAGGATCGAGGCGGGGTCGAACGAG
GAGGTTCAAGGGGGAGAGACGGGGCGGATGGAGGAAGAGGAGGCGGAGGCTTAGGGTG
TACAAAGGGCTTGACCCAGGGAGGGGGGTCAAAAGCCAAGGCTTCCCAGGTCACGATGT
AGGGGACCTGGTCTGGGTGTCCATGCGGGCCAGGTGAAAAGACCTTGATCTTAACCTGGG
TGATGAGGTCTCGGTTAAAGGTGCCGTCTCGCGGCCATCCGACGTTAAAGGTTGGCCATTC
TGCAGAGCAGAAGGTAACCCAACGTCTCTTCTTGACATCTACCGACTGGTTGTGAGCGATC
CGCTCGACATCTTTCCAGTGACCTAAGGTCAAACTTAAGGGAGTGGTAACAGTCTGGCCC
ATATTCTCAGACAAATACAGAAACACAGTCAGACAGAGACAACACAGAACGATGCTGCA
GCAGACAAGACGCGCGGCGCGGCTTCGGTCCCAAACCGAAAGCAAAAATTCAGACGGA
GGCGGGAACTGTTTTAGGTTCTCGTCTCCTACCAGAACCACATATCCCTCCTCTAAGGGGG
GTGCACCAAAGAGTCCAAAACGATCGGGATTTTTGGACTCAGGTCGGGCCACAAAAACGG
CCCCCGAAGTCCCTGGGACGTCTCCCAGGGTTGCGGCCGGGTGTTCCGAACTCGTCAGTTC
C ACC ACGGGTCCGCC AG AT AC AG AGCT AGTT AGCT AACTAGT ACCG ACGC AGGCGC AT A A
AATC AGTC ATAG AC ACT AG AC AATCGG AC AG AC AC AG AT AAGTTGCT GGCC AGCTT ACCT
CCCGGTGGTGGGTCGGTGGTCCCTGGGCAGGGGTCTCC CG
MoMLV V5' LTR 5456-5699bp[Shinnick, 1981 #335]
A-----
ATCCCGGACGAGCCCCCAAATGAAAGACCCCCGCTGACGGGTAGTCAATCACTCAGAGGA 
GACCCTCCCAAGGAACAGCGAGACCACAAGTCGGATGCAACTGCAAGAGGGTTTATTGGA 
TACACGGGTACCCGGGCGACTCAGTCAATCGGAGGACTGGCGCCCCGAGTGAGGGGTTGT 
GCTAGCTAGCTTGCCAAACCTACAGGTGGGGTCTTTCATT 3'
85
Chapter 3
3.7. TRANSFECTION OF RETROVIRAL VECTORS INTO ECOTROPIC BOSC 
PACKAGING CELLS 
All retroviral vectors were transfected into BOSC packaging cells using both 
lipofectamine (2.1.4.i.) and calcium phosphate (2.1.4.ii.) methods.
3.7.1. pCX-GFP Plasmid
Originally the method being used was lipofectamine and the retroviral vectors were 
being co-transfected along with pHIT 60, pHIT 123 and the pCX-GFP plasmids. 
Instead of transfecting four plasmids at once and therefore reducing the total amount 
of experimental vector DNA that could be transfected on each occasion, it was 
decided to introduce the pCX-GFP plasmid separately. This GFP reaction could act as 
a positive control with the same conditions being used for all transfection reactions. 
Began using the GFP positive control when first starting to use the calcium phosphate 
method (CaP04 1) and obtained a carpet of green fluorescent BOSC cells showing a 
successful transfection (see figure 3.4.).
To ascertain a quantitative value for transfection success, focused on an area of cells 
and then turned on the UV light, by contrasting the green with the non-green it was 
possible to estimate a percentage value for the number of cells which had been 
successfully transfected. It can be said, that by eye the number of cells showing green 
and therefore successful transfection, was in the region of 70-80%.
Figure 3.4. Fluorescent image (5X magnification) showing the successful transfection 
(CaP04 1) of BOSC cells with pCX-GFP.
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3.7.2. Harvested Virion
Another consideration and subsequent amendment was to use the harvested virion 
stocks immediately rather than storing them at -80°C. This meant that the ES cells to 
be used for infection needed to be prepared the day before. It was necessary to split 
the cells the day prior to infection, as the cells need to be actively dividing to allow 
the pre-integration complexes to enter the nuclei and integrate into the genome. Also, 
trypsinisation would damage all the membrane bound proteins, including the receptor 
which the Moloney hijacks, gp70, so it was essential to allow time for recovery before 
attempting to infect the ES cells.
3.8. EMBRYONIC STEM CELLS
Murine embryonic stem (ES) cells are undifferentiated, pluripotent stem cells derived 
from blastocysts.(Evans and Hunter, 2002) These cells undergo unlimited self­
renewal in the presence of the cytokine leukaemia inhibitiry factor (LIF) while 
retaining multilineage differentiation capacity and may be kept entirely karyotypically 
normal (Evans and Kaufman, 1981; Martin, 1981). They retain the ability to 
participate in normal embryonic development and following reintroduction to the 
blastocyst, they generate chimaeric animals that are mosaic in all their tissues. 
Mosaicism extends to the germ cell lineage and ES cells can contribute fully 
functional gametes (Bradley et al., 1984; Robertson et al., 1986).
3.8.1. -Karyotyping
The ES cell line used in this project was derived from C57BL/6J blastocysts, are male 
and have maintained a normal karyotype in culture.
The karyotype (2.1.8.) of these cells was studied at passage 4, 12 and 25 by 
examining metaphase spreads (Fig. 3.5.), a slight decrease was detected in the 
frequency of spreads with the normal number of chromosomes, but the modal number 
was still 40 (fig. 3.6.).
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Figure 3.5. Metaphase spread of the SHB16.3 cell line (isolated by Susan Hunter, 
Cardiff University, Wales), which was found to have a euploid chromosome 
complement with a strong modal number of 40.
Graph 3.1. Distribution of metaphase spreads with different chromosome numbers at 
passage 4, 12 and 25 of SHB16.3 ES cell line
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3.9. INFECTION OF EMBRYONIC STEM CELLS WITH HARVESTED VIRION 
Virion supernatant was harvested at 48 and 72 hours post transfection to allow 
expression of the various genes and then used to infect pre-seeded SHB16.3 ES cells.
3.9.1. -  Changing Medium
During selection, medium was being changed on an almost daily basis. This was later 
amended to every 3 or 4 days. When selection begins there is a lot of cell death and 
therefore a lot of cell debris so at this stage medium needs to be changed daily but 
after this period the cells appear to prefer being left in conditioned medium. Selection 
lasts about 12-14 days and as there are no feeders present it is mainly necessary to
89
Chapter 3
change the medium to prevent cell differentiation, by adding LIF with the medium. 
Stopped such frequent medium changes during the second calcium phosphate 
transfection (CaPC>4 2 ).
3.9.2. -  Use of Feeder Laver
Originally the ES cells were prepared with feeders for infection but this was 
something that was later amended. It was realised that mitotically inactivated feeder 
layers will mop up the retroviral particles as they can still be infected but without a 
division the virus cannot integrate. First amended this procedure with the third 
calcium phosphate transfection (CaP0 4  3).
However, it was also realised that feeders needed to be added to the ES cells once the 
resistant colonies had been selected and picked for expansion. At this stage it seemed 
essential feeders be added as there were so few ES cells being transferred to the 
multiwell plate, the feeders seemed to promote cell attachment and viability. 
Amended this procedure during the sixth calcium phosphate transfection (CaPC>4 6 ).
It seemed this was the crucial amendment to the procedure, as it was at this point 
(CaPC>4 6 ) that the first G418 resistant ES cell colonies (Fig. 3.6.) survived picking 
and were able to expand.
Figure 3.6. G418 resistant ES cell colony on feeders (40X magnification)
90
3.10. COMPARING SUCCESSFUL INFECTIONS OF SHUTTLE AND SPLICE 
ACCEPTOR SERIES
After amending certain factors as mentioned in sections 3.7. and 3.8., transfection and 
subsequent infection began to give results with calcium phosphate transfection 
number 6  (CaP0 4  6 ). There were four attempts at lipofectamine transfection prior to 
trying the calcium phosphate method. Unfortunately, both CaP0 4  8 and CaP0 4  10 had 
to be disposed of due to infection.
Table 3.1. Showing G418 resistant ES cell clones obtained for the four retroviral 
vectors used.
Transfection type 
and number of ES 
cells seeded for 
infection/construct/ 
time point.
Constructs 
transfected 
into BOSC
Clones obtained 
48Hr
Clones obtained 
72Hr
X 2 1 A X 2 1 A X 2 1 A
CaP04 6 (lxlO6) V - V V 6 - 1 4 2 - 0 7
CaP04 7 (lxlO6) V - V V 25 - 0 23 134 - 1 14
CaP04 9 ( lx l 06) V V V V 5 23 1 7 7 42 2 9
CaP04 11 ( lx l 06) V V - V 4 74 - 18 4 48 - 18
CaP04 8-11 (lxlO6) V V - - 26 38 - - 18 33 - -
LIPO 11-3 (19xl05) V V - V 83 99 - 26 INF INF - INF
Abbreviations: LIPO, Lipofectamine transfection; CaPC>4, Calcium phosphate 
transfection; INF, infected cells disposed of;
X, pCRR+SD 126T7 I-Sce; 2, pCSI+SD126 L4; 1, pSHUT+124K SD126;
A, pSHUT+124K.
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It can be seen from table 3.1. that the splice acceptor series gave rise to a far greater 
number o f resistant ES cell colonies than the shuttle series.
These results can be compared as an infection assay as opposed to an actual particle 
assay. By dividing the total number of G418R colonies obtained for each construct, by 
the number of successful infections, shows the number of ES cells infected with each 
retroviral construct per infection. Only the successful infections were included, as 
otherwise the result would be affected unfairly, as on some occasions ES cells had to 
be disposed o f due to bacterial/fungal infections.
It must also be noted that only the calcium phosphate transfections are being counted 
and compared as the lipofectamine transfection had a different number of ES cells 
seeded and a different amount of DNA transfected, so the lipofectamine result stands 
alone. It is assumed that as the same amount of DNA was transfected for each calcium 
phosphate transfection and the same number of cells were seeded it is fair to compare 
the number o f G418R colonies obtained for each construct (table 3.2.).
The shuttle series lacks splice acceptor sequence and therefore would be activated 
mostly from insertion into exons, unlike the splice acceptor series which could be 
activated from intronic insertions also. This means the splice acceptor series have a 
much greater number o f productive sites for infection compared to the shuttle series. 
The one splice acceptor vector requires in-frame fusion and at least low level gene 
expression of the trapped locus in undifferentiated ES cells for the reporter gene to be 
translated and subsequent survival o f G418 selection. The other splice acceptor vector 
has an IRES upstream of the p-geo reporter thereby allowing cap-independent 
translation of p-geo from fusion transcripts. Another factor to consider is that as all of 
these retroviral gene trap vectors require a cellular promoter for activation, the 
maximum number of genomic targets equals the number of expressed genes.
It has subsequently been noted that the use o f a positive control retroviral vector may 
have been useful in comparing successful infections and the numbers of G418R 
colonies obtained. Perhaps the ROSApGEO retroviral vector could have been used, 
without any modifications to then give a baseline figure for G418R colonies.
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Table 3.2. Shows the number of G418 resistant ES cell colonies obtained for each 
retroviral construct
RETROVIRAL CONSTRUCT
TOTAL NUMBER 
OF G418r ES 
CELL COLONIES 
PICKED
AVERAGE 
NUMBER OF 
G418R ES CELL 
COLONIES/ 
INFECTION
PSHUT+124K SD126-1 5 <1
pSHUT +124K-A 100 12.5
PCRR+SD126 T7 I-Sce -X 231 23.1
pCSI+SD126 L4 -2 258 43
The above table 3.2. shows the average number o f G418R colonies obtained after 
CaPC>4 transfection of the retroviral constructs into BOSC packaging cells and 
subsequent infection of the ES cells. These figures can be compared to an expected 
return o f about 5xl03 G418R colonies per 106 ES cells infected. This figure is 
assumed after comparing the number of expected active genes to the size of the 
genome and the fact that only about a third o f the 106 ES cells can be expected to be 
infected and integration occur.
It can be seen that the number o f G418R colonies achieved in this project is extremely 
lacking when compared to the expected numbers. This may be due to some extent to a 
lack of experience but it must also be mentioned that the numbers quoted are actually 
for the number of G418R colonies picked as opposed to the number that appeared. 
Perhaps speed was an issue as the longer the plates are kept out for the picking of the 
colonies the more likely it is that a number are lost due to inhospitable conditions.
Due to resistant clones being obtained, a reverse transcriptase assay was never 
attempted. With hindsight however, it does appear that a viral assay would have been 
beneficial to allow a value to be applied to the number of G418R colonies obtained 
compared to the amount of active virus present during infection. This would also have 
been useful to compare with the suggested positive control above, ROSApGEO, to 
see if these novel retroviral vectors allowed packaging to the same standard as 
established retroviral gene trap constructs.
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3.10.1. -PSHUT+124K SD126-1
This shuttle series vector gave less than one G418 resistant (G418R) colony per 
infection (table 3.2.). Even though a low number was expected (3.5.1.a.), this result 
was not acceptable.
A reverse transcriptase assay was considered but as G418R colonies appeared for the 
other retroviral vectors, this eliminated the concern that packaging may have failed. 
After conducting many restriction digests on pSHUT+124K SD126-1 and obtaining 
sequence data, it became apparent that the neomycin phosphotransferase (neo) 
cassette was in the wrong position. Instead of being located at the 5' end, upstream of 
the splice donor it was found to be 3' of the bacterial origin of replication (see figure 
3.7.). This could explain the lack of G418R colonies as it is likely that the neo cassette 
would be spliced out after integration, due to the splice donor now located upstream 
of the neo cassette.
Due to time constraints, no attempt was made to correct this vector and efforts for 
plasmid rescue were focused on the remaining shuttle vector, pSHUT+124K-A.
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Figure 3.7. Shows the incorrect location of the neo cassette in the plasmid 
rescue construct pSHUT+124K SD 126-1 and the possible splicing event after 
integration.
(A) pSHUT+124K SD 126-1 with the neo cassette in the correct location.
(B) pSHUT+124K SD126-1 with the neo cassette in the wrong position, 3' of 
the bacterial origin of replication. The diagram indicates how it is possible for 
the neo cassette to be spliced out after integration into genomic DNA.
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3.10.2. - pSHUT +124K-A
A total o f 100 colonies were picked after G418 selection for 8 successful infections, 
giving a result of 12.5 G418R colonies/infection.
The inclusion of the BGHpA after the neo cassette is expected to increase the number 
of G418R colonies when compared to pSHUT+124KSD 126-1, which contains a splice 
donor site instead. Although less in number, the quality o f G418R colonies retrieved 
with the splice donor trap are expected to be much greater as only insertions into
n
genes are expected to give rise to G418 colonies and background intergenic 
insertions should be lost during selection. However, this comparison cannot be made 
with pSHUT+124KSD 126-1, due to the incorrect neo position in the splice donor 
construct.
There are quite a number of G418R colonies obtained with pSHUT+124K-A but when 
compared to the splice acceptor series, it is definitely lacking.
3.10.3. -  PCRR+SD126 T7 I-Sce-X
There were a total of 231 G418 resistant ES cell clones picked after calcium 
phosphate transfection with this construct after ten successful infections. Giving a 
result o f 23.1 G418R colonies/infection.
Due to the inclusion o f a splice acceptor site in this construct a high number of  
productive insertions were expected. With the lack o f an exogenous polyA it was 
necessary that the construct inserted into an actively transcribed gene to obtain 
endogenous polyA function. It is expected that this construct will insert into an intron 
as an exogenous exon and due to the splice donor function, subsequently be spliced 
into the mRNA transcript with downstream exons still being incorporated.
3 .10 .4 .- PCSI+SD126 L4-2
This construct gave 258 G418 resistant clones after six successful infections, giving 
an average of 43 G418R colonies/infection. It can be seen that this was the most 
successful construct for obtaining G418R colonies.
The efficiency of gene trapping can be limited by the requirement for the production 
of in-frame fusion proteins that retain reporter activity, the IRES was used to allow 
independent translation of the reporter from fusion transcripts. This is predicted to 
significantly enhance the frequency o f productive integration as any insertion into an
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active gene should give functional reporter expression. The IRES appears to have 
performed as expected.
Statistical confirmation of the IRES function using the Mann-Whitney test:
To confirm the IRES function statistically, the numbers of clones obtained from 
calcium phosphate transfections of both pCRR+SD 126T7 I-Sce and pCSI+SD126 L4 
(which contains IRES) were compared in a non-parametric, Mann Whitney test.
The Mann-Whitney test was used to compare two independent samples. Unlike the t 
test, the Mann-Whitney test is valid no matter what the form of the population 
distributions therefore, it is a distribution-free type o f test. Also, as the Mann-Whitney 
does not focus on any particular parameter such as a mean or a median, it is a non- 
parametric test.
The resulting data was displayed as a box plot graph (see graph 3.2.). The interior line 
of the box depicts the median value. The lower quartile is found below the median 
and forms the bottom line of the box. The upper quartile is above the median value 
and forms the top line of the box. The minimum and maximum values can be read 
directly from the graph. If there are no outliers these numbers correspond to the ends 
of the whiskers of the graph and are connected to the upper and lower quartile lines. 
Box plot provides a visual summary that shows the median value, spread, range and 
outliers.
It can be seen from graph 3.2. that pCSI+SD126 L4 gives a much increased number 
of G418r colonies when compared to pCRR+SD 126T7 I-Sce and there is an outlie 
point of 134 for pCRR+SD 126 T7 I-Sce.
The resulting p value was 0.0196 which confirms that these two constructs give 
significantly different results.
97
Graph 3.2. -  Box plot comparing the number o f G418R colonies obtained for the two 
splice acceptor vectors
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3.11. PLASMID RESCUE SERIES RESULTS
Genomic DNA was prepared (2.2.2.xi.) from all plasmid rescue G418R ES cell 
colonies. The resulting DNA was electrophoresed on a 1% agarose gel (2.2.2.iv) to 
ensure that it was successful (fig. 3.8.).
Figure 3.8. 1% agarose gel showing resulting isolation of genomic DNA from five
NB: It has to be noted that subsequent 
investigations have led to the discovery 
that the genomic DNA shown to the left is 
not of sufficient quality for plasmid rescue 
procedures. The DNA needs to be treated 
with RNase to remove the obvious 18s and 
28s ribosomal bands that can be seen as 
bright spots in the lower region of the gel. 
The genomic DNA is of considerable size 
and will be visible at the uppermost region 
of the gel.
It can be seen from table 3.3, that only a very small number of resistant bacterial 
colonies were actually recovered when attempting plasmid rescue.
Due to the lack of rescued plasmids it was felt necessary to check that the gene trap 
construct was actually present in these resistant colonies. Neomycin 
phosphotransferase offers G418 resistance in mammalian cells but also confers 
kanamycin resistance in bacteria. The 5' flanking rescued plasmids, recovered after 
electroporation were spread out onto kanamycin (40pg/ml) agar plates.
Three out of four of the 5' flanking rescued plasmids grew on kanamycin agar plates, 
showing that the neo cassette must be present. Only rescued plasmids containing the 
5' flanking region can be tested in this way as this is where the neo cassette would be 
located (fig. 3.9.).
Negative controls of no DNA and also undigested gDNA were added to the 
electroporation mix and used to confirm that there must be a plasmid of some 
description conferring antibiotic resistance to the plasmid rescue bacterial plates. No 
resistant colonies arose from the negative control plates at any time. A positive 
control was also set up, which consisted of pUC 18 plasmid electroporated in exactly 
the same fashion as the plasmid rescued samples. Many bacterial colonies appeared 
for this positive control on all occasions.
CaP04ll  clones.
Clone G248 
Clone D348 
Clone B248 
Clone F l48 
Clone G l48 
1 kb ladder
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Figure 3.9. Schematic outline of the plasmid rescue procedure
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Table 3.3. Outcome of restriction digests for different shuttle clones
Transfection Clones 
recovered 
and gDNA 
prepared
Digested with 
restriction 
enzyme
Recovered
plasmid.
No. of 
bacterial 
colonies
Sequence data 
obatained?
CaP0 4 6 B1C Bglll 0
BamHI 2 No growth
Bell 0
SexAI 0
Spel 0
Bsu36I 0
BlpI 0
Bbsl 0
Sfil 0
C3C Bglll 0
BamHI 0
Bell 0
SexAI 0
Spel 0
Bsu36I 0
BlpI 0
Bbsl 0
Sfil 0
H2C Bglll 0
Bbsl 0
BamHI 1 No growth
SexAI 0
101
Table 3.3. Outcome of restriction digests for different shuttle clones (continued)
Transfection Clones 
recovered 
and gDNA
Digested with
restriction
enzyme
Recovered
Bacterial
Colonies
Sequence data 
obtained?
prepared +
RCA RCA
CaP049 1A5 BstEII 1 0 Bad sequence
Bglll 11 0 All grew, bad 
sequence
Bsu36I 0 0
Nael 0 0
1D1 Hindlll 0 0
BstEII 5 0 Bad sequence
Xbal 0 0
Bsu36I 2 0 Bad sequence
1A1 Hindlll 0 0
BstEII 5 0 Bad sequence
Xbal 0 0
Bsu36I 8 0 All grew, bad 
sequence
2E1 Bglll 0 1 No growth
Bbsl 0 0
BamHI 0 7 1 colony grew, bad 
sequence
SexAI 0 0
2 C1 Bglll 0 0
Bbsl 0 0
BamHI 0 3 Bad sequence
Spel 0 3 Bad sequence
SexAI 0 0
2B2 BstEII 5 0 Bad sequence
Bsu36I 0 0
Nael 0 0
Bglll 0 0
1G1 0 0
3D1 Bsu36I 0 0
Nael 0 0
Bglll 0 0
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Table 3.3. Outcome of restriction digests for different shuttle clones (continued)
Transfection Clones 
recovered 
and gDNA
Digested with 
restriction 
enzyme
Recovered
Bacterial
Colonies
Sequence data 
obtained?
prepared +
RCA RCA
CaP04l 1 G2(48) Xbal 2 3 Bad sequence
H2(48) Xbal 0 0
D2(48) Xbal 3 1 2 grew RCA+, bad 
sequence
A3(48) Xbal 0 0
B3(48) Xbal 7 5 4 RCA+ and 
3RCA-grew, bad 
sequence
Gl(48) Xbal 0 0
FI (48) Xbal 0 0
B2(48) Xbal 1 0 Bad sequence
D3(48) Xbal 0 0
C2(72) Xbal 0 0
C2(48) Xbal 2 0 Bad sequence
E2(72) Xbal 0 0
3.11.1. -Use of Glycogen when Precipitating DNA from 500pl Ligations 
It was felt that due to the small yield of rescued plasmid expected and the large 
volume o f ligation mix required perhaps the DNA needs a carrier to assist in 
precipitation.
Glycogen is a highly purified polysaccharide from mussels and can be used as a 
carrier for nucleic acid precipitation. It is an inert material compatible with most 
molecular biology procedures, including PCR, DNA sequencing and competent cell 
transformation which are the major concerns in this project.
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It can be seen when comparing (table 3.3.) the number of rescued plasmids from 
CaPC>46, where glycogen was not used, to the number recovered from CaP0 4 9 , where 
it had been used, there has been a definite improvement. The numbers of resistant 
bacterial colonies had improved and also some o f the resultant liquid medium cultures 
had grown.
3.11.2. -  Rolling Circle Amplification (RCA)
An attempt was made to amplify any rescued plasmid by rolling circle amplification 
(2.2.2.xii.d.) using TempliPhi™ DNA amplification kit (Amersham Biosciences, UK 
Ltd., Bucks, UK). As it was likely that only a tiny amount o f plasmid would be 
recovered from the ligation reaction it was felt prudent to try and amplify what there 
was prior to electroporation.
A positive control was set up using pUC19 plasmid with the RCA mix and only a few 
(~15) bacterial colonies appeared after electroporating into DH5a electrocompetent 
cells.
A total of ten bacterial colonies resulted after electroporating two RCA treated 
plasmid rescued clones (CaPC>49 - 1A1 and 2B2) into DH5a electrocompetent cells, 7 
colonies for 1A1 and 3 for 2B2, (table 3.3.). This result is not really a considerable 
improvement on the untreated samples.
When the RCA treated and untreated samples are compared in CaPCM 1 (table 3.3.) it 
can be seen that there is slight increase in the number o f bacterial colonies retrieved 
with RCA treatment but not really noteworthy.
Plasmid DNA was isolated (2.2.2.x.) from the resulting ten bacterial colonies and 
electrophoresed on a 1% agarose gel (fig. 3.10.). The resulting DNA all appeared the 
same size on the gel (about 4kb), which was not expected, as two different clones 
were used.
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3Figure 3.10. 1% agarose gel showing the results of rolling circle amplification for 
two CaPCM 1 clones, 1A1 and 2B2.
7X 1A1 colonies 3X 2B2 colonies
>  lkb 
ladder
lkb <  
ladder
Sequencing four of these products was attempted (fig. 3.9.) using both forward (gag) 
and reverse (neo) primers, resulting in unreadable sequence. There was a considerable 
amount of background, which would normally suggest that single bacterial colonies 
had not been picked adequately resulting in other plasmid DNA being present and 
therefore causing background when sequenced. However, this is extremely unlikely in 
this case as there were so few bacterial colonies present it would have been almost 
impossible for the accidental picking of two bacterial colonies together.
When next attempting RCA, another positive control, pUC19, was used as previously 
stated but also a negative control was prepared using 1 pi of water instead of DNA 
with the normal RCA mix (table 3.4.).
On this occasion a more efficient electrocompetent cell was employed, ElectroTen 
Blue, Stratagene, La Jolla, CA 92037.
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Table 3.4. Showing controls used when electroporating RCA products into 
ElectroTen Blue electrocompetent cells
Control Components Resulting Bacterial 
Colonies
RCA positive (RCA mix + pUC19 DNA) 
+ electrocompetent cells
Lots of descent sized 
colonies
RCA negative (RCA mix + water)
+ electrocompetent cells
No colonies
Electroporation positive PUC18 DNA + 
electrocompetent cells
Lots of descent sized 
colonies
Electroporation negative Water + electrocompetent 
cells
No colonies
Seven RCA treated plasmid rescue clones, the positive RCA control, the negative 
RCA control, pUC18 positive electroporation control and a negative (no plasmid) 
electroporation control were all electroporated into ElectroTen Blue electrocompetent
cells.
From all 7 of the RCA treated plasmid rescue clones there was a total o f 18 bacterial 
colonies recovered, these were picked and expanded in liquid medium.
The resulting plasmid DNA from the 18 RCA treated plasmid rescue bacterial 
colonies was amplified (section 2 .2 .2 .xv.) using both forward (gag) and reverse (neo) 
primers to try and obtain a single, discrete band product which could then be purified 
(section 2.2.2.xix) sequenced. This step was to try and eliminate background sequence 
prior to the sequencing reaction (section 2.2.2.xvi.). Unfortunately, this did not appear 
to improve the result, as the sequence data received was still unreadable.
Redesigned primers in both the gag and neo regions hoping to increase 
complementarity and thereby improve the quality o f PCR products. Again no great 
improvement was seen with the resulting sequence data.
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When comparing the positive controls for both the DH5a and the ElectroTen Blue 
electroporations it was seen that the ElectroTen Blue cells gave a much more efficient 
return of resistant bacterial colonies, so this was the eletrocompetent cell of choice in 
further plasmid rescue attempts.
3.11.3. -  Size of Resistant Colonies
On a number of occasions picked bacterial colonies never expanded when transferred 
to liquid medium. The colonies were very small at the time of picking and had taken 
longer than normal to appear, about 24 hours on some occasions.
The fact that there were no larger colonies present on the ampicillin agar plate 
eliminates the theory that these were satellite colonies. Larger ampicillin resistant 
transformants would be required to excrete beta lactamase into the medium, thereby 
depleting the antibiotic in that area and allowing the formation o f ampicillin sensitive 
satellite colonies over an extended period o f time.
When these tiny colonies were transferred to LB broth, many did not expand, even 
when left for over 24 hours. Perhaps over a period of time on the ampicillin agar plate 
a couple managed to survive due to the reduced activity of the ampicillin, but when 
introduced to the ampicillin rich liquid medium they could not perpetuate survival.
Progress was made with the plasmid rescue methodology, in as far as isolating 
resistant bacterial colonies, possibly containing the rescued plasmid. However, this 
could never be confirmed as no readable sequence data was ever forthcoming. After 
many sequencing attempts, plasmid DNA isolated from the resistant bacterial colonies 
was sent to a commercial sequencing company (Oswel Research Products Ltd., 
University of Southampton, UK), but again sequencing failed. This sequencing 
problem needed to be investigated further, but due to time constraints, a need was felt 
to prioritise as deadlines were looming, so attention was focused on the splice 
acceptor series.
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3.12. SPLICE ACCEPTOR SERIES RESULTS
All splice acceptor G418R ES cell colonies were expanded to a minimum of 5x106 
cells and then cytoplasmic RNA was prepared (section 2.2.2.xiii.). The resulting RNA 
was electrophoresed on a 1% agarose gel (section 2 .2 .2 .iv) to ensure a successful 
preparation was achieved.
Figure 3.11. 1% agarose gel showing the successful isolation of RNA for a number 
of splice acceptor series clones from CaP0 4  8 - 1 1
lkb
ladder
I
After checking the RNA (fig. 3.11.), proceeded with 3' RACE (2.4.2.) reactions. The 
clones that gave a product during 3' RACE, bacterial colonies after cloning into 
pAMPl (2.4.3.) and subsequent sequence information can be seen in table 3.5.
On each occasion, a minimum of six bacterial colonies was picked for each clone. 
Each bacterial colony was prepped and then sequenced with the appropriate primers. 
After conducting a VecScreen (NCBI Database Entrez Nucleotide) on the resulting 
sequence information, a CAP EST Assembler at IFOM was run to obtain a contiguous 
sequence for each clone.
These contiguous sequences obtained from the 3' RACE products are listed in 
Appendix III.
Table 3.5. Positive results of 3' RACE and subsequent comparison with NCBI
GenBank data using Blastn homology program showing similarity to non-redundant
gene sequences
Transfection-
clone
Sequence database 
search after 
VecScreen
Insertion
into
genome
No. of 
nt in 
BLAST 
search
% identity
CaP049 -  1A672 Blastn-Mm vaccinia 
related kinase 3
7B 2 79 12-79nt
100%
CaP04 9 -  1F872 Blastn-Mm (similar to) 
phophoglycerate kinase I
12 A l.l 67 20-67nt
97%
CaP04 8 -ll -  HI Blastn-Mm Inhibitor of 2 cM 464 21-464nt
DNA binding 1 (Idl) 84.0 95%
CaP04 8-11 -  D1 Plasmid sequence NA 72 NA
CaP04 8-11 -E 7 Blastn-Mm RIKEN 
cDNA 1500001M02 
gene, mRNA (cDNA 
clone IMAGE: 4218748)
17E1.3 447 183-436nt
92%
CaP04 8-11 -B 5 Bad sequence NA 121 NA
CaP04 8-11 -  H7 Bad sequence NA 186 NA
CaP04 8-11 -  F648 Blastn-Mm ribosomal 15 cM 618 1-434
protein L30 (Rpl30) 14.7 99%
CaP04 11 -  D6 72 Bad sequence NA 76 NA
CaP04 11 -  E1248 Bad sequence NA 82 NA
CaP04 11 -  El 148 Blastn-Mm ribosomal 7 cM 452 119-241nt
protein L28 4.0 96%
CaP04 11 — F1148 Bad sequence NA 63 NA
CaP04 11 — B248 Blastn-Mm Cytochrome 
c oxidase subunit Vb
1 B 807 16-450nt
99%
CaP04 11 -  B672 Bad sequence NA 61 NA
CaP04 11 -  D l48 Blastn-Mm Histone 
H2A.1 (AY158913)
13 395 119-378nt 
99%
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Table 3.5. Positive results of 3' RACE and subsequent comparison with NCBI 
GenBank data using Blastn homology program showing similarity to non-redundant 
gene sequences (continued)
Transfection-
done
Sequence database 
search after 
VecScreen
Insertion
into
genome
No. of 
nt in 
BLAST 
search
% identity
CaP04 11 -  H372 Bad Sequence NA 61 NA
CaP04 11 -  D448 Blastn-Mm Zinc finger 
protein 369, mRNA 
(cDNA clone 
MGC:41715 
IMAGE: 1365300)
13 283 71-238nt
97%
CaP04 11 -  H672 Bad sequence NA 145 NA
CaP04 11 -  C772 Bad sequence NA 82 NA
CaP04 8-11 -  B6 Blastn-Mm ribosomal 
protein LI2 (Rpll2)
2B 581 51-556nt
98%
CaP04 11 -  D872 Bad sequence NA 42 NA
CaP04 11 -  H872 Blastn- Mm proteasome 
(prosome, macropain) 
subunit, beta type 6
11 cM 
39.0
190 35-190nt
97%
CaP04 11 -  E572 Blastn-Mus musculus 
ribosomal protein L30
15 cM 
14.7
719 55-498nt
99%
CaP04 11 -  F772 Bad sequence NA 59 NA
CaP04 11 -  D472 Blastn-Mm HRAS like 
suppressor 3
19A 191 19-188nt
98%
CaP04 11 -  G672 Blastn-Mm peptidyl- 
prolyl isomerase A
11 cM 1.0 485 15-485nt 
99%
CaP04 11 -  G472 Bad sequence NA 142 NA
CaP04 11 -  B772 Blastn-Mm clone 
IMAGE:3968454 
mRNA
8 151 17-151 nt 
97%
CaP04 11 -  C672 Bad sequence NA 81 NA
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3.12.1 -  Use of Feeder Laver
Originally STO feeders (section 2.1.2.) were being used to support the growth of 
G418r colonies. However, it became apparent that over this long period of selection 
the STO cells were not surviving, they were curling up and coming away from the 
plate, subsequently taking any G418R colonies with them.
It was decided that instead of using STO feeders, STO-NEO feeders would be 
employed as they should survive the G418 selection.
The use of STO-NEO feeders led to further considerations when attempting 3' RACE, 
due to the feeders containing the neomycin phosphotransferase gene. The presence of 
this gene would lead to a product band from the feeders when 3' RACE products were 
analysed on an agarose gel (section 2.2.2.iv). It was therefore essential that feeders 
were removed from the G418R ES cells prior to RNA extraction.
Removal o f feeders entails passaging the cells a couple o f times onto gelatinised 
plates and leaving the cells to settle for about 20 minutes. The feeders bed down 
before the ES cells, so after twenty minutes the medium can be removed still 
containing ES cells but minus a great many feeder cells. After a couple of passages 
most o f the feeders were removed.
3.12.2. -PCR Screen
After receiving sequencing data back from 3' RACE products containing nothing but 
plasmid sequence it was felt prudent to screen the bacterial colonies prior to 
sequencing (section 2.2.2.xviii). M l3 primers were used to amplify the multiple 
cloning site of pAMPl (see Appendix II for vector diagram), which is 400bp in size. 
Single band products greater than 400bp in size were selected and sent for sequence 
analysis.
3.12.3. -mRNA isolation
An attempt was made to increase the return o f 3' RACE products by isolating 
messenger RNA (section 2.2.2.xiv). As mRNA comprises about 1% to 4% of total 
RNA it was felt that the purified sample would give rise to a higher number of 3' 
RACE PCR products.
I l l
There were a couple o f successful products using mRNA but when again compared to 
total RNA it was realised that it was other factors that had caused the positive results, 
not the purifying o f the sample. It was an adjustment o f the PCR cycle programme 
and the reduction of the MgCh concentration used in the 3' RACE PCR reaction.
With the considerable effort, time and expense to isolate mRNA, the limited 
advantage was not felt worthwhile.
3.12.4. - T7 Enrichment
As mentioned in 3.5.2.b. the pCRR+SD126 T7 I-Sce construct contains a T7 promoter 
which can be utilised once RNA has been harvested from G418R colonies and cDNA 
prepared. In theory T7 RNA polymerase should copy more RNA from the T7 
promoter through the splice donor and trapped transcript to the polyA and appended 
anchor sequences. By performing 3' RACE on this enriched template it would be 
more likely that the correct region be amplified.
The T7 transcription was attempted as detailed in 2.4.1. After incubating for 6 hours 
and then precipitating RNA, the amplified RNA concentration and quality was read 
by measuring OD260 and OD260/280 (section 2.2.2.xvii). Also, as unreliable readings 
were obtained from the spectrophotometer a small portion o f the resulting mix was 
electrophoresed on an agarose gel to see if  any RNA visible. It was expected that the 
antisenese RNA transcribed from the cDNA template would represent the size and 
complexity of the synthesised cDNA. A long smeared band was anticipated, but 
unfortunately not forthcoming.
Due to the small volume of amplified RNA loaded on the gel it was considered that it 
may not have been concentrated enough to be apparent, so proceeded with 3' RACE 
(as detailed in 2.4.2.), with one exception. As the T7 promoter is located downstream 
of the neo cassette, the neo is lost during T7 enrichment, so it is essential that an 
alternative gene specific primer is utilised. The remaining gene specific region is the 
I-Sce 1 site so a primer was designed specific for this area and named “Gene specific 
primer (I-Sce 1)” (table 2.4.1.).
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After a number of attempts, this procedure gave no products after 3' RACE PCR. Due 
to results beginning to come through with 3' RACE PCR of the splice acceptor 
constructs this T7 enrichment step was put to one side whilst efforts were 
concentrated on obtaining sequence data and injecting ES cell clones into host 
blatsocysts.
3.12.5. -Genomic DNA PCR
To test whether retroviral sequence was preserved in transduced ES cell lines, 
genomic DNA was prepared (section 2.2.2.xi.) from a number of clones and then 
subjected to genomic PCR (section 2.4.7.) using specific primers for the retroviral 
sequence called gDNANEOF and gDNANEOR (table 2.4.1.) which prime from the p- 
geo gene.
lkb
ladder
KEY:
1 - CaP04l 1 E1248
2 - CaP04l 1 D6 72
3 - CaP04l 1 G4 72
4 - CaP04l l  E5 72
5 - CaP04l 1 B6 72
6  - CaP04l l  C772
7 - CaP04l l  H8 72
8  - positive control
9 - negative control
Figure 3.12. 1% agarose gel showing the results of genomic PCR to identify those 
clones with definite retroviral insertion
It can be seen from the above agarose gel picture (fig. 3.12.) that all seven samples 
show definite retroviral insertion with an obvious 470bp p-geo product band.
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3.12.6 -Beta Galactosidase staining
A number of splice acceptor trapped clones were stained as described in section 2.4.4. 
As expression of the (5-geo relies on the activity of the trapped promoter (section
3.5.2.), all G418r clones represent gene trap events and should be (5-gal-positive. 
However, pgal activity was undetectable by X-gal staining in about 50% of colonies, 
reflecting the higher sensitivity of neo than P-gal activity.
It was also apparent that some clones gave lighter patterns of staining than others and 
not all cells in a clone stained blue. This observation is in agreement with previous 
work showing heterogeneity of staining in p-gal colonies (MacGregor et al., 1987).
Figure 3.13. Beta galactosidase staining (5X magnification) of one splice acceptor 
trapped ES cell line (CaPCM 1 D 6 7 2 )
A considerable contrast can be seen in fig. 3.13. where an individual colony shows 
much greater staining than the adjacent colony.
Of course, the inclusion of the beta galactosidase gene and the subsequent ability of 
staining really can be appreciated once germline chimeras have been created. The 
progeny can then be studied in detail to identify particular areas of expression with 
this staining technique.
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3.12.7. -High Throughput 3'RACE
In order to obtain a greater number o f positive products from 3'RACE, a high 
throughput option was considered (section 2.4.6.). A new robot (Multiprobe II HT 
EX) had been delivered to the school and so the temptation was there to try and 
increase throughput. It was necessary to try and plan the procedures in the laboratory 
before attempting anything with the robot.
A known positive clone CaPCMl- DI48 was grown up in a 96 multiwell plate and 
treated as detailed in section 2.4.6. Only the first three rows o f cells were harvested as 
the expense of all the reagents restricted the scale of this experiment. Out of 24 wells 
there was one product band on the first attempt. In subsequent attempts of this nature 
there were never more than 3 out of 24 positives. Considering these are all meant to 
be positives it was not a great return and definitely not when considering the 
investment in both time and expense.
However, whilst trying to optimise protocols for use with the robot, there was a 
definite improvement in the laboratory technique where manual procedures were 
streamlined. When watching the robot pipette and then comparing the speed with a 
manual operator, personally, I think the manual technique is faster. There were a 
number o f occasions where I witnessed the robot malfunction due to one of the 
pipettes becoming stuck and the tips not dispensing. These o f course are technical 
problems, which in time will undoubtedly be improved. Due to time constraints, 
manual procedures were put back into action, returned to attempting 3'RACE as 
previously detailed (section 2.4.2.).
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3.13. INVESTIGATING THE SPLICE ACCEPTOR CONSTRUCTS INSERTION 
SITES
After obtaining the preliminary results detailed in table 3.5. the insertion events of the 
different clones were investigated more thoroughly, at the nucleotide level. The 
recovered clone sequence was compared to the retroviral construct and cloning vector 
sequences to try and ascertain the exact insertion location. The homologous sequences 
were then highlighted in the reference sequence of the identified trapped gene.
Figure 3.13.
Sequence either side of the multiple cloning site in pAMPl cloning vector
M13/Puc 2 3 -b ase  fo rw ard  sequencing  p rim er 
5'CCCAGTCACGACGTTGTAAAACG-------- ►
5'CCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGAATTTAGGTGACACTATAGAAGAGCTATGACGTCGCA
3'GGGTCAGTGCTGCAACATTTTGCTGCCGGTCACTTAACTTAAATCCACTGTGATATCTTCTCGATACTGCAGCGT
Cloning region
I--------------1
TGCACGCGTACGTAAGCTTGGATCCTCTAGAGCGGCCGCCTACTACTACTA3'
ACGTGCGCATGCATTCGAACCTAGGAGATCTCGCCGGCG
TCGACCCGGGAATTCCGGACCGGTACCTGCAGGCGTACCAGCTTTCCCTATAGTGAGTCGTAT
3'TACTACTACTACAGCTGGGCCCTTAAGGCCTGGCCATGGACGTCCGCATGGTCGAAAGGGATATCACTCAGCATA
I_________ I
Cloning region
TAGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCT3'
ATCTCGAACCGCATTAGTACCAGTATCGACAAAGGACACACTTTAACAATAGGAGA5'
^  GGACACACTTTAACAATAGGAGA5'
M13/pUC R everse seq u en c in g  p rim er
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Figure 3.14.
Sequence surrounding the 3'RACE (NEO) primer site of the retroviral splice 
acceptor construct
CCCGACGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTT
GGGCTGCCGCTCCTAGAGCAGCACTGGGTACCGGTACGGACGAACGGCTTATAGTACCACCTTTTACCGGCGAAAA
UDG C loning re p e a ts
I I
CAU CAU CAU CAU AT ATTGC
CTGGATTCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGC
GACCTAAGTAGCTGACACCGGCCGACCCACACCGCCTGGCGATAGTCCTGTATCGCAACCGATGGGCACTATAACG
3'RACE Prim er Sequence 
TGAAGAGCTTGGCGGC ---------►
TGAAGAGCTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATC
ACTTCTCGAACCGCCGCTTACCCGACTGGCGAAGGAGCACGAAATGCCATAGCGGCGAGGGCTAAGCGTCGCGTAG
STOP Codon o f p-geo
GCCTTCTATCGCCTTCTTGACGAGTTCTTCTGATCTAGAACTAGTGGATCCAGCTTATCGAGCTTGCCAACTACAG
CGGAAGCTAGCGGAAGAACTGCTCAAGAAGACTAGATCTTGATCACCTAGGTCGAATAGCTCGAACGGTTGATGTC
S p lic e  Donor s i t e
CAGGTAAGCATATTTATGAAAAATGCTGATTGTGTTAGCTACTTGTGTCAGTGTTGTGATAGTCGAC3'
GTCCATTCGTATAAATACTTTTTACGACTAACACAATCGATGAACACAGTCACAACACTATCAGCTG5'
KEY for all the following sequence analysis:
Red = 3'RACE Primer with UDG cloning repeats
Blue = Sequence homology
Black = pAMPl cloning vector sequence
Green = Retroviral construct sequence
Pink = No Match
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3.13.1. -  Clone CaPC>49 -  IA 6 7 7  showed homology to Mus Musculus Vaccinia
Related Kinase 3 (Vrk3)
5'CGCCCAATACGCAANCCGCCTCTCCCCGCGCGTTGGCCGATTCATTAATGCAGNTGGCACGACAGGTTTCCCGAC
TGGAAAGCGGGCAGTGAGCGCAACGCAATTAATGTGAGTTAGNTCACTCATTAGGCACCCCAGGCTTTACACTTTA
TGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGNAACAGCTATGACCATGATTA
CGCCAAGCTCTAATACGACTCACTATAGGGAAAGCTGGTACGCCTGCAGGTACCGGTCCGGAATTCCCGGGTCGAC
ATCATCATCATATATTGCTGAAGAGCTTpGCGGCJGGCGGCAGCAGCCACTCCACTCCCTATGGCATTTCTGTGATG
Homologous to  Vrk3
GCATAATAAACTGTTTTTAATCAAAANNAAAAAAAAAGTACTAGTCGACGCGTGGCCTAGTAGTAGTAGGCGG3'
It can be seen from the above sequence that the neo primer (red) runs directly into the 
“trapped” gene sequence (blue). There is no retroviral construct sequence between the 
primer and the novel gene sequence, which was very unexpected. However, it can be 
seen that there are 6  bp of homology from the neo primer with the Vrk3 gene. This 
could be explained as an artefact product from the 3'RACE PCR reaction.
It can be seen from the below diagrams that the sequence homology is located in the 
final exon, number 14, of the Vaccinia Related Kinase 3 (Vrk3) gene.
EXON 14 SEQUENCE (291bp)
5'AGCTTCCGACTTGCAGCTTGAAGTAGAACATGAAGTAGTGTGACTGGAGGCCTGTTTGA
ACTCATAGCTCCTAAAAGAATCCCTTGAATGTGCATTCTCACCGCTCCCTTAGGACATAT
GAATCAGCACTTGTGTTGGGGAACCTGAGTCATGTCATGTAATGTGAAACTCCTCCCTGTC
TCAGCTCTGGCAGCTGTGGATGGAGGTAAGTGGATGCTGGCGGCGGCGGCGGCAGCAGCC
ACTCCACTCCCTATGGCATTTCTGTGATGGCATAATAAACTGTTTTTAATC3'
3' DOWNSTREAM SEQUENCE
a a a g t c t g g a g a g t t c a g t g t t c a c a g a a g t t c t g g a a g a a t c t t c c t c c . . . .
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3.13.2. -  Clone CaPOa 8-11 -  HI showed homology to Mus Musculus Inhibitor of
DNA binding 1 (Idl)
5'CCCGGGGNNNNCCCCNGCATNTTNCNCCAGNTCTAAACGCCCCCTAAAGGAAAGCTGGTAGCCTGCAGGTACGGT
CCGGAATTCCCGGGTCGACATCATCATCATATATTGCTGAAGAGCTTGGCGGCCGAGGCGGCATTTGTTCCAGCCG
ACGATCGCATCTTGTGTCGCTTAGGCGGCGCACTGAGGGCCCAGATGGCCTCCAGCCCTTCAGGAGGCAAGAGGAA
AAAAGTGCTCTCGGTTCCCCAGGGGATCTCTGGGAAAGACACTACCGCAAGCCCCCGGACTCTTGGCGGATCGGTC
CAGTGGGTAAAGGGTTTGATCAACAGAGCCTCACCCTCTCCACCTTTCAGCCTCCAGAGACTTTGGGGAGGGGGTT
AATCAACCCCGCGTGTTTCTGTTTTATTGAAAAAGCAGACATTTTTTTTTTAAATGGTCACATTTCGTGCTTCTCG
GATTTCTGAGGAAATATTTTGTATTGTATATTACAATGATCCCTGGCTGAAAATATTGTTTTACAATAGTTCTATG
GGGGTGAGTTTTTTGTTGTTATTAAACAAACCCTTTAGATAAAAAAAAAAAAAAAAAAAAGTACTAGTCGACGCGT
GGCCTAGTAGTAGTAGGCGGCCGCTCTAGAGGATCCAAGCTTACGTACGCGTGCATGCGACGTCATAGCTCTTCTA
TAGTNCACCTAAATTCAATTCNCTGGC3'
Again, the above sequence shows homologous novel sequence running directly from 
the neo primer into the “trapped” gene. On this occasion, no homology between the 
neo primer and the novel sequence can be seen, in fact there are two nucleotides of 
non-homologous sequence between the neo primer and the beginning of homology 
with Id l. Looking at the area of primer binding, immediately before homology begins 
with the 1D1 gene, it does not appear particularly GC rich, unlike the Vrk3 scenario. 
Sequence homology with the Idl gene is located at the 3' end of the single exon and 
running into 3' downstream sequence.
SINGLE EXON (1151 bp)
5'TTGTACAACCTTTCTTCAACTTCTTGTTCTCTTCCCACACTCTGTTCTCAGCCTCCTCCGCTCCCCTCCGCCTGT
TCTCAGGATCATGAAGGTCGCCAGTGGCAGTGCCGCAGCCGCTGCAGGCCCTAGCTGTTCGCTGAAGGCGGGCAGG
ACAGCGGGCGAGGTGGTACTTGGTCTGTCGGAGCAAAGCGTGGCCATCTCGCGCTGCGCTGGGACGCGCCTGCCCG
CCTTGCTGGACGAGCAGCAGGTGAACGTCCTGCTCTACGACATGAACGGCTGCTACTCACGCCTCAAGGAGCTGGT
GCCCACCCTGCCCCAGAACCGCAAAGTGAGCAAGGTGGAGATCCTGCAGCATGTAATCGACTACATCAGGGACCTG
CAGCTGGAGCTGAACTCGGAGTCTGAAGTCGGGACCACCGGAGGCCGGGGACTGCCTGTCCGCGCCCCGCTCAGCA
CCCTGAACGGCGAGATCAGTGCCTTGGCGGCCGAGGTGAGGTCCGAGGCAGAGTATTACATTATTCTTCAGTGGGA
AACCGAGGCCACGGGAGGCGGGTGTCCCCCTTCCTTACTTTTCAGGCGCATAGCTATTTAGGGGCGACTAATAGGA
AAAAGCTCGCATTTTCATCGTGCCTCCTGGAGTAGAGAAATGGGAACGCCTCTCCCCTCCTTGTCCTTTCCAGTGG
GTCTCATCCCTTATCTCGCTCTGGTGTTCACAGGCGGCATGTGTTCCAGCCGACGATCGCATCTTGTGTCGCTGAG
GCGGCGCACTGAGGGACCAGATGGACTCCAGCCCTTCAGGAGGCAAGAGGAAAAAAGTGCTCTCGGTTCCCCAGGG
GATCTCTGGGAAAGACACTACCGCAGCCACCGGACTCTTGGCGGATCGGTCCAGTGGGTAGAGGGTTTGATCAACA
GAGCCTCACCCTCTCCACCTTTCAGCCTCCAGAGACTTTGGGGAGGGGGTTAATCAACCCCGCGTGTTTCTGTTTT
ATTGAAAAAGCAGACATTTTTTTTTAAATGGTCACATTTCGTGCTTCTCGGATTTCTGAGGAAATATTTTGTATTG
TATATTACAATGATCACTGGCTGAAAATATTGTTTTACAATAGTTCTATGGGGGTGAGTTTTTTGTTGTTATTAAA
CAAACACTTTAG 3'
3' DOWNSTREAM SEQUENCE
ataacgttgctgtgacttcttggatgggggaggggcgggacaggcatgac......
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3.13.3. -  Clone CaPC>4 8-11 -  F648 showed homology to Mus Musculus Ribosomal 
protein L30 (NM 009083)
5'CGCTTTTNGCCANGCNTCCAATACNACTNNCTNTANGGCAAAGANTCGGGACACCNGCAGGTACCGGTCCGGAAT
TCCCGGGTCGACATCATCATCATATATTGCTGTAAGTAGCTTGGCGGCCTGGTGTTGGTCTGGGGGTTGTCCCGCA
CCTAAGGCAGGAAGATGGTGGCCGCAAAGAAGACGAAAAAGTCTCTGGAGTCGATCAACTCTAGGCTCCAACTTGT
TATGAAAAGTGGGAAGTACGTGCTGGGCTACAAGCAGACTCTGAAGATGATCAGACAAGGCAAAGCGAAGTTGGTT
ATCCTTGCCAACAACTGTCCAGCTTTGAGGAAATCTGAAATAGAGTACTATGCCATGTTGGCTAAAACTGGGGTCC
ATCACTACAGTGGCAATAATATTGAACTGGGCACAGCGTGTGGAAAATACTACAGAGTATGCACACTGGCTATCAT
TGACCCAGGTGATTCTGATATTATTAGAAGCATGCCAGAACAGACTGGTGAGAAGTAAACAAGAAAGTTTTCCTTT
AATAAAACTTTGCCAGAGCTCCTTTTGAAAAAAAAAAAAAAAATTAAAACCTTAAAAAAAAAAAAAAAAAAGTNCT
ATTCNACNCGNGGCCTANTANTATTAGGCGGCCNCTCTANAGGATCCAAGCTNACGTACCCNNGCGTGCGAGGTNT
TAGCTNTTTTATNGNGNCCCCTAANTNAATTCACTGGCCGNGGTTTNAAACGNGNTGGGGNNAAAAA3'
Homologous sequence runs directly from the neo primer again, but there is no direct 
overlap with the primer. However, it can be seen from the below diagram that 
homology begins at a rather “GC” rich area in the exon sequence which probably 
influenced primer binding.
Sequence homology with the Rpl30 gene is located at the 3' end of the single exon.
5' UPSTREAM SEQUENCE
g c c t a g g c a a a c c a a t g a g a t c a a t a a a a t g t t a t a t t t a a a a t a a c a a g
SINGLE EXON (462 bp)
5'CTTTCTCGCTCCCTGGCCATCTTGGCGGCTGGTGTTGGTTGGGGGTTGTCCCACACCTAA
GGCAGGAAGATAGTGGCCGCAAAGAAGACGAAAAAGTCTCTGGAGTCGATCAACTCTAGGCT
CCAACTTGTTATGAAAAGTGGGAAGTACGTGCTGGGCTACAAACAGACTCTGAAGATGATCA
GACAAGGCAAAGCGAAGTTGGTTATCCTTGCCAACAACTGTCCAGCTTTGAGGAAATCTGAA
ATAGAGTACTATGCCATGTTGGCTAAAACTGGGGTCCATCACTACAGTGGCAATAATATTGA
ACTGGGCACAGCGTGTGGAAAATACTACAGAGTATGCACACTGGCTATCATTGACCCAGGTG
ATTCTGATATTATTAGAAGCATGCCAGAACAGACTGGTGAAAAGTAAACAAGAAAGTTTTCC
TTTAATAAAACTTTGCCAGAGCTCCTTTTG 3'
3' DOWNSTREAM SEQUENCE
a a a a a a a a a t a a a t a a a t a a a a t a a a a t a a a a t a a a a t a a c a a a g t t c a g
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3.13.4. — Clone CaPC>4 11 -  B2 4 g showed homology to Mus Musculus Cytochrome c 
oxidase subunit Vb
S'NGNTNTNCCAGNCTCCCAATACGACTCACTATAGGGAAAGCTNGTACGCCTGCAGGTACCNGGTCCGGAATTCCC
GGGTCGACATCATCATCATATATTGCTGAAGAGCpGGCGGCJGCAGGCCCTGAGGGCCCACGGCCCCCGTGGCGCG
Homology to Cox5b
GCCGTGACCCGCTCCATGGCTTCTGGAGGTGGTGTCCCCACTGATGAGGAGCAGGCTACTGGGCTGGAGAGGGAGA
TCATGATAGCAGCACAGAAGGGACTGGACCCATACAATATGCTACCTCCAAAGGCAGCTTCAGGCACCAAGGAAGA
CCCTAATCTAGTCCCGTCCATCAGCAACAAGAGAATAGTGGGCTGCATCTGTGAAGAGGACAACTGTACTGTCATC
TGGTTTTGGCTGCACAAAGGCGAGAGTCAGCGATGCCCCAACTGTGGAACCCATTACAAGCTGGTGCCCCACCAAA
TGGCCCACTGAGCCCCTGTGTTATCTTTTCAGAATGTAAAGAAAAACTTCTCTCTAATAAAGATTAGCCATTGCAC
TGGCTCCTCCCATAAAAAAAAAAAAAAAGTACTANTCGACTNCTAGGCCTACGCGTGGCCTAGCTNGTNGNCNCGC
GGGCGCTNTACANGATCCNAGCTTACGTACGACGTGCATGCTACTTCATAGCNTNTTCNATAGTGNCACCTANNGT
CAATTCACTGNACNGCNGTTTNACNNGGNANNGACTGGGNAAAACCCTGNCGTTACCCATNTTAATCGACTTGCAT
TNATCCCCCTNTNGNCAATTGAAGNNAGTACCGAAAAAGNCCGCTNCGATNGACNTTNCCAAANTGATGNANNNTG
AATGGCNACNNGGNACCGCCCTNTAACNNCCNTNAACNCGGGGGNNNNGGNGGNTNNCCCANNNNTNCCN3'
It can be seen from the above diagram that there are 8  bp in the neo primer that are 
homologous to the Cox5b gene, this could definitely lead to artefact product during 3' 
RACE PCR. Sequence homology runs from exon 1 of the Cox5b gene, right through 
to exon 4 as shown below.
EXON 1
5'CATCTTGCTCAGCCTGTTCCCGGAAGTGCATCTGCTTGTCTCGGGCGAGATGGCTTCAAG
GTTACTTCGCGGAGTGGGCGCTTTGGCGGCGCAGGCCCTGAGGGCCCACGGCCCCCGTGG
CGCGGCCGTGACCCGCTCCATGGCTTCTGGAG3'
EXON 2
5'GTGGTGTCCCCACTGATGAGGAGCAGGCTACTGGGCTGGAGAGGGAGATCATGATAGCAG 
CACAGAAGGGACTG 3'
EXON 3
5'GACCCATACAATATGCTACCTCCAAAGGCAGCTTCAGGCACCAAGGAAGACCCTAATCTA 
GT CCCGTCCAT CAGCAAC AAGAGAAT AGTGGGCTGCATCT 3'
EXON 4
5'GTGAAGAGGACAACTGTACTGTCATCTGGTTTTGGCTGCACAAAGGCGAGAGTCAGCGAT
GCCCCAACTGTGGAACCCATTACAAGCTGGTGCCCCACCAAATGGCCCACTGAGCCCCTG
TGTTATCTTTTCAGAATGTAAAGAAAAACTTCTCTCTAATAAAGATTAGCCATTGCACTG
GCTCCTCCC3'
3' DOWNSTREAM SEQUENCE
a t a g c t g g c t a g t c t t a t g t c t a t a g t c t t t t t t t t t t t a a t a t a t a t a t .....................
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3.13.5. -  Clone CaPOa 11 -  DUa showed homology to Mus Musculus Histone H2A.1 
(AY158913)
5'GTATNGCCNTGATTNCNCCNAGCTTTAATNCGNCTCCCTATAGGGAAANCTGGTACGCCTGCAGGTACCGGTCCG
GAATTCCCGGGTCGACATCATCATCATATATTGCTGAAGAGCTTGGCGGCCGTGCTGGAGTACCTGACGGCCGAGA
Hom ology to H2A. 1
TCCTGGAGCTGGCGGGCAACGCGGCCCGCGACAACAAGAAAACGCGCATCATCCCGCGCCACCTGCAGCTGGCCAT
CCGCAACGACGAGGAGCTCAACAAGCTGCTGGGCCGCGTGACCATCGCGCAGGGCGGCGTCCTGCCCAACATCCAG
GCCGTGCTGCTGCCCAAGAAGACCGAGAGCCACCACAAGGCCAAGGGAAAATAAGACCAGCCGTTCACCCACCCGA
AAAAAAAAAAAAAAAAGTACTAGTCGACGCGTGGCCTAGTAGTAGTAGGCGGCCGCTCTAGAGGATCCAAGCTTAC
GTACGCGTGCATGCGACGTCATAGGTATTCTGATAGTGTCACCCTAANTCCATTC3'
From the above diagram it can be seen that, again there is homology between the neo 
primer and the “trapped” gene, 7 bp. It looks as though this sequence information is 
not from the “trapped” gene but an artefact sequence amplified during 3'RACE PCR.
Sequence homology with the H2A.1 gene is located at the 3' end of the single exon.
5' UPSTREAM SEQUENCE
g t a t a c c g t t t t t g c t t c t t a c t g c g g t g g t t a t c t a c a g c t g a g t t a t g
SINGLE EXON (390 bp)
5'TCTGGACGCGGCAAGCAGGGCGGCAAGGCTCGCGCCAAGGCCAAGACTCGCTCCTCCCGG
GCCGGCCTGCAGTTCCCCGTGGGCCGCGTGCACCGGCTGCTCCGCAAGGGCAACTACTCG
GAGCGCGTGGGCGCCGGCGCCCCGGTGTACCTGGCGGCCGTGCTGGAGTACCTGACGGCC
GAGATCCTGGAGCTGGCGGGCAACGCGGCCCGCGACAACAAGAAGACGCGCATCATCCCG
CGCCACCTGCAGCTGGCCATCCGCAACGACGAGGAGCTCAACAAGCTGCTGGGCCGCGTG
ACCATCGCGCAGGGCGGCGTCCTGCCCAACATCCAGGCCGTGCTGCTGCCCAAGAAGACC
GAGAGCCACCACAAGGCCAAGGGAAAATAAGACCAGCCGTTCACCCACCCG3'
3' DOWNSTREAM SEQUENCE
a a c c a a a c a t t a c g a a t c a c c a a a g g c t c t t t t c a g a g c c a c t c a c t t t c
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3.13.6.- Clone CaP04 11 -  H87? showed homology to Mus Musculus Proteasome
(prosome. macropain) subunit, beta type 6 (Psmb6)
5'TNGTATGTTGTGTGGAATTGTGAGCGGATACNATTTCCCACAGGNAACAGNCTATGGCCCATGATTACGCCAAGC
TCTAATACGACTCACTATAGGGAAAGCTGGTACGCCTGCAGGTACCGGTCCGGAATTCCCGGGTCGACATCATCAT
CATATATTGCTGAAGAGCTTGGCGGCCATTCAGGTGTCAGGGGTAGAGCGGCAGGTGCTTTTGGGAGACCAAATCC
I------------ 1
Homology to Psmb6
CCAAGTTCACCATTGCCACGTTGCCACCTCCCTGAGGCCTGGTGTTCTAGGGAGTAGTAAAGGATGGTTCTTACCG
ACGCAGAAGCTAATAAACAGTTTGTTAAAGAGAAAAAAAAAAAAAAAAAAAAAAAAAAAGGTCCTAGTCGACGCGT
GGCCTATTAGTAGTAGGCGGCCGCTCTAGAGGATCCAAGCTTACGTACGCGTGCATGCGACGTCATAGCTCTTCCT
ATAGTGNCACCTAATTCAATTCACTGGCCGTCGTTTTACAACGNCGGGACTGGGAAACCCCTGGCGTTACCCCAC3'
In this example there are 9 bp of homology between the neo primer and the ‘"trapped” 
gene. It appears that this sequence information is again the product of non-specific 
binding by the neo primer. An artefact product has been amplified and analysed.
It can be seen from the diagram below that homology is at the 3' end of the final exon, 
number 6 .
FINAL EXON NUMBER 6 (213 bp)
5'CTCTCGCTTTGGCCATGGAACGCGACGGCTCCAGTGGAGGGGTGATCCGCTTGGCAGCCA 
TTCAGGAGTCAGGGGTAGAGCGGCAGGTGCTTTTGGGAGACCAAATCCCCAAGTTCACCA 
TTGCCACGTTGCCACCTCCCTGAGGCCTGGTGTTCTAGGGAGTAGTAAAGGATGGTCCAT 
ACCGACGCAGAAGCTAATAAACAGTTTGTTAAA 3'
3' DOWNSTREAM SEQUENCE
g a g a c g t t t c t g t g t g a a g g t t c t t g a c t t c a a c t t c a a c t t g c c a a a a c
123
Chapter 3
3.13.7. -  Clone CaPOa 11 -  D47? showed homology to Mus Musculus HRAS like
suppressor 3 (Hrasls3)
5'CACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATTTCACACAGGAAACAGCTATGAC
CATGATTACGCCAAGCTNTAATACGACTCACTATAGGGAAAGCTGGTACGCCTGCAGGTACCGGTCCGGAATTCCC
GGGTCGACATCATCATCATATATTGCTGAAGAGCTTGGCGGCCCTGGGCCTCGTTGGAGTCATGCTCTCCAGAAAC
I________ I
Homology to Hrasls3
AAGAAACAGAAGCAATGAGCTGAATGACTGCCCAGTTTTTGGGCTCTTCTTTTGCTAGAGGGTTCGGAGTTTGATT
TATAGATTCTATTGCTTTATAATTAGGTTTATTTTCACAACATACAATAAACCACAAGAAAGGAAAAAAAAAAAAA
AAAAAGTACTAGTCGACGCGTGGCCTAGTAGTAGTAGGCGGCCGCTCTAGAGGATCCAAGCTTACGTACGCGTGCA
TGCGACGTCATAGCTCTTCTATAGTGTCACCTAAATTCAATTCAGTGGCCGTCGTTTTACAACGTCGTGACTGGG3'
It can be seen that in this example there are 9 bp of homology between the neo primer 
and the “trapped” gene. An artefact product has been amplified and analysed.
Sequence homology is located at the 3' end of the final exon, number 5.
FINAL EXON NUMBER 5 (236 bp)
5'GTCAGAGATGCGGTCAAGGCGGTAGGCATCGCTGGAGTGGGCTTGGCGGCCTTGGGCCTC 
GTTGGAGTCATGCTCTCCAGAAACAAGAAACAGAAGCAATGAGCTGAATGACTGCCCAGT 
TTTTGGGCTCTTCTTTTGCTAGAGGGTTTGGAGTTTGATTTATAGATTCTATTGCTTTAT 
AAT T AGG TTTATTTT C AC AAC AT AC AAT AAAC C AC AAG AAAG G AAT T T T T GT G AGG 3'
3' DOWNSTREAM SEQUENCE
a t a c t g c a g t a g c t a c c t g g t g t g a a g t c t c t g g a g g g a a g c t c g g g g c t
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3.13.8. — Clone CaPO* 11 -  G6 7? showed homology to Mus Musculus Peptidvl-prolyl 
Isomerase A (PPIase)
5'ACTATAGGGAAAGCTGGTACGCCTGCAGGTACCGGTCCGGAATTCCCGGGTCGACATCATCATCATATATTGCTG
AAGAGCTTGGCGGCAGGTCCATCTACGGAGAGAAGTTTGAGGATGAGAACTTCATCCTAAAGCATACAGGTCCTGG
I I
Homology to PPIase
CATCTTGTCCATGGCAAATGCTGGACCAAACACAAACGGTTCCCAGTTTTTTATCTGCACTGCCAAGACTGAATGG
CTGGATGGCAGGCATGTGGTCTTTGGGAAGGTGAAAGAAGGCATGAACATTGTGGAAGCCATGGAGCGTTTTGGGT
CCAGGAATGGCAAGACCAGCAAGAAGATCACCATTTCCGACTGTGGACAGCTCTAATTTCTTTTGACTTGCGGGCA
TTTTACCCATCAAACCATTCCTTCTGTAGCTCAGGAGAGCGTCCCTACCCCATCTGCTCGCAATGTCCTGTAATCT
CTGCTCTCACTGAAGTTCTTTGGGTTCCATATTTTCCTCATTCCCCTTCAAGTCTAGCTGGATTGCAAAGTTAAGT
TTATGATTATGAATAAAAACTAAATAAGAAAAAAAAAAAAAAGTACTAGTCGACGCGTGGCCTAGTAGTAGTAGGC
GGCCGCTCTAGAGGATCCAAGCTTACGTACGCGTGCATGCGACGTCATAGACTCTTCTATAGTGTCACCTAAATT3'
There are 7 bp of homology between the neo primer and the “trapped” gene. It 
appears another artefact product has been amplified and analysed.
Sequence homology can be seen in 3' end of the fourth exon going through to the end 
of the final exon, number 5.
EXON 4 (173 bp)
5'GGTGGTGACTTTACACGCCATAATGGCACTGGCGGCAGGTCCATCTACGGAGAGAAATTTGAGGATGAGAACTTC 
ATCCTAAAGCATACAGGTCCTGGCATCTTGTCCATGGCAAATGCTGGACCAAACACAAACGGTTCCCAGTTTTTTA 
TCTGCACTGCCAAGACTGAATG 3'
EXON 5 (340 bp)
5'GCTGGATGGCAAGCATGTGGTCTTTGGGAAGGTGAAAGAAGGCATGAACATTGTGGAAGCCATGGAGCGTTTTGG 
GTCCAGGAATGGCAAGACCAGCAAGAAGATCACCATTTCCGACTGTGGACAGCTCTAATTTCTTTTGACTTGCGGG 
CATTTTACCCATCAAACCATTCCTTCTGTAGCTCAGGAGAGCGTCCCTACCCCATCTGCTCGCAATGTCCTGTAAT 
CTCTGCTCTCACTGAAGTTCTTTGGGTTCCATATTTTCCTCATTCCCCTTCAAGTCTAGCTGGATTGCAAAGT 
TAAGTTTATGATTATGAATAAAAACTAAATAAGAACTGTT 3'
3' DOWNSTREAM SEQUENCE
tgtccttgtttgtattggagtggtataggtctctaagcaactaactggct...........
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3.13.9. -  Clone CaPOd 11 -  D4aa showed homology to Mus Musculus Zinc finger 
protein 369. mRNA (cDNA clone MGC:41715 IMAGE: 1365300) (Q8K1Y8 )
5'TAACTGGACANCCAGANGNAATCNGTNTTCTANGGTCGNGNNTGGNCAANACTAGCAGGTACCGGTCCGGAATTC
CCGGGTCGACATCATCATCATCATATATTGCTGAAGAGCTTGGCGGCCTCCGACTGGTTCAGGNCNATGANCAGA
I_______ I
Homology to Q8K.1 Y8
GAGTTCATGATTGCTTCATTTATCCTCAAAAGGAAATAAAAGATCTGAAAATGTGTCTAATGGATAACAAGCTCAA
GTTTCAAAAATTGCACTGATATTTATATACAGGGTACTGTGTGTAAGTGAACAAAACTAAAAGTATATAGATGAAT
GAATAAACTATTGTGTGGAACTTTTTTAAAAAAAAAAAAAAAAAAAAAAAAANANA3'
There are 9 bp of homology between the neo primer and the ‘‘trapped” gene. It 
appears another artefact product has been amplified and analysed.
Sequence homology can be seen in 3' end of the final exon, number 7.
EXON 7 (404 bp)
5'CCCTTGGCCAGGTTCACGTGGAAGATGGCGGGGCTGGCCCCAACCGGAATGGATCCCAGC
CTCTAGTCCGGCGGAGTTCCTTTATCCCTCTTCCTGCTGGCACAAGACCTTCTGCGATTC
TTTGGAGCTGATGTTGCGGTCCACTCACCCTTGATCCCGAGGTTCTGTGGCGTGGAGCGT
ACTCTGGAGCCCTTGGCGGCCTCCGCCTGGTTCAGGCAGAAGATCAGAGAGTTCTTAATT
GCTTCATTTATCCTCAAAAGGAAATAAAAGATCTGAAAATGTGTCTAAGGTTAACAAGCT
CAAGTTTCAAAAATTGCACTGATATTTTTATACAGGGTAAAGTGTGTAAGTGAACAAAAC
TAAAAGTATATAGATGAATGAATAAACTATTGTGTGGAACTTTT 3'
3' DOWNSTREAM SEQUENCE
t t t t t c t g c t g t g a t a g c t g t t t t t c t t t a t c a a t t t g a c a t c t g g a a t t
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3.13.10.- Clone CaPOa 11 -  Rlr> showed homology to Mus Musculus Clone 
IMAGE:3968454 mRNA
5'CGGTCCGGAATTCCTTGGGTCGACATCATCATCATATATTGCTGAAGAGCTTGGCGGCCCATCGCATCCTGTCAG
I I
Homology to clone
IMAGE:3968454
ACACATCCGACGAGGAGGACGTGAGTGTTTCCATAGGGGCTGGAGAGAAACTGAGGCTGTCAGCACACACAATGCT
CCCTGGTAGTAAGGCACGAGAGTCTTCTAGTTCTAGGCAGCAAAAAAAAAAAAAAAAGTACTAGTCGACGCGTGGC
CTAGTAGTAGTAGGCGGCCGCTCTAGAGGATCCAAGCTTACGTACGCGTGCATGCGACGTCATAGCTCTTCTATAG
TGTCACCTAAATTCAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAA
TCGCCTTGCAGCACATCCCC3'
There are 6 bp of homology between the neo primer and the “trapped” gene. Another 
artefact product has been amplified and analysed.
Sequence homology can be seen below at the 3' end of the reference sequence leading 
into the poly A tail.
Reference sequence of Mm clone IMAGE:3968454
5 'g ttg a tg a tg a a g c a a ta g c a g c a ta a a tg a a g a tc a a g ta a g g g g a g g a g a a c g a tg c c c a a g g g tg g g tg ttc
ta a a a c a c c a c a g c a a g a a g a c tttg c tc tc a g c a a c g a c a tg g tg g a g a a a c a a a c tg g g a a a a a g g a ta a a g a t
aa ag tttc tc ta ac caa g ac tcc caa g c tg g acc g cag tg a tg g c g g g aag g a g g tg a g ag aa cg ag c cac caa g c
g g aag ctg ccc ttcaccg tg g g g g ccaa tg g ag ag cag aag g ac tcg g acacag ag aag cag g g tcccg ag cg g aa
g a g g a tc a a g a a g g a g c c tg ttg c c c g g a a g tc c g g g c tg ttg ttc g g c a tg g g g c tg tc tg g g a tc c g a g c tg g a
ta c c c tc tc tc tg a g c g tc a g c a g g tg g c tc tg c tc a tg c a g a tg a c tg c tg a g g a g tc tg c a a a ta g tc c g g ta g
a c a c a a c a c c a a a g c a c c c ttc c c a g tc ta c a g tg tg tc a g a a g g g g a c c c c c a a c tc tg c c tc a a a a a c c a a a g a
taag g tg aacaag ag aaa tg aacg cg g ag ag acccg cc tg caccg ag cag c ta tccg ag g g g a tg cccg g cg ca tc
aa g g aac tc a tc a g tg a g g g c g c g g a c g tg a a c g tc a a g g a c tttg c a g g c tg g a c tg c a c tg c a c g a g g c g tg ta
a c c g g g g c ta tta c g a c a tc g c c a a g c a a c tg tta g c c g c tg g tg c a g a g g tg a a c a c ta a g g g c c tg g a tg a tg a
c a c a c c t t tg c a tg a tg c c g c c a a c a a c g g g c a c ta c a a g g tg g tg a a g ttg t tg t ta c g g ta tg g c g g a a a tc c t
c a a c a a a g c a a c a g a a a a g g a g a g a c a c c g ttg a a a g ta g c c a a ttc g c c a a c g a tg g tg a a c c tc c tg tta g g c a
a a g g c a c a ta c a c ttc c a g tg a g g a g a g c tc ta c tg a g a g c tc g g a a g a a g a g g a c g c c c c g tc a ttc g c a c c ttc
c a g c tc c g tc g a tg g c a a ta a c a c a g a c tc tg a g tttg a g a a a g g c c tc a a g c tta a g g c ta a g a a c c c a g a g c c c
c a g a a g a c tg tg a c c c c c g tc aag g a tg a g tacg a g tttg a tg ag g a cg ac g ag ca g g aca g g g tc ccc ccg g tg g
a c g a c a a g c a c c tg c tg a a g a a a g a c ta c a g g a a g g a g g c ta a g g c c a a c a g c ttc a tttc c a ta c c c a a g a tg g a
a g tg a a g a g c ta c tc a a a a a a c a a c a c g c ttg c a c c a a a g a a g g c g g c c c a tc g c a tc c tg tc a g a c a c a tc c g a c
g a g g a g g a c g tg a g tg tt tc c a ta g g g g c tg g a g a g a a a c tg a g g c tg tc a g c a c a c a c a a tg c tc c c tg g ta g ta
a g g c a c g a g a g tc ttc ta g ttc ta g g c a g c a a a a a g a a a a a a a a a a a a a a a a a a a 3 '
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3.13.11. -  Clone CaPO  ^8-11 -  E7 showed homology to Mus Musculus RIKEN
cDNA 1500001M02 gene. mRNA (cDNA clone IMAGE:4218748
5'AAGGNAANCAGCTATGGCCCATGATTTCCCCAAGCTCTAATACGCCTCCCCTATAGGGCAAGCTGGTACGCCTGC
NAGGTNCCCGGTCCCGGAATTCCCGGGTCGACATCATCATCATATATTGCTGAAGAGCTTGGCGGCCTGACCCGCC
TCTTGCGTTTGCTTGCTCACTTCCTGTCTCAGACACCCACACCCCATAGGACCTTCTGGGTGCCACTTAGTTTCTC
AGTCCCTTCCCCTCCCCCATAGGGCCTACTGTGTGCCCCTTAGTTGAGAGCTTTTTTTTTAATGTATTTATTCCAG
GCCCTTTCTGTCCCTTAGCATGAGCATAATCAGACTGGAACGGGGGACAATGTTGTAAATTGTACTGAAACCGAGA
TGCAAATAAAAAATGATCCCCTGGGAAAAAAAAAAAANGNCCTTTTGGGNNGGGGCCCNNANATTNTANGGGGCCN
CCTTTANGNAANNCCAANNTTTANAACCNGGGNNGNNANNNNAANNCCTTTTTTTNGGGCCNCAAAAAAAAAAA3’
It can be seen that there is no exact homology with the neo primer on this occasion, 
but it is a very GC rich locus and again the homology with the “trapped” gene begins 
immediately after the primer sequence.
The below diagram shows homology with the Mus musculus RIKEN cDNA 
1500001M02 gene at the 3' end running into the poly A tail.
Reference sequence of Mm RIKEN cDNA 1500001M02 gene, mRNA (cDNA 
clone IMAGE:4218748)
5 'c tc tc g g g tg tg c a g c a tc a g g tc a g a ttta a a c c g c c a c c a tg tc g a g c a a a a a a g c g a a g a c c a a g a c c a c c a  
a g a a g c g c c c tc a g c g c g c a a c c tc c a a tg tg ttc g c c a tg tt tg a c c a g tc c c a g a tc c a g g a g ttc a a a g a g g c  
c tt ta a c a tg a ttg a c c a g a a c c g g g a tg g c ttc a t tg a c a a g g a g g a c c tg c a c g a c a tg c tg g c g tc tc tg g g g  
a a g a a tc c c a c tg a tg c c ta c c tg g a c g c c a tg a tg a a c g a g g c c c c g g g c c c c a tc a a tt tc a c c a tg t tc c tc a  
c c a tg tttg g g g a g a a g c tg a a c g g c a c tg a c c c c g a g g a c g tc a tc a g a a a c g c c ttc g c ttg c tttg a tg a g g a  
ag ccacag g cacca tccag g ag g a ttacc tg a g g g ag c tg c tg a cca cca tg g g c g acc g c ttcac ag ac g ag g aa  
g tg g a tg a g c tg ta c a g a g a g g c c c c c a ttg a c a a a a a g g g g a a c ttc a a c ta c a ttg a g ttc a c a c g c a tc c tg a  
a g c a c g g c g c g a a a g a c a a a g a tg a c tg a a g a g c tg c g g c g g c tg a c a c g c c tc ttg c g tttg c ttg c tc a c ttc c  
tg tc tc a g a c a c a c a c a c c c c a ta g g a c c ta c tg c g tg c c a c t ta g tt tc tc a g tc a c ttc c c c tc c c c c a ta g g g  
c c t a c t g t g t g c c a c t t a g t t g a g a g c t t t t t t t t t a a a t g t a t t t a t t c c a g g c c c t t t c t g t c a c t t a g c a t g t  
g c a ta a tc a g a c tg g a a c g g g g g a c a a tg t tg ta a a t tg ta c tg a a a a c g a g a tg c a a a ta a a a a a tg a a c c a c tg  
tg aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aaa aa  3'
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3.13.12. -  Clone CaP04 8-11 -  B6 showed homology to Mus Musculus ribosomal
protein LI2 (Rpll2)
5'GACATCATCATCATATATTGCTGAAGAGCTTGGCGGCCCGTGCGCCTTAGGTGTACCTGAGGTGCACCGGAGGCG
AGGTCGGCGCCACATCCGCCTTGGCCCCGAAGATCGGTCCTCTGGGTCTGTCTCCGAAGAAAGTTGGCGATGACAT
TGCCAAGGCTACCGGTGACTGGAAGGGTCTCAGAATTACAGTGAAACTGACCATCCAGAACAGACAGGCCCAGATC
GAGGTGGTGCCTTCTGCCTCAGCCCTGATCATCAAAGCCCTCAAGGAGCCACCGAGAGACAGGAGGAAGCAGAAGA
ACATTAAACACAGTGGGAACATTACTTTTGATGAGATTGTCAACATTGCCCGGCAGATGAGACACCGGTCTTTGGC
TAGAGAACTTTCTGGAACTATCAAGGAGATCCTGGGTACTGCACAGTCTGTGGGCTGCAATGTGGATGGCCGCCAC
CCTCATGACATCATAGATGACATCAACAGTGGTGCAGTGGAGTGCCCAGCTNGTTAAGAAGCAACAAGAAAATATT
CC-ATTAAAGACTATCTGATAACCAGTAAAAAAAAAAAAAAAAAAAAAAAA3'
There is no homology between the neo primer and the “trapped” sequence. Also, it 
does not appear that the sequence preceding primer binding is particularly rich in GC 
nucleotides. It can also be seen that there are two non-homologous nucleotides 
between the primer sequence and the beginning of homology with the Rpll2 
sequence.
Homology with the ribosomal protein LI 2 can be seen at the 3' end of the single exon, 
as shown in the diagram below.
5' UPSTREAM SEQUENCE
c t g a a t g t t g a a a a a a a c c c t a a a t a a c c c a a t t t a a a a a a a a t g g g g c t
SINGLE EXON (629 bp)
5'TTTTCGGCTTTCGGCTCGGAGGAGGCAACGGTGCAACTTTCTTCGGTCGTCCCGAATCCG
GGTTCATCCGACACCAGCCGCCTCCACCATGCCGCCCAAGTTCGACCCCAACGAGGTCAA
AGTCGTGTACCTGAGGTGCACCGGAGGCGAGGTCGGCGCCACATCCGCCTTGGCCCCGAA
GATCGGTCCTCTGGGTCTGTCTCCGAAGAAAGTTGGCGATGACATTGCCAAGGCTACCGG
T G AC T GG AAAGG T C T C AG AAT T AC AG T G AAAC T G AC CAT C C AAAAC AG AC AG G C C C AG AT
CGAGGTGGTGCCCTCTGCCTCAGCCCTGATCATCAAAGCCCTCAAGGAGCCACCGAGAGA
C AGG AAG AAGC AG AAGAAC AT T AAAC AC AG T GGG AAC AT T AC T T T T GAT GAG AT T GT C AA
CATTGCCCGGCAGATGAGACACCGGTCTCTGGCTAGAGAACTTTCTGGAACTATCAAGGA
GATCCTGGGTACTGCACAGTCTGTGGGCTGCAATGTGGATGGCCGCCACCCTCATGACAT
CAT AG AT GAC AT C AAC AG T GG T GC AGT GG AG T GCC C AGC T AG T T AAGC AAC AAGAAAAT A
TTTCAATAAAAGACTATCTGATAACCAGT 3'
3' DOWNSTREAM SEQUENCE
t a a a a a a a a a a a a a a a a a a a a a a a a a a t g g g t t a c a g a t c t a a a c a g a a t
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3.13.13. -  Clone CaPCM 1 -  El Us showed homology to Mus Musculus ribosomal
protein L28 (Rpl28)
CNGCNATACNCCANGCTCCTCAATACGACTCACTATAGGGCAAAGCTGGTACGCCTGCAGGTACCGGTCCGGAATT
CCCGGGTCGACATCATCATACATATATCTGCTGTAAGTAGCTTGGCGGCCATCCGCAGGGTCCAGTGCCATCCTTC
| |
Homology to Rpl28
GAAGCCAGAAGCCTGTGGCGGTGAAGAGGAAACGGACCCGCCCCACCAAGAGCTCCTGAGCCCCACACGCCCGAAG 
CAATAAAGAGTTACAACTGACTTCCAAAAAAAAAAAAAAAAAANNAGCNNTNCCCNGGNNAANGNGCATTATGCCC 
NCCNGGNTAN ANNAN CNAAANTTNCNCCCGNNNAAAAGNNACCCCTTNNCTGNGGNNTANNNNCANTTAAATNAAT 
TTTNGTGGCNNGANGCNTTAACNGNAANNNGGGGGGGGAAATTTTNCCGGGNNNNNAANGGGAAAAAAAA
There are 7 bp of homology between the neo primer and the “trapped” gene, another 
artefact product.
Homology with the ribosomal protein L28 begins at the 3' terminus of exon 4 and 
continues to the 3' end of exon 5, as shown in the diagram below.
EXON 4 (119 bp)
GTCAGCGAAAACCTGCCACTTCTTATGTGAGGACCACCATCAACAAGAATGCTCGGGCTA
CCCTCAGCAGCATCAGACACATGATCCGAAAGAACAAGTACCGCCCTGATCTGCGTATG
FINAL EXON, NUMBER 5 (138 bp)
GCGGCCATCCGCAGGG-CCAGTGCCATCCTTCGAAGCCAGAAGCCTGTGGTGGTGAAGAGG
AAACGGACCCGCCCCACCAAGAGCTCCTGAGCCCCACACGCCCGAAGCAATAAAGAGTCC
ACTGACTTCCATTAGGCC
3' DOWNSTREAM SEQUENCE
t c c a a a a t g t t t t g t g c t c a t t g a g c t g t g g c t c t g c g c t g t c t t t a g t t
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3.13.14. -  Clone CaPCM 1 -  E5?? showed homology to Mus Musculus ribosomal
protein L30 (Rpl30)
CGCTTTTNGCCANGCNTCCAATACNACTNNCTNTANGGCAAAGANTCGGGACACCNGCAGGTACCGGTCCGGAATT
CCCGGGTCGACATCATCATCATATATTGCTGTAAGTAGCTTGGCGGCCTGGTGTTGGTCTGGGGGTTGTCCCGCAC
I_______ I
Homology to Rpl30
CTAAGGCAGGAAGATGGTGGCCGCAAAGAAGACGAAAAAGTCTCTGGAGTCGATCAACTCTAGGCTCCAACTTGTT
ATGAAAAGTGGGAAGTACGTGCTGGGCTACAAGCAGACTCTGAAGATGATCAGACAAGGCAAAGCGAAGTTGGTTA
TCCTTGCCAACAACTGTCCAGCTTTGAGGAAATCTGAAATAGAGTACTATGCCATGTTGGCTAAAACTGGGGTCCA
TCACTACAGTGGCAATAATATTGAACTGGGCACAGCGTGTGGAAAATACTACAGAGTATGCACACTGGCTATCATT
GACCCAGGTGATTCTGATATTATTAGAAGCATGCCAGAACAGACTGGTGAGAAGTAAACAAGAAAGTTTTCCTTTA
ATAAAACTTTGCCAGAGCTCCTTTTGAAAAAAAAAAAAAAAATTAANACCTTAAAAAAAAAAAAAAAAAAGTNCTA
TTCNACNCGNGGCCTANTANTATTAGGCGGCCNCTCTANAGGATCCAAGCTNACGTACCCNNGCGTGCGAGGTNTT
AGCTNTTTTATNGNGNCCCCTAANTNAATTCACTG
There are 9 bp of homology between the neo primer and the trapped” gene. This is 
the second time the Rpl30 gene has been identified (section 3.13.3.).
Sequence homology with the Rpl30 gene is located at the 3' end of the single exon.
SINGLE EXON (462 bp)
5'ctttctcgctccccg gccatcttg gcgg c- tggtgttggt- tgggggttgtcccgcacctaaggcaggaagatgg
TGGCCGCAAAGAAGACGAAAAAGTCTCTGGAGTCGATCAACTCTAGGCTCCAACTTTTTATGAAAAGTGGGAAGTA
CGTGCTGGGCTACAAACAGACTCTGAAGATGATCAGACAAGGCAAAGCGAAGTTGGTTATCCTTGCCAACAACTGT
CCAGCTTTGAGGAAATCTGAAATAGAATACTATGCCATGTTGGCTAAAACTGGGGTCCATCACTACAGTGGCAATA
ATATTGAACTGGGCACAGCGTGTGGAAAATACTACAGAGTATGCACTCTGGCTATCATTGACCCAGGTGATTCTGA
TATTATTAGAAGCATGCCAGAACAGACTGGTGAGAAGTAAACAAGAAAGTTTTCCTTTAATAAAACTTTGCCAGAG
CTCCTTTTG3'
3' DOWNSTREAM SEQUENCE
a a a a a a a a a t a a a t a a a t a a a a t a a a a t a a a a t a a a a t a a c a a a g t t c a g
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3.13.15. -  Clone CaPCXi 9 -  I F 8 7? showed homology with Similar to Mus Musculus
Phosphoglycerate kinase I (XM 2830481
GTTAGCTCACTCATTAGGCACCCCAGGCTTTACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGG
ATAACAATTTCCCACAGGAAACAGCTATGACCATGATTACGCCAAGCTCTAATACGACTCACTATAGGGAAAGCTG
GTACGCCTGCAGGTACCGGTCCGGAATTCCCGGGTCGACATCATCATCATATATTGCTGAAGAGCTTGGCGGCGAA
TGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTATCGCCTTCTTG
ACGAGTTCTTCTGAGGGGATCCGCTGTAAGTCTGCAGAAATTGATGATGTATTAAACAATAAAGATGTCCCCTAAA 
F g eo  
stop codon
AAAAAANGNAAAAAAAAAAAAAAAAAAAAAGTACTAGTCGACGCGTGGCCTAGTATGTAGTAGGCGGCCA
It can be seen from the above diagram that there is viral sequence present in this 
3'RACE product and it runs as far as the p-geo stop codon. This is still not as 
anticipated, it is expected that the viral sequence homology would continue as far as 
the splice donor site in the retroviral construct which is another 46 bp downstream. 
Sequence homology is shown below at the 3' end of the gene, probably untranslated 
region.
The reference sequence was run in a NCBI open reading frame search and the result 
that gave a 414 aa protein product, which was as predicted from the reference 
sequence information so homology was aligned with this sequence.
Reference Sequence of Mm (similar to) phosphoglycerate 
Kinase I (XM 283048) after locating open reading 
frame (ORF) using NCBI ORF Finder.
5 'a a a a g c g c a c g tc tg c c g c g c tg t tc tc c tc t tc c tc a tc tc c g g g c c t t tc g a c c tc a c g g tg t tg c c a a a a tg
tc g c tttc c a a c a a g c tg a c tttg g a c a a g c tg g a c g tg a a g g g g a a g c g g g tc g tg a tg a g g g tg g a c ttc a a c g
t tc c ta tg a a g a a c a a c c a g a ta a c a a a c a a c c a a a g g a tc a a g g c tg c tg ttc c a a g c a tc a a a ttc tg c t tg g a
c a a tg g a g c c a a g tc c g ttg tc c t ta tg a g c c a c c tg g g c c g g c c tg a tg g tg t tc c c a tg c c tg a c a a g ta c tc c
t ta g a g c c a g ttg c tg c tg a a c tc a a a tc tc tg c tg g g c a a g g a tg t tc tg t tc t tg a a g g a ttg tg tg g g c c c a g
a a g tc g a g a a tg c c tg tg c c a a c c c a g c g g c tg g g a c tg tc a tc c tg c tg g a a a a c c tc c g c tt tc a tg ta g a g g a
ag a a g g g a a g g g a a a a g a tg c ttc tg g a a a c a a g g tta a a g c tg a g c c g g c c a a a a ttg a tg c tttc c g a g c c tc a
c tg tc c a a a c ta g g a g a tg tc ta tg tc a a tg a tg c tt t tg g g a c tg c a c a c c g a g c c c a ta g c tc c a tg g tg g g tg
tg a a tc tg c c a c a g a a g g c tg g tg g a ttt t tg a tg a a g a a g g a g c tg a a c ta c t t tg c c a a g g c tt tg g a g a g tc c
a g a g c g a c c c ttc c tg g c ta tc t tg g g a g g c g c ta a a g ttg c a g a c a a g a tc c a g c tg a tc a a ta a ta tg c ta g a c
a a a g tc a a tg a g a tg a tc a t tg g tg g tg g a a tg g c c t t ta c c t tc c t ta a g g tg c tc a a c a a c a tg g a g a t tg g c a
c a tc tc tg ta tg a tg a a g a a g g a g c c a a g a ttg tc a a a g a tc tc a tg tc c a a a g c tg a g a a a a a tg g tg tg a a g a t
ta c c t tg c c tg t tg a c t t tg tc a c tg c tg a c a a a t t tg a tg a g a a tg c c a a g a c tg g c c a a g c ta c tg tg g c c tc t
g g ta ta c c tg c tg g c tg g a tg g g c ttg g a c tg tg g ta c tg a g a g c a g c a a g a a a ta tg c c g a g g c tg tg g g tc g a g
c ta a g c a g a t tg t t tg g a a tg g tc c tg t tg g g g ta t t tg a a tg g g a a g c c t t tg c c a g g g g a a c c a a g tc a c tc a t
g g a tg a g g tg g tg a a a g c c a c t tc ta g g g g ttg c a tc a c ta tc a ta g g tg g tg g a g a c a c tg c c a c t tg c tg tg c c
aaa tg g aac aca g ag g a ta aag tca g cca tg tg a g cac tg g g g g c g g tg c cag tc ta g ag c tcc tg g aag g taa ag
tc c t t c c tg g g g tg g a tg c t c t c a g c a a tg t t t a g t a t t t t c t t t c c tg c c t t t g g t t c c tg tg c a c a g c tc c t a a
Stop Codon 1326 bp
g tc a a c c ta g tg t t t tc c a c a tc tc c a t t tg g tg t ta g c g c a a g a t tc a g c ta g tg g c tg a g a tg tg g c a c c a g g a
a c c c t t a a a c a g t tg c a c a g c a tc tc a g c tc g tc t t t a c tg c a tc a g g a t t tg tc tg tg t t c t t c a a g a tc c c a t t
ta a a t tc c t ta g tg a c ta a a a c c a t tg tg c a t tg ta g a g g g c g tc ta t t ta ta t tc tg c c tg a g a a a g g a a g tg a g
c tg ta a a g g c tg a g c tc tc t c t c tg a c g ta tg ta g c c tc tg g t t a g c t t c g tc a c tc a c tg t t c t tg a c tc a g c a t
g g c a a tc tg a tg a a a tc c c a g c tg ta a g tc tg c a g a a a t tg a tg a tc ta t ta a a c a a ta a a g a tg tc c a c t3 '
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Table 3.6. Summary o f sequence data analysis.
CLONE
Homology 
with neo 
primer (bp)
GC rich 
locus
Viral
sequence
CaP04 9 -  1A672 - Mm Vaccinia Related 
Kinase 3 (Vrk3) 6 YES Nonepresent
CaP04 8-11 -  HI -  Mm Inhibitor of DNA 
binding (Idl) 0 NO Nonepresent
CaP04 8-11 -  F64g - Mm Ribosomal Protein 
L30 (Rpl30) 0 YES Nonepresent
CaP04 11 -  B24g -  Mm cytochrome oxidase 
subunit Vb (Cox5b) 8 YES Nonepresent
CaP04 11 — D l48 — Mm Histone H2A.1 
(AY 158913) 7 YES Nonepresent
CaP04l 1 -  H872 -  Mm proteasome (prosome, 
macropain) subunit, beta type 6  (Psmb6 ) 9 YES Nonepresent
CaP04l 1 -  D472 -  Mm HRAS like 
suppressor 3 (Hrasls3) 9 YES Nonepresent
CaP04 11 -  G672 -  Mm Peptidyl-prolyl 
Isomerase A (PPIase) 7 YES Nonepresent
CaP04 11 -  D448 -  Mm Zinc finger protein 
369, (Q8K1Y8) 9 YES Nonepresent
CaP04 11 -  B772 -  Mm clone 
IMAGE:3968454 mRNA 6 NO Nonepresent
CaP04 8-11 -  E7 -  Mm RIKEN cDNA 
1500001M02 gene 0 YES Nonepresent
CaP04 8-11 -  B6  -  Mm Ribosomal protein 
L12 (Rpll2) 0 NO Nonepresent
CaP04 11 -  El l4s -  Mm Ribosomal protein 
L28 (Rpl28) 7 NO Nonepresent
CaP04 11 -  E572 -  Mm Ribosomal protein 
L30 (Rpl30) 9 YES Nonepresent
CaP04 9 -  IF872 -  Mm (similar to) 
Phosphoglycerate kinase I (XM 283048) 0 NO PRESENT
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3.14. INJECTING CLONES INTO HOST BLASTOCYSTS
After the above detailed investigation of the sequence data, obtained from 3' RACE 
PCR products o f resistant clones, it is clear that more analysis needs to be done to 
elucidate the true trapping events for these clones.
However, it can be seen that there is one result which appears to be a true product for 
phosphoglycerate kinase 1 as it definitely contains viral construct sequence (see 
3.13.14).
At the time of printing this clone is being injected into host blastocysts.
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CHAPTER 4
DISCUSSION
4. DISCUSSION
Due to the results being presented in a single chapter, this discussion chapter 
encompasses this whole gene trapping project and looks at possible explanations of 
anomalies, improvements o f results and future work.
4.1. TRANSFECTION OF RETROVIRAL VECTORS INTO ECOTROPIC BOSC 
PACKAGING CELLS AND SUBSEQUENT INFECTION OF ES CELLS WITH 
VIRION PRODUCED
It was a major achievement to obtain G418 resistant ES cell colonies and to be able to 
expand them in culture. Overcoming this hurdle took quite a considerable time and 
was a culmination o f many amended factors in both the transfection and infection 
protocols.
4.1.1. Using pCX-GFP plasmid individually as positive control 
Amending the transfection positive control to a separate reaction, with the pCX-GFP 
plasmid being transfected individually into BOSC cells allowed more o f the proviral 
DNA to be introduced. There was never an occasion when the transfection reaction 
did not work, as green BOSC cells were always visible about 12 hours after 
transfection, regardless o f the method used. It can not be ascertained whether this 
amendment had a positive effect on the transfection reactions, as no quantitative 
measurements were taken. Also, no G418 resistant colonies were coming through at 
the time o f this change in the protocol so no comparisons can be made with possible 
virion production. However, it is felt that allowing more proviral DNA to be 
transfected could only have a positive bearing on the situation.
4.1.2. Using harvested virion immediately
Using harvested virion immediately, instead o f storing at -80°C for future infection 
reactions, again, cannot be shown conclusively to have improved results. However, it 
is definitely felt that this was an improvement, combined with other amendments 
made after the infection reaction, G418 resistant colonies began to appear.
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4.1.3. Use o f feeder cells 
The fact that feeder cells were originally being used during infection was a definite 
pitfall. Mitotically inactivated feeder layers will mop up the retroviral particles as they 
can still be infected, but without cell division the virus cannot integrate. The 
undifferentiated ES cells were maintained using medium supplemented with LIF as 
opposed to using the feeder layer.
It also seemed unfavourable to have feeders present during selection of the ES cells. 
Selection continued over a period of approximately 12 days, during which time STO 
feeders were dying, curling up, coming away from the plate and bringing any resistant 
colonies with them. STO-NEO feeders were used to try and extend the period of 
attachment, but even the resistant feeders were curling up after 12 days of selection.
This being said, it was realised that feeders were actually needed when resistant ES 
cell clones were picked and transferred to 96 well plates. There are so few ES cells 
being transferred, the feeders are needed to promote cell attachment and viability. 
This was a major turning point as resistant ES cell clones began to survive being 
picked and grew in culture. Prior to this, a small number o f ES cell clones had 
survived selection but never survived picking.
It is essential that prior to molecular manipulation all feeders are removed from the 
expanded, resistant ES cell clones, for example, if  STO-NEO feeders are used the neo 
portion can interfere with primer binding during subsequent RACE reactions.
It can be concluded that certain features o f feeder cells are necessary at particular 
times during a gene trapping experiment but for some procedures it is better to 
substitute medium supplemented with LIF to maintain pluripotentiality. Feeder cells 
are thought to have generalised effects, such as medium detoxification, in addition to 
more specific effects in promoting cell attachment and viability and of course, 
preventing ES cell differentiation (Nichols et al., 1990).
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4.2. COMPARING SHUTTLE AND SPLICE ACCEPTOR CONSTRUCTS: 
RESULTS OF INFECTION PROCEDURE
All retroviral vectors were transfected into BOSC packaging cells using both the 
lipofectamine and calcium phosphate methods. Neither emerged as an optimal method 
but as it was the calcium phosphate method being used when results began to appear, 
this method was maintained. As the same number of ES cells were seeded and the 
same amount o f construct DNA was transfected for subsequent infections, this 
enabled comparisons to be made between a number o f transfection attempts (table
3.1.).
The shuttle and splice acceptor series constructs were compared as an infection assay, 
as opposed to an actual particle assay because no viral titres were known. The 
infection assay was calculated by dividing the total number o f G418R colonies 
recovered for each retroviral construct by the total number o f successful infections for 
each construct. This resulting figure gives an average value o f the number o f G418R 
colonies retrieved for each construct during an infection reaction (table 3.2.).
4.2.1. Splice acceptor versus shuttle series
It was clear that the splice acceptor series gave rise to a far greater number of resistant 
ES cell clones than the shuttle series. The shuttle series are activated from insertion 
into exons but as the splice acceptor constructs survive splicing events they can be 
activated from intron as well as exon insertions. This means that the splice acceptor 
constructs have more productive sites available when compared to the shuttle series. 
A major factor to be considered is that as all the retroviral vectors require a cellular 
promoter for activation, the maximum number o f genomic targets equals the number 
of expressed genes.
4.2.2. Splice acceptor with IRES versus splice acceptor without IRES
It can also be seen that the splice acceptor construct with an IRES included upstream 
of the p-geo reporter gave the best result out o f all the constructs (table 3.2.). The fact 
that the IRES performed as expected, by increasing the number of G418R colonies 
retrieved when compared to the splice acceptor construct without IRES, was
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confirmed by applying a non-parametric, Mann Whitney test. The resulting p value of 
0.0196 confirmed that the two constructs gave significantly different results.
The splice acceptor construct without the IRES has several limitations due to the 
requirement o f translational fusions with endogenous tagged sequences and only some 
insertions will be fully productive. Only those trapping events generating a 
transcriptional fusion between the reporter and the coding region o f the tagged gene in 
the correct frame and orientation can be detected. Insertions o f the p-geo in the wrong 
frame or orientation, or fusion to the 5' or 3' untranslated regions o f the host transcript 
will not be detected. Also, a partial or complete loss of reporter and/or selection 
activity might occur when p-geo protein is fused to certain endogenous protein 
sequences and some classes o f genes might be absent or under represented. For 
instance, it has been shown that P-gal activity is lost when P-geo is fused to a signal 
peptide, therefore P-geo fusion with secreted molecules cannot be detected (Skames 
etal., 1995).
The splice acceptor construct containing the IRES almost doubled the number of 
G418r colonies recovered during infection (table 3.2.). The IRES allows for cap- 
independent translation o f the p-geo from fusion transcripts with host sequences 
without the above constraints. Production o f reporter/selection activity is independent 
of the reading frame of the tagged gene when IRES is present. Therefore, translation 
of p-geo depends only on the orientation and half o f the insertions within 
chromosomal transcriptional units should be productive. As a consequence, the total 
number of G418R colonies is higher and fewer experiments are needed to obtain more 
colonies.
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4.3. PLASMID RESCUE SERIES RESULTS
Unfortunately, no reproducible results were achieved in this area o f the project. After 
amending many factors (section 3.11.) involved with plasmid rescue more resistant 
bacterial colonies were obtained but no resulting sequence data of any worth was 
attained. A brief discussion o f successful amendments follows.
4.3.1. Glycogen
Using glycogen when precipitating DNA from the 500pl ligation reaction was a 
definite improvement as resistant bacterial colonies began to appear more readily. 
Prior to this, as the reactions were so dilute, the DNA was probably being lost. It can 
be seen that (table 3.3.), for CaPC>46 where glycogen was not used, a total of 3 
resistant bacterial colonies appeared. However, in CaP0 4 9  where glycogen was used 
14 resistant bacterial colonies appeared, which is a considerable improvement. It is 
also notable that some o f these resistant bacterial colonies actually grew up when 
transferred to liquid growth medium.
Using glycogen as a carrier for nucleic acid precipitation definitely improved the 
return o f resistant bacterial colonies, which was a step in the right direction.
4.3.2. Rolling circle amplification (RCA)
To try and improve results, rolling circle amplification (RCA) was attempted (section 
1.8.). Resistant bacterial colonies appeared after RCA, but there was not really any 
great increase in the numbers obtained. The plasmid DNA retrieved from two separate 
shuttle clones was treated with RCA and electroporated. When the resulting resistant 
bacterial colonies were grown up and the plasmid DNA isolated and examined by 
agarose gel electrophoresis, the resulting plasmids all appeared to be the same size 
(~4 kb). This similarity was very unexpected as two different clones were used. It was 
considered whether these were random products o f the RCA and that 4 kb was the 
maximum amplification size that could be reached during the incubation period. 
However, this does not account for the ability o f the bacteria to survive selection. 
Sequencing a number o f these products resulted in unreadable sequence with a 
considerable amount o f background. This would normally suggest that single bacterial 
colonies had not been picked, but with so few colonies present on the plate this would 
have been very unlikely.
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Occasionally the picked bacterial colonies did not grow when transferred to liquid 
medium. These colonies were particularly small and had taken an extended period of 
time to appear, sometimes > 24 hours. It may be due to the length of incubation that 
some o f colonies managed to survive due to the reducing activity of the ampicillin. 
When the colonies were then transferred to ampicillin rich liquid medium, growth 
could not be maintained.
It can be concluded that RCA offered no great advantage to the plasmid rescue 
method o f gene trapping. Due to the continued lack o f readable sequence data 
obtained after sequencing any plasmid rescue products, some were sent to a 
commercial sequencing company (Oswel Research Products Ltd., University of 
Southampton, UK) where they were also unable to sequence the plasmids effectively. 
As no sequence data was going to be obtainable without considerably more 
investigative work, attention was focused on the splice acceptor series.
With hindsight, it must be stated that if  the unacceptable condition o f the genomic 
DNA being used ( Fig 3.8) had been appreciated earlier, steps could have been taken 
that may have improved the outcome o f the plasmid rescue portion of this project.
Due to RNA contamination and lack o f good quality gDNA, it was unlikely that there 
would be a sufficient amount o f gDNA available after digestion for ligation and 
subsequent plasmid rescue.
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4.4. SPLICE ACCEPTOR SERIES RESULTS
Once G418 ES cell colonies were obtainable, which indicates successful gene trap 
events, efforts were centred on obtaining sequence data to identify the insertion 
location o f the construct.
4.4.1. y  RACE PCR
Primarily, attempts were made with 5' RACE PCR (Frohman et al., 1988; Skames et 
al., 1992). However, it proved to be extremely cumbersome when compared to the 
more accessible 3' RACE PCR procedure. Results began to appear with 3' RACE 
PCR and it was decided to proceed with this route o f investigation. This was an 
original idea as 3' RACE PCR has never been used to analyse splice acceptor traps in 
previous studies.
It had to be considered that by concentrating on 3' RACE PCR, it was insertion events 
occurring in the 3' regions o f trapped genes that were being optimally amplified. 
Insertion events at the 3' end can lead to more subtle phenotypes, with the majority o f  
the gene remaining intact to produce a truncated protein. It is possible that the 
truncated protein retains sufficient normal activity to rescue the phenotype.
Another concern was whether the distance between the two priming positions for 3' 
RACE PCR would be too great if the insertion event had occurred towards the 5' end 
of the gene. The fact that 3' RACE PCR is the amplification o f cDNA, there is no 
concern over the size o f intronic sequence. The average size of mRNA is 
approximately 2-3 kb and that o f untranslated regions is about 300 bp. With advances 
in technology it is possible to efficiently produce PCR products up to 10 kb in length 
(Nielson et al., 1994). These facts considered, it was felt that the benefits of the more 
refined 3' RACE PCR procedure outweighed the possible reduction in PCR products 
due to 5' insertion events.
4.4.2. Beta Galactosidase staining
The P-geo gene depends on the expression o f the endogenous gene for the production 
of neo and lacZ activities. Therefore, trapping with a P-geo vector should theoretically 
select for genes that are expressed in ES cells and the proportion of p-gal positive
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colonies among the G418R colonies should be close to 100% (Friedrich and Soriano, 
1991). Using the splice acceptor traps only about 50% gave a positive result when 
stained for lacZ activity. There was a broad range in the distribution and intensity of 
P-gal staining among the different gene trapped cell lines, suggesting that the splice 
acceptor vectors are able to capture genes with different levels o f expression in ES 
cells. The fact that some clones gave lighter patterns o f staining than others and not all 
cells o f a “clonal” population stained blue is in agreement with previous work 
showing heterogeneity o f staining in P-gal colonies (MacGregor et al., 1987).
Theoretically, every G418R clone should be positive for p-gal activity when the IRES 
construct is used. The low frequency o f p-gal positive cells observed might be due to 
the capture o f genes with weak promoter activities so that lacZ expression cannot be 
detected. The fact that P-geo is a fusion protein, suggests expect that all G418R ES 
cell lines represent active gene trap events and should be p-gal positive, but the low 
frequency of P-gal positive cells, perhaps reflects the higher sensitivity of neo than P- 
gal activity.
The trapping o f a weak promoter is also suggested by very faint and sometimes barely 
detectable dot-like expression found in several gene-trapped cell lines only after 
extensive p-gal staining. Another theory o f this faint staining after extended periods 
of incubation could be that the pH optimum for the bacterial enzyme is between pH 
7.0 and 7.5 (Reithel and Kim, 1960) whereas the optima o f the two mammalian p- 
galactosidases lie between pH 3 and 6  (Lojda, 1970). Therefore, by extended staining 
incubation it may be possible that the staining solution becomes more acidic leading 
to endogenous P-gal activity being seen on these occasions.
The major advantage for the inclusion o f the beta galactosidase gene will mainly be 
appreciated once germline chimeras have been created. The progeny can then be 
studied in detail to identify particular areas o f expression with this staining technique.
4.4.3. High throughput 
In principle, high-throughput analysis sounds very straightforward and it definitely 
does seem the way forward. There are many ES cell lines that have been created
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during gene trapping experiments and are still awaiting analysis. For example, in this 
study alone a total o f 671 G418R ES cell lines were isolated using splice acceptor 
constructs and around 230 were subjected to 3' RACE PCR amplification, this was 
less than half, leaving about another 400 to be analysed.
An attempt was made during this project to create a high throughput protocol, 
beginning when the G418R colonies had been harvested and transferred to 96 well 
plates, continuing through RNA isolation, 3' RACE PCR amplification up to the 
sequencing reaction. This proved difficult due to time constraints and a lack of 
experience with the new robot (Multiprobe II HT EX). This being said, it has to be 
acknowledged that a high throughput protocol would prevent the need for ES cell 
lines to be stored in liquid nitrogen awaiting analysis.
An example of high throughput analysis has been demonstrated by Hansen and co­
workers. Using four different gene trap vectors and robotics after the stage of  
manually picking resistant clones, they generated 5,142 sequences adjacent to the 
gene trap integration sites (gene-trap sequence tags; http://genetrap.de) from > 11 ,000  
ES cell clones (Hansen et al., 2003). The preparation o f mRNA, subsequent 5' RACE 
PCR and direct sequencing o f PCR products were all automated procedures, thereby 
allowing the analysis o f >11,000 ES cell clones. This is definitely the way gene trap 
screens should be progressing, thereby reducing the number o f unanalysed ES cell 
lines.
One area o f the gene trap phenomenon that would greatly benefit from automation is 
the picking of G418R ES cell cones. This is an extremely uncomfortable and time- 
consuming process when attempted manually. It would necessary for the 
identification of any resistant ES cell clones to be apparent to an automated system. 
Perhaps one way would be a colour marker to be identified by a scanning beam. The 
ES cells need to remain viable after picking so it could not be the blue of lacZ 
staining, a more feasible option would be green fluorescent protein (GFP). GFP could 
be introduced into the cells as a fusion protein with neo, replacing the lacZ o f present 
constructs. Perhaps if  a Cre-mutant lox system (Araki et al., 1999) was utilised it
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would be possible to exchange GFP for lacZ activity in the ES cell line at a later stage 
of experimental procedures.
If a high throughput method had been established in this study, perhaps more than one 
true gene trap event would have been recovered, but possibly, also a lot of artefact 
sequence data. This demonstrates the necessity for the thorough analysis of resulting 
data at all stages o f experimentation. It must be stated that even though no high 
throughput protocol was developed in this study, due to optimising procedures for use 
with the robot, a definite improvement in laboratory technique was achieved with 
manual procedures being streamlined.
4.5. SEQUENCING RESULTS OF THE SPLICE ACCEPTOR SERIES 
When analysing 3' RACE PCR sequence products by comparing with NCBI GenBank 
data, a number of interesting insertion locations were discovered (table 3.5.). There 
was one in particular that caused excitement.
4.5.1. Mm Vaccinia-related kinase 3 fVRK3f 
VRK3 is a member of the VRK proteins, which have recently been identified in the 
human kinome as a new family o f p53 regulators (Manning et al., 2002). The VRK 
proteins, of which there are three, are members o f a new signalling pathway but their 
targets have not yet been characterised despite their presence in almost all cell types 
tested. In adult organs the three genes are widely expressed and the ratio of each is 
similar, suggesting that VRK genes are likely to play a basic role in cell biology 
(Vega et al., 2003). A major concern is that as they are expressed during early phases 
o f liver development suggesting that there is a significant risk that knock-out animals 
will be non-viable, as in C. elegans (Kamath et al., 2003), unless they are generated as 
conditional knock-out mice and the genes are induced after liver development. This 
was most exciting as it was thought we had this gene trapped in an ES cell line ready 
to inject. Also, it appeared that the gene was trapped at the 3' end, leading to the 
possible production of a hypomorph with a mild phenotype, reducing the possibility 
of embryo lethality.
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4.6. SEQUENCING ANOMALIES
After obtaining the preliminary sequence analysis results detailed in table 3.5, it was 
felt that the exact insertion location o f the constructs should be investigated further, at 
the nucleotide level, before proceeding any further (section 3.13.).
From the pAMPl cloned 3' RACE products it was expected that we would see viral 
sequence running from the 3' RACE primer sequence to the end of the P-geo 
sequence and further downstream to the splice donor site. At this site, novel sequence 
relating to the endogenous trapped gene would be identified. Unfortunately, this is not 
what occurred on the majority o f occasions. It can be seen from table 3.6, that 14 out 
of 15 (93%) o f the sequencing results showed no viral sequence. This means that 
when the resulting sequence from the pAMPl cloned 3' RACE product was analysed 
closely, the 3' RACE primer sequence could be identified along with some of the 
cloning region from the pAMPl cloning vector (fig. 3.13.), but there was no traceable 
sequence relating to the construct. Immediately after the identified 3' RACE primer 
sequence, endogenous gene sequence was found. Without the presence of any 
construct sequence, questions were raised as to the efficacy o f these “gene trap” 
events.
When studied closely, it appeared that 12 out o f 14 o f these sequenced pAMPl cloned 
3' RACE products, showed a considerable amount of homology between the 3' RACE 
primer sequence and the endogenous “trapped” gene. This homology o f the 3' RACE 
primer sequence with the endogenous “trapped” genes varied between 6  and 9 bp. It 
can be safely assumed that these 3' RACE products are artefact and cannot be 
included in any future analysis o f these ES cell lines.
It appears that the 3' RACE primer sequence is GC rich and unspecific. However, it 
has to be considered that about 230 G418R ES cell clones were subjected to 3' RACE 
PCR and out of all those analysed by agarose gel electrophoresis only 15 revealed a 
product band. This seems most strange, surely if  the primer was so unspecific these 
products would have been picked up time and time again, as the population of mRNA 
is the same on each occasion? It had been expected that a reduced number of 3' 
RACE PCR products would be seen, as amplification from the polyA would be
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unlikely to reach as far as the neo priming locus, if  insertions were in the 5' region of 
endogenous genes. If a lot o f 3' RACE PCR products were being seen, then this may 
have prompted investigative action sooner. When a discrete, single band was not seen 
from a 3' RACE PCR product being analysed on an agarose gel, then nested PCR was 
attempted. The fact that most o f the 3' RACE PCR products were artefacts explains 
why the nested PCR reaction never picked up any products, because the specific 
product had not been present in the first instance. Perhaps nested PCR should be used 
to specifically amplify a certain product from a large, varied population of initial 
amplifications.
There are two results that do not show any particular homology with the primer and 
priming does not appear to have begun in an obviously GC rich locus, but there is still 
no viral sequence present. These are probably the result o f mispriming early on in the 
3' RACE PCR cycles, as amplification progressed misprimed products primed from a 
locus within a certain distance from the polyA to produce an amplified product.
All o f these results point to the fact that the 3' RACE primer sequence is not suitable 
for this amplification procedure. The primer sequence needs to be redesigned and 
possibly used in conjunction with a nested PCR reaction.
4.6.1. Similar to Mm phosphoglvcerate kinase I (pgkl)
One pAMPl cloned 3' RACE sequence result does look more promising (section 
3.13.15.), similar to Mm phosphoglycerate kinase I. It can be seen that there is 
definitely viral sequence present in this cloned 3' RACE product and it runs as far as 
the P-geo stop codon. This is still an anomaly as it is expected that the viral sequence 
homology would continue as far as the splice donor site corresponding to the 
retroviral construct, which is another 46 bp downstream. It may be that there was a 
cryptic splice donor site, which caused this early splicing event, or it could simply be 
a putative sequence mistake introduced by the molecular manipulation during RACE 
PCR procedures.
It appears from the analysed sequence information, that this ES cell line is a true gene 
trap event as it contains viral construct sequence running from immediately after the
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3' RACE primer sequence for 93 bp downstream to the p-geo stop codon. The 
homology between the trapped sequence and the identified reference sequence 
(XM 283048) appears to be in the 3' untranslated region. The fact that the sequence 
homology o f the trapped gene sequence has been matched with “similar to” pgkl after 
searching the NCBI GenBank database using the Blastn homology program, required 
further investigation. The “similar to” pgkl sequence (XM 283048) was the product 
of NCBI Annotation Project and has been directly submitted (17.02.03) to the 
National Centre for Biotechnology Information.
When the “similar to” pgkl was aligned with the NCBI GenBank database pgkl gene 
there was a large area o f 100% homology at the 5' end o f both sequences. This 
homology did not extend into the 3' end of the two sequences. Both the “similar to” 
pgkl and the pgkl gene sequences were compared against the mouse genome 
sequence using the NCBI GenBank database and both mapped to the same 
chromosomal locations. This suggests that they are in fact the same gene but maybe 
the “similar to” sequence is a splice variant o f the pgkl sequence.
This 3' location, where the “similar to” pgkl and the pgkl sequences do not show 
homology is where the gene trap insertion is expected to have occurred. More 
genomic DNA analysis needs to be done to confirm this insertion location.
However, with no record o f a knock-out for pgkl having been published, at the time 
of printing this ES cell line is being injected into host blastocysts.
4.7. CONCLUSION OF AIMS
The retroviral gene trap vectors examined in this study performed with a vaiying 
degree of success, depending on the sequence information contained. It was 
confirmed that the plasmid rescue construct pSHUT+124K SD126-1 does not perform 
as intended due to the incorrect location o f the neo cassette (fig. 3.7.). The other 
plasmid rescue construct, pSHUT+124K-A, did result in a reasonable number of  
G418r ES cell clones. However, there was no success past this point of the plasmid 
rescue, gene trap procedure. This is possibly due to technical difficulties and not
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attributable to the construct itself. Further work needs to be carried out to try and 
evaluate the true performance o f this construct and ascertain where the problems lie.
The splice acceptor series vectors both resulted in a good number of G418R ES cell 
clones and also produced sequence data. Due to the problems arising with 3' RACE 
PCR it is not possible to make any speculations as to the quality o f the trapping events 
and subsequent sequence information obtained. Additional sequence information 
contained in these constructs was assessed. The splice acceptor construct 
(pCSI+SD 126-2) containing an IRES performed as expected, by almost doubling the 
number o f G418R ES cell clones retrieved. This construct also contains a 330 bp lox P 
stuffer region which when trapped lines are crossed through a ere expressing strain, 
should be lost, aiding the identification o f heterozygous and homozygous progeny. 
This was not tested as no transgenics were produced.
The splice acceptor construct (pCRR+SD126 T7 I-Sce-X) contains a T7 promoter just 
upstream of the splice donor site. This promoter site can be utilised once RNA has 
been harvested from G418R colonies and cDNA prepared. In theory, T7 RNA 
polymerase will be able to copy more RNA from the T7 promoter site, through the 
splice donor and trapped transcript to the polyA and appended sequence. By 
performing 3' RACE PCR on this enriched template it would be more likely that the 
correct region would be amplified. This procedure was attempted on 16 separate 
occasions, but no RNA amplification was identified and subsequently no 3' RACE 
PCR products. It can be said that this modification does not function as expected, but 
again, it may be technical procedures that need attention and not a malfunction of the 
construct.
Three out of four constructs produced G418R ES cell clones, confirming their ability 
to function as productive gene trap constructs. However, it was only the IRES 
modification that has been shown conclusively to function as expected.
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4.8. FUTURE WORK
Firstly, it would be wise to attempt a genomic PCR on the pgkl ES cell line to confirm 
the insertion location is as expected. This would mean designing primers to amplify 
the boundary regions, thereby confirming the locus of the gene trap event.
The fact that genomic PCR (section 3.12.5.) amplified a 470 bp region of the p-geo 
gene in a number o f splice acceptor trapped ES cell lines allows us to confirm that 
they are gene trap clones. All o f the ES cell lines isolated survived G418 selection, so 
it can therefore be assumed that they are all gene trap events. This means that there 
are a total o f 671 splice acceptor G418R ES cell clones that need to be analysed. It 
would be interesting to repeat 3' RACE PCR using an improved primer on the 15 ES 
cell lines that have already been analysed, to see if  any similar results are obtained or 
if they were just artefact products. Maybe some adaptations to the 3' RACE PCR 
protocol would be advantageous, reducing the number o f cycles to 15 during the first 
round of PCR and then perform nested PCR on this specific product. This should 
ensure that only specific amplification is possible.
The plasmid rescue construct needs more investigation. The fact that G418R ES cell 
lines were retrieved, indicates that the construct performed as an insertional tag, but 
further work is needed to be able to obtain sequence data from rescued plasmids. 
Plasmid rescue is a very neat method o f retrieving trapped sequence as demonstrated 
by a number of groups (Araki et al., 1999; Hicks et al., 1997).
If possible, it would be interesting to attempt to analyse the splice acceptor trapped ES 
cell lines by 5' RACE PCR to see how many trap events may have been missed by 
using the 3' RACE PCR procedure.
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4.9. SUMMARY
Large-scale insertional mutations in mammalian cells can be induced effectively with 
gene traps. By selecting for gene expression, recombinants are obtained in which the 
reporter gene is fused to the regulatory elements o f an endogenous gene. Transcripts 
generated by these fusions reflect the activity o f individual cellular genes and serve as 
molecular tags to identify and/or clone any genes linked to specific functions (Floss 
and Wurst, 2002; Hicks et al., 1995; Stanford et al., 2001). Application of this 
technique in a genome-wide manner should allow the identification of most, if not all, 
active transcripts in the genome and thus it is an important tool for genome 
annotation. More importantly, gene trapping in mouse ES cells enables the 
establishment o f ES cell libraries with mutations in most genes, which then can be 
used to make transgenic mice. This opens the possibility to assign a function to each 
gene in the context o f an entire organism.
It has been shown that gene trap vectors can disrupt all functional classes o f genes and 
are highly mutagenic in transgenic mice (Hansen et al., 2003). However, it must be 
considered that individual gene trap vectors contain their own biases for insertion into 
the genome. They complement each other in gene targeting, suggesting that the most 
effective way o f saturating the mouse genome with mutations is by using a 
combination of different gene trap vectors.
In the future, new entrapment vectors and automation will have an important impact 
on tagged sequence mutagenesis.
151
BIBLIOGRAPHY
Adam, M.A. and Dusty Miller, A. (1988) Identification of a Signal in a Murine 
Retrovirus That is Sufficient for Packaging o f Nonretroviral RNA into 
Virions. Journal o f  Virology, 62, 3802-3806.
Adams, M.D., Rudner, D.Z. and Rio, D.C. (1996) Biochemistry and regulation of pre- 
mRNA splicing. Curr Opin Cell Biol, 8, 331-339.
Akiyama, N., Matsuo, Y., Sai, H., Noda, M. and Kizaka-Kondoh, S. (2000)
Identification o f a Series o f Transforming Growth Factor ^-Responsive Genes 
by Retrovirus-Mediated Gene Trap Screening. Molecular and Cellular 
Biology, 20, 3266-3273.
Allen, N.D., Cran, D.G., Barton, S.C., Hettle, S., Reik, W. and Surani, M.A. (1988)
Transgenes as probes for active chromosomal domains in mouse development. 
Nature, 333, 852-855.
Anderson, K.V. and Ingham, P. W. (2003) The transformation o f the model organism: 
a decade of developmental genetics. Nature Genetics, 33, 285-293.
Araki, K., Imaizumi, T., Sekimoto, T., Yoshinobu, K., Yoshimuta, J., Akizuki, M., 
Miura, K., Araki, M. and Yamamura, K. (1999) Exchangeable Gene Trap 
Using The Cre/Mutated Lox System. Cellular and Molecular Biology, 45, 
737-750.
Armentano, D., Yu, S.-F., Kantoff, P.W., von Ruden, T., Anderson, W.F. and Gilboa, 
E. (1987) Effect o f Internal Viral Sequences on the Utility o f Retroviral 
Vectors. Journal o f  Virology, 61, 1647-1650.
Baker, R.K., Haendel, M.A., Swanson, B.J., Shambaugh, J.C., Micales, B.K. and 
Lyons, G.E. (1997) In Vitro Preselection of Gene-Trapped Embryonic Stem 
Cell Clones for Characterising Novel Developmentally Regulated Genes in the 
Mouse. Developmental Biology, 185, 201-214.
Beaudoing, E., Freier, S., Wyatt, J.R., Claverie, J.M. and Gautheret, D. (2000)
Patterns of variant polyadenylation signal usage in human genes. Genome Res, 
10, 1001- 1010 .
Bellen, H.J., O'Kane, C.J., Wilson, C., Grossniklaus, U., Pearson, R.K. and Gehring, 
W.J. (1989) P-element-mediated enhancer detection: a versatile method to 
study development in Drosophila. Genes and Development, 3, 1288-1300.
Bender, M.A., Palmer, T.D., Gelinas, R.E. and Dusty Miller, A. (1987) Evidence that 
the Packaging Signal of Moloney Murine Leukemia Virus Extends into the 
gag Region. Journal o f Virology, 61, 1639-1646.
152
Blanco, L., Bemad, A., Lazaro, J.M., Martin, G., Garmendia, C. and Salas, M. (1989) 
Highly efficient DNA synthesis by the phage phi 29 DNA polymerase. 
Symmetrical mode o f DNA replication. J  Biol Chem, 264, 8935-8940.
Blanco, L. and Salas, M. (1984) Characterization and purification of a phage phi 29- 
encoded DNA polymerase required for the initiation of replication. Proc Natl 
AcadSci U S A , 81, 5325-5329.
Blattner, F. R., Plunkett, G., Bloch, C. A., Pema, N. T., Burland, V., Riley, M., 
Collado-Vides, J., Glasner, J. D., Rode, C. K., Mayhew, G. F., Gregor, J., 
Davis, N. W., Kirkpatrick, H. A., Goeden, M. A., Rose, D. J., Mau, B. and 
Shao, Y. (1997) The Complete Genome Sequence o f Escherichai coli K-12. 
Science, 277, 1453-1474.
Bradley, A., Evans, M.J., Kaufman, M.H. and Robertson, E. (1984) Formation of
germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature, 
309, 255-256.
Breitbart, R.E. and Nadal-Ginard, B. (1987) Developmentally induced, muscle- 
specific trans factors control the differential splicing of alternative and 
constitutive troponin T exons. Cell, 49, 793-803.
Brinster, R.L., Chen, H.Y., Trumbauer, M., Senear, A.W., Warren, R. and Palmiter, 
R.D. (1981) Somatic expression o f herpes thymidine kinase in mice following 
injection of a fusion gene into eggs. Cell, 27, 223-231.
Bronson, S.K. and Smithies, O. (1994) Altering mice by homologous recombination 
using embryonic stem cells. Journal o f  Biological Chemistry, 269, 27155- 
27158.
Brown, S.D. and Balling, R. (2001) Systematic approaches to mouse mutagenesis. 
Curr Opin Genet Dev, 11, 268-273.
Bukrinsky, M.I., Sharova, N., Dempsey, M.P., Stanwick, T.L., Bukrinskaya, A.G., 
Haggerty, S. and Stevenson, M. (1992) Active nuclear import o f human 
immunodeficiency virus type 1 preintegration complexes. Proc. Natl. Acad. 
Sci. USA, 89, 6580-6584.
Burdon, T., Smith, A.G. and Savatier, P. (2002) Signalling, cell cycle and
pluripotency in embryonic stem cells. Trends in Cell Biology, 12, 432-438.
Capecchi, M. (1989) The New Mouse Genetics: Altering the Genome by Gene 
Targeting. Trends in Genetics, 5, 70-76.
Chowdhury, K., Bonaldo, P., Torres, M., Stoykova, A. and Gruss, P. (1997) Evidence 
for the stochastic integration of gene trap vectors into the mouse germline. 
Nucleic Acids Research, 25, 1531-1536.
Chuck, A.S., Clarke, M.F. and Palsson, B.O. (1996) Retroviral Infection Is Limited by 
Brownian Motion. Human Gene Therapy, 7, 1527-1534.
153
Chuck, A.S. and Palsson, B.O. (1996) Consistent and high rates of gene transfer can 
be obtained using flow-through transduction over a wide range of retroviral 
titers. Hum Gene Ther, 7, 743-750.
Coffin, J.M. (1979) Structure, replication, and recombination o f retrovirus genomes: 
some unifying hypotheses. J  Gen Virol, 42, 1-26.
Cone, R.D. and Mulligan, R.C. (1984) High-efficiency gene transfer into mammalian 
cells: Generation o f helper-free recombinant retrovirus with broad mammalian 
host range. Proc. Natl Acad. Sci. USA, 81, 6349-6353.
Couldrey, C., Carlton, M.B.L., Ferrier, J., Colledge, W.H. and Evans, M.J. (1998) 
Disruption o f Murine alpha-Enolase by a Retroviral Gene Trap Results in 
Early Embryonic Lethality. Developmental Dynamics, 212, 284-292.
Craigie, R. (1992) Hotspots and warm spots: integration specificity of retroelements. 
Trends in Genetics, 8, 187-190.
Davis, H.E., Morgan, J.R. and Yarmush, M.L. (2002) Polybrene increases retrovirus 
gene transfer efficiency by enhancing receptor-independent virus adsorption 
on target cell membranes. Biophysical Chemistry, 159-172.
Davis, S., Aldrich, T.H., Stahl, N., Pan, L., Taga, T., Kishimoto, T., Ip, N.Y. and 
Yancopoulos, G.D. (1993) LIFR beta and gpl30 as heterodimerizing signal 
transducers of the tripartite CNTF receptor. Science, 260, 1805-1808.
Dymecki, S.M. (1996) Flp recombinase promotes site-specific DNA recombination in 
embryonic stem cells and transgenic mice. Proc Natl Acad Sci USA,  93, 
6191-6196.
Eizinger, A., Jungblut, B. and Sommer, R. J. (1999) Evolutionary Change in the 
Functional Specificity o f Genes. Trends in Genetics, 15, 197-202.
Engels, W.R. (1993) Contributing software to the internet: the Amplify program. 
Trends in Biochemical Sciences, 18, 448-450.
Evans, M. and Kaufman, M.H. (1981) Establishment in Culture o f pluripotential cells 
from Mouse Embryos. Nature, 292, 154-156.
Evans, M.J. and Hunter, S. (2002) Source and nature o f embryonic stem cells. C.R. 
Biologies, 325, 1-5.
Ewing, B. and Green, P. (2000) Analysis o f expressed sequence tags indicates 35,000 
human genes. Nature Genetics, 25, 232-234.
Floss, T. and Wurst, W. (2002) Functional Genomics by Gene-Trapping in 
Embryonic Stem Cells. Methods in Molecular Biology, 185, 347-379.
154
Friedrich, G. and Soriano, P. (1991) Promoter traps in embryonic stem cells: a genetic 
screen to identify and mutate developmental genes in mice. Genes and 
Development, 5, 1513-1523.
Frohman, M.A., Dush, M.K. and Martin, G.R. (1988) Rapid production of full-length 
cDNAs from rare transcripts: Amplification using a single gene-specific 
oligonucleotide primer. Proc. Natl. Acad. Sci. USA, 85, 8998-9002.
Gearing, D.P., Thut, C.J., VandeBos, T., Gimpel, S.D., Delaney, P.B., King, J., Price, 
V., Cosman, D. and Beckmann, M.P. (1991) Leukemia inhibitory factor 
receptor is structurally related to the IL-6 signal transducer, gpl30. Embo J,
10, 2839-2848.
Gilbert, W. (1978) Why Genes in Pieces? Nature, 271, 501.
Gilboa, E., Goff, S., Shields, A., Yoshimura, F., Mitra, S. and Baltimore, D. (1979) In 
vitro synthesis o f a 9 kbp terminally redundant DNA carrying the infectivity of 
Moloney murine leukemia virus. Cell, 16, 863-874.
Goff, S.P. (2001) Intracellular trafficking o f retroviral genomes during the early phase 
of infection: viral exploitation o f cellular pathways. The Journal o f Gene 
Medicine, 3, 517-528.
Goffeau, A., Barrell, B.G., Bussey, H., Davis, R.W., Dujon, B., Feldmann, H.,
Galibert, F., Hoheisel, J.D., Jacq, C., Johnston, M., Louis, E.J., Mewes, H.W., 
Murakami, Y., Philippsen, P., Tettelin, H. and Oliver, S.G. (1996) Life with 
6000 genes. Science, 274, 546, 563-547.
Gossler, A., Joyner, A.L., Rossant, J. and Skames, W.C. (1989) Mouse Embryonic 
Stem Cells and Reporter Constructs to Detect Developmentally Regulated 
Genes. Science, 244, 463-465.
Hansen, J., Floss, T., Van Sloun, P., Fuchtbauer, E.M., Vauti, F., Arnold, H.H.,
Schnutgen, F., Wurst, W., von Melchner, H. and Ruiz, P. (2003) A large-scale, 
gene-driven mutagenesis approach for the functional analysis of the mouse 
genome. Proc. Natl. Acad. Sci. USA, 100, 9918-9922.
Hardison, R.C., Oeltjen, J. and Miller, W. (1997) Long human-mouse sequence
alignments reveal novel regulatory elements: a reason to sequence the mouse 
genome. Genome Res, 1, 959-966.
Hicks, G.C., Shi, E.-g., Lei, X.-M., Li, C.-H., Pawlak, M. and Ruley, H.E. (1997) 
Functional genomics in mice by tagged sequence mutagenesis. Nature 
Genetics, 16, 338-344.
Hicks, G.G., Shi, E.G., Chen, J., Roshon, M., Williamson, D., Scherer, C. and Ruley, 
H.E. (1995) Retrovirus gene traps. Methods Enzymol, 254, 263-275.
Hill, D.P. and Wurst, W. (1993) Gene and enhancer trapping: mutagenic strategies for 
developmental studies. Curr Top Dev Biol, 28, 181 -206.
155
Hooper, M., Hardy, K., Handyside, A., Hunter, S. and Monk, M. (1987) HPRT- 
Deficient (Lesch-Nyhan) Mouse Embryos Derived from Germline 
Colonization by Cultured Cells. Nature, 326, 292-295.
Ishida, Y. and Leder, P. (1999) RET: a poly A-trap retrovirus vector for reversible 
disruption and expression monitoring o f genes in living cells. Nucleic Acids 
Research, 27, e35 i-viii.
Jaenisch, R. (1976) Germ line integration and Mendelian transmission of the
exogenous Moloney leukemia virus. Proc Natl Acad Sci U S  A, 73, 1260- 
1264.
Jaenisch, R. (1988) Transgenic Animals. Science, 240, 1468-1474.
Jareborg, N., Bimey, E. and Durbin, R. (1999) Comparative Analysis of Noncoding 
Regions o f 77 Orthologous Mouse and Human Gene Pairs. Genome Research, 
9, 815-824.
Jenkins, N.A. and Copeland, N.G. (1985) High frequency germline acquisition of 
ecotropic MuLV proviruses in SWR/J-RF/J hybrid mice. Cell, 43, 811-819.
Joyner, A.L. (1991) Gene Targeting and Gene Trap Screens Using Embryonic Stem 
Cells: New Approaches to Mammalian Development. BioEssays, 13, 649-656.
Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M., Kanapin, A., 
Le Bot, N., Moreno, S., Sohrmann, M., Welchman, D.P., Zipperlen, P. and 
Ahringer, J. (2003) Systematic functional analysis of the Caenorhabditis 
elegans genome using RNAi. Nature, 421, 231-237.
Kan, Z., Rouchka, E.C., Gish, W.R. and States, D.J. (2001) Gene Structure Prediction 
and Alternative Splicing Analysis Using Genomically Aligned ESTs. Genome 
Research, 11, 889-900.
Kim, D.G., Kang, H.M., Jang, S.K. and Shin, H.S. (1992) Construction of a
bifunctional mRNA in the mouse by using the internal ribosome entry site of 
the encephalomyocarditis virus. Molecular and Cellular Biology, 12, 3636- 
3643.
Kim, J.W., Closs, E.I., Albritton, L.M. and Cunningham, J.M. (1991) Transport of 
cationic amino acids by the mouse ecotropic retrovirus receptor. Nature, 352, 
725-728.
Kimura, S., Niwa, H., Moriyama, M., Araki, K., Abe, K., Miike, T. and Yamamura, 
K.-I. (1994) Improvement o f germ line transmission by targeting beta- 
galactosidase to nuclei in transgenic mice. Development Growth and 
Differentiation, 36, 521-527.
156
Komada, M., McLean, D.J., Griswold, M.D., Russell, L.D. and Soriano, P. (2000) E- 
MAP-115, encoding a microtubule-associated protein, is a retinoic acid- 
inducible gene required for spermatogenesis. Genes and Development, 14, 
1332-1342.
Kotani, H., Newton, P.B., 3rd, Zhang, S., Chiang, Y.L., Otto, E., Weaver, L., Blaese, 
R.M., Anderson, W.F. and McGarrity, G.J. (1994) Improved methods of 
retroviral vector transduction and production for gene therapy. Hum Gene 
Ther, 5, 19-28.
Kothary, R., Clapoff, S., Brown, A., Campbell, R., Peterson, A. and Rossant, J.
(1988) A transgene containing lacZ inserted into the dystonia locus is 
expressed in neural tube. Nature, 335, 435-437.
Lakso, M., Sauer, B., Mosinger, B., Jr., Lee, E.J., Manning, R.W., Yu, S.H., Mulder, 
K.L. and Westphal, H. (1992) Targeted oncogene activation by site-specific 
recombination in transgenic mice. Proc Natl Acad Sci U S A , 89, 6232-6236.
Lander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Devon, 
K., Dewar, K., Doyle, M., FitzHugh, W., Funke, R., Gage, D., Harris, K., 
Heaford, A., Howland, J., Kann, L., Lehoczky, J., LeVine, R., McEwan, P., 
McKeman, K., Meldrim, J., Mesirov, J.P., Miranda, C., Morris, W., Naylor, J., 
Raymond, C., Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange- 
Thomann, N., Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., 
Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, 
N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I.,
Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., 
Hunt, A., Jones, M., Lloyd, C., McMurray, A., Matthews, L., Mercer, S., 
Milne, S., Mullikin, J.C., Mungall, A., Plumb, R., Ross, M., Shownkeen, R., 
Sims, S., Waterston, R.H., Wilson, R.K., Hillier, L.W., McPherson, J.D., 
Marra, M.A., Mardis, E.R., Fulton, L.A., Chinwalla, A.T., Pepin, K.H., Gish, 
W.R., Chissoe, S.L., Wendl, M.C., Delehaunty, K.D., Miner, T.L.,
Delehaunty, A., Kramer, J.B., Cook, L.L., Fulton, R.S., Johnson, D.L., Minx, 
P.J., Clifton, S.W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., 
Wenning, S., Slezak, T., Doggett, N., Cheng, J.F., Olsen, A., Lucas, S., Elkin, 
C., Uberbacher, E., Frazier, M., Gibbs, R.A., Muzny, D.M., Scherer, S.E., 
Bouck, J.B., Sodergren, E.J., Worley, K.C., Rives, C.M., Gorrell, J.H., 
Metzker, M.L., Naylor, S.L., Kucherlapati, R.S., Nelson, D.L., Weinstock,
G.M., Sakaki, Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T., 
Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T., Weissenbach, J., Heilig,
R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier, E., Robert, C., 
Wincker, P., Smith, D.R., Doucette-Stamm, L., Rubenfield, M., Weinstock,
K., Lee, H.M., Dubois, J., Rosenthal, A., Platzer, M., Nyakatura, G., Taudien,
S., Rump, A., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, L., Rowen, 
L., Madan, A., Qin, S., Davis, R.W., Federspiel, N.A., Abola, A.P., Proctor, 
M.J., Myers, R.M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D.R.,
Olson, M.V., Kaul, R., Shimizu, N., Kawasaki, K., Minoshima, S., Evans,
G.A., Athanasiou, M., Schultz, R., Roe, B.A., Chen, F., Pan, H., Ramser, J., 
Lehrach, H., Reinhardt, R., McCombie, W.R., de la Bastide, M., Dedhia, N., 
Blocker, H., Homischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey,
157
J.A., Bateman, A., Batzoglou, S., Bimey, E., Bork, P., Brown, D.G., Burge, 
C.B., Cerutti, L., Chen, H.C., Church, D., Clamp, M., Copley, R.R., Doerks,
T., Eddy, S.R., Eichler, E.E., Furey, T.S., Galagan, J., Gilbert, J.G., Harmon, 
C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., 
Johnson, L.S., Jones, T.A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W.J., 
Kitts, P., Koonin, E.V., Korf, I., Kulp, D., Lancet, D., Lowe, T.M., 
McLysaght, A., Mikkelsen, T., Moran, J.V., Mulder, N., Pollara, V.J., Ponting, 
C.P., Schuler, G., Schultz, J., Slater, G., Smit, A.F., Stupka, E., Szustakowski, 
J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., Wallis, J., Wheeler, R., 
Williams, A., Wolf, Y.I., Wolfe, K.H., Yang, S.P., Yeh, R.F., Collins, F., 
Guyer, M.S., Peterson, J., Felsenfeld, A., Wetterstrand, K.A., Patrinos, A., 
Morgan, M.J., Szustakowki, J., de Jong, P., Catanese, J.J., Osoegawa, K., 
Shizuya, H., Choi, S. and Chen, Y.J. (2001) Initial sequencing and analysis of 
the human genome. Nature, 409, 860-921.
Lewis, P.F. and Emerman, M. (1994) Passage through Mitosis Is Required for
Oncoretroviruses but Not for Human Immunodeficiency Virus. Journal o f  
Virology, 68, 510-516.
Lojda, Z. (1970) Indigogenic methods for glycosidases. II. An improved method for 
beta-D-galactosidase and its application to localization studies of the enzymes 
in the intestine and in other tissues. Histochemie, 23, 266-288.
MacGregor, G.R., Mogg, A.E., Burke, J.F. and Caskey, C.T. (1987) Histochemical 
Staining of Clonal Mammalian Cell Lines Expressing E. coli (3 Galactosidase 
Indicates Heterogeneous Expression of the Bacterial Gene. Somatic Cell and 
Molecular Genetics, 13, 253-265.
Mann, R., Mulligan, R.C. and Baltimore, D. (1983) Construction o f a Retrovirus
Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus. 
Cell, 33, 153-159.
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The 
protein kinase complement o f the human genome. Science, 298, 1912-1934.
Martin, G.R. (1981) Isolation o f a pluripotent cell line from early mouse embryos 
cultured in medium conditioned by teratocarcinoma. Proc. Natl. Acad. Sci.
USA, 78, 7634-7638.
Miller, A.D. (1990) Retrovirus Packaging Cells. Human Gene Therapy, 1, 5-14.
Miller, A.D. and Buttimore, C. (1986) Redesign o f Retrovirus Packaging Cell Lines 
To Avoid Recombination Leading to Helper Virus Production. Molecular and 
Cellular Biology, 6, 2895-2902.
Miller, A.D., Law, M.-F. and Verma, I.M. (1985) Generation of Helper-Free
Amphotropic Retroviruses That Transduce a Dominant-Acting, Methotrexate- 
Resistant Dihydrofolate Reductase Gene. Molecular and Cellular Biology, 5, 
431-437.
158
Miller, A.D. and Rosman, G.J. (1989) Improved Retroviral Vectors for Gene Transfer 
and Expression. BioTechniques, 7, 980-990.
Miller, A.D., Trauber, D.R. and Buttimore, C. (1986) Factors Involved in Production 
of Helper Virus-Free Retrovirus Vectors. Somatic Cell and Molecular 
Genetics, 12, 175-183.
Mills, A.A. and Bradley, A. (2001) From mouse to man: generating megabase 
chromosome rearrangements. Trends Genet, 17, 331-339.
Mironov, A.A., Fickett, J.W. and Gelfand, M.S. (1999) Frequent alternative splicing 
of human genes. Genome Res, 9, 1288-1293.
Mitchell, K.J., Pinson, K.I., Kelly, O.G., Brennan, J., Zupicich, J., Scherz, P., 
Leighton, P.A., Goodrich, L.V., Lu, X., Avery, B.J., Tate, P., Dill, K., 
Pangilinan, E., Wakenight, P., Tessier-Lavigne, M. and Skames, W.C. (2001) 
Functional Analysis o f Secreted and Transmembrane Proteins Critical to 
Mouse Development. Nature Genetics, 28, 241-249.
Modrek, B. and Lee, C. (2002) A genomic view of alternative splicing. Nat Genet, 30, 
13-19.
Mountford, P.S. and Smith, A.G. (1995) Internal Ribosome Entry Sites and
Dicistronic RNAs in Mammalian Transgenesis. Trends in Genetics, 11, 179- 
184.
Nagy, A., Perrimon, N., Sandmeyer, S. and Plasterk, R. (2003) Tailoring the genome: 
the power o f genetic approaches. Nat Genet, 33 Suppl, 276-284.
Neilan, E.G. and Barsh, G.S. (1999) Gene Trap Insertional Mutagenesis in Mice: New 
Vectors and Germ Line Mutations in Two Novel Genes. Transgenic Research, 
8, 451-458.
Nichols, J., Evans, E.P. and Smith, A.G. (1990) Establishment o f Germ-line-
competent embryonic stem (ES) cells using differentiation inhibiting activity. 
Development, 110, 1341-1348.
Nielson, K.B., Schoettlin, W., Bauer, J.C. and Mathur, E. (1994) Taq extender PCR 
Additive for improved length, yield and reliability o f PCR product. Strategies, 
7, 27-29.
Niwa, H., Araki, K., Kimura, S., Taniguchi, S., Wakasugi, S. and Yamamura, K. 
(1993) An Efficient Gene-Trap Method Using Poly A Trap Vectors and 
Characterization o f Gene-Trap Events. Journal o f  Biochemistry, 113, 343-349.
Niwa, H., Burdon, T., Chambers, I. and Smith, A. (1998) Self-renewal of pluripotent 
embryonic stem cells is mediated via activation of STAT3. Genes Dev, 12, 
2048-2060.
159
Nolan, P.M., Peters, J., Strivens, M., Rogers, D., Hagan, J., Spurr, N., Gray, I.C.,
Vizor, L., Brooker, D., Whitehill, E., Washboume, R., Hough, T., Greenaway,
S., Hewitt, M., Liu, X., McCormack, S., Pickford, K., Selley, R., Wells, C., 
Tymowska-Lalanne, Z., Roby, P., Glenister, P., Thornton, C., Thaung, C., 
Stevenson, J.A., Arkell, R., Mburu, P., Hardisty, R., Kieman, A., Erven, A., 
Steel, K.P., Voegeling, S., Guenet, J.L., Nickols, C., Sadri, R., Nasse, M., 
Isaacs, A., Davies, K., Browne, M., Fisher, E.M., Martin, J., Rastan, S.,
Brown, S.D. and Hunter, J. (2000) A systematic, genome-wide, phenotype- 
driven mutagenesis programme for gene function studies in the mouse. Nat 
Genet, 25, 440-443.
O'Kane, C.J. and Gehring, W.J. (1987) Detection in situ o f genomic regulatory 
elements in Drosophila. Proc. Natl Acad. Sci. USA, 84, 9123-9127.
Oliver, S.G. (1996) From DNA sequence to biological function. Nature, 379, 597- 
600.
Orban, P.C., Chui, D. and Marth, J.D. (1992) Tissue- and site-specific DNA
recombination in transgenic mice. Proc Natl Acad Sci US A,  89, 6861-6865.
Palmiter, R.D., Brinster, R.L., Hammer, R.E., Trumbauer, M.E., Rosenfeld, M.G.,
Bimberg, N.C. and Evans, R.M. (1982) Dramatic growth o f mice that develop 
from eggs microinjected with metallothionein-growth hormone fusion genes. 
Nature, 300, 611-615.
Palu, G., Parolin, C., Takeuchi, Y. and Pizzato, M. (2000) Progress with retroviral 
gene vectors. Reviews in Medical Virology, 10, 185-202.
Pear, W.S., Nolan, G.P., Scott, M.L. and Baltimore, D. (1993) Production of high-titer 
helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA, 
90, 8392-8396.
Reithel, F.J. and Kim, J.C. (1960) Studies on the beta-galactosidase isolated from
Escherichia coli ML 308. 1. The effect of some ions on enzymic activity. Arch 
Biochem Biophys, 90, 271-277.
Robertson, E. (1987) Teratocarcinomas and Embryonic Stem Cells: A Practical 
Approach. IRL Press Ltd, Oxford.
Robertson, E., Bradley, A., Kuehn, M. and Evans, M.J. (1986) Germ-line
transmission of genes introduced into cultured pluripotential cells by retroviral 
vector. Nature, 323, 445-448.
Roe, T., Reynolds, T.C., Yu, G. and Brown, P.O. (1993) Integration o f murine 
leukemia virus DNA depends on mitosis. Embo J, 12, 2099-2108.
Rohdewohld, H., Weiher, H., Reik, W., Jaenisch, R. and Breindl, M. (1987)
Retrovirus Integration and Chromatin Structure: Moloney Murine Leukemia 
Proviral Integration Sites Map Near DNase I-Hypersensitive Sites. Journal o f  
Virology, 61, 336-343.
160
Salminen, M., Meyer, B.I. and Gruss, P. (1998) Efficient Poly A Trap Approach
Allows the Capture of Genes Specifically Active in Differentiated Embryonic 
Stem Cells and in Mouse Embryos. Developmental Dynamics, 212, 326-333.
Sambrook, J. and Gething, M.J. (1989) Chaperones, paperones. Nature, 342, 224-225.
Scherdin, U., Rhodes, K. and Breindl, M. (1990) Transcriptionally Active Genome
Regions Are Preferred Targets for Retrovirus Integration. Journal o f Virology, 
64, 907-912.
Schweizer, M., Roberts, L.M., Holtke, J., Takabayashi, K., Muller, G., Hoja, U., 
Hollerer, E., Schuh, B. and Scheizer, E. (1986) Molecular structure and 
expression o f fatty acid synthetase genes in yeast. Biochem Soc Trans, 14, 
572-574.
Shirai, M., Miyashita, A., Ishii, N., Itoh, Y., Satokata, I., Watanabe, Y.G. and
Kuwano, R. (1996) A Gene Trap Strategy for Identifying the Gene Expressed 
in the Embryonic Nervous System. Zoological Science, 13, 277-283.
Skames, W.C., Auerbach, B.A. and Joyner, A.L. (1992) A gene trap approach in 
mouse embryonic stem cells: the lac Z  reporter is activated by splicing, 
reflects endogenous gene expression, and is mutagenic in mice. Genes and 
Development, 6, 903-918.
Skames, W.C., Moss, J.E., Hurtley, S.M. and Beddington, R.S.P. (1995) Capturing 
genes encoding membrane and secreted proteins important for mouse 
development. Proc. Natl. Acad. Sci. USA, 92, 6592-6596.
Soriano, P. (1995) Gene Targeting in ES Cells. Annual Reviews in Neuroscience, 18, 
1-18.
Soriano, P., Friedrich, G. and Lawinger, P. (1991) Promoter Interactions in Retrovirus 
Vectors Introduced into Fibroblasts and Embryonic Stem Cells. Journal o f  
Virology, 65, 2314-2319.
Speck, N.A. and Baltimore, D. (1987) Six distinct nuclear factors interact with the 75- 
base-pair repeat of the Moloney murine leukemia vims enhancer. Mol Cell 
Biol, 7, 1101-1110.
Spence, S.E., Gilbert, D.J., Swing, D.A., Copeland, N.G. and Jenkins, N.A. (1989)
Spontaneous germ line vims infection and retroviral insertional mutagenesis in 
eighteen transgenic Srev lines o f mice. Mol Cell Biol, 9, 177-184.
Stanford, W., Cohn, J. and Cordes, S. (2001) Gene Trap Mutagenesis: Past, Present 
and Beyond. Nature Reviews Genetics, 2, 756-768.
Sulston, J., Du, Z., Thomas, K., Wilson, R., Hillier, L., Staden, R., Halloran, N.,
Green, P., Thierry-Mieg, J., Qiu, L. and et al. (1992) The C. elegans genome 
sequencing project: a beginning. Nature, 356, 37-41.
161
Takeuchi, T., Yamazaki, Y., Katoh-Fukui, Y., Tsuchiya, R., Kondo, S., Motoyama, J. 
and Higashinakagawa, T. (1995) Gene trap capture of a novel mouse gene, 
jumonji, required for neural tube formation. Genes and Development, 9,1211- 
1222.
Temin, H.M. (1981) Structure, Variation and Synthesis of Retrovirus Long Terminal 
Repeat. Cell, 27, 1-3.
Temin, H.M. (1982) Function o f the Retrovirus Long Terminal Repeat. Cell, 28, 3-5.
Thomas, T., Voss, A.K., Chowdhury, K. and Grass, P. (2000) A New Gene Trap
Construct Enriching for Insertion Events Near the 5' End of Genes. Transgenic 
Research, 9, 395-404.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J.,
Marshall, V.S. and Jones, J.M. (1998) Embryonic stem cell lines derived from 
human blastocysts. Science, 282, 1145-1147.
Toyoshima, K. and Vogt, P.K. (1969) Enhancement and inhibition of avian sarcoma 
viruses by polycations and polyanions. Virology, 38, 414-426.
Tsukiyama, T., Niwa, O. and Yokoro, K. (1989) Mechanism o f suppression of the 
long terminal repeat o f Moloney leukemia virus in mouse embryonal 
carcinoma cells. Mol Cell Biol, 9, 4670-4676.
Varmus, H.E. (1982) Form and Function o f Retroviral Pro viruses. Science, 216, 812- 
820.
Varmus, H.E., Heasley, S., Kung, H.J., Oppermann, H., Smith, V.C., Bishop, J.M. 
and Shank, P.R. (1978) Kinetics o f synthesis, structure and purification of 
avian sarcoma virus-specific DNA made in the cytoplasm o f acutely infected 
cells. J  Mol Biol, 120, 55-82.
Vega, F.M., Gonzalo, P., Gaspar, M.L. and Lazo, P.A. (2003) Expression of the VRK 
(vaccinia-related kinase) gene family o f p53 regulators in murine 
hematopoietic development. FEBS Lett, 544, 176-180.
Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, 
H.O., Yandell, M., Evans, C.A., Holt, R.A., Gocayne, J.D., Amanatides, P., 
Ballew, R.M., Huson, D.H., Wortman, J.R., Zhang, Q., Kodira, C.D., Zheng, 
X.H., Chen, L., Skupski, M., Subramanian, G., Thomas, P.D., Zhang, J.,
Gabor Miklos, G.L., Nelson, C., Broder, S., Clark, A.G., Nadeau, J., 
McKusick, V.A., Zinder, N., Levine, A.J., Roberts, R.J., Simon, M., Slayman, 
C., Hunkapiller, M., Bolanos, R., Delcher, A., Dew, I., Fasulo, D., Flanigan, 
M., Florea, L., Halpem, A., Hannenhalli, S., Kravitz, S., Levy, S., Mobarry,
C., Reinert, K., Remington, K., Abu-Threideh, J., Beasley, E., Biddick, K., 
Bonazzi, V., Brandon, R., Cargill, M., Chandramouliswaran, I., Charlab, R., 
Chaturvedi, K., Deng, Z., Di Francesco, V., Dunn, P., Eilbeck, K.,
Evangelista, C., Gabrielian, A.E., Gan, W., Ge, W., Gong, F., Gu, Z., Guan,
P., Heiman, T.J., Higgins, M.E., Ji, R.R., Ke, Z., Ketchum, K.A., Lai, Z., Lei,
162
Y., Li, Z., Li, J., Liang, Y., Lin, X., Lu, F., Merkulov, G.V., Milshina, N., 
Moore, H.M., Naik, A.K., Narayan, V.A., Neelam, B., Nusskem, D., Rusch,
D.B., Salzberg, S., Shao, W., Shue, B., Sun, J., Wang, Z., Wang, A., Wang,
X., Wang, J., Wei, M., Wides, R., Xiao, C., Yan, C., Yao, A., Ye, J., Zhan, M., 
Zhang, W., Zhang, H., Zhao, Q., Zheng, L., Zhong, F., Zhong, W., Zhu, S., 
Zhao, S., Gilbert, D., Baumhueter, S., Spier, G., Carter, C., Cravchik, A., 
Woodage, T., Ali, F., An, H., Awe, A., Baldwin, D., Baden, H., Bamstead, M., 
Barrow, I., Beeson, K., Busam, D., Carver, A., Center, A., Cheng, M.L.,
Curry, L., Danaher, S., Davenport, L., Desilets, R., Dietz, S., Dodson, K., 
Doup, L., Ferriera, S., Garg, N., Gluecksmann, A., Hart, B., Haynes, J., 
Haynes, C., Heiner, C., Hladun, S., Hostin, D., Houck, J., Howland, T., 
Ibegwam, C., Johnson, J., Kalush, F., Kline, L., Koduru, S., Love, A., Mann, 
F., May, D., McCawley, S., McIntosh, T., McMullen, I., Moy, M., Moy, L., 
Murphy, B., Nelson, K., Pfannkoch, C., Pratts, E., Puri, V., Qureshi, H., 
Reardon, M., Rodriguez, R., Rogers, Y.H., Romblad, D., Ruhfel, B., Scott, R., 
Sitter, C., Smallwood, M., Stewart, E., Strong, R., Suh, E., Thomas, R., Tint, 
N.N., Tse, S., Vech, C., Wang, G., Wetter, J., Williams, S., Williams, M., 
Windsor, S., Winn-Deen, E., Wolfe, K., Zaveri, J., Zaveri, K., Abril, J.F., 
Guigo, R., Campbell, M.J., Sjolander, K.V., Karlak, B., Kejariwal, A., Mi, H., 
Lazareva, B., Hatton, T., Narechania, A., Diemer, K., Muruganujan, A., Guo, 
N., Sato, S., Bafiia, V., Istrail, S., Lippert, R., Schwartz, R., Walenz, B., 
Yooseph, S., Allen, D., Basu, A., Baxendale, J., Blick, L., Caminha, M., 
Cames-Stine, J., Caulk, P., Chiang, Y.H., Coyne, M., Dahlke, C., Mays, A., 
Dombroski, M., Donnelly, M., Ely, D., Esparham, S., Fosler, C., Gire, H., 
Glanowski, S., Glasser, K., Glodek, A., Gorokhov, M., Graham, K., Gropman,
B., Harris, M., Heil, J., Henderson, S., Hoover, J., Jennings, D., Jordan, C., 
Jordan, J., Kasha, J., Kagan, L., Kraft, C., Levitsky, A., Lewis, M., Liu, X., 
Lopez, J., Ma, D., Majoros, W., McDaniel, J., Murphy, S., Newman, M., 
Nguyen, T., Nguyen, N., Nodell, M., Pan, S., Peck, J., Peterson, M., Rowe,
W., Sanders, R., Scott, J., Simpson, M., Smith, T., Sprague, A., Stockwell, T., 
Turner, R., Venter, E., Wang, M., Wen, M., Wu, D., Wu, M., Xia, A.,
Zandieh, A. and Zhu, X. (2001) The sequence o f the human genome. Science, 
291, 1304-1351.
Vijaya, S., Steffen, D.L. and Robinson, H.L. (1986) Acceptor Sites for Retroviral
Integrations Map Near DNase I-Hypersensitive Sites in Chromatin. Journal o f  
Virology, 60, 683-692.
von Melchner, H., DeGregori, J.V., Raybum, H., Reddy, S., Friedel, C. and Ruley,
H.E. (1992) Selective Disruption o f Genes Expressed in Totipotent Embryonal 
Stem Cells. Genes and Development, 6, 919-927.
Wang, H., Kavanaugh, M.P., North, R.A. and Kabat, D. (1991) Cell-surface receptor 
for ecotropic murine retroviruses is a basic amino-acid transporter. Nature,
352, 729-731.
Ware, L.M. and Axelrad, A.A. (1972) Inherited Resistance to N- and B-tropic Murine 
Leukemia Viruses In Vitro: Evidence that Congenic Mouse Strains SIM and 
SIM.R Differ at the Fv-1 Locus. Virology, 50, 339-348.
163
Waterston, R.H., Lindblad-Toh, K., Bimey, E., Rogers, J., Abril, J.F., Agarwal, P., 
Agarwala, R., Ainscough, R., Alexandersson, M., An, P., Antonarakis, S.E., 
Attwood, J., Baertsch, R., Bailey, J., Barlow, K., Beck, S., Berry, E., Birren,
B., Bloom, T., Bork, P., Botcherby, M., Bray, N., Brent, M.R., Brown, D.G., 
Brown, S.D., Bult, C., Burton, J., Butler, J., Campbell, R.D., Caminci, P., 
Cawley, S., Chiaromonte, F., Chinwalla, A.T., Church, D.M., Clamp, M., 
Clee, C., Collins, F.S., Cook, L.L., Copley, R.R., Coulson, A., Couronne, O., 
Cuff, J., Curwen, V., Cutts, T., Daly, M., David, R., Davies, J., Delehaunty, 
K.D., Deri, J., Dermitzakis, E.T., Dewey, C., Dickens, N.J., Diekhans, M., 
Dodge, S., Dubchak, I., Dunn, D.M., Eddy, S.R., Elnitski, L., Ernes, R.D., 
Eswara, P., Eyras, E., Felsenfeld, A., Fewell, G.A., Flicek, P., Foley, K., 
Frankel, W.N., Fulton, L.A., Fulton, R.S., Furey, T.S., Gage, D., Gibbs, R.A., 
Glusman, G., Gnerre, S., Goldman, N., Goodstadt, L., Grafham, D., Graves, 
T.A., Green, E.D., Gregory, S., Guigo, R., Guyer, M., Hardison, R.C., 
Haussler, D., Hayashizaki, Y., Hillier, L.W., Hinrichs, A., Hlavina, W., 
Holzer, T., Hsu, F., Hua, A., Hubbard, T., Hunt, A., Jackson, I., Jaffe, D.B., 
Johnson, L.S., Jones, M., Jones, T.A., Joy, A., Kamal, M., Karlsson, E.K., 
Karolchik, D., Kasprzyk, A., Kawai, J., Keibler, E., Kells, C., Kent, W.J., 
Kirby, A., Kolbe, D.L., Korf, I., Kucherlapati, R.S., Kulbokas, E.J., Kulp, D., 
Landers, T., Leger, J.P., Leonard, S., Letunic, I., Levine, R., Li, J., Li, M., 
Lloyd, C., Lucas, S., Ma, B., Maglott, D.R., Mardis, E.R., Matthews, L., 
Mauceli, E., Mayer, J.H., McCarthy, M., McCombie, W.R., McLaren, S., 
McLay, K., McPherson, J.D., Meldrim, J., Meredith, B., Mesirov, J.P., Miller, 
W., Miner, T.L., Mongin, E., Montgomery, K.T., Morgan, M., Mott, R., 
Mullikin, J.C., Muzny, D.M., Nash, W.E., Nelson, J.O., Nhan, M.N., Nicol, 
R., Ning, Z., Nusbaum, C., O'Connor, M.J., Okazaki, Y., Oliver, K., Overton- 
Larty, E., Pachter, L., Parra, G., Pepin, K.H., Peterson, J., Pevzner, P., Plumb, 
R., Pohl, C.S., Poliakov, A., Ponce, T.C., Ponting, C.P., Potter, S., Quail, M., 
Reymond, A., Roe, B.A., Roskin, K.M., Rubin, E.M., Rust, A.G., Santos, R., 
Sapojnikov, V., Schultz, B., Schultz, J., Schwartz, M.S., Schwartz, S., Scott,
C., Seaman, S., Searle, S., Sharpe, T., Sheridan, A., Shownkeen, R., Sims, S., 
Singer, J.B., Slater, G., Smit, A., Smith, D.R., Spencer, B., Stabenau, A., 
Stange-Thomann, N., Sugnet, C., Suyama, M., Tesler, G., Thompson, J., 
Torrents, D., Trevaskis, E., Tromp, J., Ucla, C., Ureta-Vidal, A., Vinson, J.P., 
VonNiederhausem, A.C., Wade, C.M., Wall, M., Weber, R.J., Weiss, R.B., 
Wendl, M.C., West, A.P., Wetterstrand, K., Wheeler, R., Whelan, S., 
Wierzbowski, J., Willey, D., Williams, S., Wilson, R.K., Winter, E., Worley, 
K.C., Wyman, D., Yang, S., Yang, S.P., Zdobnov, E.M., Zody, M.C. and 
Lander, E.S. (2002) Initial sequencing and comparative analysis of the mouse 
genome. Nature, 420, 520-562.
Weber, F., de Villiers, J. and Schaffiier, W. (1984) An SV40 "enhancer trap" 
incorporates exogenous enhancers or generates enhancers from its own 
sequences. Cell, 36, 983-992.
Weiss, R. (1998) Viral RNA-dependent DNA polymerase RNA-dependent DNA 
polymerase in virions o f Rous sarcoma virus. Rev Med Virol, 8, 3-11.
Weiss, R.A. and Tailor, C.S. (1995) Retrovirus Receptors. Cell, 82, 531-533.
164
Westerman, K.A. and Leboulch, P. (1996) Reversible immortalization of mammalian 
cells mediated by retroviral transfer and site specific recombination. Proc. 
Natl Acad. Set USA, 93, 8971-8976.
Wiles, M.V., Vauti, F., Otte, J., Fuchtbauer, E.M., Ruiz, P., Fuchtbauer, A., Arnold,
H.H., Lehrach, H., Metz, T., von Melchner, H. and Wurst, W. (2000) 
Establishment o f a gene-trap sequence tag library to generate mutant mice 
from embryonic stem cells. Nat Genet, 24, 13-14.
Wurst, W., Rossant, J., Prideaux, V., Kownacka, M., Joyner, A.L., Hill, D.P.,
Guillemot, F., Gasca, S., Cado, D., Auerbach, A. and Ang, S.-L. (1995) A 
Large-Scale Gene-Trap Screen for Insertional Mutations in Developmentally 
Regulated Genes in Mice. Genetics, 139, 889-899.
Xu, C., Inokuma, M.S., Denham, J., Golds, K., Kundu, P., Gold, J.D. and Carpenter, 
M.K. (2001) Feeder-free growth o f undifferentiated human embryonic stem 
cells. Nature Biotechnology, 19, 971-974.
Yoshida, M., Yagi, T., Furuta, Y., Takayanagi, K., Kominami, R., Takeda, N.,
Tokunaga, T., Chiba, J., Ikawa, Y. and Aizawa, S. (1995) A new strategy of 
gene trapping in ES cells using 3'RACE. Transgenic Research, 4, 277-287.
Yu, Y. and Bradley, A. (2001) Engineering Chromosomal Rearrangements in Mice. 
Nature Reviews Genetics, 2, 780-790.
Zambrowicz, B.P., Friedrich, G.A., Buxton, E.C., Lilleberg, S.L., Person, C. and 
Sands, A.T. (1998) Disruption and sequence identification of 2000 genes in 
mouse embryonic stem cells. Nature, 392, 608-611.
165
APPENDIX I
PLASMIDS USED 
pCX-GFP
chicken
beta-actin
promoter
CMV-IE
enhancer
amp
pCX-GFP  
5.6 kb
ori
SV40 ori GFP
Rabbit beta- 
globin poly-A
166
pHIT 123
SV40 ori
CMV promoter
amp
pH IT 123 
9.7 kb
MLV ecotropic 
envelope
gP*
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pHIT 60
amp CMV promoter
pH IT 60  
13.3 kb
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gpt
pol
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pA M Pl
Lac OPZ’
T7
promoter
fl intergen ic 
region
SP6
promoter
pAMP 1 
4.1 kb
Amp
ori
Lac I Promoter
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pSHUT + 124K (A)
Kozak ATG
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o . Eco R1
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APPENDIX II
Sequence information of retroviral constructs: 
proviral pSHUT+124K (A)
1 A A T G A A A G A C  C C C C G C T G A C  G G G T A G T C A A  T C A C T C A G A G  G A G A C C C T C C  C A A G G A A C A G  
6 1  C G A G A C C A C A  A G T C G G A T G C  A A C T G C A A G A  G G G T T T A T T G  G A T A C A C G G G  TA C C C G G G C G  
1 2 1  A C T C A G T C A A  T C G G A G G A C T  G G C G C C C C G A  G T G A G G G G T T  G T G C T A G C T T  G C C A A A C C T A  
1 8 1  C A G G T G G G G T  C T T T C A T T C C  C C C C T T T T T C  T G G A G A C T A A  A T A A A A T C T T  T T A T T T T A T C  
2 4 1  G A T A A G C T T A  C C A T G G G A A T  T G A A C A A G A C  G G A T T G C A C G  C A G G T T C T C C  G G C C G C TT G G  
3 0 1  G T G G A G A G G C  T A T T C G G C T A  T G A C T G G G C A  C A A C A G A C A A  T C G G C T G C T C  TG A T G C C G C C  
3 6 1  G T G T T C C G G C  T G T C A G C G C A  G G G G C G C C C G  G T T C T T T T T G  T C A A G A C C G A  C C T G T C C G G T  
4 2 1  G C C C T G A A T G  A A C T G C A G G A  C G A G G C A G C G  C G G C T A T C G T  G G C T G G C C A C  G A C G G G C G TT  
4 8 1  C C T T G C G C A G  C T G T G C T C G A  C G T T G T C A C T  G A A G C G G G A A  G G G A C T G G C T  G C T A T T G G G C  
5 4 1  G A A G T G C C G G  G G C A G G A T C T  C C T G T C A T C T  C A C C T T G C T C  C T G C C G A G A A  A G T A T C C A T C  
6 0 1  A T G G C T G A T G  C A A T G C G G C G  G C T G C A T A C G  C T T G A T C C G G  C T A C C T G C C C  A T T C G A C C A C  
6 6 1  C A G C G A A A C A  T C G C A T C G A G  C G A G C A C G T A  C T C G G A T G G A  A G C C G G T C T T  G T C G A T C A G G  
7 2 1  A T G A T C T G G A  C G A A G A G C A T  C A G G G G C T C G  C G C C A G C C G A  A C T G T T C G C C  A G G C T C A A G G  
7 8 1  C G C G C A T G C C  C G A C G G C G A G  G A T C T C G T C G  T G A C C C A T G G  C G A T G C C T G C  T T G C C G A A T A  
8 4 1  T C A T G G T G G A  A A A T G G C C G C  T T T T C T G G A T  T C A T C G A C T G  T G G C C G G C T G  G G TG TG G C G G  
9 0 1  A C C G C T A T C A  G G A C A T A G C G  T T G G C T A C C C  G T G A T A T T G C  T G A A G A G C T T  G G C G G C G A A T  
9 6 1  G G G C T G A C C G  C T T C C T C G T G  C T T T A C G G T A  T C G C C G C T C C  C G A T T C G C A G  C G C A T C G C C T  
1 0 2 1  T C T A T C G C C T  T C T T G A C G A G  T T C T T C T G A T  C T A G A G A G C T  C A G C T G T G C C  T T C T A G T T G C  
1 0 8 1  C A G C C A T C T G  T T G T T T G C C C  C T C C C C C G T G  C C T T C C T T G A  C C C T G G A A G G  T G C C A C T C C C  
1 1 4 1  A C T G T C C T T T  C C T A A T A A A A  T G A G G A A A T T  G C A T C G C A T T  G T C T G A G T A G  G T G T C A T T C T  
1 2 0 1  A T T C T G G G G G  G TG G G G TG G G  G C A G G A C A G C  AA G G G G G A G G  A T T G G G A A G A  C A A T A G C A G G  
1 2  6 1  C A T G C T G G G G  A T G C G G T G G G  C T C T A T G G C T  T C T G A G G C G G  A A A G A A C G T C  G A C G A A T T C G  
1 3 2 1  A G C T C G G C C G  A C T T G G C C A A  T T C G C C C T A T  A G T G A G T C G T  A T T A C A A T T C  A C T G G C C G T C  
1 3 8 1  G T T T T A C A A C  G T C G T G A C T G  G G A A A A C C C T  G G C G T T A C C C  A A C T T A A T C G  C C T T G C A G C A  
1 4  4 1  C A T C C C C C T T  T C G C C A G C T G  G C G T A A T A G C  G A A G A G G C C C  G C A C C G A T C G  C C C T T C C C A A  
1 5 0 1  C A G T T G C G C A  G C C T G A A T G G  C G A A T G G A C G  C G C C C T G T A G  C G G C G C A T T A  A G C G C G G C G G  
1 5 6 1  G T G T G G T G G T  T A C G C G C A G C  G T G A C C G C T A  C A C T T G C C A G  C G C C C T A G C G  C C C G C T C C T T  
1 6 2 1  T C G C T T T C T T  C C C T T C C T T T  C T C G C C A C G T  T C G C C G G C T T  T C C C C G T C A A  G C T C T A A A T C  
1 6 8 1  G G G G G C T C C C  T T T A G G G T T C  C G A T T T A G A G  C T T T A C G G C A  C C T C G A C C G C  A A A A A A C T T G
1 7  4 1  A T T T G G G T G A  T G G T T C A C G T  A G T G G G C C A T  C G C C C T G A T A  G A C G G T T T T T  C G C C C T T T G A  
1 8 0 1  C G T T G G A G T C  C A C G T T C T T T  A A T A G T G G A C  T C T T G T T C C A  A A C T G G A A C A  A C A C T C A A C C
1 8  6 1  C T A T C T C G G T  C T A T T C T T T T  G A T T T A T A A G  G G A T T T T G C C  G A T T T C G G C C  T A T T G G T T A A  
1 9 2 1  A A A A T G A G C T  G A T T T A A C A A  A T A T T T A A C G  C G A A T T T T A A  C A A A A T A T T A  A C G T T T A C A A  
1 9 8 1  T T T C G C C T G A  T G C G G T A T T T  T C T C C T T A C G  C A T C T G T G C G  G T A T T T C A C A  C C G C A T A T G G  
2 0 4 1  T G C A C T C T C A  G T A C A A T C T G  C T C T G A T G C C  G C A T A G T T A A  G C C A G C C C C G  A C A C C C G C C A  
2 1 0 1  A C A C C C G C T G  A C G C G C C C T G  A C G G G C T T G T  C T G C T C C C G G  C A T C C G C T T A  C A G A C A A G C T  
2 1 6 1  G T G A C C G T C T  C C G G G A G C T G  C A T G T G T C A G  A G G T T T T C A C  C G T C A T C A C C  G A A A C G C G C G  
2 2 2 1  A G A C G A A A G G  G C C T C G T G A T  A C G C C T A T T T  T T A T A G G T T A  A T G T C A T G A T  A A T A A T G G T T  
2 2 8 1  T C T T A G A C G T  C A G G T G G C A C  T T T T C G G G G A  A A T G T G C G C G  G A A C C C C T A T  T T G T T T A T T T  
2  3 4 1  T T C T A A A T A C  A T T C A A A T A T  G T A T C C G C T C  A T G A G A C A A T  A A C C C T G A T A  A A T G C T T C A A  
2 4  0 1  T A A T A T T G A A  A A A G G A A G A G  T A T G A G T A T T  C A A C A T T T C C  G T G T C G C C C T  T A T T C C C T T T  
2 4  6 1  T T T G C G G C A T  T T T G C C T T C C  T G T T T T T G C T  C A C C C A G A A A  C G C T G G T G A A  A G T A A A A G A T  
2  5 2 1  G C T G A A G A T C  A G T T G G G T G C  A C G A G T G G G T  T A C A T C G A A C  T G G A T C T C A A  C A G C G G T A A G  
2 5 8 1  A T C C T T G A G A  G T T T T C G C C C  C G A A G A A C G T  T T T C C A A T G A  T G A G C A C T T T  T A A A G T T C T G  
2  6 4 1  C T A T G T C A T A  C A C T A T T A T C  C C G T A T T G A C  G C C G G G C A A G  AGCAACTCGG TCGCCGGGCG  
2 7  0 1  C G G T A T T C T C  A G A A T G A C T T  G G T T G A G T A C  T C A C C A G T C A  C A G A A A A G C A  T C T T A C G G A T  
2 7  6 1  G G C A T G A C A G  T A A G A G A A T T  A T G C A G T G C T  G C C A T A A C C A  T G A G T G A T A A  C A C T G C G G C C  
2 8 2 1  A A C T T A C T T C  T G A C A A C G A T  C G G A G G A C C G  A A G G A G C T A A  C C G C T T T T T T  G C A C A A C A T G  
2 8 8 1  G G G G A T C A T G  T A A C T C G C C T  T G A T C G T T G G  G A A C C G G A G C  T G A A T G A A G C  C A T A C C A A A C  
2  9 4 1  G A C G A G C G T G  A C A C C A C G A T  G C C T G T A G C A  A T G C C A A C A A  C G T T G C G C A A  A C T A T T A A C T  
3 0 0 1  G G C G A A C T A C  T T A C T C T A G C  T T C C C G G C A A  C A A T T A A T A G  A C T G G A T G G A  G G C G G A TA A A  
3 0 6 1  G T T G C A G G A C  C A C T T C T G C G  C T C G G C C C T T  C C G G C T G G C T  G G T T T A T T G C  T G A T A A A T C T
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3 1 2 1  G G A G C C G G T G  A G C G T G G G T C  T C G C G G T A T C  A T T G C A G C A C  TG G G G C C A G A  TG G T A A G C C C
3 1 8 1  T C C C G T A T C G  T A G T T A T C T A  C A C G A C G G G G  A G T C A G G C A A  C T A T G G A T G A  A C G A A A T A G A
3 2  4 1  C A G A T C G C T G  A G A T A G G T G C  C T C A C T G A T T  A A G C A T T G G T  A A C T G T C A G A  C C A A G T T T A C
3 3 0 1  T C A T A T A T A C  T T T A G A T T G A  T T T A A A A C T T  C A T T T T T A A T  T T A A A A G G A T  C T A G G T G A A G
3 3 6 1  A T C C T T T T T G  A T A A T C T C A T  G A C C A A A A T C  C C T T A A C G T G  A G T T T T C G T T  C C A C T G A G C G
3 4  2 1  T C A G A C C C C G  T A G A A A A G A T  C A A A G G A T C T  T C T T G A G A T C  C T T T T T T T C T  G C G C G T A A T C
3 4  8 1  T G C T G C T T G C  A A A C A A A A A A  A C C A C C G C T A  C C A G C G G T G G  T T T G T T T G C C  G G A TC A A G A G
3 5 4 1  C T A C C A A C T C  T T T T T C C G A A  G G T A A C T G G C  T T C A G C A G A G  C G C A G A T A C C  A A A T A C T G T C
3 6 0 1  C T T C T A G T G T  A G C C G T A G T T  A G G C C A C C A C  T T C A A G A A C T  C T G T A G C A C C  G C C T A C A T A C
3 6 6 1  C T C G C T C T G C  T A A T C C T G T T  A C C A G T G G C T  G C T G C C A G T G  G C G A T A A G T C  G T G T C T T A C C
3 7 2 1  G G G T T G G A C T  C A A G A C G A T A  G T T A C C G G A T  A A G G C G C A G C  G G TC G G G C TG  AACG G G G G G T
3 7  8 1  T C G T G C A C A C  A G C C C A G C T T  G G A G C G A A C G  A C C T A C A C C G  A A C T G A G A T A  C C T A C A G C G T
3 8 4 1  G A G C T A T G A G  A A A G C G C C A C  G C T T C C C G A A  G G G A G A A A G G  C G G A C A G G T A  TC C G G T A A G C
3 9 0 1  G G C A G G G T C G  G A A C A G G A G A  G C G C A C G A G G  G A G C T T C C A G  G G G G A A A C G C  C T G G T A T C T T
3 9 6 1  T A T A G T C C T G  T C G G G T T T C G  C C A C C T C T G A  C T T G A G C G T C  G A T T T T T G T G  A T G C T C G T C A
4 0 2 1  G G G G G G C G G A  G C C T A T C G A A  A A A C G C C A G C  A A C G C G G C C T  T T T T A C G G T T  C C T G G C C T T T
4 0 8 1  T G C T G G C C T T  T T G C T C A C A T  G T T C T T T C C T  G C G T T A T C C C  C T G A T T C T G T  G G A T A A C C G T
4 1 4 1  A T T A C C G C C T  T T G A G T G A G C  T G A T A C C G C T  C G C C G C A G C C  G A A C G A C C G A  G CG CAG CG AG  
4 2 0 1  T C A G T G A G C G  A G G A A G C G G A  A G A G C G C C C A  A T A C G C A A A C  C G C C T C T C C C  C G C G C G T T G G
4 2  6 1  C C G A T T C A T T  A A T G C A G C T G  G C A C G A C A G G  T T T C C C G A C T  G G A A A G C G G G  C A G T G A G C G C
4 3 2 1  A A C G C A A T T A  A T G T G A G T T A  G C T C A C T C A T  T A G G C A C C C C  A G G C T T T A C A  C T T T A T G C T T
4 3 8 1  C C G G C T C G T A  T G T T G T G T G G  A A T T G T G A G C  G G A T A A C A A T  T T C A C A C A G G  A A A C A G C T A T
4 4 4 1  G A C C A T G A T T  A C G C C A A G C T  A T T T A G G T G A  C A C T A T A G A A  T A C T C A A G C T  T A T G C A T G C G  
4 5 0 1  G C C G C A T C T A  G C G A A T T C G G  C G C C T A G A G A  A G G A G T G A G G  G C T G G A T A A A  G G G A G G A TC G
4 5 6 1  A G G C G G G G T C  G A A C G A G G A G  G T T C A A G G G G  G A G A G A C G G G  G C G G A T G G A G  G AAG AG G AG G
4 6 2 1  C G G A G G C T T A  G G G T G T A C A A  A G G G C T T G A C  CCA G G G A G G G  G G G T C A A A A G  C C A A G G C T T C
4 6 8 1  C C A G G T C A C G  A T G T A G G G G A  C C T G G T C T G G  G T G T C C A T G C  G G G C C A G G T G  A A A A G A C C T T
4 7 4 1  G A T C T T A A C C  T G G G T G A T G A  G G T C T C G G T T  A A A G G T G C C G  T C T C G C G G C C  A T C C G A C G T T
4 8 0 1  A A A G G T T G G C  C A T T C T G C A G  A G C A G A A G G T  A A C C C A A C G T  C T C T T C T T G A  C A T C T A C C G A
4 8  6 1  C T G G T T G T G A  G C G A T C C G C T  C G A C A T C T T T  C C A G T G A C C T  A A G G T C A A A C  T T A A G G G A G T
4 9 2 1  G G T A A C A G T C  T G G C C C A T A T  T C T C A G A C A A  A T A C A G A A A C  A C A G T C A G A C  A G A G A C A A C A
4 9 8 1  C A G A A C G A T G  C T G C A G C A G A  C A A G A C G C G C  G G C G C G G C T T  C G G T C C C A A A  C C G A A A G C A A
5 0 4 1  A A A T T C A G A C  G G A G G C G G G A  A C T G T T T T A G  G T T C T C G T C T  C C T A C C A G A A  C C A C A T A T C C
5 1 0 1  C T C C T C T A A G  G G G G G T G C A C  C A A A G A G T C C  A A A A C G A T C G  G G A T T T T T G G  A C T C A G G T C G
5 1 6 1  G G C C A C A A A A  A C G G C C C C C G  A A G T C C C T G G  G A C G T C T C C C  A G G G T T G C G G  C C G G G T G T T C
5 2 2 1  C G A A C T C G T C  A G T T C C A C C A  C G G G T C C G C C  A G A T A C A G A G  C T A G T T A G C T  A A C T A G T A C C
5 2 8 1  G A C G C A G G C G  C A T A A A A T C A  G T C A T A G A C A  C T A G A C A A T C  G G A C A G A C A C  A G A T A A G T T G
5 3 4 1  C T G G C C A G C T  T A C C T C C C G G  T G G T G G G T C G  G T G G T C C C T G  G G C A G G G G T C  T C C C G A T C C C
5 4  0 1  G G A C G A G C C C  C C A A A T G A A A  G A C C C C C G C T  G A C G G G T A G T  C A A T C A C T C A  G A G G A G A C C C
5 4  6 1  T C C C A A G G A A  C A G C G A G A C C  A C A A G T C G G A  T G C A A C T G C A  A G A G G G T T T A  T T G G A T A C A C
5 5 2 1  G G G TA C C C G G  G C G A C T C A G T  C A A T C G G A G G  A C T G G C G C C C  C G A G T G A G G G  G T T G T G C T A G
5 5 8 1  A T A A C T T C G T  A T A G T A T A C A  T T A T A C G A A G  T T A T C T A G C T  T G C C A A A C C T  A C A G G T G G G G
5 6 4 1  T C T T T C A T T
173
proviral pSHUT+124k SD126 (1)
1 A A T G A A A G A C  C C C C G C T G A C  G G G T A G T C A A  T C A C T C A G A G  G A G A C C C T C C  C A A G G A A C A G  
6 1  C G A G  A C C  A C  A  A G T C G G A T G C  A A C T G C A A G A  G G G T T T A T T G  G A T A C A C G G G  TA C C C G G G C G  
1 2 1  A C T C A G T C A A  T C G G A G G A C T  G G C G C C C C G A  G T G A G G G G T T  G T G C T A G C T T  G C C A A A C C T A  
1 8 1  C A G G T G G G G T  C T T T C A T T C C  C C C C T T T T T C  T G G A G A C T A A  A T A A A A T C T T  T T A T T T T A T C  
2 4 1  G A T A A G C T T A  C C A T G G G A A T  T G A A C A A G A C  G G A T T G C A C G  C A G G T T C T C C  G G C C G C TT G G  
3 0 1  G T G G A G A G G C  T A T T C G G C T A  T G A C T G G G C A  C A A C A G A C A A  T C G G C T G C T C  T G A T G C C G C C  
3 6 1  G T G T T C C G G C  T G T C A G C G C A  G G G G C G C C C G  G T T C T T T T T G  T C A A G A C C G A  C C T G T C C G G T  
4 2 1  G C C C T G A A T G  A A C T G C A G G A  C G A G G C A G C G  C G G C T A T C G T  G G C T G G C C A C  G ACG G G CG TT  
4 8 1  C C T T G C G C A G  C T G T G C T C G A  C G T T G T C A C T  G A A G C G G G A A  G G G A C T G G C T  G C T A T T G G G C  
5 4 1  G A A G T G C C G G  G G C A G G A T C T  C C T G T C A T C T  C A C C T T G C T C  C T G C C G A G A A  A G T A T C C A T C  
6 0 1  A T G G C T G A T G  C A A T G C G G C G  G C T G C A T A C G  C T T G A T C C G G  C T A C C T G C C C  A T T C G A C C A C  
6 6 1  C A A G C G A A A C  A T C G C A T C G A  G C G A G C A C G T  A C T C G G A T G G  A A G C C G G T C T  T G T C G A T C A G  
7 2 1  G A T G A T C T G G  A C G A A G A G C A  T C A G G G G C T C  G C G C C A G C C G  A A C T G T T C G C  C A G G C T C A A G  
7 8 1  G C G C G C A T G C  C C G A C G G C G A  G G A T C T C G T C  G T G A C C C A T G  G C G A T G C C T G  C T T G C C G A A T  
8 4 1  A T C A T G G T G G  A A A A T G G C C G  C T T T T C T G G A  T T C A T C G A C T  G T G G C C G G C T  G G G TG TG G CG  
9 0 1  G A C C G C T A T C  A G G A C A T A G C  G T T G G C T A C C  C G T G A T A T T G  C T G A A G A G C T  TG G C G G C G A A  
9 6 1  T G G G C T G A C C  G C T T C C T C G T  G C T T T A C G G T  A T C G C C G C T C  C C G A T T C G C A  G C G C A T C G C C  
1 0 2 1  T T C T A T C G C C  T T C T T G A C G A  G T T C T T C T G A  T C T A G A A C T A  G T G G A T C C A G  C T T A T C G A G C  
1 0 8 1  T T G C C A A C T A  C A G C A G G T A A  G C A T A T T T A T  G A A A A A T G C T  G A T T G T G T T A  G C T A C T T G T G  
1 1 4 1  T C A G T G T T G T  G A T A G T C G A C  G A A T T C G A G C  T C G G C C G A C T  T G G C C A A T T C  G C C C T A T A G T  
1 2 0 1  G A G T C G T A T T  A C A A T T C A C T  G G C C G T C G T T  T T A C A A C G T C  G T G A C T G G G A  A A A C C C T G G C  
1 2 6 1  G T T A C C C A A C  T T A A T C G C C T  T G C A G C A C A T  C C C C C T T T C G  C C A G C T G G C G  T A A T A G C G A A  
1 3 2 1  G A G G C C C G C A  C C G A T C G C C C  T T C C C A A C A G  T T G C G C A G C C  T G A A T G G C G A  A TG G A C G C G C  
1 3 8 1  C C T G T A G C G G  C G C A T T A A G C  G C G G C G G G T G  T G G T G G T T A C  G C G C A G C G T G  A C C G C T A C A C  
1 4  4 1  T T G C C A G C G C  C C T A G C G C C C  G C T C C T T T C G  C T T T C T T C C C  T T C C T T T C T C  G C C A C G T T C G  
1 5 0 1  C C G G C T T T C C  C C G T C A A G C T  C T A A A T C G G G  G G C T C C C T T T  A G G G T T C C G A  T T T A G A G C T T  
1 5 6 1  T A C G G C A C C T  C G A C C G C A A A  A A A C T T G A T T  T G G G T G A T G G  T T C A C G T A G T  G G G C C A T C G C  
1 6 2 1  C C T G A T A G A C  G G T T T T T C G C  C C T T T G A C G T  T G G A G T C C A C  G T T C T T T A A T  A G T G G A C T C T  
1 6 8 1  T G T T C C A A A C  T G G A A C A A C A  C T C A A C C C T A  T C T C G G T C T A  T T C T T T T G A T  T T A T A A G G G A  
1 7 4 1  T T T T G C C G A T  T T C G G C C T A T  T G G T T A A A A A  A T G A G C T G A T  T T A A C A A A T A  T T T A A C G C G A  
1 8  0 1  A T T T T A A C A A  A A T A T T A A C G  T T T A C A A T T T  C G C C T G A T G C  G G T A T T T T C T  C C T T A C G C A T
1 8  6 1  C T G T G C G G T A  T T T C A C A C C G  C A T A T G G T G C  A C T C T C A G T A  C A A T C T G C T C  T G A T G C C G C A
1 9 2 1  T A G T T A A G C C  A G C C C C G A C A  C C C G C C A A C A  C C C G C T G A C G  C G C C C T G A C G  G G C T T G T C T G  
1 9 8 1  C T C C C G G C A T  C C G C T T A C A G  A C A A G C T G T G  A C C G T C T C C G  G G A G C T G C A T  G T G T C A G A G G  
2 0 4 1  T T T T C A C C G T  C A T C A C C G A A  A C G C G C G A G A  C G A A A G G G C C  T C G T G A T A C G  C C T A T T T T T A  
2 1 0 1  T A G G T T A A T G  T C A T G A T A A T  A A T G G T T T C T  T A G A C G T C A G  G T G G C A C T T T  T C G G G G A A A T  
2 1 6 1  G T G C G C G G A A  C C C C T A T T T G  T T T A T T T T T C  T A A A T A C A T T  C A A A T A T G T A  T C C G C T C A T G  
2 2 2 1  A G A C A A T A A C  C C T G A T A A A T  G C T T C A A T A A  T A T T G A A A A A  G G A A G A G T A T  G A G T A T T C A A  
2  2 8 1  C A T T T C C G T G  T C G C C C T T A T  T C C C T T T T T T  G C G G C A T T T T  G C C T T C C T G T  T T T T G C T C A C
2  3 4 1  C C A G A A A C G C  T G G T G A A A G T  A A A A G A T G C T  G A A G A T C A G T  T G G G T G C A C G  A G T G G G T T A C
2 4  0 1  A T C G A A C T G G  A T C T C A A C A G  C G G T A A G A T C  C T T G A G A G T T  T T C G C C C C G A  A G A A C G T T T T
2 4  6 1  C C A A T G A T G A  G C A C T T T T A A  A G T T C T G C T A  T G T C A T A C A C  T A T T A T C C C G  T A T T G A C G C C
2  5 2 1  G G G C A A G A G C  A A C T C G G T C G  C C G G G C G C G G  T A T T C T C A G A  A T G A C T T G G T  T G A G T A C T C A
2  5 8 1  C C A G T C A C A G  A A A A G C A T C T  T A C G G A T G G C  A T G A C A G T A A  G A G A A T T A T G  C A G T G C T G C C
2  6 4 1  A T A A C C A T G A  G T G A T A A C A C  T G C G G C C A A C  T T A C T T C T G A  C A A C G A T C G G  A G G A C C G A A G
2 7 0 1  G A G C T A A C C G  C T T T T T T G C A  C A A C A T G G G G  G A T C A T G T A A  C T C G C C T T G A  T C G T T G G G A A  
2 7  6 1  C C G G A G C T G A  A T G A A G C C A T  A C C A A A C G A C  G A G C G T G A C A  C C A C G A T G C C  T G T A G C A A T G  
2 8 2 1  C C A A C A A C G T  T G C G C A A A C T  A T T A A C T G G C  G A A C T A C T T A  C T C T A G C T T C  C C G G C A A C A A  
2 8 8 1  T T A A T A G A C T  G G A T G G A G G C  G G A T A A A G T T  G C A G G A C C A C  T T C T G C G C T C  G G C C C T T C C G  
2  9 4 1  G C T G G C T G G T  T T A T T G C T G A  T A A A T C T G G A  G C C G G T G A G C  G T G G G T C T C G  C G G T A T C A T T  
3 0 0 1  G C A G C A C T G G  G G C C A G A T G G  T A A G C C C T C C  C G T A T C G T A G  T T A T C T A C A C  G A C G G G G AG T  
3 0 6 1  C A G G C A A C T A  T G G A T G A A C G  A A A T A G A C A G  A T C G C T G A G A  T A G G T G C C T C  A C T G A T T A A G  
3 1 2 1  C A T T G G T A A C  T G T C A G A C C A  A G T T T A C T C A  T A T A T A C T T T  A G A T T G A T T T  A A A A C T T C A T  
3 1 8 1  T T T T A A T T T A  A A A G G A T C T A  G G T G A A G A T C  C T T T T T G A T A  A T C T C A T G A C  C A A A A T C C C T  
3 2 4 1  T A A C G T G A G T  T T T C G T T C C A  C T G A G C G T C A  G A C C C C G T A G  A A A A G A T C A A  A G G A T C T T C T  
3 3 0 1  T G A G A T C C T T  T T T T T C T G C G  C G T A A T C T G C  T G C T T G C A A A  C A A A A A A A C C  A C C G C T A C C A  
3 3 6 1  G C G G T G G T T T  G T T T G C C G G A  T C A A G A G C T A  C C A A C T C T T T  T T C C G A A G G T  A A C T G G C T T C  
3 4  2 1  A G C A G A G C G C  A G A T A C C A A A  T A C T G T C C T T  C T A G T G T A G C  C G T A G T T A G G  C C A C C A C T T C  
3 4  8 1  A A G A A C T C T G  T A G C A C C G C C  T A C A T A C C T C  G C T C T G C T A A  T C C T G T T A C C  A G T G G C T G C T
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3 5 4 1
3 6 0 1
3 6 6 1
3 7 2 1
3 7 8 1
3 8 4 1
3 9 0 1
3 9 6 1
4 0 2 1
4 0 8 1
4 1 4 1
4 2 0 1
4 2 6 1
4 3 2 1
4 3 8 1
4 4 4  1
4 5 0 1
4 5 6 1
4 6 2 1
4 6 8 1
4 7 4 1
4 8 0 1
4 8 6 1
4 9 2 1
4 9 8 1
5 0 4 1
5 1 0 1
5 1 6 1
5 2 2 1
5 2 8 1
5 3 4 1
5 4 0 1
G C C A G T G G C G  
G C G C A G C G G T  
T A C A C  C G AAC  
A G A A A G G C G G  
C T T C C A G G G G  
G A G C G T C G A T  
G C G G C C T T T T  
T T A T C C C C T G  
C G C A G C C G A A  
C G C A A A C C G C  
C C C G A C T G G A  
G C A C C C C A G G  
T A A C A A T T T C  
T A T A G A A T A C  
A G T G A G G G C T  
A G A C G G G G C G  
G G G A G G G G G G  
T C C A T G C G G G  
G G T G C C G T C T  
C C A A C G T C T C  
G T G A C C T A A G  
C A G A A A C A C A  
G C G G C T T C G G  
C T C G T C T C C T  
A C G A T C G G G A  
G T C T C C C A G G  
T A C A G A G C T A  
G A C A A T C G G A  
G T C C C T G G G C  
G G G T A G T C A A  
A A C T G C A A G A  
G G C G C C C C G A
A T A A G T C G T G
C G G G C T G A A C
T G A G A T A C C T
A C A G G T A T C C
G A A A C G C C T G
T T T T G T G A T G
T A C G G T T C C T
A T T C T G T G G A
C G A C C G A G C G
C T C T C C C C G C
A A G C G G G C A G
C T T T A C A C T T
A C A C A G G A A A
T C A A G C T T A T
G G A T A A A G G G
G A T G G A G G A A
T C A A A A G C C A
C C A G G T G A A A
C G C G G C C A T C
T T C T T G A C A T
G T C A A A C T T A
G T C A G A C A G A
T C C C A A A C C G
A C C A G A A C C A
T T T T T G G A C T
G T T G C G G C C G
G T T A G C T A A C
C A G A C A C A G A
A G G G G T C T C C
T C A C T C A G A G
G G G T T T A T T G
G T G A G G G G T T
T C T T A C C G G G
G G G G G G T T C G
A C A G C G T G A G
G G T A A G C G G C
G T A T C T T T A T
C T C G T C A G G G
G G C C T T T T G C
T A A C C G T A T T
C A G C G A G T C A
G C G T T G G C C G
T G A G C G C A A C
T A T G C T T C C G
C A G C T A T G A C
G C A T G C G G C C
A G G A T C G A G G
GAG G AG G CG G
A G G C T T C C C A
A G A C C T T G A T
C G A C G T T A A A
C T A C C G A C T G
A G G G A G T G G T
G A C A A C A C A G
A A A G C A A A A A
C A T A T C C C T C
C A G G T C G G G C
G G T G T T C C G A
T A G T A C C G A C
T A A G T T G C T G
C G A T C C C G G A
G A G A C C C T C C
G A T A C A C G G G
G T G C T A G C T T
T T G G A C T C A A  
T G C A C A C A G C  
C T A T  G A G A A A  
A G G G T C G G A A  
A G T C C T G T C G  
G G G C G G A G C C  
T G G C C T T T T G  
A C C G C C T T T G  
G T G A G C G A G G  
A T T C A T T A A T  
G C A A T T A A T G  
G C T C G T A T G T  
C A T G A T T A C G  
G C A T C T A G C G  
C G G G G T C G A A  
A G G C T T A G G G  
G G T C A C G A T G  
C T T A A C C T G G  
G G T T G G C C A T  
G T T G T G A G C G  
A A C A G T C T G G  
A A C G A T G C T G  
T T C A G A C G G A  
C T C T A A G G G G  
C A C A A A A A C G  
A C T C G T C A G T  
G C A G G C G C A T  
G C C A G C T T A C  
C G A G C C C C C A  
C A A G G A A C A G  
T A C C C G G G C G  
G C C A A A C C T A
G A C G A T A G T T  
C C A G C T T G G A  
G C G C C A C G C T  
CAG G A G A G C G  
G G T T T C G C C A  
T A T C G A A A A A  
C T C A C A T G T T  
A G T G A G C T G A  
A A G C G G A A G A  
G C A G C T G G C A  
T G A G T T A G C T  
T G T G T G G A A T  
C C A A G C T A T T  
A A T T C G G C G C  
C G A G G A G G T T  
T G T A C A A A G G  
T A G G G G A C C T  
G T G A T G A G G T  
T C T G C A G A G C  
A T C C G C T C G A  
C C C A T A T T C T  
C A G C A G A C A A  
G G C G G G A A C T  
G G T G C A C C A A  
G C C C C C G A A G  
T C C A C C A C G G  
A A A A T C A G T C  
C T C C C G G T G G  
A A T G A A A G A C  
C G A G A C C A C A  
A C T C A G T C A A  
C A G G T G G G G T
A C C G G A T A A G
G C G A A C G A C C
TC C C G A A G G G
CACG AG G G AG
C C T C T G A C T T
C G C C A G C A A C
C T T T C C T G C G
TA C C G C T C G C
G C G C C C A A T A
C G A C A G G T T T
C A C T C A T T A G
T G T G A G C G G A
TA G G T G A C A C
CTA G A G A A G G
CAAG G G G G AG
G C T T G A C C C A
G G TC T G G G T G
C T C G G T T A A A
A G A A G G T A A C
C A T C T T T C C A
C A G A C A A A T A
G ACG CG CG G C
G T T T T A G G T T
A G A G T C C A A A
T C C C T G G G A C
G T C C G C C A G A
A T A G A C A C T A
T G G G T C G G T G
C C C C G C T G A C
A G T C G G A T G C
T C G G A G G A C T
C T T T C A T T
175
proviral pCSI+SD126 L4 (2)
1 A A T G A A A G A C  C C C C G C T G A C  G G G T A G T C A A  T C A C T C A G A G  G A G A C C C T C C  C A A G G A A C A G
6 1  C G A G A C C A C A  A G T C G G A T G C  A A C T G C A A G A  G G G T T T A T T G  G A TA C A C G G G  TA C C C G G G C G
1 2 1  A C T C A G T C A A  T C G G A G G A C T  G G C G C C C C G A  G T G A G G G G T T  G T G C T A G C T T  G C C A A A C C T A
1 8 1  C A G G T G G G G T  C T T T C A T T C C  C C C C T T T T T C  T G G A G A C T A A  A T A A A A T C T T  T T A T T T T A T C
2 4 1  T A T G G C T C G T  A C T C T A T A G G  C T T C A G C T G G  T G A T A T T G T T  G A G T C A A A A C  T A G A G C C TG G
3 0 1  A C C A C T G A T A  T C C T G T C T T T  A A C A A A T T G G  A C T A A T C G A T  C T C G A C C T C G  A G A C T A G T G G
3 6 1  A T C C C C C G G G  C T G C A G A T C T  G T A G G G C G C A  G T A G T C C A G G  G T T T T C C T T G  A T G A T G T C A T
4 2 1  A C T T A T C C C T  G T C C C T T T T T  T T T C C A C A G C  T C G C G G T T G A  G G A C A A A C T C  T T C G C G G T C T
4 8 1  T T C C A G T G G G  G A T C G A C G G T  A T C G A T A A A G  C T A A T T C C G C  C C C C C C C C C C  C C C C C C C C C T
5 4 1  C T C C C T C C C C  C C C C C C T A A C  G T T A C T G G C C  G A A G C C G C T T  G G A A T A A G G C  CG G TG TG C G T
6 0 1  T T G T C T A T A T  G T T A T T T T C C  A C C A T A T T G C  C G T C T T T T G G  C A A T G T G A G G  G C C C G G A A A C
6 6 1  C T G G C C C T G T  C T T C T T G A C G  A G C A T T C C T A  G G G G T C T T T C  C C C T C T C G C C  A A A G G A A T G C
7 2 1  A A G G T C T G T T  G A A T G T C G T G  A A G G A A G C A G  T T C C T C T G G A  A G C T T C T T G A  A G A C A A A C A A
7 8 1  C G T C T G T A G C  G A C C C T T T G C  A G G C A G C G G A  A C C C C C C A C C  T G G C G A C A G G  T G C C T C T G C G
8 4 1  G C C A A A A G C C  A C G T G T A T A A  G A T A C A C C T G  C A A A G G C G G C  A C A A C C C C A G  T G C C A C G T T G
9 0 1  T G A G T T G G A T  A G T T G T G G A A  A G A G T C A A A T  G G C T C T C C T C  A A G C G T A T T C  A A C A A G G G G C
9 6 1  T G A A G G A T G C  C C A G A A G G T A  C C C C A T T G T A  T G G G A T C T G A  T C T G G G G C C T  C G G T G C A C A T
1 0 2 1  G C T T T A C G T G  T G T T T A G T C G  A G G T T A A A A A  A C G T C T A G G C  C C C C C G A A C C  A C G G G G A C G T
1 0 8 1  G G T T T T C C T T  T G A A A A A C A C  G A T G A T A A T A  T G G C C A T G A G  C T T G A T G A T C  T G T G A C A T G G
1 1 4 1  C G G A T C C C G T  C G T T T T A C A A  C G T C G T G A C T  G G G A A A A C C C  T G G C G T T A C C  C A A C T T A A T C
1 2 0 1  G C C T T G C A G C  A C A T C C C C C T  T T C G C C A G C T  G G C G T A A T A G  C G A A G A G G C C  C G C A C C G A T C
1 2 6 1  G C C C T T C C C A  A C A G T T G C G C  A G C C T G A A T G  G C G A A T G G C G  C T T T G C C T G G  T T T C C G G C A C
1 3 2 1  C A G A A G C G G T  G C C G G A A A G C  T G G C T G G A G T  G C G A T C T T C C  T G A G G C C G A T  A C T G T C G T C G
1 3 8 1  T C C C C T C A A A  C T G G C A G A T G  C A C G G T T A C G  A T G C G C C C A T  C T A C A C C A A C  G T A A C C T A T C
1 4 4 1  C C A T T A C G G T  C A A T C C G C C G  T T T G T T C C C A  C G G A G A A T C C  G A C G G G T T G T  T A C T C G C T C A
1 5 0 1  C A T T T A A T G T  T G A T G A A A G C  T G G C T A C A G G  A A G G C C A G A C  G C G A A T T A T T  T T T G A T G G C G
1 5 6 1  T T A A C T C G G C  G T T T C A T C T G  T G G T G C A A C G  G G C G C TG G G T C G G T T A C G G C  C A G G A C A G T C
1 6 2 1  G T T T G C C G T C  T G A A T T T G A C  C T G A G C G C A T  T T T T A C G C G C  C G G A G A A A A C  C G C C T C G C G G
1 6 8 1  T G A T G G T G C T  G C G T T G G A G T  G A C G G C A G T T  A T C T G G A A G A  T C A G G A T A T G  T G G C G G A T G A
1 7 4 1  G C G G C A T T T T  C C G T G A C G T C  T C G T T G C T G C  A T A A A C C G A C  T A C A C A A A T C  A G C G A T T T C C
1 8 0 1  A T G T T G C C A C  T C G C T T T A A T  G A T G A T T T C A  G C C G C G C T G T  A C T G G A G G C T  G A A G T T C A G A
1 8  6 1  T G T G C G G C G A  G T T G C G T G A C  T A C C T A C G G G  T A A C A G T T T C  T T T A T G G C A G  G G T G A A A C G C
1 9 2 1  A G G T C G C C A G  C G G C A C C G C G  C C T T T C G G C G  G T G A A A T T A T  C G A T G A G C G T  G G T G G T T A T G
1 9 8 1  C C G A T C G C G T  C A C A C T A C G T  C T G A A C G T C G  A A A A C C C G A A  A C T G T G G A G C  G C C G A A A T C C
2 0 4 1  C G A A T C T C T A  T C G T G C G G T G  G T T G A A C T G C  A C A C C G C C G A  C G G C A C G C T G  A T T G A A G C A G
2 1 0 1  A A G C C T G C G A  T G T C G G T T T C  C G C G A G G T G C  G G A T T G A A A A  T G G T C T G C T G  C T G C T G A A C G
2 1 6 1  G C A A G C C G T T  G C T G A T T C G A  G G C G T T A A C C  G T C A C G A G C A  T C A T C C T C T G  C A T G G T C A G G
2 2 2 1  T C A T G G A T G A  G C A G A C G A T G  G T G C A G G A T A  T C C T G C T G A T  G A A G C A G A A C  A A C T T T A A C G
2 2 8 1  C C G T G C G C T G  T T C G C A T T A T  C C G A A C C A T C  C G C T G T G G T A  C A C G C T G T G C  G A C C G C T A C G
2  3 4 1  G C C T G T A T G T  G G T G G A T G A A  G C C A A T A T T G  A A A C C C A C G G  C A T G G T G C C A  A T G A A T C G T C
2 4  0 1  T G A C C G A T G A  T C C G C G C T G G  C T A C C G G C G A  T G A G C G A A C G  C G T A A C G C G A  A T G G T G C A G C
2 4  6 1  G C G A T C G T A A  T C A C C C G A G T  G T G A T C A T C T  G G T C G C T G G G  G A A T G A A T C A  G G C C A C G G C G
2  5 2 1  C T A A T C A C G A  C G C G C T G T A T  C G C T G G A T C A  A A T C T G T C G A  T C C T T C C C G C  C C G G T G C A G T
2  5 8 1  A T G A A G G C G G  C G G A G C C G A C  A C C A C G G C C A  C C G A T A T T A T  T T G C C C G A T G  T A C G C G C G C G
2  6 4 1  T G G A T G A A G A  C C A G C C C T T C  C C G G C T G T G C  C G A A A T G G T C  C A T C A A A A A A  T G G C T T T C G C
2 7 0 1  T A C C T G G A G A  G A C G C G C C C G  C T G A T C C T T T  G C G A A T A C G C  C C A C G C G A T G  G G T A A C A G T C
2 7  6 1  T T G G C G G T T T  C G C T A A A T A C  T G G C A G G C G T  T T C G T C A G T A  T C C C C G T T T A  C A G G G C G G C T
2 8 2 1  T C G T C T G G G A  C T G G G T G G A T  C A G T C G C T G A  T T A A A T A T G A  T G A A A A C G G C  A A C C C G T G G T
2 8 8 1  C G G C T T A C G G  C G G T G A T T T T  G G C G A T A C G C  C G A A C G A T C G  C C A G T T C T G T  A T G A A C G G T C
2  9 4 1  T G G T C T T T G C  C G A C C G C A C G  C C G C A T C C A G  C G C T G A C G G A  A G C A A A A C A C  C A G C A G C A G T
3 0 0 1  T T T T C C A G T T  C C G T T T A T C C  G G G C A A A C C A  T C G A A G T G A C  C A G C G A A T A C  C T G T T C C G T C
3 0 6 1  A T A G C G A T A A  C G A G C T C C T G  C A C T G G A T G G  T G G C G C T G G A  T G G T A A G C C G  C TG G C A A G C G
3 1 2 1  G T G A A G T G C C  T C T G G A T G T C  G C T C C A C A A G  G T A A A C A G T T  G A T T G A A C T G  C C T G A A C T A C
3 1 8 1  C G C A G C C G G A  G A G C G C C G G G  C A A C T C T G G C  T C A C A G T A C G  C G T A G T G C A A  C C G A A C G C G A
3 2 4 1  C C G C A T G G T C  A G A A G C C G G G  C A C A T C A G C G  C C T G G C A G C A  G T G G C G T C T G  G C G G A A A A C C
3 3 0 1  T C A G T G T G A C  G C T C C C C G C C  G C G T C C C A C G  C C A T C C C G C A  T C T G A C C A C C  A G C G A A A T G G
3 3 6 1  A T T T T T G C A T  C G A G C T G G G T  A A T A A G C G T T  G G C A A T T T A A  C C G C C A G T C A  G G C T T T C T T T
3 4 2 1  C A C A G A T G T G  G A T T G G C G A T  A A A A A A C A A C  T G C T G A C G C C  G C T G C G C G A T  C A G T T C A C C C
3 4  8 1  G T G C A C C G C T  G G A T A A C G A C  A T T G G C G T A A  G T G A A G C G A C  C C G C A T T G A C  C C T A A C G C C T
176
3 5 4 1  G G G T C G A A C G  C T G G A A G G C G  G C G G G C C A T T  A C C A G G C C G A  A G C A G C G T T G  T T G C A G T G C A
3 6 0 1  C G G C A G A T A C  A C T T G C T G A T  G C G G T G C T G A  T T A C G A C C G C  T C A C G C G T G G  C A G C A T C A G G
3 6 6 1  G G A A A A C C T T  A T T T A T C A G C  C G G A A A A C C T  A C C G G A T T G A  T G G T A G T G G T  C A A A T G G C G A
3 7  2 1  T T A C C G T T G A  T G T T G A A G T G  G C G A G C G A T A  C A C C G C A T C C  G G C G C G G A TT  G G C C T G A A C T
3 7  8 1  G C C A G C T G G C  G C A G G T A G C A  G A G C G G G T A A  A C T G G C T C G G  A T T A G G G C C G  C A A G A A A A C T
3 8  4 1  A T C C C G A C C G  C C T T A C T G C C  G C C T G T T T T G  A C C G C T G G G A  T C T G C C A T T G  T C A G A C A T G T
3 9 0 1  A T A C C C C G T A  C G T C T T C C C G  A G C G A A A A C G  G T C T G C G C T G  CG G G A C G C G C  G A A T T G A A T T
3 9 6 1  A T G G C C C A C A  C C A G T G G C G C  G G C G A C T T C C  A G T T C A A C A T  C A G C C G C T A C  A G T C A A C A G C
4 0 2 1  A A C T G A T G G A  A A C C A G C C A T  C G C C A T C T G C  T G C A C G C G G A  A G A A G G C A C A  T G G C T G A A T A
4 0 8 1  T C G A C G G T T T  C C A T A T G G G G  A T T G G T G G C G  A C G A C T C C T G  G A G C C C G T C A  G TA T C G G C G G
4 1 4 1  A A T T C C A G C T  G A G C G C C G G T  C G C T A C C A T T  A C C A G T T G G T  C T G G T G T C A G  G G G A TC C C C C
4 2 0 1  G G G C T G C A G C  C A A T A T G G G A  T C G G C C A T T G  A A C A A G A T G G  A T T G C A C G C A  G G T T C TC C G G
4 2 6 1  C C G C T T G G G T  G G A G A G G C T A  T T C G G C T A T G  A C T G G G C A C A  A C A G A C A A T C  G G C T G C T C T G
4 3 2 1  A T G C C G C C G T  G T T C C G G C T G  T C A G C G C A G G  G G C G C C C G G T  T C T T T T T G T C  A A G A C C G A C C
4 3 8 1  T G T C C G G T G C  C C T G A A T G A A  C T G C A G G A C G  A G G C A G C G C G  G C T A T C G T G G  C T G G C C A C G A
4 4 4 1  C G G G C G T T C C  T T G C G C A G C T  G T G C T C G A C G  T T G T C A C T G A  A G C G G G A A G G  G A C T G G C T G C
4 5 0 1  T A T T G G G C G A  A G T G C C G G G G  C A G G A T C T C C  T G T C A T C T C A  C C T T G C T C C T  G C C G A G A A A G
4 5 6 1  T A T C C A T C A T  G G C T G A T G C A  A T G C G G C G G C  T G C A T A C G C T  T G A T C C G G C T  A C C T G C C C A T
4 6 2 1  T C G A C C A C C A  A G C G A A A C A T  C G C A T C G A G C  G A G C A C G T A C  T C G G A T G G A A  G C C G G T C T T G
4 6 8 1  T C G A T C A G G A  T G A T C T G G A C  G A A G A G C A T C  A G G G G C T C G C  G C C A G C C G A A  C T G T T C G C C A
4 7 4 1  G G C T C A A G G C  G C G C A T G C C C  G A C G G C G A G G  A T C T C G T C G T  G A C C C A T G G C  G A T G C C T G C T
4 8 0 1  T G C C G A A T A T  C A T G G T G G A A  A A T G G C C G C T  T T T C T G G A T T  C A T C G A C T G T  G G C C G G C TG G
4 8  6 1  G T G T G G C G G A  C C G C T A T C A G  G A C A T A G C G T  T G G C T A C C C G  T G A T A T T G C T  G A A G A G C T T G
4 9 2 1  G C G G C G A A T G  G G C T G A C C G C  T T C C T C G T G C  T T T A C G G T A T  C G C C G C T C C C  G A T T C G C A G C
4 9 8 1  G C A T C G C C T T  C T A T C G C C T T  C T T G A C G A G T  T C T T C T G A T C  T A G A A C T A G T  G G A T C C A G C T
5 0 4 1  T A T C G A G C T T  G C C A A C T A C A  G C A G G T A A G C  A T A T T T A T G A  A A A A T G C T G A  T T G T G T T A G C
5 1 0 1  T A C T T G T G T C  A G T G T T G T G A  T A G T C G A C A T  A A C T T C G T A T  A G C A T A C A T T  A T A C G A A G T T
5 1 6 1  A T A C T A G A T G  T G T G G A A T T G  T G G C G G A T A A  C A T T T C A C A C  A T C T A G T G A C  G G C T A C A C C A
5 2 2 1  A C A G T A T C T A  T A C A C T G T C C  A T C A G C A G C G  C C A C A C A G T T  C G G C A A T G T G  C C C T G G T A C A
5 2 8 1  G T G A G G C C T G  C T C C T C C A C A  C T G G C C A C C A  C C T A C A G C A G  C G G C A A C C A G  A A T G A G A A G C
5 3 4 1  A G A T C G T G A G  T C T T G C C T G G  C T G G G G C T G G  G A A G G A G G C C  T C C T G C T C T C  C T C A G G G C C A
5 4  0 1  C A T T A G G C T C  T C T C T G A C C T  C A T C C C T G T G  A T A G T G G C T C  A G G C A T C A T G  A G A T C C T G T G
5 4  6 1  T G G A A T T G T G  A G C G G A T A A C  A A T T T C A C A C  A T G A T C T A T A  A C T T C G T A T A  G C A T A C A T T A
5 5 2 1  T A C G A A G T T A  T G A T C T C G A G  T T G T G A T A G T  C G A G G C G C C T  A G A G A A G G A G  T G A G G G C T G G
5 5 8 1  A T A A A G G G A G  G A T C G A G G C G  G G G T C G A A C G  A G G A G G T T C A  A G G G G G A G A G  A C G G G G C G G A
5 6 4 1  T G G A G G A A G A  G G A G G C G G A G  G C T T A G G G T G  T A C A A A G G G C  T T G A C C C A G G  G AG G G G GG TC
5 7  0 1  A A A A G C C A A G  G C T T C C C A G G  T C A C G A T G T A  G G G G A C C T G G  T C T G G G T G T C  C A T G C G G G C C
5 7  6 1  A G G T G A A A A G  A C C T T G A T C T  T A A C C T G G G T  G A T G A G G T C T  C G G T T A A A G G  T G C C G T C T C G
5 8 2 1  C G G C C A T C C G  A C G T T A A A G G  T T G G C C A T T C  TG C A G A G C A G  A A G G T A A C C C  A A C G T C T C T T
5 8 8 1  C T T G A C A T C T  A C C G A C T G G T  T G T G A G C G A T  C C G C T C G A C A  T C T T T C C A G T  G A C C T A A G G T
5 9 4 1  C A A A C T T A A G  G G A G T G G T A A  C A G T C T G G C C  C A T A T T C T C A  G A C A A A T A C A  G A A A C A C A G T
6 0 0 1  C A G A C A G A G A  C A A C A C A G A A  C G A T G C T G C A  G C A G A C A A G A  C G C G C G G C G C  G G C T T C G G T C
6 0 6 1  C C A A A C C G A A  A G C A A A A A T T  C A G A C G G A G G  C G G G A A C T G T  T T T A G G T T C T  C G T C T C C T A C
6 1 2 1  C A G A A C C A C A  T A T C C C T C C T  C T A A G G G G G G  T G C A C C A A A G  A G T C C A A A A C  G A T C G G G A T T
6 1 8 1  T T T G G A C T C A  G G T C G G G C C A  C A A A A A C G G C  C C C C G A A G T C  C C T G G G A C G T  C T C C C A G G G T
6 2  4 1  TG C G G C C G G G  T G T T C C G A A C  T C G T C A G T T C  C A C C A C G G G T  C C G C C A G A T A  C A G A G C T A G T
6 3 0 1  T A G C T A A C T A  G T A C C G A C G C  A G G C G C A T A A  A A T C A G T C A T  A G A C A C T A G A  C A A T C G G A C A
6 3 6 1  G A C A C A G A T A  A G T T G C T G G C  C A G C T T A C C T  C C C G G T G G T G  G G T C G G T G G T  C C C T G G G C A G
6 4 2 1  G G G T C T C C C G  A T C C C G G A C G  A G C C C C C A A A  T G A A A G A C C C  C C G C T G A C G G  G T A G T C A A T C
6 4  8 1  A C T C A G A G G A  G A C C C T C C C A  A G G A A C A G C G  A G A C C A C A A G  T C G G A T G C A A  C T G C A A G A G G
6 5 4 1  G T T T A T T G G A  T A C A C G G G T A  C C C G G G C G A C  T C A G T C A A T C  G G A G G A C T G G  C G C C C C G A G T
6 6 0 1  G A G G G G T T G T  G C T A G C T A G C  T T G C C A A A C C  T A C A G G T G G G  G T C T T T C A T T
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proviral pCRR+SD126T7 I-Sce (X)
1 A A T G A A A G A C  C C C C G C T G A C  G G G T A G T C A A  T C A C T C A G A G  G A G A C C C T C C  C A A G G A A C A G
6 1  C G A G A C C A C A  A G T C G G A T G C  A A C T G C A A G A  G G G T T T A T T G  G A T A C A C G G G  TA C C C G G G C G
1 2 1  A C T C A G T C A A  T C G G A G G A C T  G G C G C C C C G A  G T G A G G G G T T  G T G C T A G C T T  G C C A A A C C T A
1 8 1  C A G G T G G G G T  C T T T C A T T C C  C C C C T T T T T C  T G G A G A C T A A  A T A A A A T C T T  T T A T T T T A T C
2 4 1  T A T G G C T C G T  A C T C T A T A G G  C T T C A G C T G G  T G A T A T T G T T  G A G T C A A A A C  T A G A G C C T G G
3 0 1  A C C A C T G A T A  T C C T G T C T T T  A A C A A A T T G G  A C T A A T C G A T  C T C G A C C T C G  A G A C T A G T G G
3 6 1  A T C C C C C G G G  C T G C A G A T C T  G T A G G G C G C A  G T A G T C C A G G  G T T T T C C T T G  A T G A T G T C A T
4 2 1  A C T T A T C C C T  G T C C C T T T T T  T T T C C A C A G C  T C G C G G T T G A  G G A C A A A C T C  T T C G C G G T C T
4 8 1  T T C C A G T G G G  G A T C G A C G G T  A T C G A T A A G C  T T G A T G A T C T  G T G A C A T G G C  G G A T C C C G T C
5 4 1  G T T T T A C A A C  G T C G T G A C T G  G G A A A A C C C T  G G C G T T A C C C  A A C T T A A T C G  C C T T G C A G C A
6 0 1  C A T C C C C C T T  T C G C C A G C T G  G C G T A A T A G C  G A A G A G G C C C  G C A C C G A T C G  C C C T T C C C A A
6 6 1  C A G T T G C G C A  G C C T G A A T G G  C G A A T G G C G C  T T T G C C T G G T  T T C C G G C A C C  A G A A G C G G T G
7 2 1  C C G G A A A G C T  G G C T G G A G T G  C G A T C T T C C T  G A G G C C G A T A  C T G T C G T C G T  C C C C T C A A A C
7 8 1  T G G C A G A T G C  A C G G T T A C G A  T G C G C C C A T C  T A C A C C A A C G  T A A C C T A T C C  C A T T A C G G T C
8 4 1  A A T C C G C C G T  T T G T T C C C A C  G G A G A A T C C G  A C G G G T T G T T  A C T C G C T C A C  A T T T A A T G T T
9 0 1  G A T G A A A G C T  G G C T A C A G G A  A G G C C A G A C G  C G A A T T A T T T  T T G A T G G C G T  T A A C T C G G C G
9 6 1  T T T C A T C T G T  G G T G C A A C G G  G C G C T G G G T C  G G T T A C G G C C  A G G A C A G T C G  T T T G C C G T C T
1 0 2 1  G A A T T T G A C C  T G A G C G C A T T  T T T A C G C G C C  G G A G A A A A C C  G C C T C G C G G T  G A T G G T G C T G
1 0 8 1  C G T T G G A G T G  A C G G C A G T T A  T C T G G A A G A T  C A G G A T A T G T  G G C G G A T G A G  C G G C A T T T T C
1 1 4 1  C G T G A C G T C T  C G T T G C T G C A  T A A A C C G A C T  A C A C A A A T C A  G C G A T T T C C A  T G T T G C C A C T
1 2 0 1  C G C T T T A A T G  A T G A T T T C A G  C C G C G C T G T A  C T G G A G G C T G  A A G T T C A G A T  G TG C G G C G A G
1 2  6 1  T T G C G T G A C T  A C C T A C G G G T  A A C A G T T T C T  T T A T G G C A G G  G T G A A A C G C A  G G T C G C C A G C
1 3 2 1  G G C A C C G C G C  C T T T C G G C G G  T G A A A T T A T C  G A T G A G C G T G  G T G G T T A T G C  C G A T C G C G T C
1 3 8 1  A C A C T A C G T C  T G A A C G T C G A  A A A C C C G A A A  C T G T G G A G C G  C C G A A A T C C C  G A A T C T C T A T
1 4  4 1  C G T G C G G T G G  T T G A A C T G C A  C A C C G C C G A C  G G C A C G C T G A  T T G A A G C A G A  A G C C T G C G A T
1 5 0 1  G T C G G T T T C C  G C G A G G T G C G  G A T T G A A A A T  G G T C T G C T G C  T G C T G A A C G G  C A A G C C G T T G
1 5 6 1  C T G A T T C G A G  G C G T T A A C C G  T C A C G A G C A T  C A T C C T C T G C  A T G G T C A G G T  C A T G G A T G A G
1 6 2 1  C A G A C G A T G G  T G C A G G A T A T  C C T G C T G A T G  A A G C A G A A C A  A C T T T A A C G C  C G T G C G C T G T
1 6 8 1  T C G C A T T A T C  C G A A C C A T C C  G C T G T G G T A C  A C G C T G T G C G  A C C G C T A C G G  C C T G T A T G T G
1 7 4 1  G T G G A T G A A G  C C A A T A T T G A  A A C C C A C G G C  A T G G T G C C A A  T G A A T C G T C T  G A C C G A T G A T
1 8 0 1  C C G C G C T G G C  T A C C G G C G A T  G A G C G A A C G C  G T A A C G C G A A  T G G T G C A G C G  C G A T C G T A A T
1 8  6 1  C A C C C G A G T G  T G A T C A T C T G  G T C G C T G G G G  A A T G A A T C A G  G C C A C G G C G C  T A A T C A C G A C
1 9 2 1  G C G C T G T A T C  G C T G G A T C A A  A T C T G T C G A T  C C T T C C C G C C  C G G T G C A G T A  TG A A G G C G G C
1 9 8 1  G G A G C C G A C A  C C A C G G C C A C  C G A T A T T A T T  T G C C C G A T G T  A C G C G C G C G T  G G A T G A A G A C
2 0 4 1  C A G C C C T T C C  C G G C T G T G C C  G A A A T G G T C C  A T C A A A A A A T  G G C T T T C G C T  A C C T G G A G A G
2 1 0 1  A C G C G C C C G C  T G A T C T T T G C  G A A T A C G C C C  A C G C G A T G G G  T A A C A G T C T T  G G C G G T T T C G
2 1 6 1  C T A A A T A C T G  G C A G G C G T T T  C G T C A G T A T C  C C C G T T T A C A  G G G C G G C T T C  G T C T G G G A C T
2 2  2 1  G G G T G G A T C A  G T C G C T G A T T  A A A T A T G A T G  A A A A C G G C A A  C C C G T G G T C G  G C T T A C G G C G
2 2 8 1  G T G A T T T T G G  C G A T A C G C C G  A A C G A T C G C C  A G T T C T G T A T  G A A C G G T C T G  G T C T T T G C C G
2  3 4 1  A C C G C A C G C C  G C A T C C A G C G  C T G A C G G A A G  C A A A A C A C C A  G C A G C A G T T T  T T C C A G T T C C
2 4  0 1  G T T T A T C C G G  G C A A A C C A T C  G A A G T G A C C A  G C G A A T A C C T  G T T C C G T C A T  A G C G A T A A C G
2 4  6 1  A G C T C C T G C A  C T G G A T G G T G  G C G C T G G A T G  G T A A G C C G C T  G G C A A G C G G T  G A A G T G C C T C
2 5 2 1  T G G A T G T C G C  T C C A C A A G G T  A A A C A G T T G A  T T G A A C T G C C  T G A A C T A C C G  C A G C C G G A G A
2  5 8 1  G C G C C G G G C A  A C T C T G G C T C  A C A G T A C G C G  T A G T G C A A C C  G A A C G C G A C C  G C A T G G T C A G
2  6 4 1  A A G C C G G G C A  C A T C A G C G C C  T G G C A G C A G T  G G C G T C T G G C  G G A A A A C C T C  A G T G T G A C G C
2 7  0 1  T C C C C G C C G C  G T C C C A C G C C  A T C C C G C A T C  T G A C C A C C A G  C G A A A T G G A T  T T T T G C A T C G
2 7  6 1  A G C T G G G T A A  T A A G C G T T G G  C A A T T T A A C C  G C C A G T C A G G  C T T T C T T T C A  C A G A T G T G G A
2  8 2 1  T T G G C G A T A A  A A A A C A A C T G  C T G A C G C C G C  T G C G C G A T C A  G T T C A C C C G T  G C A C C G C T G G
2 8 8 1  A T A A C G A C A T  T G G C G T A A G T  G A A G C G A C C C  G C A T T G A C C C  T A A C G C C T G G  G T C G A A C G C T
2  9 4 1  G G A A G G C G G C  G G G C C A T T A C  C A G G C C G A A G  C A G C G T T G T T  G C A G T G C A C G  G C A G A T A C A C
3 0 0 1  T T G C T G A T G C  G G T G C T G A T T  A C G A C C G C T C  A C G C G T G G C A  G C A T C A G G G G  A A A A C C T T A T
3 0 6 1  T T A T C A G C C G  G A A A A C C T A C  C G G A T T G A T G  G T A G T G G T C A  A A T G G C G A T T  A C C G T T G A T G
3 1 2 1  T T G A A G T G G C  G A G C G A T A C A  C C G C A T C C G G  C G C G G A T T G G  C C T G A A C T G C  C A G C T G G C G C
3 1 8 1  A G G T A G C A G A  G C G G G T A A A C  T G G C T C G G A T  T A G G G C C G C A  A G A A A A C T A T  C C C G A C C G C C
3 2 4 1  T T A C T G C C G C  C T G T T T T G A C  C G C T G G G A T C  T G C C A T T G T C  A G A C A T G T A T  A C C C C G T A C G
3 3 0 1  T C T T C C C G A G  C G A A A A C G G T  C T G C G C T G C G  G G A C G C G C G A  A T T G A A T T A T  G G C C C A C A C C
3 3 6 1  A G T G G C G C G G  C G A C T T C C A G  T T C A A C A T C A  G C C G C T A C A G  T C A A C A G C A A  C T G A T G G A A A
3 4  2 1  C C A G C C A T C G  C C A T C T G C T G  C A C G C G G A A G  A A G G C A C A T G  G C T G A A T A T C  G A C G G T T T C C
3 4  8 1  A T A T G G G G A T  T G G T G G C G A C  G A C T C C T G G A  G C C C G T C A G T  A T C G G C G G A A  T T C C A G C T G A
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3 5 4 1
3 6 0 1
3 6 6 1
3 7 2 1
3 7 8 1
3 8 4 1
3 9 0 1
3 9 6 1
4 0 2 1
4 0 8 1
4 1 4 1
4 2 0 1
4 2 6 1
4 3 2 1
4 3 8 1
4 4 4 1
4 5 0 1
4 5 6 1
4 6 2 1
4 6 8 1
4 7 4 1
4 8 0 1
4 8 6 1
4 9 2 1
4 9 8 1
5 0 4 1
5 1 0 1
5 1 6 1
5 2 2 1
5 2 8 1
5 3 4 1
5 4 0 1
5 4 6 1
5 5 2 1
5 5 8 1
5 6 4 1
G C G C C G G T C G  C T A C C A T T A C  C A G T T G G T C T  
A T A T G G G A T C  G G C C A T T G A A  C A A G A T G G A T  
A G A G G C T A T T  C G G C T A T G A C  T G G G C A C A A C  
T C C G G C T G T C  A G C G C A G G G G  C G C C C G G T T C  
T G A A T G A A C T  G C A G G A C G A G  G C A G C G C G G C  
G C G C A G C T G T  G C T C G A C G T T  G T C A C T G A A G  
T G C C G G G G C A  G G A T C T C C T G  T C A T C T C A C C  
C T G A T G C A A T  G C G G C G G C T G  C A T A C G C T T G  
C G A A A C A T C G  C A T C G A G C G A  G C A C G T A C T C  
A T C T G G A C G A  A G A G C A T C A G  G G G C T C G C G C  
G C A T G C C C G A  C G G C G A G G A T  C T C G T C G T G A  
T G G T G G A A A A  T G G C C G C T T T  T C T G G A T T C A  
G C T A T C A G G A  C A T A G C G T T G  G C T A C C C G T G  
C T G A C C G C T T  C C T C G T G C T T  T A C G G T A T C G  
A T C G C C T T C T  T G A C G A G T T C  T T C T G A T C T A  
T A C G C T A G G G  A T A A C A G G G T  A A T A T A G T C T  
C C A A C T A C A G  C A G G T A A G C A  T A T T T A T G A A  
G T G T T G T G A T  A G T C G A C G G C  G C C T A G A G A A  
G G C G G G G T C G  A A C G A G G A G G  T T C A A G G G G G  
G G A G G C T T A G  G G T G T A C A A A  G G G C T T G A C C  
C A G G T C A C G A  T G T A G G G G A C  C T G G T C T G G G  
A T C T T A A C C T  G G G T G A T G A G  G T C T C G G T T A  
A A G G T T G G C C  A T T C T G C A G A  G C A G A A G G T A  
T G G T T G T G A G  C G A T C C G C T C  G A C A T C T T T C  
G T A A C A G T C T  G G C C C A T A T T  C T C A G A C A A A  
A G A A C G A T G C  T G C A G C A G A C  A A G A C G C G C G  
A A T T C A G A C G  G A G G C G G G A A  C T G T T T T A G G  
T C C T C T A A G G  G G G G T G C A C C  A A A G A G T C C A  
G C C A C A A A A A  C G G C C C C C G A  A G T C C C T G G G  
G A A C T C G T C A  G T T C C A C C A C  G G G T C C G C C A  
A C G C A G G C G C  A T A A A A T C A G  T C A T A G A C A C  
T G G C C A G C T T  A C C T C C C G G T  G G TG G G TC G G  
G A C G A G C C C C  C A A A T G A A A G  A C C C C C G C T G  
C C C A A G G A A C  A G C G A G A C C A  C A A G T C G G A T  
G G T A C C C G G G  C G A C T C A G T C  A A T C G G A G G A  
T A G C T T G C C A  A A C C T A C A G G  T G G G G T C T T T
G G T G T C A G G G  G A T C C C C C G G  G C T G C A G C C A  
TG C A C G C A G G  T T C T C C G G C C  G C TT G G G T G G  
A G A C A A T C G G  C T G C T C T G A T  G C C G C C G T G T  
T T T T T G T C A A  G A C C G A C C T G  T C C G G T G C C C  
T A T C G T G G C T  G G C C A C G A C G  G G C G T T C C T T  
C G G G A A G G G A  C T G G C T G C T A  TT G G G C G A A G  
T T G C T C C T G C  C G A G A A A G T A  T C C A T C A T G G  
A T C C G G C T A C  C T G C C C A T T C  G A C C A C C A A G  
G G A T G G A A G C  C G G T C T T G T C  G A T C A G G A T G  
C A G C C G A A C T  G T T C G C C A G G  C T C A A G G C G C  
C C C A T G G C G A  T G C C T G C T T G  C C G A A T A T C A  
T C G A C T G T G G  C C G G C T G G G T  G TG G CG G ACC  
A T A T T G C T G A  A G A G C T T G G C  G G C G AATG G G  
C C G C T C C C G A  T T C G C A G C G C  A T C G C C T T C T  
G T A A T A C G A C  T C A C T A T A G G  G C G A TC G A G T  
A G A A C T A G T G  G A T C C A G C T T  A T C G A G C T T G  
A A A T G C T G A T  T G T G T T A G C T  A C T T G T G T C A  
G G A G TG A G G G  C T G G A T A A A G  G G A G G A TC G A  
A G A G A C G G G G  C G G A T G G A G G  AAG A G G A G G C  
C A G G G A G G G G  G G T C A A A A G C  C A A G G C T T C C  
T G T C C A T G C G  G G C C A G G T G A  A A A G A C C T T G  
A A G G T G C C G T  C T C G C G G C C A  T C C G A C G T T A  
A C C C A A C G T C  T C T T C T T G A C  A T C T A C C G A C  
C A G T G A C C T A  A G G T C A A A C T  TA A G G G A G T G  
T A C A G A A A C A  C A G T C A G A C A  G A G A C A A C A C  
G C G C G G C T T C  G G T C C C A A A C  C G A A A G C A A A  
T T C T C G T C T C  C T A C C A G A A C  C A C A T A T C C C  
A A A C G A T C G G  G A T T T T T G G A  C T C A G G T C G G  
A C G T C T C C C A  G G G T T G C G G C  C G G G T G T T C C  
G A T A C A G A G C  T A G T T A G C T A  A C T A G T A C C G  
T A G A C A A T C G  G A C A G A C A C A  G A T A A G T T G C  
T G G T C C C T G G  G C A G G G G T C T  C C C G A T C C C G  
A C G G G T A G T C  A A T C A C T C A G  A G G A G A C C C T  
G C A A C T G C A A  G A G G G T T T A T  T G G A T A C A C G  
C T G G C G C C C C  G A G T G A G G G G  T T G T G C T A G C  
C A T T
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APPENDIX III
Sequence data obtained from 3' RACE products:
CaPC>4 8-11 - E7 -  Mus musculus RIKEN cDNA 1500001M02 gene, mRNA (cDNA 
clone IMAGE: 4218748)
N N N A C G N N N N T NT NC N C C CC C G N N CN N N NN N A A AC C C CC C N CC C C TN TT TTT TT TTT TT G N G G
C C C N A A A A A A A G G N N T T N N N N T N N C N N C C C N G G T T N T A A A N N T T G G N N T T N C N T A A A G G N G G
C C CC N TA N AATNTNNG G G CCCCN NCCCAAAAG G NCNTTTTTTTTTTTTCCCAG G G G ATCA TTTT
TTATTTGCATCTCG G TTTCAG TACAATTTACAACATTG TCCCCCG TTCCAG TCTG ATTATG CTC
A T G C T A A G G G A C A G A A A G G G C C TG G A A T A A A TA C A TTA A A A A A A A A G C T C T C A A C TA A G G G G
C ACACAG TAG G C C C TA TG G G G G A G G G G A A G G G A C TG AG AA A C TA A G TG G CA C C CA G A A G G T
C CTATG G G G TG TG G G TG TCTG AG ACAG G AAG TG AG CAAG CAAACG CAAG AG G CG G G TCAG G C
C G C A A A G C T
CaP0 4  9 -  1A 6 7 2  * Mus musculus vaccinia related kinase 3 (AI428238)
TTTTTTTTTN N TTTTG A TTA A A AA C A G TTTA TTATG C C ATC AC A G A A ATG C C ATAG G G A G TG G A
GTGGCTGCTGCCGCC
CaP0 4  9 - 1 F872 - Similar to phosphoglycerate kinase 1 (XM283048)
TTTTNCNTTTTTTTTTAG G G G ACATCTTTATTG TTTAATACATC ATCAATTTCTG CAG ACTTACA
GC
CaPC>4 8-11 - HI -  Mus musculus Idbl Inhibitor of DNA binding 1 (NM010495)
TT TT TTT TTTTTTTCTTTTTATCTAAAG G G TTNG TTTAATAAC AACAAAAAACTCACCCCC
A T A G A A C T A T T G TA A A A C A A T A TTT TC A G C C A G G G A TC A TTG TA A TA TA C A A T A C A A A A T
A TTTC C T C A G A A A TC C G A G A A G C A C G A A A TG T G A C C A TT TA A A A A A A A A A TG T C TG C TT T
TTCAATAAA A CA G A A A CA C G C G G G G TTG A TTA A C CC C C TC C CC A A A G TC TC TG G A G G C TG
AAAG G TG G AG AG G G TG AG G CTC TG TTG ATCAAACCCTTTACCCACTG G ACCG ATCCG CCA
A G AG TCCG G G G G CTTG CG G TAG TG TCTTTCCCAG AG ATCCCCTG G G G AACCG AG AG CACT
TTTTTCCTCTTG CCTCCTG AAGG GCTGG AG GCCATCTGGGCCCTCAGTGCGCCGCCTAAG
C G A C A CAAG A TG CG A TCG TCG G CTG G AACAAATG CCG CCTCG G
180
C aP 0 4 8 - 1 1  - B6  -  Mus musculus ribosomal protein L12 (Rpll2) (XM_192893.1)
GACATCATCATCATATATTG CTG AAG AG CTTG G CG G CCCG TG CG CCTTAG G TG TACCTG AG G T
G CACCG GAGGCGAGGTCG GCGCCACATCCGCCTTGG CCCCGAAG ATCGGTCCTCTGGGTCTGT
CTCCG AAG AAAG TTG G CG ATG ACATTG C CAAG G CTACCG G TG ACTG G AAG G G TC TCAG AATT
ACAG TG AAACTG ACC ATCCAG AACAG ACAG G CCCAG ATCG AG G TG G TG CCTTCTG CCTCAG C
C C T G A T C A T C A A A G C C C T C A A G G A G C C AC C G A G A G A C AG G A G G A A G C AG AA G A A C AT TA A A
CACAG TG G NAACA TTACTTTTG ATG AG ATTG TCAACATTG CCCG G CAG ATG AG ACACCG G TCT
TTGGCTAG AG AACTTTCTG G AACTATCAAG G AG ATCCTG G G TACTG CACAG TCTG TG G G CTG C
A A TG TG G ATG G CCG CCACCCTC ATG ACATC ATAG ATG ACATCAACAG TG G TG CAG TG G AG TG
C C C A N C T N G T T A A G A A G C A A C A A G A A A A T N T TC C A T TA A A G A C T A T C TG A TA A C C A G T A A A A
A A A A A A A A A A A A A A A A A A A A
C aP 0 4 11 - F648 -  Mus musculus ribosomal protein L30 (Rpl30)
TG GTGTTG G TCTG G G G G TTG TCCCG CACCTAAG G CAG G AAG ATG G TG G CCG CAAAG AAG ACG
AAAAAG TC TCTG G A G TC G ATC AA C TC TA G G CTC CA A C TTG TTA TG A AA A G TG G G A A G TA C G TG
CTG G G CTA C AA G C A G A C TC TG A A G A TG ATCA G A C A A G G C A AA G C G A A G TTG G TTA TC C TTG C
CAACAA CTG TC C A G C TTTG A G G A A A TC TG A A A TA G A G TA C TA TG C CA TG TTG G C TA A AA C TG G
G G TC CA TCA C TA C A G TG G CA A TA A TA TTG A A C TG G G C A C AG CG TG TG G A A AA TAC TAC A G A G
TA TG CAC A C TG G C TATC ATTG A C C CA G G TG A TTC TG A TA TTA TTA G A A G C A TG C C A G A AC A G A
C TG G TG A G A A G TA A A CA A G A A A G TT TTC C TT TA A TA AA A C TT TG C C A G A G C TC CT TT TG A A A A
A A A A A A A A A A A A A A A A A A G T N C T N T T C A A C C C G G G G C C T A N T A N T A T T A G G C G G C C G C T T T A
A A G G A T C C A A G N T TA C N T A C G C G N G C N TG C N A N N N N A TA N N T TT TTT A TN G G G N C N C C T A A N
T N A A T T C A C T G G C C G N G G T T T N N A A C G N N N T G G G G N N A A A A A A A N N N N N N N N N N N N
C aP 0 4 11 - E U 48 -  Mus musculus ribosomal protein L28
ACATATATCTG CTG TAAG TAG CTTG G CG G CCATCCG CAG G G TCCAG TG C CATCCTTCG AAG CC
A G N A AG CC TG TG G CG G TG A A G A G G A A A CG G A CC C G C C C CA C C AA G N A G C TC C TG A G C C C C AC
A C G C C C G A A G C A A T A A A G A G T C C A C T G A C T T C C A A A A A A A A A A A A A A A N A A N T A G T C G A A N
C N N N N A N N A A A N N T T T T T G G C G G C G N G G N N T A A A G G A T C C A A G N T N N N G C C C T T T T A A A N G A
A A N A N N T T A A C T T T N C T A TN G N G G C A N C T A A A TT C T TT TTT TT G G N N G N C C N TT A A N A A N A TT
C N G N N G G G G A A A N T T T N A N A N N N N G G G N A N G G G A A A A A A N N N N N N N
C aP 0 4 11 - F1148 -  Arabidopsis thaliana Wee 1
G A A T T CA C TA G T G A TTN A G A G A A G A TA TC N N CT TTG TC A AG AT G A TC A TA G T TC TC A TTA A G T
ATTTCTTG AG G CATATA ACG TG CATCCCCCTCTTC G ATCG G CTG G CTC TTATCAAG AAG AG TTG
C A C A TC C A A A A TC A C C AA G C TTA TA C AC A C CA C TTTTC A C A TA AA TATTA TC TG G C TTTA CA TC
TAAATG AG CTACCCCTCTCTG ATG G ATA TATTG CAATG CCTTG G CTACCTG ATACATTG CTTCC
A A AACTG CTACCTCCG AAG ATAG TTTAG AATATTTTTTG TTG G ATA AG CTG TG G TCACAG AG C
TC C A TTT G G ATG TAAAG ATG CTCATTCTCAAA CCACG AAATCG AATTCCCG CG G C CG G CAG TT
TTG G A A G C A ATG TA TC A G G TA G C CA A G G C A TTG C AA TATA TC CA TCA G A G A G G G G TAG CTCA
TTTAG ATG TAAAG C CAG ATAATATTTATG TG A AAAG TG G TG TG TATAAG CTTG G TG ATTTTG G
ATG TG CAACTC TTCTTG ATAAG AG CCA G CCG ATCG AAG AG G G G G ATG C ACG TTATATG CCTCA
A G A A ATAC TTA A TG A G A A CTA TG A TC A TC TTG A C AA A G TG G A TA TC TTC TC TA A TC A CTA G TG
AATTCG
181
CaP0 4  11 - B24* -  Mus musculus cytochrome oxidase subunit Vb
ATATTGCTGAAGAGCTTGGCGGCGCAGGCCCTGAGGG CCCACGGCCCCCGTG GCGCGGCCGT
GACCCGCTCCATG GCTTCTGGAGGTGGTG TCCCCACTGATG AG GAGCAG GCTACTGG GCTGGA
G A G G G AG A TC ATG A TA G C A G C AC A G A A G G G A C TG G A CC C A TA C AA TATG C TA C CTC CA A A G G
CAG CTTCA G G C A C CA A G G A A G A C CC TAA TCTAG TC C CG TC C ATCA G C A A C AA G A G A A TA G TG
GGCTG CATCTG TG AAG AG G ACAACTG TAC TG TCATCTG G TTTTG G CTG CACAAAG G CG AG AG T
CAGCGATG CCCCAA CTG TG G AACC CATTACAAG CTG G TG C CCCACCAAA TG G CCCACTG AG C C
CCTG TG TTATCTTTTCAG A ATG TAAAG AAAAACTTCTCTCTAATAAAG ATTA G CCATTG CACTG
G C TC C TC C C AT A AA A A AA A A AA A A A AG TA CT A NT C G A CT NC T AG G C CT A CG CG TG G C C TA G C
TN G TNG CNC G CG G G CG CTNTACANG ATCCNAG CTTACG TACG ACG TG CATG CNTACTTC ATAG
CNTTTCNATA G TG N C AC C TA N N G TC A ATTC A C TG N A CN G C N G TTTN A C NN G G NA N M G A C TG G
G AAAAC C C TG N C G TTA CC C A TN TTAA TC G A C TTG C A TTN A TC C C CC TN TNG N C A A TTG A AG NA
G T A C C G A A A A A G N C C G C TN C G A T N G A C N T TN C C A A A N T G A TG N A N N N T G A A T G G C N A C N G G N
A C C G C C C T N T A A C N N C C N T N A A C N C G G G G G N N N N G G N G G N T N N C C C A N N N N T N C C N
C aP 04 11 - D Im -  Mus musculus Histone H2A.1 (AY158913)
GTATNG CCN TG ATTN C N C C N A G C TTTA ATNC G N C TC C C TA TA G G G AA A N C TG G TA CG CC TG C A
G G TACCG G TCCG G AATTCCCG G G TCG ACATCATCATCATATATTG CTG AAG AG CTTG G CG G CC
GTG CTG G AG TACCTG ACG G CCG AG ATCCTG G AG CTG G CG G G CAACG CG G CCCG CG ACAACAA
G A A A AC G C G CATCA TCCCG CG CCACCTG CAG CTG G CCATCCG CA ACG ACG AG G AG CTCAACA
AGCTGCTGGGCCGCGTG ACCATCGCGCAGGGCGG CG TCCTGCCCAACATCCAGG CCGTGCTGC
TG C C C A A G A A G A C C G A G A G C C AC C A CA A G G C C A AG G G A A AA T AA G A C C A G CC G T TC A C CC A C
C C G A A A A A A A A A A A A A A A A A
C aP 04 11 - E S 7 2  -  Mus musculus ribosomal protein L30
C G C TTTTN G C C A NG CN T CC A A TA C NA C TN N C TN TA N G G C A AA G A N TC G G G A CA C C N G CA G
GTACCG G TCCG G AATTCCCG G G TCG ACATCATCATCATATATTG CTG TAAG TAG CTTG G C
GGCCTG GTGTTG G TCTG G G G G TTG TCCCG CACCTAAG G CAG G AAG ATG G TG G CCG CAAAG
AAG ACG AA A A AG TC TC TG G A G TC G A TC A A CTC TA G G C TC C A AC TTG TTA TG A A A AG TG G G
A A G T A C G TG CT G G G C T AC A A G C AG AC T CT G A AG AT G A TC A G A C AA G G CA A A G C G A AG TTG G T
TA TCCTTG C C A A C A AC TG TC C A G C TTTG A G G A A ATC TG A A A TA G A G TA C TA TG CC A TG
TTG G CTAAA AC TG G G G TC CA TCA C TA C A G TG G CA A TA A TA TTG A A CTG G G CA C A G C G TG T
G G AA A A TA CTA CA G A G TA TG C A CA C TG G C TA TC A TTG AC C C A G G TG ATTC TG ATA TTA TT
A G A A G C A T G C C A G A A C A G A C T G G T G A G A A G TA A A C A A G A A A G T TTT C C T TT A A TA A A A C T
T T G C C A G A G C T C C T T T T G A A A A A A A A A A A A A A A A T T A A N A C C T T A A A A A A A A A A A A A A A A A A
G TN C TA TTC N A C N CG NG G C CTA NTA NTATTA G G C G G CC N C TC TA N A G G A TC C A AG CTNA C G TA
CC CN N G C G TG CG AG G TN TTA G C TN TTTTA TN G N G N C C C CTAA N TN A A TTCA C TG
C aP 04 11 - D472 -  Mus musculus HRAS like suppressor 3 (NM139269)
TTTTTTTTTTTTTTTTTTCCTTTCTTG TG G TTTATTG TATG TTG TG AAAATAAACCTAATTAAAAG
C A A T A G A A T C T A TA A A T C A A A C T C C G A A C C C T C TA G C A A A A G A A G A G C C C A A A A A C TG G G C A
G TCATTCAG CTCATTGCTTCTGTTTCTTGTTTCTGGAGAGCATGACTCCAACGAGGCCCAGGG
182
C aP 0 4 11- G672  -  Mus musculus Peptidylprolyl isomerase A (NM008907)
TTTrTTTTTTTTTTCTT ATTT AGTTTTT ATTC AT A ATC AT A A ACTT A ACTTTGC AATCC AGCT AG A
C TT G A A G G G G A A TG A G G AA A A TA TG G AA C C C AA A G A A CT TC A G TG AG AG CA G A G A TT A CA G
G ACATTG CG AG CAG ATG G G G TAG G G ACG CTCTCCTG AG CTACAG AAG G AATG G TTTG ATG G G
TA AAATG CCCG CAAG TCAAAAG AAA TTAG AG CTG TCCAC AG TCG G AAATG G TG ATCTTCTTG C
TG G TCTTG CCATTCCTGGACCCAAAACG CTCCATG GCTTCCACAATG TTCATG CCTTCTTTCAC
C TTCCCAAAG ACCACATG CCTG CCATCCAG CCATTCAG TC TTG G CAG TG CAG ATAAAAAACTG
GGAACCG TTTG TG TTTG G TCCAG CATTTG CCATG G ACAAG ATG CCAG G ACCTG TATG
CTTTAGG ATG AAG TTCTCATCCTCAAACTTCTCTCCG TAG ATG G ACCTG
C aP 0 4 11 - B7 72 -  Mus musculus clone IMAGE:3968454 mRNA (BC005576.1)
TTTTmTTTTTTTTTGCTGCCTAGAACTAGAAGACTCTCGTGCCTTACTACCAGGGAGCATTGT
GTGTGCTGACAGCCTCAGTTTCTCTCCAGCCCCTATTNNAACACTCACGTCCTCCTCG TCGGAT
GTGTCTG ACAGGATGCGATGGG
C aP 0 4 11 - H 8 7 2 -  Mus musculus proteasome (prosome, macropain) subunit, beta 
type 6  (NM008946.2)
GACCTTTTTTTTTTTTTTTTTTTTTTTTTTTCTCTTTAACAAACTGTTTATTAGCTTCTGCGTCGGT
AAGAACCATCCTTTACTACTCCCTAG AACACCAG G CCTCA G G G AG G TG G CAACG TG G C AATG
GTGAACTTGGG GATTTGGTCTCCCAAAAGCACCTGCCGCTCTACCCCTG ACACCTGAATGG
C aP 0 4 11 - D448 -  Mus musculus zinc finger protein 369, mRNA (cDNA clone 
MGC:41715 IMAGE: 1365300)
C A TC ATA TA G TA TG C ATG A AG AG CTTG G CG NC C TC C G A C TG G TN CA G N N C N ATG A NC A G A N N
AG N TC A TG A TTG C TTCA TTTA TC C TC A A AA G G AA A TA A A AG ATC TG A A A ATG TG TC TA A TG G A
TA ACAAG CTCA A G TTTC A A AA A TTG C AC TG A TA TTTA TA TA C A G G G TAC TG TG TG TA A G TG A A
C A A A A C T A A A A G T A T A TA G A TG A A TG A A TA A A C TA TTG TG T G G A A C T TT TTT A A A A A A A A A A
A N A N N A N A A A A A A A A N A N A N N N N N N N N N N N N N N
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